European Medic@@ ines Agency
E@@ ME@@ A@@ / H@@ / C@@ / 4@@ 71
EU@@ RO@@ P@@ E@@ AN P@@ U@@ BL@@ IC AS@@ S@@ ES@@ SM@@ EN@@ T RE@@ P@@ OR@@ T (@@ EP@@ AR@@ )
AB@@ IL@@ I@@ F@@ Y
EP@@ AR sum@@ mary for the public
It explains how the Committee for Medic@@ inal Produc@@ ts for Human Use (@@ CH@@ MP@@ ) asse@@ ssed the studies per@@ for@@ med@@ , to reach their recommendations on how to use the medic@@ ine@@ .
If you need more information about your medical condition or your treat@@ ment@@ , read the Pack@@ age Le@@ af@@ let (@@ also part of the EP@@ AR@@ ) or contact your doctor or pharmac@@ ist@@ .
If you want more information on the basis of the CH@@ MP recommend@@ ations@@ , read the Scienti@@ fic Dis@@ c@@ ussion (@@ also part of the EP@@ AR@@ )@@ .
What is A@@ bili@@ f@@ y@@ ?
A@@ bili@@ fy is a medicine containing the active substance ari@@ pi@@ pra@@ z@@ ole@@ .
It is available as 5 m@@ g@@ , 10 m@@ g@@ , 15 mg and 30 mg tab@@ le@@ ts@@ , as 10 m@@ g@@ , 15 mg and 30 mg or@@ o@@ disp@@ er@@ sible tab@@ lets (@@ tab@@ lets that dis@@ solve in the mou@@ th@@ )@@ , as an oral solution (@@ 1 m@@ g@@ / m@@ l@@ ) and as a solution for in@@ jection (@@ 7.5 m@@ g@@ / m@@ l@@ )@@ .
What is A@@ bili@@ fy used for@@ ?
A@@ bili@@ fy is used to treat adults with the following mental ill@@ nes@@ ses@@ : • sch@@ iz@@ op@@ hren@@ i@@ a@@ , a mental illness with a number of symp@@ tom@@ s@@ , including disor@@ gan@@ ised thinking and speech@@ , hall@@ u@@ cin@@ ations (@@ hearing or seeing things that are not ther@@ e@@ )@@ , suspici@@ ousness and del@@ u@@ sions (@@ mistak@@ en belie@@ fs@@ )@@ ; • bi@@ pol@@ ar I disor@@ der@@ , a mental illness in which patients have man@@ ic episodes (@@ periods of ab@@ normally high m@@ ood@@ )@@ , altern@@ ating with periods of normal m@@ ood@@ .
They may also have episodes of depres@@ sion@@ .
A@@ bili@@ fy is used to treat moderate to severe man@@ ic episodes and to prevent man@@ ic episodes in patients who have responded to the medicine in the pa@@ st@@ .
The solution for in@@ jection is used for the rapid control of ag@@ itation or distur@@ bed behaviour when taking the medicine by mouth is not appropri@@ ate@@ .
The medicine can only be obtained with a prescri@@ p@@ tion@@ .
How is A@@ bili@@ fy use@@ d@@ ?
For sch@@ iz@@ op@@ hren@@ i@@ a@@ , the recommended starting dose is 10 or 15 mg by mouth per day@@ .
The maintenance dose is 15 mg once a day@@ , but higher d@@ oses may benefit some pati@@ ent@@ s.
Some patients may benefit from a higher d@@ os@@ e@@ .
For both ill@@ nes@@ ses@@ , the oral solution or or@@ o@@ disp@@ er@@ sible tab@@ lets can be used in patients who have difficulty swal@@ lowing tab@@ le@@ ts@@ .
The or@@ o@@ disp@@ er@@ sible tab@@ lets are taken by being placed on the ton@@ gu@@ e@@ , where they dis@@ integr@@ ate quickly in the s@@ ali@@ v@@ a@@ , or by mi@@ xing them in water before swal@@ low@@ ing@@ .
The solution for in@@ jection is only for short@@ -@@ term use and should be replaced by tab@@ le@@ ts@@ , or@@ o@@ disp@@ er@@ sible tab@@ lets or oral solution as soon as possi@@ ble@@ : the usual dose is 9.@@ 75 mg as a single in@@ jection into the upper arm or but@@ to@@ ck mus@@ cle@@ , but effective d@@ oses range between 5.@@ 25 and 15 m@@ g.
7 West@@ fer@@ ry Cir@@ cus@@ , Can@@ ary W@@ har@@ f@@ , London E@@ 14 4@@ HB@@ , UK Tel@@ .
(@@ 44@@ -@@ 20@@ ) 74 18 84 00 Fax (@@ 44@@ -@@ 20@@ ) 74 18 84 16 E@@ -@@ mail@@ : mail@@ @@@ eme@@ a. europa@@ . e@@ u htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . e@@ u
© European Medic@@ ines Agen@@ cy@@ , 200@@ 8.
Re@@ production is author@@ ised provided the source is acknowle@@ dge@@ d.
A@@ bili@@ fy can be taken with or without f@@ ood@@ .
The daily dose of A@@ bili@@ fy should not exce@@ ed 30 m@@ g@@ , but this dose should be used with caution in patients who have severe problems with their li@@ ver@@ .
The dose of A@@ bili@@ fy should be adjusted in patients who are taking other medic@@ ines that are broken down in the same way as A@@ bili@@ f@@ y@@ .
A@@ bili@@ fy has not been studied in children aged below 18 years or adults aged over 65 ye@@ ar@@ s.
For more inform@@ ation@@ , see the Pack@@ age Le@@ af@@ let@@ .
How does A@@ bili@@ fy work@@ ?
The active substance in A@@ bili@@ f@@ y@@ , ari@@ pi@@ pra@@ z@@ ole@@ , is an anti@@ p@@ sycho@@ tic medic@@ ine@@ .
Its exact mechan@@ ism of action is unk@@ no@@ wn@@ , but it atta@@ ches to several different rec@@ ep@@ tors on the surface of nerve cells in the bra@@ in@@ .
This disrup@@ ts signals trans@@ mitted between brain cells by ‘ neur@@ ot@@ ran@@ s@@ mit@@ ters@@ ’@@ , chemicals that allow nerve cells to communicate with each o@@ ther@@ .
Ari@@ pi@@ pra@@ z@@ ole is thought to act mainly by being a ‘ partial agon@@ ist ’ for the rec@@ ep@@ tors for the neur@@ ot@@ ran@@ s@@ mit@@ ters d@@ op@@ amine and 5@@ -@@ hydro@@ x@@ y@@ tr@@ yp@@ t@@ amine (@@ also called ser@@ ot@@ on@@ in@@ )@@ .
This means that ari@@ pi@@ pra@@ z@@ ole acts like 5@@ -@@ hydro@@ x@@ y@@ tr@@ yp@@ t@@ amine and d@@ op@@ amine to activ@@ ate the rec@@ ep@@ tor@@ s@@ , but to a less@@ er extent than the neur@@ ot@@ ran@@ s@@ mit@@ ters@@ .
Since d@@ op@@ amine and 5@@ -@@ hydro@@ x@@ y@@ tr@@ yp@@ t@@ amine are involved in sch@@ iz@@ op@@ hren@@ ia and bi@@ pol@@ ar disor@@ der@@ , ari@@ pi@@ pra@@ z@@ ole helps to nor@@ mali@@ se the activity of the bra@@ in@@ , reducing p@@ sycho@@ tic or man@@ ic symptoms and preventing them from retur@@ n@@ ing@@ .
How has A@@ bili@@ fy been studi@@ ed@@ ?
For the treatment of sch@@ iz@@ op@@ hren@@ i@@ a@@ , there were three main short@@ -@@ term studies of A@@ bili@@ fy tab@@ lets lasting four to six wee@@ ks@@ , which involved 1,@@ 20@@ 3 patients and compared A@@ bili@@ fy with pla@@ c@@ eb@@ o (@@ a dum@@ my treat@@ ment@@ )@@ .
The effec@@ tiveness of A@@ bili@@ fy in preventing symptoms from returning was asse@@ ssed in three studies lasting up to a ye@@ ar@@ , two of which used hal@@ operi@@ dol (@@ another anti@@ p@@ sycho@@ tic medic@@ ine@@ ) as a compar@@ ator@@ .
The effec@@ tiveness of the solution for in@@ jection was compared with pla@@ c@@ eb@@ o over a period of two hours in two studies involving 8@@ 05 patients with sch@@ iz@@ op@@ hren@@ ia or related conditions who were experiencing symptoms of ag@@ it@@ ation@@ .
All of the studies measured the change in the pati@@ ent@@ ’ s symptoms using a standard scale for sch@@ iz@@ op@@ hren@@ i@@ a.
For the treatment of bi@@ pol@@ ar disor@@ der@@ , there were eight main studies looking at A@@ bili@@ fy taken by mou@@ th@@ .
There were five short@@ -@@ term studies that compared the effec@@ tiveness of A@@ bili@@ fy and pla@@ c@@ eb@@ o over three weeks in a total of 1,@@ 900 pati@@ ent@@ s.
Two of these studies used hal@@ operi@@ dol and li@@ thi@@ um (@@ another anti@@ p@@ sycho@@ tic medic@@ ine@@ ) as compar@@ ators and continued for a further nine weeks to look at the maintenance of the effect of the medi@@ cin@@ es@@ .
Another study compared A@@ bili@@ fy with hal@@ operi@@ dol over 12 weeks in 3@@ 47 pati@@ ent@@ s@@ , and a further study compared the effec@@ tiveness of A@@ bili@@ fy and pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence in 160 patients whose man@@ ic symptoms had already been stabili@@ sed using A@@ bili@@ f@@ y@@ .
The eighth study looked at the effect of adding A@@ bili@@ fy or pla@@ c@@ eb@@ o to existing treatment with li@@ thi@@ um or val@@ pro@@ ate (@@ another anti@@ p@@ sycho@@ tic medic@@ ine@@ ) in 38@@ 4 pati@@ ent@@ s.
The effec@@ tiveness of A@@ bili@@ fy solution for in@@ jection was compared with that of lor@@ az@@ ep@@ am (@@ another anti@@ p@@ sycho@@ tic medic@@ ine@@ ) and of pla@@ c@@ eb@@ o over a period of two hours in one study involving 30@@ 1 patients with bi@@ pol@@ ar disorder who were experiencing symptoms of ag@@ it@@ ation@@ .
All of these studies looked at the change in symptoms using a standard scale for bi@@ pol@@ ar disorder or at the number of patients who responded to treat@@ ment@@ .
The company also carried out studies looking at the absor@@ ption of the or@@ o@@ disp@@ er@@ sible tab@@ lets and oral solution by the body@@ .
What benefit has A@@ bili@@ fy shown during the stu@@ dies@@ ?
When used to treat sch@@ iz@@ op@@ hren@@ i@@ a@@ , A@@ bili@@ fy was more effective than pla@@ c@@ eb@@ o in the short@@ -@@ term stu@@ dies@@ .
In the long@@ -@@ term stu@@ dies@@ , A@@ bili@@ fy was more effective than pla@@ c@@ ebo@@ , and as effective as hal@@ operi@@ dol@@ , after up to a year of treat@@ ment@@ .
In both studies of the solution for in@@ jec@@ tion@@ , patients receiving A@@ bili@@ fy at d@@ oses of 5.@@ 25@@ , 9.@@ 75 or 15 mg had a significantly greater reduction in symptoms of ag@@ itation than those receiving pla@@ c@@ ebo@@ .
When used to treat bi@@ pol@@ ar disor@@ der@@ , A@@ bili@@ fy was more effective than pla@@ c@@ eb@@ o at reducing man@@ ic symptoms in four of the five short@@ -@@ term stu@@ dies@@ .
A@@ bili@@ fy also had a similar effect to hal@@ operi@@ dol and to li@@ thi@@ um over three wee@@ ks@@ .
This effect was maintained for up to 12 wee@@ ks@@ .
A@@ bili@@ fy was also more effective than pla@@ c@@ eb@@ o at preventing man@@ ic episodes returning in previously treated patients for up to 74 wee@@ ks@@ , and when it was used as an ad@@ d@@ -@@ on to existing treat@@ ment@@ .
In@@ jections of A@@ bili@@ fy at d@@ oses of 10 or 15 mg were also more effective than pla@@ c@@ eb@@ o in reducing the symptoms of ag@@ it@@ ation@@ , and were of similar effec@@ tiveness to lor@@ az@@ ep@@ am@@ .
2@@ / 3 What is the risk associated with A@@ bili@@ f@@ y@@ ?
The most common side effects when taking A@@ bili@@ fy by mouth (@@ seen in between 1 and 10 patients in 100@@ ) are ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disorder (@@ un@@ controlled twi@@ t@@ ching or j@@ erk@@ ing@@ )@@ , ak@@ ath@@ i@@ sia (@@ constant urge to mo@@ ve@@ )@@ , tre@@ m@@ or (@@ sha@@ king@@ )@@ , som@@ n@@ ol@@ ence (@@ sle@@ ep@@ in@@ ess@@ )@@ , se@@ dation (@@ dro@@ w@@ sin@@ ess@@ )@@ , hea@@ da@@ che@@ , bl@@ urred visi@@ on@@ , dy@@ sp@@ ep@@ sia (@@ heart@@ bur@@ n@@ )@@ , vo@@ mit@@ ing@@ , nau@@ sea (@@ feeling sick@@ )@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion (@@ increased production of s@@ ali@@ v@@ a@@ )@@ , f@@ ati@@ gue (@@ ti@@ re@@ dn@@ ess@@ )@@ , rest@@ less@@ ness@@ , ins@@ om@@ nia (@@ difficulty sle@@ ep@@ ing@@ ) and anx@@ ie@@ ty@@ .
Ak@@ ath@@ i@@ sia is more common in patients with bi@@ pol@@ ar disorder than in those with sch@@ iz@@ op@@ hren@@ i@@ a.
Between 1 and 10 patients in 100 receiving in@@ jections of A@@ bili@@ fy experience som@@ n@@ ol@@ en@@ ce@@ , di@@ zz@@ in@@ ess@@ , hea@@ da@@ che@@ , ak@@ ath@@ isi@@ a@@ , nau@@ sea and vo@@ mit@@ ing@@ .
For the full list of all side effects reported with A@@ bili@@ f@@ y@@ , see the Pack@@ age Le@@ af@@ let@@ .
A@@ bili@@ fy should not be used in people who may be hyper@@ sensitive (@@ aller@@ gi@@ c@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredi@@ ent@@ s.
Why has A@@ bili@@ fy been appro@@ v@@ ed@@ ?
The Committee for Medic@@ inal Produc@@ ts for Human Use (@@ CH@@ MP@@ ) decided that A@@ bili@@ f@@ y@@ ’ s benefits are greater than its risks for the treatment of sch@@ iz@@ op@@ hren@@ ia and of moderate to severe man@@ ic episodes in bi@@ pol@@ ar I disor@@ der@@ , and for the pre@@ vention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
It also decided that the benefits of the solution for in@@ jection out@@ weighed its risks for the rapid control of ag@@ itation and distur@@ bed behavi@@ ours in patients with sch@@ iz@@ op@@ hren@@ ia or in patients with man@@ ic episodes in bi@@ pol@@ ar I disor@@ der@@ , when oral therapy is not appropri@@ ate@@ .
The Committee recommended that A@@ bili@@ fy be given marketing author@@ is@@ ation@@ .
Other information about A@@ bili@@ f@@ y@@ :
The European Commission granted a marketing author@@ isation val@@ id throughout the European Union for A@@ bili@@ fy to Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d. on 4 June 200@@ 4.
The full EP@@ AR for A@@ bili@@ fy can be found her@@ e@@ .
This sum@@ mary was last updated in 07@@ -@@ 200@@ 8.
3@@ / 3
EU Number
Inv@@ ented name
St@@ ren@@ g@@ th
P@@ harm@@ ac@@ eu@@ tical Form
Route of Administration
Pack@@ aging
Cont@@ ent
Pack@@ age size
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 1
A@@ bili@@ fy
5 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
14 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 2
A@@ bili@@ fy
5 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
28 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 3
A@@ bili@@ fy
5 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
49 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 4
A@@ bili@@ fy
5 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
56 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 5
A@@ bili@@ fy
5 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
98 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 6
A@@ bili@@ fy
10 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
14 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 7
A@@ bili@@ fy
10 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
28 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 8
A@@ bili@@ fy
10 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
49 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 9
A@@ bili@@ fy
10 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
56 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 10
A@@ bili@@ fy
10 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
98 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 11
A@@ bili@@ fy
15 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
14 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 12
A@@ bili@@ fy
15 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
28 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 13
A@@ bili@@ fy
15 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
49 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 14
A@@ bili@@ fy
15 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
56 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 15
A@@ bili@@ fy
15 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
98 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 16
A@@ bili@@ fy
30 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
14 x 1
1@@ / 2 EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 17
A@@ bili@@ fy
30 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
28 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 18
A@@ bili@@ fy
30 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
49 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 19
A@@ bili@@ fy
30 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
56 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 20
A@@ bili@@ fy
30 mg
Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
98 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 24
A@@ bili@@ fy
10 mg
O@@ ro@@ disp@@ er@@ sible Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
14 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 25
A@@ bili@@ fy
10 mg
O@@ ro@@ disp@@ er@@ sible Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
28 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 26
A@@ bili@@ fy
10 mg
O@@ ro@@ disp@@ er@@ sible Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
49 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 27
A@@ bili@@ fy
15 mg
O@@ ro@@ disp@@ er@@ sible Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
14 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 28
A@@ bili@@ fy
15 mg
O@@ ro@@ disp@@ er@@ sible Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
28 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 29
A@@ bili@@ fy
15 mg
O@@ ro@@ disp@@ er@@ sible Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
49 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 30
A@@ bili@@ fy
30 mg
O@@ ro@@ disp@@ er@@ sible Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
14 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 31
A@@ bili@@ fy
30 mg
O@@ ro@@ disp@@ er@@ sible Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
28 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 32
A@@ bili@@ fy
30 mg
O@@ ro@@ disp@@ er@@ sible Tablet
O@@ ral use
unit dose per@@ for@@ ated bli@@ ster (@@ alu@@ / alu@@ )
49 x 1
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 33
A@@ bili@@ fy
1 m@@ g@@ / ml
O@@ ral solution
O@@ ral use
bottle (@@ P@@ ET@@ )
50 ml
1 bottle + 1 cup + 1 cali@@ br@@ ated dro@@ pper
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 34
A@@ bili@@ fy
1 m@@ g@@ / ml
O@@ ral solution
O@@ ral use
bottle (@@ P@@ ET@@ )
150 ml
1 bottle + 1 cup + 1 cali@@ br@@ ated dro@@ pper
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 35
A@@ bili@@ fy
1 m@@ g@@ / ml
O@@ ral solution
O@@ ral use
bottle (@@ P@@ ET@@ )
4@@ 80 ml
1 bottle + 1 cup + 1 cali@@ br@@ ated dro@@ pper
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 36
A@@ bili@@ fy
7.5 m@@ g@@ / ml
Sol@@ ution for in@@ jection
In@@ tra@@ mus@@ cular use
vi@@ al (@@ g@@ las@@ s@@ )
1.3 ml
1 vi@@ al
2@@ / 2
AN@@ NE@@ X I
SU@@ M@@ MAR@@ Y O@@ F P@@ RO@@ D@@ UC@@ T CH@@ AR@@ AC@@ TER@@ IS@@ T@@ IC@@ S
1 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 5 mg tab@@ lets
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each tab@@ let contains 5 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
Ex@@ cip@@ i@@ ent@@ :
67 mg la@@ ct@@ ose per tab@@ let
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Tablet Rec@@ tan@@ gu@@ lar and blu@@ e@@ , en@@ gra@@ ved with "@@ A@@ -@@ 00@@ 7@@ " and "@@ 5@@ " on one si@@ de.
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hren@@ i@@ a.
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the pre@@ vention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pi@@ pra@@ z@@ ole treatment (@@ see section 5.@@ 1@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
O@@ ral use@@ .
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 10 or 15 m@@ g@@ / day with a maintenance dose of 15 m@@ g@@ / day administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to me@@ al@@ s.
AB@@ IL@@ I@@ F@@ Y is effective in a dose range of 10 to 30 m@@ g@@ / day@@ .
En@@ h@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
M@@ anic epis@@ o@@ des@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 15 mg administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy (@@ see section 5.@@ 1@@ )@@ .
Some patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
Rec@@ ur@@ r@@ ence pre@@ vention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pi@@ pra@@ z@@ ole@@ , continue therapy at the same d@@ os@@ e@@ .
Ad@@ ju@@ st@@ ments of daily d@@ os@@ age@@ , including dose reduction should be considered on the basis of clinical stat@@ us@@ .
Children and adol@@ es@@ cent@@ s@@ : there is no experience in children and adol@@ es@@ cents under 18 years of age@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required for patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
In patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ , the data available are in@@ sufficient to establish recommend@@ ations@@ .
Ho@@ we@@ ver@@ , the
2 maximum daily dose of 30 mg should be used with caution in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required in patients with ren@@ al im@@ pa@@ ir@@ ment@@ .
El@@ der@@ ly@@ : the effec@@ tiveness of AB@@ IL@@ I@@ F@@ Y in the treatment of sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been establi@@ sh@@ ed@@ .
O@@ wing to the greater sensi@@ tivity of this pop@@ ula@@ tion@@ , a lower starting dose should be considered when clinical factors warrant (@@ see section 4.@@ 4@@ )@@ .
Gen@@ der@@ : no d@@ os@@ age adju@@ st@@ ment is required for female patients as compared to male patients (@@ see section 5.@@ 2@@ )@@ .
Smo@@ king stat@@ us@@ : according to the met@@ aboli@@ c path@@ way of AB@@ IL@@ I@@ F@@ Y no d@@ os@@ age adju@@ st@@ ment is required for smo@@ kers (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ ors with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be re@@ duc@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ or is with@@ drawn from the combination therap@@ y@@ , ari@@ pi@@ pra@@ z@@ ole dose should then be increased (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be increas@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therap@@ y@@ , the ari@@ pi@@ pra@@ z@@ ole dose should then be reduced to the recommended dose (@@ see section 4.@@ 5@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
During anti@@ p@@ sycho@@ tic treat@@ ment@@ , improvement in the pati@@ ent@@ '@@ s clinical condition may take several days to some wee@@ ks@@ .
Pati@@ ents should be closely monit@@ ored throughout this peri@@ od@@ .
The occ@@ ur@@ r@@ ence of suici@@ dal behaviour is inher@@ ent in p@@ sycho@@ tic ill@@ nesses and mood disor@@ ders and in some cases has been reported early after initi@@ ation or switch of anti@@ p@@ sycho@@ tic therap@@ y@@ , including treatment with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
C@@ lose super@@ vision of high@@ -@@ risk patients should ac@@ company anti@@ p@@ sycho@@ tic therap@@ y@@ .
Res@@ ults of an epide@@ mi@@ ological study found that there was no increased risk of suici@@ d@@ ality with ari@@ pi@@ pra@@ z@@ ole compared to other anti@@ p@@ sycho@@ tics among patients with bi@@ pol@@ ar disor@@ der@@ .
Cardi@@ ov@@ as@@ cular disor@@ der@@ s@@ :
Ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with known cardi@@ ov@@ as@@ cular disease (@@ history of m@@ yo@@ cardi@@ al inf@@ ar@@ ction or i@@ scha@@ e@@ mic heart dise@@ as@@ e@@ , heart fail@@ ure@@ , or conduc@@ tion ab@@ nor@@ mali@@ ti@@ es@@ )@@ , cer@@ eb@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ ension (@@ de@@ hy@@ dra@@ tion@@ , hypo@@ vol@@ emi@@ a@@ , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations@@ ) or hyper@@ ten@@ sion@@ , including acceler@@ ated or mal@@ ign@@ ant@@ .
Con@@ duction ab@@ nor@@ mali@@ ti@@ es@@ :
In clinical trials of ari@@ pi@@ pra@@ z@@ ole@@ , the inci@@ dence of Q@@ T pro@@ long@@ ation was compar@@ able to pla@@ c@@ ebo@@ .
As with other anti@@ p@@ sycho@@ tic@@ s@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with a family history of Q@@ T pro@@ long@@ ation@@ .
T@@ ardi@@ ve Dy@@ sk@@ ine@@ si@@ a@@ : in clinical trials of one year or less dur@@ ation@@ , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ ine@@ sia during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
If signs and symptoms of tar@@ di@@ ve dy@@ sk@@ ine@@ sia appear in a patient on AB@@ IL@@ I@@ F@@ Y@@ , dose reduction or dis@@ continu@@ ation should be consider@@ ed@@ .
These symptoms can tempor@@ ally deterior@@ ate or can even ari@@ se after dis@@ continu@@ ation of treat@@ ment@@ .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ :
N@@ MS is a potentially fatal symp@@ tom complex associated with anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ .
In clinical tri@@ al@@ s@@ , rare cases of N@@ MS were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
3 mental status and evidence of auton@@ omic inst@@ ability (@@ ir@@ regular pul@@ se or blood pressu@@ re@@ , ta@@ ch@@ y@@ cardi@@ a@@ , di@@ aph@@ ore@@ sis and cardi@@ ac dys@@ rhyth@@ mi@@ a@@ )@@ .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ as@@ e@@ , m@@ yo@@ glob@@ in@@ uri@@ a (@@ r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ )@@ , and ac@@ ute ren@@ al fail@@ ure@@ .
Ho@@ we@@ ver@@ , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , not necessarily in association with N@@ M@@ S@@ , have also been repor@@ te@@ d.
If a patient develop@@ s signs and symptoms indic@@ ative of N@@ M@@ S@@ , or presents with un@@ explained high fe@@ ver without additional clinical manifest@@ ations of N@@ M@@ S@@ , all anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ , including AB@@ IL@@ I@@ F@@ Y@@ , must be dis@@ continu@@ ed@@ .
Sei@@ zu@@ re@@ : in clinical tri@@ al@@ s@@ , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Ther@@ e@@ fore@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients who have a history of sei@@ z@@ ure disorder or have conditions associated with sei@@ zu@@ res@@ .
El@@ derly patients with demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s@@ :
In@@ cre@@ ased mort@@ al@@ it@@ y@@ : in three pla@@ c@@ ebo@@ -@@ controlled trials (@@ n@@ = 9@@ 38@@ ; mean age@@ :
8@@ 2.@@ 4 ye@@ ar@@ s@@ ; ran@@ ge@@ :
56@@ -@@ 99 ye@@ ar@@ s@@ ) of ari@@ pi@@ pra@@ z@@ ole in elderly patients with p@@ sycho@@ sis associated with Al@@ z@@ hei@@ mer@@ '@@ s dise@@ as@@ e@@ , patients treated with ari@@ pi@@ pra@@ z@@ ole were at increased risk of death compared to pla@@ c@@ ebo@@ .
The rate of death in ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients was 3.@@ 5@@ % compared to 1.@@ 7@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
Although the causes of deaths were var@@ ie@@ d@@ , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular (@@ e@@ . g. heart fail@@ ure@@ , sudden de@@ ath@@ ) or inf@@ ec@@ tious (@@ e@@ . g. p@@ ne@@ um@@ oni@@ a@@ ) in nat@@ ure@@ .
Cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse event@@ s@@ : in the same tri@@ al@@ s@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events (@@ e@@ . g. stro@@ ke@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ )@@ , including fat@@ ali@@ ti@@ es@@ , were reported in patients (@@ mean age@@ :
84 ye@@ ar@@ s@@ ; ran@@ ge@@ :
78@@ -@@ 88 ye@@ ar@@ s@@ )@@ .
Over@@ all@@ , 1.@@ 3@@ % of ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients reported cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events compared with 0.@@ 6@@ % of pla@@ c@@ ebo@@ -@@ treated patients in these tri@@ al@@ s.
This difference was not stati@@ st@@ ically signific@@ ant@@ .
Ho@@ we@@ ver@@ , in one of these tri@@ al@@ s@@ , a fix@@ ed@@ -@@ dose tri@@ al@@ , there was a significant dose response relationship for cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events in patients treated with ari@@ pi@@ pra@@ z@@ ole@@ .
AB@@ IL@@ I@@ F@@ Y is not approved for the treatment of demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s.
Hy@@ per@@ g@@ ly@@ ca@@ emi@@ a and Diabetes Mel@@ li@@ t@@ us@@ : hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , in some cases extreme and associated with ket@@ o@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or de@@ ath@@ , has been reported in patients treated with at@@ yp@@ ical anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ris@@ k factors that may pre@@ disp@@ ose patients to severe complic@@ ations include obesity and family history of di@@ abet@@ es@@ .
In clinical trials with ari@@ pi@@ pra@@ z@@ ole@@ , there were no significant differences in the inci@@ dence rates of hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events (@@ including di@@ abet@@ es@@ ) or in ab@@ normal g@@ ly@@ ca@@ emi@@ a lab@@ oratory values compared to pla@@ c@@ ebo@@ .
Pre@@ cise risk estimates for hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events in patients treated with AB@@ IL@@ I@@ F@@ Y and with other at@@ yp@@ ical anti@@ p@@ sycho@@ tic agents are not available to allow direct compar@@ is@@ ons@@ .
Pati@@ ents treated with any anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ , should be observed for signs and symptoms of hyper@@ g@@ ly@@ ca@@ emi@@ a (@@ such as poly@@ di@@ p@@ si@@ a@@ , poly@@ uri@@ a@@ , poly@@ ph@@ ag@@ ia and weak@@ ness@@ ) and patients with diabetes mel@@ li@@ tus or with risk factors for diabetes mel@@ li@@ tus should be monit@@ ored regularly for wor@@ sen@@ ing of glu@@ c@@ ose contro@@ l.
Wei@@ ght ga@@ in@@ : weight gain is commonly seen in sch@@ iz@@ op@@ hren@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ti@@ es@@ , use of anti@@ p@@ sycho@@ tics known to cause weight ga@@ in@@ , poor@@ ly managed li@@ fe@@ -@@ sty@@ le@@ , and might lead to severe complic@@ ations@@ .
Wei@@ ght gain has been reported post@@ -@@ marketing among patients prescri@@ bed AB@@ IL@@ I@@ F@@ Y@@ .
When se@@ en@@ , it is usually in those with significant risk factors such as history of di@@ abet@@ es@@ , th@@ y@@ ro@@ id disorder or pit@@ u@@ it@@ ary aden@@ om@@ a.
In clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight gain (@@ see section 5.@@ 1@@ )@@ .
Dy@@ sph@@ ag@@ i@@ a@@ : o@@ es@@ op@@ ha@@ ge@@ al dy@@ smo@@ tili@@ ty and aspi@@ ration have been associated with anti@@ p@@ sycho@@ tic drug use@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ari@@ pi@@ pra@@ z@@ ole and other anti@@ p@@ sycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for aspi@@ ration p@@ ne@@ um@@ oni@@ a.
L@@ act@@ os@@ e@@ : patients with rare her@@ edi@@ tary problems of gal@@ act@@ ose int@@ oler@@ anc@@ e@@ , the l@@ app la@@ ct@@ ase def@@ ici@@ ency or glu@@ cos@@ e@@ -@@ gal@@ act@@ ose mal@@ absor@@ ption should not take this medic@@ inal produc@@ t.
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ : as with other medic@@ ations hyper@@ sensi@@ tivity re@@ ac@@ tions@@ , character@@ ised by aller@@ gic symp@@ tom@@ s@@ , may occur with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
4 4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
D@@ ue to its α 1@@ -@@ ad@@ ren@@ er@@ gic rec@@ ep@@ tor ant@@ agon@@ is@@ m@@ , ari@@ pi@@ pra@@ z@@ ole has the potential to enh@@ ance the effect of certain anti@@ hyper@@ ten@@ sive ag@@ ent@@ s.
Given the primary CN@@ S effects of ari@@ pi@@ pra@@ z@@ ole@@ , caution should be used when ari@@ pi@@ pra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping un@@ desi@@ rable effects such as se@@ dation (@@ see section 4.@@ 8@@ )@@ .
If ari@@ pi@@ pra@@ z@@ ole is administ@@ ered con@@ co@@ mit@@ antly with medic@@ ines known to cause Q@@ T pro@@ long@@ ation or elec@@ tro@@ ly@@ te im@@ bal@@ anc@@ e@@ , caution should be use@@ d.
Pot@@ ential for other medic@@ inal products to affect AB@@ IL@@ I@@ F@@ Y@@ :
A ga@@ stri@@ c acid blo@@ cker@@ , the H@@ 2 ant@@ agon@@ ist f@@ amo@@ ti@@ d@@ ine@@ , redu@@ ces ari@@ pi@@ pra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relev@@ ant@@ .
Ari@@ pi@@ pra@@ z@@ ole is met@@ aboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ ym@@ es but not C@@ Y@@ P@@ 1@@ A enz@@ ym@@ es@@ .
Th@@ us@@ , no d@@ os@@ age adju@@ st@@ ment is required for smo@@ ker@@ s.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ qu@@ ini@@ d@@ ine@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C by 10@@ 7@@ %@@ , while C@@ max was un@@ ch@@ ange@@ d.
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , decre@@ ased by 32@@ % and 47@@ %@@ .
AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed dose when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y with qu@@ ini@@ dine occ@@ urs@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 2@@ D@@ 6@@ , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 3@@ A4 (@@ ket@@ o@@ con@@ az@@ ole@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C and C@@ max by 6@@ 3@@ % and 37@@ %@@ , respec@@ ti@@ vel@@ y@@ .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole increased by 77@@ % and 43@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor met@@ aboli@@ ser@@ s@@ , con@@ co@@ mit@@ ant use of pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 may result in higher p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive met@@ aboli@@ zer@@ s.
When considering con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors with AB@@ IL@@ I@@ F@@ Y@@ , potential benefits should out@@ weigh the potential risks to the pati@@ ent@@ .
When con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ o@@ z@@ ole with AB@@ IL@@ I@@ F@@ Y occ@@ urs@@ , AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed d@@ os@@ e@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A@@ 4@@ , such as it@@ ra@@ con@@ az@@ ole and HIV prot@@ ease in@@ hi@@ bit@@ or@@ s@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hi@@ bit@@ or@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be increased to the level prior to the initi@@ ation of the con@@ co@@ mit@@ ant therap@@ y@@ .
When weak in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 (@@ e@@ . g@@ .@@ , dil@@ ti@@ az@@ em or esc@@ ital@@ op@@ ra@@ m@@ ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ co@@ mit@@ antly with AB@@ IL@@ I@@ F@@ Y@@ , modest increases in ari@@ pi@@ pra@@ z@@ ole conc@@ ent@@ rations might be expec@@ te@@ d.
Following con@@ co@@ mit@@ ant administration of car@@ b@@ amaz@@ ep@@ ine@@ , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A@@ 4@@ , the ge@@ omet@@ ric means of C@@ max and AU@@ C for ari@@ pi@@ pra@@ z@@ ole were 68@@ % and 7@@ 3@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , compared to when ari@@ pi@@ pra@@ z@@ ole (@@ 30 m@@ g@@ ) was administ@@ ered al@@ one@@ .
Simi@@ lar@@ ly@@ , for de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole the ge@@ omet@@ ric means of C@@ max and AU@@ C after car@@ b@@ amaz@@ ep@@ ine co@@ -@@ administration were 69@@ % and 7@@ 1@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , than those following treatment with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
AB@@ IL@@ I@@ F@@ Y dose should be doubled when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y occ@@ urs with car@@ b@@ amaz@@ ep@@ ine@@ .
John@@ '@@ s Wort@@ ) may be expected to have similar effects and similar dose increases should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be reduced to the recommended d@@ os@@ e@@ .
5 When either val@@ pro@@ ate or li@@ thi@@ um were administ@@ ered con@@ co@@ mit@@ antly with ari@@ pi@@ pra@@ z@@ ole@@ , there was no clin@@ ically significant change in ari@@ pi@@ pra@@ z@@ ole conc@@ entra@@ tions@@ .
Pot@@ ential for AB@@ IL@@ I@@ F@@ Y to affect other medic@@ inal produc@@ ts@@ :
In clinical stu@@ dies@@ , 10@@ -@@ 30 m@@ g@@ / day d@@ oses of ari@@ pi@@ pra@@ z@@ ole had no significant effect on the met@@ aboli@@ sm of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ / 3@@ -@@ metho@@ x@@ y@@ mor@@ ph@@ in@@ an rati@@ o@@ )@@ , 2@@ C@@ 9 (@@ war@@ far@@ in@@ )@@ , 2@@ C@@ 19 (@@ om@@ ep@@ raz@@ ole@@ )@@ , and 3@@ A4 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ )@@ .
Addi@@ tion@@ all@@ y@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole did not show potential for al@@ tering C@@ Y@@ P@@ 1@@ A@@ 2@@ -@@ medi@@ ated met@@ aboli@@ sm in vit@@ ro@@ .
Th@@ us@@ , ari@@ pi@@ pra@@ z@@ ole is unlikely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ ym@@ es@@ .
When ari@@ pi@@ pra@@ z@@ ole was administ@@ ered con@@ co@@ mit@@ antly with either val@@ pro@@ ate or li@@ thi@@ um@@ , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ thi@@ um conc@@ entra@@ tions@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled trials of ari@@ pi@@ pra@@ z@@ ole in pregnant wom@@ en@@ .
Ani@@ mal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
D@@ ue to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive stu@@ dies@@ , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ et@@ us@@ .
Ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during la@@ ct@@ ation@@ .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pi@@ pra@@ z@@ ole@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been per@@ for@@ med@@ .
Ho@@ we@@ ver@@ , as with other anti@@ p@@ sycho@@ tic@@ s@@ , patients should be cau@@ tioned about operating ha@@ z@@ ard@@ ous mach@@ in@@ es@@ , including motor v@@ ehic@@ les@@ , until they are reas@@ onably certain that ari@@ pi@@ pra@@ z@@ ole does not affect them adver@@ sel@@ y@@ .
4.@@ 8 Un@@ desi@@ rable effects
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ )@@ :
The frequ@@ ency listed below is defined using the following conven@@ tion@@ : common (@@ > 1@@ / 100 ,@@ < 1@@ /@@ 10@@ ) and un@@ common (@@ > 1@@ /@@ 1 ,@@ 00@@ 0@@ , < 1@@ /@@ 100@@ )@@ .
Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous System disor@@ ders Common@@ : ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disor@@ der@@ , ak@@ ath@@ isi@@ a@@ , tre@@ mor@@ , di@@ zz@@ in@@ ess@@ , som@@ n@@ ol@@ en@@ ce@@ , se@@ d@@ ation@@ , hea@@ da@@ che E@@ ye disor@@ ders Common@@ : bl@@ urred vision Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : dy@@ sp@@ ep@@ si@@ a@@ , vo@@ mit@@ ing@@ , nau@@ se@@ a@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ * General disor@@ ders and administration site conditions Common@@ : f@@ ati@@ gue P@@ sychiatri@@ c disor@@ ders Common@@ : rest@@ less@@ ness@@ , ins@@ om@@ ni@@ a@@ , anxiety Un@@ common@@ : depres@@ sion@@ *
6 Ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symptoms (@@ EP@@ S@@ )@@ :
Sch@@ iz@@ op@@ hren@@ ia - in a long term 5@@ 2@@ -@@ week controlled tri@@ al@@ , ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients had an over@@ all@@ -@@ lower inci@@ dence (@@ 25.@@ 8@@ %@@ ) of E@@ PS including par@@ kin@@ son@@ is@@ m@@ , ak@@ ath@@ isi@@ a@@ , dy@@ st@@ onia and dy@@ sk@@ ine@@ sia compared with those treated with hal@@ operi@@ dol (@@ 5@@ 7.@@ 3@@ %@@ )@@ .
In a long term 26@@ -@@ week pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 19@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 13.@@ 1@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In another long@@ -@@ term 26@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 14.@@ 8@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 1@@ % for ol@@ anz@@ ap@@ ine@@ -@@ treated pati@@ ent@@ s.
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 23.@@ 5@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 5@@ 3.@@ 3@@ % for hal@@ operi@@ dol@@ -@@ treated pati@@ ent@@ s.
In another 12@@ -@@ week tri@@ al@@ , the inci@@ dence of E@@ PS was 26.@@ 6@@ % for patients treated with ari@@ pi@@ pra@@ z@@ ole and 17.@@ 6@@ % for those treated with li@@ thi@@ um@@ .
In the long term 26@@ -@@ week maintenance phase of a pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 18.@@ 2@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 7@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ s@@ , the inci@@ dence of ak@@ ath@@ i@@ sia in bi@@ pol@@ ar patients was 12.@@ 1@@ % with ari@@ pi@@ pra@@ z@@ ole and 3.@@ 2@@ % with pla@@ c@@ ebo@@ .
In sch@@ iz@@ op@@ hren@@ ia patients the inci@@ dence of ak@@ ath@@ i@@ sia was 6.@@ 2@@ % with ari@@ pi@@ pra@@ z@@ ole and 3@@ .0@@ % with pla@@ c@@ ebo@@ .
Com@@ par@@ is@@ ons between ari@@ pi@@ pra@@ z@@ ole and pla@@ c@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine lab@@ oratory par@@ ame@@ ters revealed no medi@@ cally important differ@@ en@@ c@@ es@@ .
Ele@@ v@@ ations of C@@ P@@ K (@@ Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ )@@ , generally tran@@ si@@ ent and as@@ ymp@@ tom@@ ati@@ c@@ , were observed in 3.@@ 5@@ % of ari@@ pi@@ pra@@ z@@ ole treated patients as compared to 2@@ .0@@ % of patients who received pla@@ c@@ ebo@@ .
Other fin@@ d@@ ings@@ :
Un@@ desi@@ rable effects known to be associated with anti@@ p@@ sycho@@ tic therapy and also reported during treatment with ari@@ pi@@ pra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ dro@@ me@@ , tar@@ di@@ ve dy@@ sk@@ ine@@ si@@ a@@ , sei@@ zu@@ re@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly de@@ mented pati@@ ent@@ s@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ tus (@@ see section 4.@@ 4@@ )@@ .
Post@@ -@@ Market@@ ing@@ :
The following ad@@ verse events have been reported during post@@ -@@ marketing sur@@ veil@@ lan@@ ce@@ .
The frequ@@ ency of these events is considered not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Investig@@ ations@@ :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ , blood glu@@ c@@ ose increas@@ ed@@ , blood glu@@ c@@ ose flu@@ ctu@@ ation@@ , g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in increased
Cardi@@ ac disor@@ der@@ s@@ :
Q@@ T pro@@ long@@ ation@@ , vent@@ ri@@ cular arr@@ hyth@@ mi@@ as@@ , sudden un@@ explained de@@ ath@@ , cardi@@ ac ar@@ rest@@ , tor@@ sa@@ des de poin@@ tes@@ , bra@@ dy@@ car@@ dia
Bloo@@ d and the lymp@@ h@@ atic system disor@@ der@@ s@@ :
leu@@ kop@@ eni@@ a@@ , neut@@ rop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia
Ner@@ v@@ ous system disor@@ der@@ s@@ :
speech disor@@ der@@ , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ , grand mal con@@ vul@@ sion
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ s@@ :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m@@ , lar@@ yn@@ g@@ os@@ pas@@ m@@ , aspi@@ ration p@@ ne@@ um@@ onia
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
pan@@ cre@@ ati@@ tis@@ , dy@@ sph@@ ag@@ i@@ a@@ , ab@@ dom@@ inal dis@@ comfort@@ , stomach dis@@ comfort@@ , di@@ arr@@ ho@@ ea
Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
ur@@ inary in@@ contin@@ en@@ ce@@ , ur@@ inary re@@ tention
Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
ra@@ sh@@ , ph@@ otos@@ en@@ si@@ tivity re@@ ac@@ tion@@ , al@@ op@@ eci@@ a@@ , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , my@@ al@@ gi@@ a@@ , sti@@ ff@@ ness
En@@ do@@ cr@@ ine disor@@ der@@ s@@ :
hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , diabetes mel@@ li@@ t@@ us@@ , di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s@@ , di@@ abe@@ tic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
weight ga@@ in@@ , weight decre@@ as@@ ed@@ , an@@ or@@ ex@@ i@@ a@@ , h@@ yp@@ on@@ at@@ re@@ mia
V@@ as@@ cular disor@@ der@@ s@@ :
syn@@ cop@@ e@@ , hyper@@ ten@@ sion@@ , thro@@ mbo@@ em@@ bo@@ lic events
General disor@@ ders and administration site condi@@ tions@@ :
temperature regulation disorder (@@ e@@ . g. hypo@@ ther@@ mi@@ a@@ , py@@ re@@ xi@@ a@@ )@@ , chest pain@@ , peri@@ pher@@ al oe@@ de@@ ma
Immun@@ e system disor@@ der@@ s@@ :
aller@@ gic reaction (@@ e@@ . g. an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ , an@@ gi@@ oe@@ de@@ ma including s@@ wollen ton@@ gu@@ e@@ , ton@@ gue oe@@ de@@ ma@@ , face oe@@ de@@ ma@@ , p@@ ru@@ rit@@ us@@ , or ur@@ tic@@ ari@@ a@@ )
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ der@@ s@@ :
ja@@ un@@ di@@ ce@@ , he@@ pati@@ tis@@ , increased A@@ lan@@ ine A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ AL@@ T@@ )@@ , increased A@@ spar@@ tate A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ A@@ ST@@ )@@ , increased G@@ amm@@ a Gl@@ ut@@ am@@ yl Transfer@@ ase (@@ G@@ GT@@ )@@ , increased al@@ kal@@ ine ph@@ osp@@ hat@@ ase
Re@@ productive system and breast disor@@ der@@ s@@ :
pri@@ ap@@ ism
P@@ sychiatri@@ c disor@@ der@@ s@@ :
ag@@ it@@ ation@@ , nerv@@ ous@@ ness@@ ; suicide attemp@@ t@@ , suici@@ dal ide@@ ation@@ , and completed suicide (@@ see section 4.@@ 4@@ )
4.@@ 9 Over@@ dose
In clinical trials and post@@ -@@ marketing experi@@ en@@ ce@@ , acci@@ dental or inten@@ tional ac@@ ute over@@ d@@ os@@ age of ari@@ pi@@ pra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy@@ , increased blood pressu@@ re@@ , som@@ n@@ ol@@ en@@ ce@@ , ta@@ ch@@ y@@ cardi@@ a@@ , nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ e@@ a.
In addi@@ tion@@ , reports of acci@@ dental over@@ dose with ari@@ pi@@ pra@@ z@@ ole alone (@@ up to 19@@ 5 m@@ g@@ ) in children have been received with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ en@@ ce@@ , tran@@ si@@ ent loss of consci@@ ousness and ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symp@@ tom@@ s.
Management of over@@ dose should concentrate on supportive therap@@ y@@ , maintaining an adequate air@@ wa@@ y@@ , oxy@@ gen@@ ation and v@@ enti@@ la@@ tion@@ , and management of symp@@ tom@@ s.
The possibility of multiple medic@@ inal product involvement should be consider@@ ed@@ .
Ther@@ efore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continu@@ ous elec@@ tro@@ cardi@@ o@@ graphic monitoring to dete@@ ct possible arr@@ hyth@@ mi@@ as@@ .
Following any confirmed or suspected over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , close medical super@@ vision and monitoring should continue until the patient reco@@ vers@@ .
Ac@@ tiv@@ ated char@@ coal (@@ 50 g@@ )@@ , administ@@ ered one hour after ari@@ pi@@ pra@@ z@@ ole@@ , decre@@ ased ari@@ pi@@ pra@@ z@@ ole C@@ max by about 4@@ 1@@ % and AU@@ C by about 5@@ 1@@ %@@ , suggesting that char@@ coal may be effective in the treatment of over@@ d@@ os@@ e@@ .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in treating an over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , ha@@ emo@@ di@@ aly@@ sis is unlikely to be useful in over@@ dose management since ari@@ pi@@ pra@@ z@@ ole is highly bound to p@@ las@@ ma prot@@ ein@@ s.
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ p@@ sycho@@ tic@@ s@@ , AT@@ C co@@ de@@ :
N@@ 05@@ A@@ X@@ 12
8 It has been proposed that ari@@ pi@@ pra@@ z@@ ole@@ ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ amine D@@ 2 and ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a rec@@ ep@@ tors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hypo@@ activ@@ it@@ y@@ .
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited high bin@@ ding aff@@ in@@ ity in vit@@ ro for d@@ op@@ amine D@@ 2 and D@@ 3@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a and 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tors and moderate aff@@ in@@ ity for d@@ op@@ amine D@@ 4@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ c and 5@@ H@@ T@@ 7@@ , alp@@ ha@@ -@@ 1 ad@@ ren@@ er@@ gic and hist@@ amine H@@ 1 rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole also exhi@@ bited moderate bin@@ ding aff@@ in@@ ity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ in@@ ity for mus@@ car@@ ini@@ c rec@@ ep@@ tor@@ s.
Inter@@ action with rec@@ ep@@ tors other than d@@ op@@ amine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pi@@ pra@@ z@@ ole@@ .
Ari@@ pi@@ pra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a d@@ os@@ e@@ -@@ dependent reduction in the bin@@ ding of 11@@ C@@ -@@ ra@@ clo@@ pri@@ de@@ , a D@@ 2@@ / D@@ 3 rec@@ ep@@ tor lig@@ and@@ , to the cau@@ date and put@@ amen dete@@ cted by posi@@ tr@@ on e@@ mission tom@@ o@@ grap@@ hy@@ .
Further information on clinical tri@@ al@@ s@@ :
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
In three short@@ -@@ term (@@ 4 to 6 wee@@ ks@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 1,@@ 228 sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s@@ , presenting with positive or negative symp@@ tom@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was associated with stati@@ st@@ ically significantly greater improvements in p@@ sycho@@ tic symptoms compared to pla@@ c@@ ebo@@ .
AB@@ IL@@ I@@ F@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment respon@@ se@@ .
In a hal@@ operi@@ dol@@ -@@ controlled tri@@ al@@ , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2@@ -@@ weeks was similar in both groups (@@ ari@@ pi@@ pra@@ z@@ ole 77@@ % and hal@@ operi@@ dol 7@@ 3@@ %@@ )@@ .
The overall comple@@ tion rate was significantly higher for patients on ari@@ pi@@ pra@@ z@@ ole (@@ 43@@ %@@ ) than for hal@@ operi@@ dol (@@ 30@@ %@@ )@@ .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ poin@@ ts@@ , including P@@ AN@@ SS and the Montgom@@ er@@ y@@ -@@ As@@ berg Depression R@@ ating Sc@@ ale showed a significant improvement over hal@@ operi@@ dol@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hren@@ i@@ a@@ , ari@@ pi@@ pra@@ z@@ ole had significantly greater reduction in re@@ lap@@ se rat@@ e@@ , 34@@ % in ari@@ pi@@ pra@@ z@@ ole group and 57@@ % in pla@@ c@@ ebo@@ .
Wei@@ ght ga@@ in@@ : in clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight ga@@ in@@ .
In a 26@@ -@@ week@@ , ol@@ anz@@ ap@@ ine@@ -@@ contro@@ lle@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , multi@@ -@@ national study of sch@@ iz@@ op@@ hren@@ ia which included 3@@ 14 patients and where the primary end@@ -@@ point was weight ga@@ in@@ , significantly less patients had at least 7@@ % weight gain over bas@@ eline (@@ i@@ . e@@ . a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~@@ 8@@ 0.5 k@@ g@@ ) on ari@@ pi@@ pra@@ z@@ ole (@@ N@@ = 18@@ , or 13@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ , compared to ol@@ anz@@ ap@@ ine (@@ N@@ = 45@@ , or 33@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ .
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
In two 3@@ -@@ week@@ , flexi@@ ble@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o in reduction of man@@ ic symptoms over 3 wee@@ ks@@ .
These trials included patients with or without p@@ sycho@@ tic features and with or without a rap@@ id@@ -@@ cycling cour@@ se@@ .
In one 3@@ -@@ week@@ , fix@@ ed@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to pla@@ c@@ ebo@@ .
In two 12@@ -@@ week@@ , pla@@ c@@ ebo@@ - and ac@@ ti@@ ve@@ -@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o at week 3 and a maintenance of effect compar@@ able to li@@ thi@@ um or hal@@ operi@@ dol at week 12.
Ari@@ pi@@ pra@@ z@@ ole also demonstrated a compar@@ able proportion of patients in symp@@ tom@@ atic re@@ mission from man@@ ia as li@@ thi@@ um or hal@@ operi@@ dol at week 12.
In a 6@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , who were parti@@ ally non@@ -@@ respon@@ sive to li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeu@@ tic ser@@ um level@@ s@@ , the addition of ari@@ pi@@ pra@@ z@@ ole as ad@@ jun@@ ctive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therap@@ y@@ .
9 In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , followed by a 7@@ 4@@ -@@ week exten@@ sion@@ , in man@@ ic patients who achieved re@@ mission on ari@@ pi@@ pra@@ z@@ ole during a stabili@@ zation phase prior to rand@@ omi@@ z@@ ation@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ ren@@ ce@@ , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depres@@ sion@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ab@@ sor@@ p@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is well absor@@ bed@@ , with peak p@@ las@@ ma conc@@ ent@@ rations occ@@ urring within 3@@ -@@ 5 hours after d@@ os@@ ing@@ .
Ari@@ pi@@ pra@@ z@@ ole under@@ goes minimal pre@@ -@@ sy@@ ste@@ mic met@@ aboli@@ sm@@ .
The absolute oral bio@@ availability of the tab@@ let formu@@ lation is 8@@ 7@@ %@@ .
There is no effect of a high fat meal on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Distri@@ bu@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is widely distri@@ buted throughout the body with an apparent volume of distribution of 4.@@ 9 l@@ / k@@ g@@ , indic@@ ating extensive extra@@ v@@ as@@ cular distri@@ bu@@ tion@@ .
At therapeu@@ tic conc@@ entra@@ tions@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole are greater than 99@@ % bound to ser@@ um prot@@ ein@@ s@@ , bin@@ ding primarily to alb@@ umin@@ .
Met@@ aboli@@ sm@@ :
Ari@@ pi@@ pra@@ z@@ ole is exten@@ sively met@@ aboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ wa@@ ys@@ : de@@ hydro@@ gen@@ ation@@ , hydro@@ x@@ y@@ la@@ tion@@ , and N@@ -@@ deal@@ k@@ y@@ la@@ tion@@ .
Based on in vit@@ ro stu@@ dies@@ , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ ym@@ es are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ y@@ lation of ari@@ pi@@ pra@@ z@@ ole@@ , and N@@ -@@ deal@@ k@@ y@@ lation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A@@ 4.
Ari@@ pi@@ pra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ iety in sy@@ ste@@ mic circu@@ la@@ tion@@ .
At steady stat@@ e@@ , de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , represents about 40@@ % of ari@@ pi@@ pra@@ z@@ ole AU@@ C in p@@ las@@ ma@@ .
Eli@@ min@@ ation@@ :
The mean elim@@ ination half@@ -@@ lives for ari@@ pi@@ pra@@ z@@ ole are approximately 75 hours in extensive met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6.
The total body clear@@ ance of ari@@ pi@@ pra@@ z@@ ole is 0.@@ 7 m@@ l@@ / min@@ / k@@ g@@ , which is primarily he@@ pati@@ c.
Following a single oral dose of [@@ 14@@ C@@ ]@@ -@@ lab@@ elled ari@@ pi@@ pra@@ z@@ ole@@ , approximately 27@@ % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60@@ % in the fa@@ ec@@ es@@ .
L@@ ess than 1@@ % of un@@ changed ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18@@ % was recovered un@@ changed in the fa@@ ec@@ es@@ .
P@@ harm@@ ac@@ ok@@ ine@@ tics in special patient groups
El@@ der@@ ly@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy elderly and younger adult sub@@ jec@@ ts@@ , nor is there any dete@@ ct@@ able effect of age in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Gen@@ der@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy male and female subjects nor is there any dete@@ ct@@ able effect of gender in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Smo@@ king and Rac@@ e@@ :
Pop@@ ulation pharmac@@ ok@@ ine@@ tic ev@@ al@@ uation has revealed no evidence of clin@@ ically significant ra@@ ce@@ -@@ related differences or effects from smoking upon the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Ren@@ al Di@@ seas@@ e@@ :
The pharmac@@ ok@@ ine@@ tic characterist@@ ics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy sub@@ jec@@ ts@@ .
10 H@@ ep@@ atic Di@@ seas@@ e@@ :
A sing@@ le@@ -@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis (@@ Chil@@ d@@ -@@ Pu@@ gh Clas@@ ses A@@ , B@@ , and C@@ ) did not reveal a significant effect of he@@ pati@@ c im@@ pa@@ ir@@ ment on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ si@@ s@@ , which is in@@ sufficient to draw conclu@@ sions on their met@@ aboli@@ c cap@@ ac@@ it@@ y@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
Non@@ -@@ clinical safety data revealed no special ha@@ zard for humans based on conventional studies of safety pharmac@@ olog@@ y@@ , repe@@ at@@ -@@ dose tox@@ ic@@ it@@ y@@ , gen@@ oto@@ x@@ ic@@ it@@ y@@ , car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ , and tox@@ ic@@ ity to re@@ produc@@ tion@@ .
To@@ x@@ ic@@ ologi@@ cally significant effects were observed only at d@@ oses or exp@@ os@@ ures that were suff@@ ici@@ ently in excess of the maximum human dose or exp@@ os@@ ure@@ , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use@@ .
These inclu@@ de@@ d@@ : d@@ os@@ e@@ -@@ dependent ad@@ reno@@ cor@@ tical tox@@ ic@@ ity (@@ li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and@@ / or par@@ en@@ ch@@ y@@ mal cell los@@ s@@ ) in rats after 104 weeks at 20 to 60 m@@ g@@ / k@@ g@@ / day (@@ 3 to 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ ) and increased ad@@ reno@@ cor@@ tical car@@ cin@@ om@@ as and combined ad@@ reno@@ cor@@ tical aden@@ om@@ as@@ / car@@ cin@@ om@@ as in female rats at 60 m@@ g@@ / k@@ g@@ / day (@@ 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ )@@ .
The highest non@@ tum@@ ori@@ gen@@ ic exposure in female rats was 7 times the human exposure at the recommended d@@ os@@ e@@ .
An additional finding was chol@@ eli@@ thi@@ asi@@ s as a consequ@@ ence of pre@@ cip@@ itation of sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy met@@ aboli@@ tes of ari@@ pi@@ pra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 m@@ g@@ / k@@ g@@ / day (@@ 1 to 3 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on m@@ g@@ / m@@ 2@@ )@@ .
Ho@@ we@@ ver@@ , the conc@@ ent@@ rations of the sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy ari@@ pi@@ pra@@ z@@ ole in human b@@ ile at the highest dose propos@@ ed@@ , 30 mg per day@@ , were no more than 6@@ % of the b@@ ile conc@@ ent@@ rations found in the mon@@ keys in the 39@@ -@@ week study and are well below (@@ 6@@ %@@ ) their limits of in vit@@ ro sol@@ u@@ bili@@ ty@@ .
Based on results of a full range of standard gen@@ oto@@ x@@ ic@@ ity test@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was considered non@@ -@@ gen@@ oto@@ x@@ ic@@ .
Ari@@ pi@@ pra@@ z@@ ole did not im@@ pair fertili@@ ty in re@@ productive tox@@ ic@@ ity stu@@ dies@@ .
Develop@@ mental tox@@ ic@@ it@@ y@@ , including d@@ os@@ e@@ -@@ dependent delayed fo@@ et@@ al ossi@@ fication and possible ter@@ at@@ o@@ gen@@ ic effec@@ ts@@ , were observed in rats at d@@ oses resulting in sub@@ therapeu@@ tic exp@@ os@@ ures (@@ based on AU@@ C@@ ) and in ra@@ bb@@ its at d@@ oses resulting in exp@@ os@@ ures 3 and 11 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical d@@ os@@ e@@ .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ it@@ y@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
L@@ act@@ ose mon@@ oh@@ y@@ dr@@ ate Mai@@ ze star@@ ch Mic@@ ro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ ose Hy@@ dro@@ x@@ y@@ prop@@ yl cell@@ ul@@ ose Mag@@ ne@@ si@@ um ste@@ ar@@ ate
Indi@@ go car@@ mine al@@ uminium lake (@@ E@@ 13@@ 2@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
Not applic@@ ab@@ le@@ .
6.@@ 3 Shel@@ f life
3 years
11 6.@@ 4 Special prec@@ au@@ tions for storage
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
6.5 Nature and cont@@ ents of container
Al@@ uminium per@@ for@@ ated unit dose bli@@ sters in car@@ tons of 14 x 1@@ , 28 x 1@@ , 49 x 1@@ , 56 x 1@@ , 98 x 1 tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 1@@ -@@ 00@@ 5
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
D@@ ate of first author@@ is@@ ation@@ :
4 June 2004
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
{@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
12 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 10 mg tab@@ lets
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each tab@@ let contains 10 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
Ex@@ cip@@ i@@ ent@@ :
6@@ 2.@@ 18 mg la@@ ct@@ ose per tab@@ let
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Tablet Rec@@ tan@@ gu@@ lar and p@@ ink@@ , en@@ gra@@ ved with "@@ A@@ -@@ 00@@ 8@@ " and "@@ 10@@ " on one si@@ de.
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hren@@ i@@ a.
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the pre@@ vention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pi@@ pra@@ z@@ ole treatment (@@ see section 5.@@ 1@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
O@@ ral use@@ .
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 10 or 15 m@@ g@@ / day with a maintenance dose of 15 m@@ g@@ / day administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to me@@ al@@ s.
AB@@ IL@@ I@@ F@@ Y is effective in a dose range of 10 to 30 m@@ g@@ / day@@ .
En@@ h@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
M@@ anic epis@@ o@@ des@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 15 mg administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy (@@ see section 5.@@ 1@@ )@@ .
Some patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
Rec@@ ur@@ r@@ ence pre@@ vention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pi@@ pra@@ z@@ ole@@ , continue therapy at the same d@@ os@@ e@@ .
Ad@@ ju@@ st@@ ments of daily d@@ os@@ age@@ , including dose reduction should be considered on the basis of clinical stat@@ us@@ .
Children and adol@@ es@@ cent@@ s@@ : there is no experience in children and adol@@ es@@ cents under 18 years of age@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required for patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
In patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ , the data available are in@@ sufficient to establish recommend@@ ations@@ .
Ho@@ we@@ ver@@ , the
13 maximum daily dose of 30 mg should be used with caution in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required in patients with ren@@ al im@@ pa@@ ir@@ ment@@ .
El@@ der@@ ly@@ : the effec@@ tiveness of AB@@ IL@@ I@@ F@@ Y in the treatment of sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been establi@@ sh@@ ed@@ .
O@@ wing to the greater sensi@@ tivity of this pop@@ ula@@ tion@@ , a lower starting dose should be considered when clinical factors warrant (@@ see section 4.@@ 4@@ )@@ .
Gen@@ der@@ : no d@@ os@@ age adju@@ st@@ ment is required for female patients as compared to male patients (@@ see section 5.@@ 2@@ )@@ .
Smo@@ king stat@@ us@@ : according to the met@@ aboli@@ c path@@ way of AB@@ IL@@ I@@ F@@ Y no d@@ os@@ age adju@@ st@@ ment is required for smo@@ kers (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ ors with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be re@@ duc@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ or is with@@ drawn from the combination therap@@ y@@ , ari@@ pi@@ pra@@ z@@ ole dose should then be increased (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be increas@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therap@@ y@@ , the ari@@ pi@@ pra@@ z@@ ole dose should then be reduced to the recommended dose (@@ see section 4.@@ 5@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
During anti@@ p@@ sycho@@ tic treat@@ ment@@ , improvement in the pati@@ ent@@ '@@ s clinical condition may take several days to some wee@@ ks@@ .
Pati@@ ents should be closely monit@@ ored throughout this peri@@ od@@ .
The occ@@ ur@@ r@@ ence of suici@@ dal behaviour is inher@@ ent in p@@ sycho@@ tic ill@@ nesses and mood disor@@ ders and in some cases has been reported early after initi@@ ation or switch of anti@@ p@@ sycho@@ tic therap@@ y@@ , including treatment with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
C@@ lose super@@ vision of high@@ -@@ risk patients should ac@@ company anti@@ p@@ sycho@@ tic therap@@ y@@ .
Res@@ ults of an epide@@ mi@@ ological study found that there was no increased risk of suici@@ d@@ ality with ari@@ pi@@ pra@@ z@@ ole compared to other anti@@ p@@ sycho@@ tics among patients with bi@@ pol@@ ar disor@@ der@@ .
Cardi@@ ov@@ as@@ cular disor@@ der@@ s@@ :
Ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with known cardi@@ ov@@ as@@ cular disease (@@ history of m@@ yo@@ cardi@@ al inf@@ ar@@ ction or i@@ scha@@ e@@ mic heart dise@@ as@@ e@@ , heart fail@@ ure@@ , or conduc@@ tion ab@@ nor@@ mali@@ ti@@ es@@ )@@ , cer@@ eb@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ ension (@@ de@@ hy@@ dra@@ tion@@ , hypo@@ vol@@ emi@@ a@@ , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations@@ ) or hyper@@ ten@@ sion@@ , including acceler@@ ated or mal@@ ign@@ ant@@ .
Con@@ duction ab@@ nor@@ mali@@ ti@@ es@@ :
In clinical trials of ari@@ pi@@ pra@@ z@@ ole@@ , the inci@@ dence of Q@@ T pro@@ long@@ ation was compar@@ able to pla@@ c@@ ebo@@ .
As with other anti@@ p@@ sycho@@ tic@@ s@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with a family history of Q@@ T pro@@ long@@ ation@@ .
T@@ ardi@@ ve Dy@@ sk@@ ine@@ si@@ a@@ : in clinical trials of one year or less dur@@ ation@@ , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ ine@@ sia during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
If signs and symptoms of tar@@ di@@ ve dy@@ sk@@ ine@@ sia appear in a patient on AB@@ IL@@ I@@ F@@ Y@@ , dose reduction or dis@@ continu@@ ation should be consider@@ ed@@ .
These symptoms can tempor@@ ally deterior@@ ate or can even ari@@ se after dis@@ continu@@ ation of treat@@ ment@@ .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ :
N@@ MS is a potentially fatal symp@@ tom complex associated with anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ .
In clinical tri@@ al@@ s@@ , rare cases of N@@ MS were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
14 mental status and evidence of auton@@ omic inst@@ ability (@@ ir@@ regular pul@@ se or blood pressu@@ re@@ , ta@@ ch@@ y@@ cardi@@ a@@ , di@@ aph@@ ore@@ sis and cardi@@ ac dys@@ rhyth@@ mi@@ a@@ )@@ .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ as@@ e@@ , m@@ yo@@ glob@@ in@@ uri@@ a (@@ r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ )@@ , and ac@@ ute ren@@ al fail@@ ure@@ .
Ho@@ we@@ ver@@ , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , not necessarily in association with N@@ M@@ S@@ , have also been repor@@ te@@ d.
If a patient develop@@ s signs and symptoms indic@@ ative of N@@ M@@ S@@ , or presents with un@@ explained high fe@@ ver without additional clinical manifest@@ ations of N@@ M@@ S@@ , all anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ , including AB@@ IL@@ I@@ F@@ Y@@ , must be dis@@ continu@@ ed@@ .
Sei@@ zu@@ re@@ : in clinical tri@@ al@@ s@@ , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Ther@@ e@@ fore@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients who have a history of sei@@ z@@ ure disorder or have conditions associated with sei@@ zu@@ res@@ .
El@@ derly patients with demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s@@ :
In@@ cre@@ ased mort@@ al@@ it@@ y@@ : in three pla@@ c@@ ebo@@ -@@ controlled trials (@@ n@@ = 9@@ 38@@ ; mean age@@ :
8@@ 2.@@ 4 ye@@ ar@@ s@@ ; ran@@ ge@@ :
56@@ -@@ 99 ye@@ ar@@ s@@ ) of ari@@ pi@@ pra@@ z@@ ole in elderly patients with p@@ sycho@@ sis associated with Al@@ z@@ hei@@ mer@@ '@@ s dise@@ as@@ e@@ , patients treated with ari@@ pi@@ pra@@ z@@ ole were at increased risk of death compared to pla@@ c@@ ebo@@ .
The rate of death in ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients was 3.@@ 5@@ % compared to 1.@@ 7@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
Although the causes of deaths were var@@ ie@@ d@@ , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular (@@ e@@ . g. heart fail@@ ure@@ , sudden de@@ ath@@ ) or inf@@ ec@@ tious (@@ e@@ . g. p@@ ne@@ um@@ oni@@ a@@ ) in nat@@ ure@@ .
Cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse event@@ s@@ : in the same tri@@ al@@ s@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events (@@ e@@ . g. stro@@ ke@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ )@@ , including fat@@ ali@@ ti@@ es@@ , were reported in patients (@@ mean age@@ :
84 ye@@ ar@@ s@@ ; ran@@ ge@@ :
78@@ -@@ 88 ye@@ ar@@ s@@ )@@ .
Over@@ all@@ , 1.@@ 3@@ % of ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients reported cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events compared with 0.@@ 6@@ % of pla@@ c@@ ebo@@ -@@ treated patients in these tri@@ al@@ s.
This difference was not stati@@ st@@ ically signific@@ ant@@ .
Ho@@ we@@ ver@@ , in one of these tri@@ al@@ s@@ , a fix@@ ed@@ -@@ dose tri@@ al@@ , there was a significant dose response relationship for cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events in patients treated with ari@@ pi@@ pra@@ z@@ ole@@ .
AB@@ IL@@ I@@ F@@ Y is not approved for the treatment of demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s.
Hy@@ per@@ g@@ ly@@ ca@@ emi@@ a and Diabetes Mel@@ li@@ t@@ us@@ : hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , in some cases extreme and associated with ket@@ o@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or de@@ ath@@ , has been reported in patients treated with at@@ yp@@ ical anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ris@@ k factors that may pre@@ disp@@ ose patients to severe complic@@ ations include obesity and family history of di@@ abet@@ es@@ .
In clinical trials with ari@@ pi@@ pra@@ z@@ ole@@ , there were no significant differences in the inci@@ dence rates of hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events (@@ including di@@ abet@@ es@@ ) or in ab@@ normal g@@ ly@@ ca@@ emi@@ a lab@@ oratory values compared to pla@@ c@@ ebo@@ .
Pre@@ cise risk estimates for hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events in patients treated with AB@@ IL@@ I@@ F@@ Y and with other at@@ yp@@ ical anti@@ p@@ sycho@@ tic agents are not available to allow direct compar@@ is@@ ons@@ .
Pati@@ ents treated with any anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ , should be observed for signs and symptoms of hyper@@ g@@ ly@@ ca@@ emi@@ a (@@ such as poly@@ di@@ p@@ si@@ a@@ , poly@@ uri@@ a@@ , poly@@ ph@@ ag@@ ia and weak@@ ness@@ ) and patients with diabetes mel@@ li@@ tus or with risk factors for diabetes mel@@ li@@ tus should be monit@@ ored regularly for wor@@ sen@@ ing of glu@@ c@@ ose contro@@ l.
Wei@@ ght ga@@ in@@ : weight gain is commonly seen in sch@@ iz@@ op@@ hren@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ti@@ es@@ , use of anti@@ p@@ sycho@@ tics known to cause weight ga@@ in@@ , poor@@ ly managed li@@ fe@@ -@@ sty@@ le@@ , and might lead to severe complic@@ ations@@ .
Wei@@ ght gain has been reported post@@ -@@ marketing among patients prescri@@ bed AB@@ IL@@ I@@ F@@ Y@@ .
When se@@ en@@ , it is usually in those with significant risk factors such as history of di@@ abet@@ es@@ , th@@ y@@ ro@@ id disorder or pit@@ u@@ it@@ ary aden@@ om@@ a.
In clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight gain (@@ see section 5.@@ 1@@ )@@ .
Dy@@ sph@@ ag@@ i@@ a@@ : o@@ es@@ op@@ ha@@ ge@@ al dy@@ smo@@ tili@@ ty and aspi@@ ration have been associated with anti@@ p@@ sycho@@ tic drug use@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ari@@ pi@@ pra@@ z@@ ole and other anti@@ p@@ sycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for aspi@@ ration p@@ ne@@ um@@ oni@@ a.
L@@ act@@ os@@ e@@ : patients with rare her@@ edi@@ tary problems of gal@@ act@@ ose int@@ oler@@ anc@@ e@@ , the l@@ app la@@ ct@@ ase def@@ ici@@ ency or glu@@ cos@@ e@@ -@@ gal@@ act@@ ose mal@@ absor@@ ption should not take this medic@@ inal produc@@ t.
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ : as with other medic@@ ations hyper@@ sensi@@ tivity re@@ ac@@ tions@@ , character@@ ised by aller@@ gic symp@@ tom@@ s@@ , may occur with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
15 4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
D@@ ue to its α 1@@ -@@ ad@@ ren@@ er@@ gic rec@@ ep@@ tor ant@@ agon@@ is@@ m@@ , ari@@ pi@@ pra@@ z@@ ole has the potential to enh@@ ance the effect of certain anti@@ hyper@@ ten@@ sive ag@@ ent@@ s.
Given the primary CN@@ S effects of ari@@ pi@@ pra@@ z@@ ole@@ , caution should be used when ari@@ pi@@ pra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping un@@ desi@@ rable effects such as se@@ dation (@@ see section 4.@@ 8@@ )@@ .
If ari@@ pi@@ pra@@ z@@ ole is administ@@ ered con@@ co@@ mit@@ antly with medic@@ ines known to cause Q@@ T pro@@ long@@ ation or elec@@ tro@@ ly@@ te im@@ bal@@ anc@@ e@@ , caution should be use@@ d.
Pot@@ ential for other medic@@ inal products to affect AB@@ IL@@ I@@ F@@ Y@@ :
A ga@@ stri@@ c acid blo@@ cker@@ , the H@@ 2 ant@@ agon@@ ist f@@ amo@@ ti@@ d@@ ine@@ , redu@@ ces ari@@ pi@@ pra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relev@@ ant@@ .
Ari@@ pi@@ pra@@ z@@ ole is met@@ aboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ ym@@ es but not C@@ Y@@ P@@ 1@@ A enz@@ ym@@ es@@ .
Th@@ us@@ , no d@@ os@@ age adju@@ st@@ ment is required for smo@@ ker@@ s.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ qu@@ ini@@ d@@ ine@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C by 10@@ 7@@ %@@ , while C@@ max was un@@ ch@@ ange@@ d.
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , decre@@ ased by 32@@ % and 47@@ %@@ .
AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed dose when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y with qu@@ ini@@ dine occ@@ urs@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 2@@ D@@ 6@@ , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 3@@ A4 (@@ ket@@ o@@ con@@ az@@ ole@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C and C@@ max by 6@@ 3@@ % and 37@@ %@@ , respec@@ ti@@ vel@@ y@@ .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole increased by 77@@ % and 43@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor met@@ aboli@@ ser@@ s@@ , con@@ co@@ mit@@ ant use of pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 may result in higher p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive met@@ aboli@@ zer@@ s.
When considering con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors with AB@@ IL@@ I@@ F@@ Y@@ , potential benefits should out@@ weigh the potential risks to the pati@@ ent@@ .
When con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ o@@ z@@ ole with AB@@ IL@@ I@@ F@@ Y occ@@ urs@@ , AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed d@@ os@@ e@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A@@ 4@@ , such as it@@ ra@@ con@@ az@@ ole and HIV prot@@ ease in@@ hi@@ bit@@ or@@ s@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hi@@ bit@@ or@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be increased to the level prior to the initi@@ ation of the con@@ co@@ mit@@ ant therap@@ y@@ .
When weak in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 (@@ e@@ . g@@ .@@ , dil@@ ti@@ az@@ em or esc@@ ital@@ op@@ ra@@ m@@ ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ co@@ mit@@ antly with AB@@ IL@@ I@@ F@@ Y@@ , modest increases in ari@@ pi@@ pra@@ z@@ ole conc@@ ent@@ rations might be expec@@ te@@ d.
Following con@@ co@@ mit@@ ant administration of car@@ b@@ amaz@@ ep@@ ine@@ , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A@@ 4@@ , the ge@@ omet@@ ric means of C@@ max and AU@@ C for ari@@ pi@@ pra@@ z@@ ole were 68@@ % and 7@@ 3@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , compared to when ari@@ pi@@ pra@@ z@@ ole (@@ 30 m@@ g@@ ) was administ@@ ered al@@ one@@ .
Simi@@ lar@@ ly@@ , for de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole the ge@@ omet@@ ric means of C@@ max and AU@@ C after car@@ b@@ amaz@@ ep@@ ine co@@ -@@ administration were 69@@ % and 7@@ 1@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , than those following treatment with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
AB@@ IL@@ I@@ F@@ Y dose should be doubled when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y occ@@ urs with car@@ b@@ amaz@@ ep@@ ine@@ .
John@@ '@@ s Wort@@ ) may be expected to have similar effects and similar dose increases should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be reduced to the recommended d@@ os@@ e@@ .
16 When either val@@ pro@@ ate or li@@ thi@@ um were administ@@ ered con@@ co@@ mit@@ antly with ari@@ pi@@ pra@@ z@@ ole@@ , there was no clin@@ ically significant change in ari@@ pi@@ pra@@ z@@ ole conc@@ entra@@ tions@@ .
Pot@@ ential for AB@@ IL@@ I@@ F@@ Y to affect other medic@@ inal produc@@ ts@@ :
In clinical stu@@ dies@@ , 10@@ -@@ 30 m@@ g@@ / day d@@ oses of ari@@ pi@@ pra@@ z@@ ole had no significant effect on the met@@ aboli@@ sm of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ / 3@@ -@@ metho@@ x@@ y@@ mor@@ ph@@ in@@ an rati@@ o@@ )@@ , 2@@ C@@ 9 (@@ war@@ far@@ in@@ )@@ , 2@@ C@@ 19 (@@ om@@ ep@@ raz@@ ole@@ )@@ , and 3@@ A4 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ )@@ .
Addi@@ tion@@ all@@ y@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole did not show potential for al@@ tering C@@ Y@@ P@@ 1@@ A@@ 2@@ -@@ medi@@ ated met@@ aboli@@ sm in vit@@ ro@@ .
Th@@ us@@ , ari@@ pi@@ pra@@ z@@ ole is unlikely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ ym@@ es@@ .
When ari@@ pi@@ pra@@ z@@ ole was administ@@ ered con@@ co@@ mit@@ antly with either val@@ pro@@ ate or li@@ thi@@ um@@ , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ thi@@ um conc@@ entra@@ tions@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled trials of ari@@ pi@@ pra@@ z@@ ole in pregnant wom@@ en@@ .
Ani@@ mal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
D@@ ue to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive stu@@ dies@@ , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ et@@ us@@ .
Ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during la@@ ct@@ ation@@ .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pi@@ pra@@ z@@ ole@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been per@@ for@@ med@@ .
Ho@@ we@@ ver@@ , as with other anti@@ p@@ sycho@@ tic@@ s@@ , patients should be cau@@ tioned about operating ha@@ z@@ ard@@ ous mach@@ in@@ es@@ , including motor v@@ ehic@@ les@@ , until they are reas@@ onably certain that ari@@ pi@@ pra@@ z@@ ole does not affect them adver@@ sel@@ y@@ .
4.@@ 8 Un@@ desi@@ rable effects
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ )@@ :
The frequ@@ ency listed below is defined using the following conven@@ tion@@ : common (@@ > 1@@ / 100 ,@@ < 1@@ /@@ 10@@ ) and un@@ common (@@ > 1@@ /@@ 1 ,@@ 00@@ 0@@ , < 1@@ /@@ 100@@ )@@ .
Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous System disor@@ ders Common@@ : ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disor@@ der@@ , ak@@ ath@@ isi@@ a@@ , tre@@ mor@@ , di@@ zz@@ in@@ ess@@ , som@@ n@@ ol@@ en@@ ce@@ , se@@ d@@ ation@@ , hea@@ da@@ che E@@ ye disor@@ ders Common@@ : bl@@ urred vision Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : dy@@ sp@@ ep@@ si@@ a@@ , vo@@ mit@@ ing@@ , nau@@ se@@ a@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ * General disor@@ ders and administration site conditions Common@@ : f@@ ati@@ gue P@@ sychiatri@@ c disor@@ ders Common@@ : rest@@ less@@ ness@@ , ins@@ om@@ ni@@ a@@ , anxiety Un@@ common@@ : depres@@ sion@@ *
17 Ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symptoms (@@ EP@@ S@@ )@@ :
Sch@@ iz@@ op@@ hren@@ ia - in a long term 5@@ 2@@ -@@ week controlled tri@@ al@@ , ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients had an over@@ all@@ -@@ lower inci@@ dence (@@ 25.@@ 8@@ %@@ ) of E@@ PS including par@@ kin@@ son@@ is@@ m@@ , ak@@ ath@@ isi@@ a@@ , dy@@ st@@ onia and dy@@ sk@@ ine@@ sia compared with those treated with hal@@ operi@@ dol (@@ 5@@ 7.@@ 3@@ %@@ )@@ .
In a long term 26@@ -@@ week pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 19@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 13.@@ 1@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In another long@@ -@@ term 26@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 14.@@ 8@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 1@@ % for ol@@ anz@@ ap@@ ine@@ -@@ treated pati@@ ent@@ s.
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 23.@@ 5@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 5@@ 3.@@ 3@@ % for hal@@ operi@@ dol@@ -@@ treated pati@@ ent@@ s.
In another 12@@ -@@ week tri@@ al@@ , the inci@@ dence of E@@ PS was 26.@@ 6@@ % for patients treated with ari@@ pi@@ pra@@ z@@ ole and 17.@@ 6@@ % for those treated with li@@ thi@@ um@@ .
In the long term 26@@ -@@ week maintenance phase of a pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 18.@@ 2@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 7@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ s@@ , the inci@@ dence of ak@@ ath@@ i@@ sia in bi@@ pol@@ ar patients was 12.@@ 1@@ % with ari@@ pi@@ pra@@ z@@ ole and 3.@@ 2@@ % with pla@@ c@@ ebo@@ .
In sch@@ iz@@ op@@ hren@@ ia patients the inci@@ dence of ak@@ ath@@ i@@ sia was 6.@@ 2@@ % with ari@@ pi@@ pra@@ z@@ ole and 3@@ .0@@ % with pla@@ c@@ ebo@@ .
Com@@ par@@ is@@ ons between ari@@ pi@@ pra@@ z@@ ole and pla@@ c@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine lab@@ oratory par@@ ame@@ ters revealed no medi@@ cally important differ@@ en@@ c@@ es@@ .
Ele@@ v@@ ations of C@@ P@@ K (@@ Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ )@@ , generally tran@@ si@@ ent and as@@ ymp@@ tom@@ ati@@ c@@ , were observed in 3.@@ 5@@ % of ari@@ pi@@ pra@@ z@@ ole treated patients as compared to 2@@ .0@@ % of patients who received pla@@ c@@ ebo@@ .
Other fin@@ d@@ ings@@ :
Un@@ desi@@ rable effects known to be associated with anti@@ p@@ sycho@@ tic therapy and also reported during treatment with ari@@ pi@@ pra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ dro@@ me@@ , tar@@ di@@ ve dy@@ sk@@ ine@@ si@@ a@@ , sei@@ zu@@ re@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly de@@ mented pati@@ ent@@ s@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ tus (@@ see section 4.@@ 4@@ )@@ .
Post@@ -@@ Market@@ ing@@ :
The following ad@@ verse events have been reported during post@@ -@@ marketing sur@@ veil@@ lan@@ ce@@ .
The frequ@@ ency of these events is considered not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Investig@@ ations@@ :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ , blood glu@@ c@@ ose increas@@ ed@@ , blood glu@@ c@@ ose flu@@ ctu@@ ation@@ , g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in increased
Cardi@@ ac disor@@ der@@ s@@ :
Q@@ T pro@@ long@@ ation@@ , vent@@ ri@@ cular arr@@ hyth@@ mi@@ as@@ , sudden un@@ explained de@@ ath@@ , cardi@@ ac ar@@ rest@@ , tor@@ sa@@ des de poin@@ tes@@ , bra@@ dy@@ car@@ dia
Bloo@@ d and the lymp@@ h@@ atic system disor@@ der@@ s@@ :
leu@@ kop@@ eni@@ a@@ , neut@@ rop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia
Ner@@ v@@ ous system disor@@ der@@ s@@ :
speech disor@@ der@@ , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ , grand mal con@@ vul@@ sion
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ s@@ :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m@@ , lar@@ yn@@ g@@ os@@ pas@@ m@@ , aspi@@ ration p@@ ne@@ um@@ onia
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
pan@@ cre@@ ati@@ tis@@ , dy@@ sph@@ ag@@ i@@ a@@ , ab@@ dom@@ inal dis@@ comfort@@ , stomach dis@@ comfort@@ , di@@ arr@@ ho@@ ea
Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
ur@@ inary in@@ contin@@ en@@ ce@@ , ur@@ inary re@@ tention
Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
ra@@ sh@@ , ph@@ otos@@ en@@ si@@ tivity re@@ ac@@ tion@@ , al@@ op@@ eci@@ a@@ , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , my@@ al@@ gi@@ a@@ , sti@@ ff@@ ness
En@@ do@@ cr@@ ine disor@@ der@@ s@@ :
hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , diabetes mel@@ li@@ t@@ us@@ , di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s@@ , di@@ abe@@ tic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
weight ga@@ in@@ , weight decre@@ as@@ ed@@ , an@@ or@@ ex@@ i@@ a@@ , h@@ yp@@ on@@ at@@ re@@ mia
V@@ as@@ cular disor@@ der@@ s@@ :
syn@@ cop@@ e@@ , hyper@@ ten@@ sion@@ , thro@@ mbo@@ em@@ bo@@ lic events
General disor@@ ders and administration site condi@@ tions@@ :
temperature regulation disorder (@@ e@@ . g. hypo@@ ther@@ mi@@ a@@ , py@@ re@@ xi@@ a@@ )@@ , chest pain@@ , peri@@ pher@@ al oe@@ de@@ ma
Immun@@ e system disor@@ der@@ s@@ :
aller@@ gic reaction (@@ e@@ . g. an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ , an@@ gi@@ oe@@ de@@ ma including s@@ wollen ton@@ gu@@ e@@ , ton@@ gue oe@@ de@@ ma@@ , face oe@@ de@@ ma@@ , p@@ ru@@ rit@@ us@@ , or ur@@ tic@@ ari@@ a@@ )
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ der@@ s@@ :
ja@@ un@@ di@@ ce@@ , he@@ pati@@ tis@@ , increased A@@ lan@@ ine A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ AL@@ T@@ )@@ , increased A@@ spar@@ tate A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ A@@ ST@@ )@@ , increased G@@ amm@@ a Gl@@ ut@@ am@@ yl Transfer@@ ase (@@ G@@ GT@@ )@@ , increased al@@ kal@@ ine ph@@ osp@@ hat@@ ase
Re@@ productive system and breast disor@@ der@@ s@@ :
pri@@ ap@@ ism
P@@ sychiatri@@ c disor@@ der@@ s@@ :
ag@@ it@@ ation@@ , nerv@@ ous@@ ness@@ ; suicide attemp@@ t@@ , suici@@ dal ide@@ ation@@ , and completed suicide (@@ see section 4.@@ 4@@ )
4.@@ 9 Over@@ dose
In clinical trials and post@@ -@@ marketing experi@@ en@@ ce@@ , acci@@ dental or inten@@ tional ac@@ ute over@@ d@@ os@@ age of ari@@ pi@@ pra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy@@ , increased blood pressu@@ re@@ , som@@ n@@ ol@@ en@@ ce@@ , ta@@ ch@@ y@@ cardi@@ a@@ , nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ e@@ a.
In addi@@ tion@@ , reports of acci@@ dental over@@ dose with ari@@ pi@@ pra@@ z@@ ole alone (@@ up to 19@@ 5 m@@ g@@ ) in children have been received with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ en@@ ce@@ , tran@@ si@@ ent loss of consci@@ ousness and ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symp@@ tom@@ s.
Management of over@@ dose should concentrate on supportive therap@@ y@@ , maintaining an adequate air@@ wa@@ y@@ , oxy@@ gen@@ ation and v@@ enti@@ la@@ tion@@ , and management of symp@@ tom@@ s.
The possibility of multiple medic@@ inal product involvement should be consider@@ ed@@ .
Ther@@ efore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continu@@ ous elec@@ tro@@ cardi@@ o@@ graphic monitoring to dete@@ ct possible arr@@ hyth@@ mi@@ as@@ .
Following any confirmed or suspected over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , close medical super@@ vision and monitoring should continue until the patient reco@@ vers@@ .
Ac@@ tiv@@ ated char@@ coal (@@ 50 g@@ )@@ , administ@@ ered one hour after ari@@ pi@@ pra@@ z@@ ole@@ , decre@@ ased ari@@ pi@@ pra@@ z@@ ole C@@ max by about 4@@ 1@@ % and AU@@ C by about 5@@ 1@@ %@@ , suggesting that char@@ coal may be effective in the treatment of over@@ d@@ os@@ e@@ .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in treating an over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , ha@@ emo@@ di@@ aly@@ sis is unlikely to be useful in over@@ dose management since ari@@ pi@@ pra@@ z@@ ole is highly bound to p@@ las@@ ma prot@@ ein@@ s.
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ p@@ sycho@@ tic@@ s@@ , AT@@ C co@@ de@@ :
N@@ 05@@ A@@ X@@ 12
19 It has been proposed that ari@@ pi@@ pra@@ z@@ ole@@ ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ amine D@@ 2 and ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a rec@@ ep@@ tors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hypo@@ activ@@ it@@ y@@ .
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited high bin@@ ding aff@@ in@@ ity in vit@@ ro for d@@ op@@ amine D@@ 2 and D@@ 3@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a and 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tors and moderate aff@@ in@@ ity for d@@ op@@ amine D@@ 4@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ c and 5@@ H@@ T@@ 7@@ , alp@@ ha@@ -@@ 1 ad@@ ren@@ er@@ gic and hist@@ amine H@@ 1 rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole also exhi@@ bited moderate bin@@ ding aff@@ in@@ ity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ in@@ ity for mus@@ car@@ ini@@ c rec@@ ep@@ tor@@ s.
Inter@@ action with rec@@ ep@@ tors other than d@@ op@@ amine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pi@@ pra@@ z@@ ole@@ .
Ari@@ pi@@ pra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a d@@ os@@ e@@ -@@ dependent reduction in the bin@@ ding of 11@@ C@@ -@@ ra@@ clo@@ pri@@ de@@ , a D@@ 2@@ / D@@ 3 rec@@ ep@@ tor lig@@ and@@ , to the cau@@ date and put@@ amen dete@@ cted by posi@@ tr@@ on e@@ mission tom@@ o@@ grap@@ hy@@ .
Further information on clinical tri@@ al@@ s@@ :
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
In three short@@ -@@ term (@@ 4 to 6 wee@@ ks@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 1,@@ 228 sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s@@ , presenting with positive or negative symp@@ tom@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was associated with stati@@ st@@ ically significantly greater improvements in p@@ sycho@@ tic symptoms compared to pla@@ c@@ ebo@@ .
AB@@ IL@@ I@@ F@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment respon@@ se@@ .
In a hal@@ operi@@ dol@@ -@@ controlled tri@@ al@@ , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2@@ -@@ weeks was similar in both groups (@@ ari@@ pi@@ pra@@ z@@ ole 77@@ % and hal@@ operi@@ dol 7@@ 3@@ %@@ )@@ .
The overall comple@@ tion rate was significantly higher for patients on ari@@ pi@@ pra@@ z@@ ole (@@ 43@@ %@@ ) than for hal@@ operi@@ dol (@@ 30@@ %@@ )@@ .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ poin@@ ts@@ , including P@@ AN@@ SS and the Montgom@@ er@@ y@@ -@@ As@@ berg Depression R@@ ating Sc@@ ale showed a significant improvement over hal@@ operi@@ dol@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hren@@ i@@ a@@ , ari@@ pi@@ pra@@ z@@ ole had significantly greater reduction in re@@ lap@@ se rat@@ e@@ , 34@@ % in ari@@ pi@@ pra@@ z@@ ole group and 57@@ % in pla@@ c@@ ebo@@ .
Wei@@ ght ga@@ in@@ : in clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight ga@@ in@@ .
In a 26@@ -@@ week@@ , ol@@ anz@@ ap@@ ine@@ -@@ contro@@ lle@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , multi@@ -@@ national study of sch@@ iz@@ op@@ hren@@ ia which included 3@@ 14 patients and where the primary end@@ -@@ point was weight ga@@ in@@ , significantly less patients had at least 7@@ % weight gain over bas@@ eline (@@ i@@ . e@@ . a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~@@ 8@@ 0.5 k@@ g@@ ) on ari@@ pi@@ pra@@ z@@ ole (@@ N@@ = 18@@ , or 13@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ , compared to ol@@ anz@@ ap@@ ine (@@ N@@ = 45@@ , or 33@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ .
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
In two 3@@ -@@ week@@ , flexi@@ ble@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o in reduction of man@@ ic symptoms over 3 wee@@ ks@@ .
These trials included patients with or without p@@ sycho@@ tic features and with or without a rap@@ id@@ -@@ cycling cour@@ se@@ .
In one 3@@ -@@ week@@ , fix@@ ed@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to pla@@ c@@ ebo@@ .
In two 12@@ -@@ week@@ , pla@@ c@@ ebo@@ - and ac@@ ti@@ ve@@ -@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o at week 3 and a maintenance of effect compar@@ able to li@@ thi@@ um or hal@@ operi@@ dol at week 12.
Ari@@ pi@@ pra@@ z@@ ole also demonstrated a compar@@ able proportion of patients in symp@@ tom@@ atic re@@ mission from man@@ ia as li@@ thi@@ um or hal@@ operi@@ dol at week 12.
In a 6@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , who were parti@@ ally non@@ -@@ respon@@ sive to li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeu@@ tic ser@@ um level@@ s@@ , the addition of ari@@ pi@@ pra@@ z@@ ole as ad@@ jun@@ ctive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therap@@ y@@ .
20 In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , followed by a 7@@ 4@@ -@@ week exten@@ sion@@ , in man@@ ic patients who achieved re@@ mission on ari@@ pi@@ pra@@ z@@ ole during a stabili@@ zation phase prior to rand@@ omi@@ z@@ ation@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ ren@@ ce@@ , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depres@@ sion@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ab@@ sor@@ p@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is well absor@@ bed@@ , with peak p@@ las@@ ma conc@@ ent@@ rations occ@@ urring within 3@@ -@@ 5 hours after d@@ os@@ ing@@ .
Ari@@ pi@@ pra@@ z@@ ole under@@ goes minimal pre@@ -@@ sy@@ ste@@ mic met@@ aboli@@ sm@@ .
The absolute oral bio@@ availability of the tab@@ let formu@@ lation is 8@@ 7@@ %@@ .
There is no effect of a high fat meal on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Distri@@ bu@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is widely distri@@ buted throughout the body with an apparent volume of distribution of 4.@@ 9 l@@ / k@@ g@@ , indic@@ ating extensive extra@@ v@@ as@@ cular distri@@ bu@@ tion@@ .
At therapeu@@ tic conc@@ entra@@ tions@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole are greater than 99@@ % bound to ser@@ um prot@@ ein@@ s@@ , bin@@ ding primarily to alb@@ umin@@ .
Met@@ aboli@@ sm@@ :
Ari@@ pi@@ pra@@ z@@ ole is exten@@ sively met@@ aboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ wa@@ ys@@ : de@@ hydro@@ gen@@ ation@@ , hydro@@ x@@ y@@ la@@ tion@@ , and N@@ -@@ deal@@ k@@ y@@ la@@ tion@@ .
Based on in vit@@ ro stu@@ dies@@ , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ ym@@ es are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ y@@ lation of ari@@ pi@@ pra@@ z@@ ole@@ , and N@@ -@@ deal@@ k@@ y@@ lation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A@@ 4.
Ari@@ pi@@ pra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ iety in sy@@ ste@@ mic circu@@ la@@ tion@@ .
At steady stat@@ e@@ , de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , represents about 40@@ % of ari@@ pi@@ pra@@ z@@ ole AU@@ C in p@@ las@@ ma@@ .
Eli@@ min@@ ation@@ :
The mean elim@@ ination half@@ -@@ lives for ari@@ pi@@ pra@@ z@@ ole are approximately 75 hours in extensive met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6.
The total body clear@@ ance of ari@@ pi@@ pra@@ z@@ ole is 0.@@ 7 m@@ l@@ / min@@ / k@@ g@@ , which is primarily he@@ pati@@ c.
Following a single oral dose of [@@ 14@@ C@@ ]@@ -@@ lab@@ elled ari@@ pi@@ pra@@ z@@ ole@@ , approximately 27@@ % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60@@ % in the fa@@ ec@@ es@@ .
L@@ ess than 1@@ % of un@@ changed ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18@@ % was recovered un@@ changed in the fa@@ ec@@ es@@ .
P@@ harm@@ ac@@ ok@@ ine@@ tics in special patient groups
El@@ der@@ ly@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy elderly and younger adult sub@@ jec@@ ts@@ , nor is there any dete@@ ct@@ able effect of age in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Gen@@ der@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy male and female subjects nor is there any dete@@ ct@@ able effect of gender in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Smo@@ king and Rac@@ e@@ :
Pop@@ ulation pharmac@@ ok@@ ine@@ tic ev@@ al@@ uation has revealed no evidence of clin@@ ically significant ra@@ ce@@ -@@ related differences or effects from smoking upon the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Ren@@ al Di@@ seas@@ e@@ :
The pharmac@@ ok@@ ine@@ tic characterist@@ ics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy sub@@ jec@@ ts@@ .
21 H@@ ep@@ atic Di@@ seas@@ e@@ :
A sing@@ le@@ -@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis (@@ Chil@@ d@@ -@@ Pu@@ gh Clas@@ ses A@@ , B@@ , and C@@ ) did not reveal a significant effect of he@@ pati@@ c im@@ pa@@ ir@@ ment on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ si@@ s@@ , which is in@@ sufficient to draw conclu@@ sions on their met@@ aboli@@ c cap@@ ac@@ it@@ y@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
Non@@ -@@ clinical safety data revealed no special ha@@ zard for humans based on conventional studies of safety pharmac@@ olog@@ y@@ , repe@@ at@@ -@@ dose tox@@ ic@@ it@@ y@@ , gen@@ oto@@ x@@ ic@@ it@@ y@@ , car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ , and tox@@ ic@@ ity to re@@ produc@@ tion@@ .
To@@ x@@ ic@@ ologi@@ cally significant effects were observed only at d@@ oses or exp@@ os@@ ures that were suff@@ ici@@ ently in excess of the maximum human dose or exp@@ os@@ ure@@ , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use@@ .
These inclu@@ de@@ d@@ : d@@ os@@ e@@ -@@ dependent ad@@ reno@@ cor@@ tical tox@@ ic@@ ity (@@ li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and@@ / or par@@ en@@ ch@@ y@@ mal cell los@@ s@@ ) in rats after 104 weeks at 20 to 60 m@@ g@@ / k@@ g@@ / day (@@ 3 to 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ ) and increased ad@@ reno@@ cor@@ tical car@@ cin@@ om@@ as and combined ad@@ reno@@ cor@@ tical aden@@ om@@ as@@ / car@@ cin@@ om@@ as in female rats at 60 m@@ g@@ / k@@ g@@ / day (@@ 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ )@@ .
The highest non@@ tum@@ ori@@ gen@@ ic exposure in female rats was 7 times the human exposure at the recommended d@@ os@@ e@@ .
An additional finding was chol@@ eli@@ thi@@ asi@@ s as a consequ@@ ence of pre@@ cip@@ itation of sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy met@@ aboli@@ tes of ari@@ pi@@ pra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 m@@ g@@ / k@@ g@@ / day (@@ 1 to 3 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on m@@ g@@ / m@@ 2@@ )@@ .
Ho@@ we@@ ver@@ , the conc@@ ent@@ rations of the sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy ari@@ pi@@ pra@@ z@@ ole in human b@@ ile at the highest dose propos@@ ed@@ , 30 mg per day@@ , were no more than 6@@ % of the b@@ ile conc@@ ent@@ rations found in the mon@@ keys in the 39@@ -@@ week study and are well below (@@ 6@@ %@@ ) their limits of in vit@@ ro sol@@ u@@ bili@@ ty@@ .
Based on results of a full range of standard gen@@ oto@@ x@@ ic@@ ity test@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was considered non@@ -@@ gen@@ oto@@ x@@ ic@@ .
Ari@@ pi@@ pra@@ z@@ ole did not im@@ pair fertili@@ ty in re@@ productive tox@@ ic@@ ity stu@@ dies@@ .
Develop@@ mental tox@@ ic@@ it@@ y@@ , including d@@ os@@ e@@ -@@ dependent delayed fo@@ et@@ al ossi@@ fication and possible ter@@ at@@ o@@ gen@@ ic effec@@ ts@@ , were observed in rats at d@@ oses resulting in sub@@ therapeu@@ tic exp@@ os@@ ures (@@ based on AU@@ C@@ ) and in ra@@ bb@@ its at d@@ oses resulting in exp@@ os@@ ures 3 and 11 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical d@@ os@@ e@@ .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ it@@ y@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
L@@ act@@ ose mon@@ oh@@ y@@ dr@@ ate Mai@@ ze star@@ ch Mic@@ ro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ ose Hy@@ dro@@ x@@ y@@ prop@@ yl cell@@ ul@@ ose Mag@@ ne@@ si@@ um ste@@ ar@@ ate
Red iron oxide (@@ E@@ 17@@ 2@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
Not applic@@ ab@@ le@@ .
6.@@ 3 Shel@@ f life
3 years
22 6.@@ 4 Special prec@@ au@@ tions for storage
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
6.5 Nature and cont@@ ents of container
Al@@ uminium per@@ for@@ ated unit dose bli@@ sters in car@@ tons of 14 x 1@@ , 28 x 1@@ , 49 x 1@@ , 56 x 1@@ , 98 x 1 tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 6@@ -@@ 0@@ 10
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
D@@ ate of first author@@ is@@ ation@@ :
4 June 2004
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
{@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
23 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 15 mg tab@@ lets
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each tab@@ let contains 15 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
Ex@@ cip@@ i@@ ent@@ :
57 mg la@@ ct@@ ose per tab@@ let
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Tablet Round and y@@ el@@ low@@ , en@@ gra@@ ved with "@@ A@@ -@@ 00@@ 9@@ " and "@@ 15@@ " on one si@@ de.
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hren@@ i@@ a.
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the pre@@ vention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pi@@ pra@@ z@@ ole treatment (@@ see section 5.@@ 1@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
O@@ ral use@@ .
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 10 or 15 m@@ g@@ / day with a maintenance dose of 15 m@@ g@@ / day administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to me@@ al@@ s.
AB@@ IL@@ I@@ F@@ Y is effective in a dose range of 10 to 30 m@@ g@@ / day@@ .
En@@ h@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
M@@ anic epis@@ o@@ des@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 15 mg administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy (@@ see section 5.@@ 1@@ )@@ .
Some patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
Rec@@ ur@@ r@@ ence pre@@ vention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pi@@ pra@@ z@@ ole@@ , continue therapy at the same d@@ os@@ e@@ .
Ad@@ ju@@ st@@ ments of daily d@@ os@@ age@@ , including dose reduction should be considered on the basis of clinical stat@@ us@@ .
Children and adol@@ es@@ cent@@ s@@ : there is no experience in children and adol@@ es@@ cents under 18 years of age@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required for patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
In patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ , the data available are in@@ sufficient to establish recommend@@ ations@@ .
Ho@@ we@@ ver@@ , the
24 maximum daily dose of 30 mg should be used with caution in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required in patients with ren@@ al im@@ pa@@ ir@@ ment@@ .
El@@ der@@ ly@@ : the effec@@ tiveness of AB@@ IL@@ I@@ F@@ Y in the treatment of sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been establi@@ sh@@ ed@@ .
O@@ wing to the greater sensi@@ tivity of this pop@@ ula@@ tion@@ , a lower starting dose should be considered when clinical factors warrant (@@ see section 4.@@ 4@@ )@@ .
Gen@@ der@@ : no d@@ os@@ age adju@@ st@@ ment is required for female patients as compared to male patients (@@ see section 5.@@ 2@@ )@@ .
Smo@@ king stat@@ us@@ : according to the met@@ aboli@@ c path@@ way of AB@@ IL@@ I@@ F@@ Y no d@@ os@@ age adju@@ st@@ ment is required for smo@@ kers (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ ors with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be re@@ duc@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ or is with@@ drawn from the combination therap@@ y@@ , ari@@ pi@@ pra@@ z@@ ole dose should then be increased (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be increas@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therap@@ y@@ , the ari@@ pi@@ pra@@ z@@ ole dose should then be reduced to the recommended dose (@@ see section 4.@@ 5@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
During anti@@ p@@ sycho@@ tic treat@@ ment@@ , improvement in the pati@@ ent@@ '@@ s clinical condition may take several days to some wee@@ ks@@ .
Pati@@ ents should be closely monit@@ ored throughout this peri@@ od@@ .
The occ@@ ur@@ r@@ ence of suici@@ dal behaviour is inher@@ ent in p@@ sycho@@ tic ill@@ nesses and mood disor@@ ders and in some cases has been reported early after initi@@ ation or switch of anti@@ p@@ sycho@@ tic therap@@ y@@ , including treatment with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
C@@ lose super@@ vision of high@@ -@@ risk patients should ac@@ company anti@@ p@@ sycho@@ tic therap@@ y@@ .
Res@@ ults of an epide@@ mi@@ ological study found that there was no increased risk of suici@@ d@@ ality with ari@@ pi@@ pra@@ z@@ ole compared to other anti@@ p@@ sycho@@ tics among patients with bi@@ pol@@ ar disor@@ der@@ .
Cardi@@ ov@@ as@@ cular disor@@ der@@ s@@ :
Ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with known cardi@@ ov@@ as@@ cular disease (@@ history of m@@ yo@@ cardi@@ al inf@@ ar@@ ction or i@@ scha@@ e@@ mic heart dise@@ as@@ e@@ , heart fail@@ ure@@ , or conduc@@ tion ab@@ nor@@ mali@@ ti@@ es@@ )@@ , cer@@ eb@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ ension (@@ de@@ hy@@ dra@@ tion@@ , hypo@@ vol@@ emi@@ a@@ , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations@@ ) or hyper@@ ten@@ sion@@ , including acceler@@ ated or mal@@ ign@@ ant@@ .
Con@@ duction ab@@ nor@@ mali@@ ti@@ es@@ :
In clinical trials of ari@@ pi@@ pra@@ z@@ ole@@ , the inci@@ dence of Q@@ T pro@@ long@@ ation was compar@@ able to pla@@ c@@ ebo@@ .
As with other anti@@ p@@ sycho@@ tic@@ s@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with a family history of Q@@ T pro@@ long@@ ation@@ .
T@@ ardi@@ ve Dy@@ sk@@ ine@@ si@@ a@@ : in clinical trials of one year or less dur@@ ation@@ , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ ine@@ sia during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
If signs and symptoms of tar@@ di@@ ve dy@@ sk@@ ine@@ sia appear in a patient on AB@@ IL@@ I@@ F@@ Y@@ , dose reduction or dis@@ continu@@ ation should be consider@@ ed@@ .
These symptoms can tempor@@ ally deterior@@ ate or can even ari@@ se after dis@@ continu@@ ation of treat@@ ment@@ .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ :
N@@ MS is a potentially fatal symp@@ tom complex associated with anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ .
In clinical tri@@ al@@ s@@ , rare cases of N@@ MS were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
25 mental status and evidence of auton@@ omic inst@@ ability (@@ ir@@ regular pul@@ se or blood pressu@@ re@@ , ta@@ ch@@ y@@ cardi@@ a@@ , di@@ aph@@ ore@@ sis and cardi@@ ac dys@@ rhyth@@ mi@@ a@@ )@@ .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ as@@ e@@ , m@@ yo@@ glob@@ in@@ uri@@ a (@@ r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ )@@ , and ac@@ ute ren@@ al fail@@ ure@@ .
Ho@@ we@@ ver@@ , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , not necessarily in association with N@@ M@@ S@@ , have also been repor@@ te@@ d.
If a patient develop@@ s signs and symptoms indic@@ ative of N@@ M@@ S@@ , or presents with un@@ explained high fe@@ ver without additional clinical manifest@@ ations of N@@ M@@ S@@ , all anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ , including AB@@ IL@@ I@@ F@@ Y@@ , must be dis@@ continu@@ ed@@ .
Sei@@ zu@@ re@@ : in clinical tri@@ al@@ s@@ , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Ther@@ e@@ fore@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients who have a history of sei@@ z@@ ure disorder or have conditions associated with sei@@ zu@@ res@@ .
El@@ derly patients with demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s@@ :
In@@ cre@@ ased mort@@ al@@ it@@ y@@ : in three pla@@ c@@ ebo@@ -@@ controlled trials (@@ n@@ = 9@@ 38@@ ; mean age@@ :
8@@ 2.@@ 4 ye@@ ar@@ s@@ ; ran@@ ge@@ :
56@@ -@@ 99 ye@@ ar@@ s@@ ) of ari@@ pi@@ pra@@ z@@ ole in elderly patients with p@@ sycho@@ sis associated with Al@@ z@@ hei@@ mer@@ '@@ s dise@@ as@@ e@@ , patients treated with ari@@ pi@@ pra@@ z@@ ole were at increased risk of death compared to pla@@ c@@ ebo@@ .
The rate of death in ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients was 3.@@ 5@@ % compared to 1.@@ 7@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
Although the causes of deaths were var@@ ie@@ d@@ , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular (@@ e@@ . g. heart fail@@ ure@@ , sudden de@@ ath@@ ) or inf@@ ec@@ tious (@@ e@@ . g. p@@ ne@@ um@@ oni@@ a@@ ) in nat@@ ure@@ .
Cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse event@@ s@@ : in the same tri@@ al@@ s@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events (@@ e@@ . g. stro@@ ke@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ )@@ , including fat@@ ali@@ ti@@ es@@ , were reported in patients (@@ mean age@@ :
84 ye@@ ar@@ s@@ ; ran@@ ge@@ :
78@@ -@@ 88 ye@@ ar@@ s@@ )@@ .
Over@@ all@@ , 1.@@ 3@@ % of ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients reported cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events compared with 0.@@ 6@@ % of pla@@ c@@ ebo@@ -@@ treated patients in these tri@@ al@@ s.
This difference was not stati@@ st@@ ically signific@@ ant@@ .
Ho@@ we@@ ver@@ , in one of these tri@@ al@@ s@@ , a fix@@ ed@@ -@@ dose tri@@ al@@ , there was a significant dose response relationship for cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events in patients treated with ari@@ pi@@ pra@@ z@@ ole@@ .
AB@@ IL@@ I@@ F@@ Y is not approved for the treatment of demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s.
Hy@@ per@@ g@@ ly@@ ca@@ emi@@ a and Diabetes Mel@@ li@@ t@@ us@@ : hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , in some cases extreme and associated with ket@@ o@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or de@@ ath@@ , has been reported in patients treated with at@@ yp@@ ical anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ris@@ k factors that may pre@@ disp@@ ose patients to severe complic@@ ations include obesity and family history of di@@ abet@@ es@@ .
In clinical trials with ari@@ pi@@ pra@@ z@@ ole@@ , there were no significant differences in the inci@@ dence rates of hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events (@@ including di@@ abet@@ es@@ ) or in ab@@ normal g@@ ly@@ ca@@ emi@@ a lab@@ oratory values compared to pla@@ c@@ ebo@@ .
Pre@@ cise risk estimates for hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events in patients treated with AB@@ IL@@ I@@ F@@ Y and with other at@@ yp@@ ical anti@@ p@@ sycho@@ tic agents are not available to allow direct compar@@ is@@ ons@@ .
Pati@@ ents treated with any anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ , should be observed for signs and symptoms of hyper@@ g@@ ly@@ ca@@ emi@@ a (@@ such as poly@@ di@@ p@@ si@@ a@@ , poly@@ uri@@ a@@ , poly@@ ph@@ ag@@ ia and weak@@ ness@@ ) and patients with diabetes mel@@ li@@ tus or with risk factors for diabetes mel@@ li@@ tus should be monit@@ ored regularly for wor@@ sen@@ ing of glu@@ c@@ ose contro@@ l.
Wei@@ ght ga@@ in@@ : weight gain is commonly seen in sch@@ iz@@ op@@ hren@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ti@@ es@@ , use of anti@@ p@@ sycho@@ tics known to cause weight ga@@ in@@ , poor@@ ly managed li@@ fe@@ -@@ sty@@ le@@ , and might lead to severe complic@@ ations@@ .
Wei@@ ght gain has been reported post@@ -@@ marketing among patients prescri@@ bed AB@@ IL@@ I@@ F@@ Y@@ .
When se@@ en@@ , it is usually in those with significant risk factors such as history of di@@ abet@@ es@@ , th@@ y@@ ro@@ id disorder or pit@@ u@@ it@@ ary aden@@ om@@ a.
In clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight gain (@@ see section 5.@@ 1@@ )@@ .
Dy@@ sph@@ ag@@ i@@ a@@ : o@@ es@@ op@@ ha@@ ge@@ al dy@@ smo@@ tili@@ ty and aspi@@ ration have been associated with anti@@ p@@ sycho@@ tic drug use@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ari@@ pi@@ pra@@ z@@ ole and other anti@@ p@@ sycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for aspi@@ ration p@@ ne@@ um@@ oni@@ a.
L@@ act@@ os@@ e@@ : patients with rare her@@ edi@@ tary problems of gal@@ act@@ ose int@@ oler@@ anc@@ e@@ , the l@@ app la@@ ct@@ ase def@@ ici@@ ency or glu@@ cos@@ e@@ -@@ gal@@ act@@ ose mal@@ absor@@ ption should not take this medic@@ inal produc@@ t.
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ : as with other medic@@ ations hyper@@ sensi@@ tivity re@@ ac@@ tions@@ , character@@ ised by aller@@ gic symp@@ tom@@ s@@ , may occur with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
26 4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
D@@ ue to its α 1@@ -@@ ad@@ ren@@ er@@ gic rec@@ ep@@ tor ant@@ agon@@ is@@ m@@ , ari@@ pi@@ pra@@ z@@ ole has the potential to enh@@ ance the effect of certain anti@@ hyper@@ ten@@ sive ag@@ ent@@ s.
Given the primary CN@@ S effects of ari@@ pi@@ pra@@ z@@ ole@@ , caution should be used when ari@@ pi@@ pra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping un@@ desi@@ rable effects such as se@@ dation (@@ see section 4.@@ 8@@ )@@ .
If ari@@ pi@@ pra@@ z@@ ole is administ@@ ered con@@ co@@ mit@@ antly with medic@@ ines known to cause Q@@ T pro@@ long@@ ation or elec@@ tro@@ ly@@ te im@@ bal@@ anc@@ e@@ , caution should be use@@ d.
Pot@@ ential for other medic@@ inal products to affect AB@@ IL@@ I@@ F@@ Y@@ :
A ga@@ stri@@ c acid blo@@ cker@@ , the H@@ 2 ant@@ agon@@ ist f@@ amo@@ ti@@ d@@ ine@@ , redu@@ ces ari@@ pi@@ pra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relev@@ ant@@ .
Ari@@ pi@@ pra@@ z@@ ole is met@@ aboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ ym@@ es but not C@@ Y@@ P@@ 1@@ A enz@@ ym@@ es@@ .
Th@@ us@@ , no d@@ os@@ age adju@@ st@@ ment is required for smo@@ ker@@ s.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ qu@@ ini@@ d@@ ine@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C by 10@@ 7@@ %@@ , while C@@ max was un@@ ch@@ ange@@ d.
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , decre@@ ased by 32@@ % and 47@@ %@@ .
AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed dose when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y with qu@@ ini@@ dine occ@@ urs@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 2@@ D@@ 6@@ , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 3@@ A4 (@@ ket@@ o@@ con@@ az@@ ole@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C and C@@ max by 6@@ 3@@ % and 37@@ %@@ , respec@@ ti@@ vel@@ y@@ .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole increased by 77@@ % and 43@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor met@@ aboli@@ ser@@ s@@ , con@@ co@@ mit@@ ant use of pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 may result in higher p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive met@@ aboli@@ zer@@ s.
When considering con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors with AB@@ IL@@ I@@ F@@ Y@@ , potential benefits should out@@ weigh the potential risks to the pati@@ ent@@ .
When con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ o@@ z@@ ole with AB@@ IL@@ I@@ F@@ Y occ@@ urs@@ , AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed d@@ os@@ e@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A@@ 4@@ , such as it@@ ra@@ con@@ az@@ ole and HIV prot@@ ease in@@ hi@@ bit@@ or@@ s@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hi@@ bit@@ or@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be increased to the level prior to the initi@@ ation of the con@@ co@@ mit@@ ant therap@@ y@@ .
When weak in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 (@@ e@@ . g@@ .@@ , dil@@ ti@@ az@@ em or esc@@ ital@@ op@@ ra@@ m@@ ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ co@@ mit@@ antly with AB@@ IL@@ I@@ F@@ Y@@ , modest increases in ari@@ pi@@ pra@@ z@@ ole conc@@ ent@@ rations might be expec@@ te@@ d.
Following con@@ co@@ mit@@ ant administration of car@@ b@@ amaz@@ ep@@ ine@@ , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A@@ 4@@ , the ge@@ omet@@ ric means of C@@ max and AU@@ C for ari@@ pi@@ pra@@ z@@ ole were 68@@ % and 7@@ 3@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , compared to when ari@@ pi@@ pra@@ z@@ ole (@@ 30 m@@ g@@ ) was administ@@ ered al@@ one@@ .
Simi@@ lar@@ ly@@ , for de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole the ge@@ omet@@ ric means of C@@ max and AU@@ C after car@@ b@@ amaz@@ ep@@ ine co@@ -@@ administration were 69@@ % and 7@@ 1@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , than those following treatment with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
AB@@ IL@@ I@@ F@@ Y dose should be doubled when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y occ@@ urs with car@@ b@@ amaz@@ ep@@ ine@@ .
John@@ '@@ s Wort@@ ) may be expected to have similar effects and similar dose increases should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be reduced to the recommended d@@ os@@ e@@ .
27 When either val@@ pro@@ ate or li@@ thi@@ um were administ@@ ered con@@ co@@ mit@@ antly with ari@@ pi@@ pra@@ z@@ ole@@ , there was no clin@@ ically significant change in ari@@ pi@@ pra@@ z@@ ole conc@@ entra@@ tions@@ .
Pot@@ ential for AB@@ IL@@ I@@ F@@ Y to affect other medic@@ inal produc@@ ts@@ :
In clinical stu@@ dies@@ , 10@@ -@@ 30 m@@ g@@ / day d@@ oses of ari@@ pi@@ pra@@ z@@ ole had no significant effect on the met@@ aboli@@ sm of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ / 3@@ -@@ metho@@ x@@ y@@ mor@@ ph@@ in@@ an rati@@ o@@ )@@ , 2@@ C@@ 9 (@@ war@@ far@@ in@@ )@@ , 2@@ C@@ 19 (@@ om@@ ep@@ raz@@ ole@@ )@@ , and 3@@ A4 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ )@@ .
Addi@@ tion@@ all@@ y@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole did not show potential for al@@ tering C@@ Y@@ P@@ 1@@ A@@ 2@@ -@@ medi@@ ated met@@ aboli@@ sm in vit@@ ro@@ .
Th@@ us@@ , ari@@ pi@@ pra@@ z@@ ole is unlikely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ ym@@ es@@ .
When ari@@ pi@@ pra@@ z@@ ole was administ@@ ered con@@ co@@ mit@@ antly with either val@@ pro@@ ate or li@@ thi@@ um@@ , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ thi@@ um conc@@ entra@@ tions@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled trials of ari@@ pi@@ pra@@ z@@ ole in pregnant wom@@ en@@ .
Ani@@ mal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
D@@ ue to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive stu@@ dies@@ , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ et@@ us@@ .
Ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during la@@ ct@@ ation@@ .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pi@@ pra@@ z@@ ole@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been per@@ for@@ med@@ .
Ho@@ we@@ ver@@ , as with other anti@@ p@@ sycho@@ tic@@ s@@ , patients should be cau@@ tioned about operating ha@@ z@@ ard@@ ous mach@@ in@@ es@@ , including motor v@@ ehic@@ les@@ , until they are reas@@ onably certain that ari@@ pi@@ pra@@ z@@ ole does not affect them adver@@ sel@@ y@@ .
4.@@ 8 Un@@ desi@@ rable effects
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ )@@ :
The frequ@@ ency listed below is defined using the following conven@@ tion@@ : common (@@ > 1@@ / 100 ,@@ < 1@@ /@@ 10@@ ) and un@@ common (@@ > 1@@ /@@ 1 ,@@ 00@@ 0@@ , < 1@@ /@@ 100@@ )@@ .
Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous System disor@@ ders Common@@ : ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disor@@ der@@ , ak@@ ath@@ isi@@ a@@ , tre@@ mor@@ , di@@ zz@@ in@@ ess@@ , som@@ n@@ ol@@ en@@ ce@@ , se@@ d@@ ation@@ , hea@@ da@@ che E@@ ye disor@@ ders Common@@ : bl@@ urred vision Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : dy@@ sp@@ ep@@ si@@ a@@ , vo@@ mit@@ ing@@ , nau@@ se@@ a@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ * General disor@@ ders and administration site conditions Common@@ : f@@ ati@@ gue P@@ sychiatri@@ c disor@@ ders Common@@ : rest@@ less@@ ness@@ , ins@@ om@@ ni@@ a@@ , anxiety Un@@ common@@ : depres@@ sion@@ *
28 Ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symptoms (@@ EP@@ S@@ )@@ :
Sch@@ iz@@ op@@ hren@@ ia - in a long term 5@@ 2@@ -@@ week controlled tri@@ al@@ , ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients had an over@@ all@@ -@@ lower inci@@ dence (@@ 25.@@ 8@@ %@@ ) of E@@ PS including par@@ kin@@ son@@ is@@ m@@ , ak@@ ath@@ isi@@ a@@ , dy@@ st@@ onia and dy@@ sk@@ ine@@ sia compared with those treated with hal@@ operi@@ dol (@@ 5@@ 7.@@ 3@@ %@@ )@@ .
In a long term 26@@ -@@ week pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 19@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 13.@@ 1@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In another long@@ -@@ term 26@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 14.@@ 8@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 1@@ % for ol@@ anz@@ ap@@ ine@@ -@@ treated pati@@ ent@@ s.
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 23.@@ 5@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 5@@ 3.@@ 3@@ % for hal@@ operi@@ dol@@ -@@ treated pati@@ ent@@ s.
In another 12@@ -@@ week tri@@ al@@ , the inci@@ dence of E@@ PS was 26.@@ 6@@ % for patients treated with ari@@ pi@@ pra@@ z@@ ole and 17.@@ 6@@ % for those treated with li@@ thi@@ um@@ .
In the long term 26@@ -@@ week maintenance phase of a pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 18.@@ 2@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 7@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ s@@ , the inci@@ dence of ak@@ ath@@ i@@ sia in bi@@ pol@@ ar patients was 12.@@ 1@@ % with ari@@ pi@@ pra@@ z@@ ole and 3.@@ 2@@ % with pla@@ c@@ ebo@@ .
In sch@@ iz@@ op@@ hren@@ ia patients the inci@@ dence of ak@@ ath@@ i@@ sia was 6.@@ 2@@ % with ari@@ pi@@ pra@@ z@@ ole and 3@@ .0@@ % with pla@@ c@@ ebo@@ .
Com@@ par@@ is@@ ons between ari@@ pi@@ pra@@ z@@ ole and pla@@ c@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine lab@@ oratory par@@ ame@@ ters revealed no medi@@ cally important differ@@ en@@ c@@ es@@ .
Ele@@ v@@ ations of C@@ P@@ K (@@ Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ )@@ , generally tran@@ si@@ ent and as@@ ymp@@ tom@@ ati@@ c@@ , were observed in 3.@@ 5@@ % of ari@@ pi@@ pra@@ z@@ ole treated patients as compared to 2@@ .0@@ % of patients who received pla@@ c@@ ebo@@ .
Other fin@@ d@@ ings@@ :
Un@@ desi@@ rable effects known to be associated with anti@@ p@@ sycho@@ tic therapy and also reported during treatment with ari@@ pi@@ pra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ dro@@ me@@ , tar@@ di@@ ve dy@@ sk@@ ine@@ si@@ a@@ , sei@@ zu@@ re@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly de@@ mented pati@@ ent@@ s@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ tus (@@ see section 4.@@ 4@@ )@@ .
Post@@ -@@ Market@@ ing@@ :
The following ad@@ verse events have been reported during post@@ -@@ marketing sur@@ veil@@ lan@@ ce@@ .
The frequ@@ ency of these events is considered not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Investig@@ ations@@ :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ , blood glu@@ c@@ ose increas@@ ed@@ , blood glu@@ c@@ ose flu@@ ctu@@ ation@@ , g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in increased
Cardi@@ ac disor@@ der@@ s@@ :
Q@@ T pro@@ long@@ ation@@ , vent@@ ri@@ cular arr@@ hyth@@ mi@@ as@@ , sudden un@@ explained de@@ ath@@ , cardi@@ ac ar@@ rest@@ , tor@@ sa@@ des de poin@@ tes@@ , bra@@ dy@@ car@@ dia
Bloo@@ d and the lymp@@ h@@ atic system disor@@ der@@ s@@ :
leu@@ kop@@ eni@@ a@@ , neut@@ rop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia
Ner@@ v@@ ous system disor@@ der@@ s@@ :
speech disor@@ der@@ , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ , grand mal con@@ vul@@ sion
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ s@@ :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m@@ , lar@@ yn@@ g@@ os@@ pas@@ m@@ , aspi@@ ration p@@ ne@@ um@@ onia
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
pan@@ cre@@ ati@@ tis@@ , dy@@ sph@@ ag@@ i@@ a@@ , ab@@ dom@@ inal dis@@ comfort@@ , stomach dis@@ comfort@@ , di@@ arr@@ ho@@ ea
Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
ur@@ inary in@@ contin@@ en@@ ce@@ , ur@@ inary re@@ tention
Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
ra@@ sh@@ , ph@@ otos@@ en@@ si@@ tivity re@@ ac@@ tion@@ , al@@ op@@ eci@@ a@@ , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , my@@ al@@ gi@@ a@@ , sti@@ ff@@ ness
En@@ do@@ cr@@ ine disor@@ der@@ s@@ :
hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , diabetes mel@@ li@@ t@@ us@@ , di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s@@ , di@@ abe@@ tic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
weight ga@@ in@@ , weight decre@@ as@@ ed@@ , an@@ or@@ ex@@ i@@ a@@ , h@@ yp@@ on@@ at@@ re@@ mia
V@@ as@@ cular disor@@ der@@ s@@ :
syn@@ cop@@ e@@ , hyper@@ ten@@ sion@@ , thro@@ mbo@@ em@@ bo@@ lic events
General disor@@ ders and administration site condi@@ tions@@ :
temperature regulation disorder (@@ e@@ . g. hypo@@ ther@@ mi@@ a@@ , py@@ re@@ xi@@ a@@ )@@ , chest pain@@ , peri@@ pher@@ al oe@@ de@@ ma
Immun@@ e system disor@@ der@@ s@@ :
aller@@ gic reaction (@@ e@@ . g. an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ , an@@ gi@@ oe@@ de@@ ma including s@@ wollen ton@@ gu@@ e@@ , ton@@ gue oe@@ de@@ ma@@ , face oe@@ de@@ ma@@ , p@@ ru@@ rit@@ us@@ , or ur@@ tic@@ ari@@ a@@ )
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ der@@ s@@ :
ja@@ un@@ di@@ ce@@ , he@@ pati@@ tis@@ , increased A@@ lan@@ ine A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ AL@@ T@@ )@@ , increased A@@ spar@@ tate A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ A@@ ST@@ )@@ , increased G@@ amm@@ a Gl@@ ut@@ am@@ yl Transfer@@ ase (@@ G@@ GT@@ )@@ , increased al@@ kal@@ ine ph@@ osp@@ hat@@ ase
Re@@ productive system and breast disor@@ der@@ s@@ :
pri@@ ap@@ ism
P@@ sychiatri@@ c disor@@ der@@ s@@ :
ag@@ it@@ ation@@ , nerv@@ ous@@ ness@@ ; suicide attemp@@ t@@ , suici@@ dal ide@@ ation@@ , and completed suicide (@@ see section 4.@@ 4@@ )
4.@@ 9 Over@@ dose
In clinical trials and post@@ -@@ marketing experi@@ en@@ ce@@ , acci@@ dental or inten@@ tional ac@@ ute over@@ d@@ os@@ age of ari@@ pi@@ pra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy@@ , increased blood pressu@@ re@@ , som@@ n@@ ol@@ en@@ ce@@ , ta@@ ch@@ y@@ cardi@@ a@@ , nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ e@@ a.
In addi@@ tion@@ , reports of acci@@ dental over@@ dose with ari@@ pi@@ pra@@ z@@ ole alone (@@ up to 19@@ 5 m@@ g@@ ) in children have been received with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ en@@ ce@@ , tran@@ si@@ ent loss of consci@@ ousness and ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symp@@ tom@@ s.
Management of over@@ dose should concentrate on supportive therap@@ y@@ , maintaining an adequate air@@ wa@@ y@@ , oxy@@ gen@@ ation and v@@ enti@@ la@@ tion@@ , and management of symp@@ tom@@ s.
The possibility of multiple medic@@ inal product involvement should be consider@@ ed@@ .
Ther@@ efore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continu@@ ous elec@@ tro@@ cardi@@ o@@ graphic monitoring to dete@@ ct possible arr@@ hyth@@ mi@@ as@@ .
Following any confirmed or suspected over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , close medical super@@ vision and monitoring should continue until the patient reco@@ vers@@ .
Ac@@ tiv@@ ated char@@ coal (@@ 50 g@@ )@@ , administ@@ ered one hour after ari@@ pi@@ pra@@ z@@ ole@@ , decre@@ ased ari@@ pi@@ pra@@ z@@ ole C@@ max by about 4@@ 1@@ % and AU@@ C by about 5@@ 1@@ %@@ , suggesting that char@@ coal may be effective in the treatment of over@@ d@@ os@@ e@@ .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in treating an over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , ha@@ emo@@ di@@ aly@@ sis is unlikely to be useful in over@@ dose management since ari@@ pi@@ pra@@ z@@ ole is highly bound to p@@ las@@ ma prot@@ ein@@ s.
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ p@@ sycho@@ tic@@ s@@ , AT@@ C co@@ de@@ :
N@@ 05@@ A@@ X@@ 12
30 It has been proposed that ari@@ pi@@ pra@@ z@@ ole@@ ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ amine D@@ 2 and ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a rec@@ ep@@ tors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hypo@@ activ@@ it@@ y@@ .
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited high bin@@ ding aff@@ in@@ ity in vit@@ ro for d@@ op@@ amine D@@ 2 and D@@ 3@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a and 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tors and moderate aff@@ in@@ ity for d@@ op@@ amine D@@ 4@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ c and 5@@ H@@ T@@ 7@@ , alp@@ ha@@ -@@ 1 ad@@ ren@@ er@@ gic and hist@@ amine H@@ 1 rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole also exhi@@ bited moderate bin@@ ding aff@@ in@@ ity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ in@@ ity for mus@@ car@@ ini@@ c rec@@ ep@@ tor@@ s.
Inter@@ action with rec@@ ep@@ tors other than d@@ op@@ amine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pi@@ pra@@ z@@ ole@@ .
Ari@@ pi@@ pra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a d@@ os@@ e@@ -@@ dependent reduction in the bin@@ ding of 11@@ C@@ -@@ ra@@ clo@@ pri@@ de@@ , a D@@ 2@@ / D@@ 3 rec@@ ep@@ tor lig@@ and@@ , to the cau@@ date and put@@ amen dete@@ cted by posi@@ tr@@ on e@@ mission tom@@ o@@ grap@@ hy@@ .
Further information on clinical tri@@ al@@ s@@ :
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
In three short@@ -@@ term (@@ 4 to 6 wee@@ ks@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 1,@@ 228 sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s@@ , presenting with positive or negative symp@@ tom@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was associated with stati@@ st@@ ically significantly greater improvements in p@@ sycho@@ tic symptoms compared to pla@@ c@@ ebo@@ .
AB@@ IL@@ I@@ F@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment respon@@ se@@ .
In a hal@@ operi@@ dol@@ -@@ controlled tri@@ al@@ , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2@@ -@@ weeks was similar in both groups (@@ ari@@ pi@@ pra@@ z@@ ole 77@@ % and hal@@ operi@@ dol 7@@ 3@@ %@@ )@@ .
The overall comple@@ tion rate was significantly higher for patients on ari@@ pi@@ pra@@ z@@ ole (@@ 43@@ %@@ ) than for hal@@ operi@@ dol (@@ 30@@ %@@ )@@ .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ poin@@ ts@@ , including P@@ AN@@ SS and the Montgom@@ er@@ y@@ -@@ As@@ berg Depression R@@ ating Sc@@ ale showed a significant improvement over hal@@ operi@@ dol@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hren@@ i@@ a@@ , ari@@ pi@@ pra@@ z@@ ole had significantly greater reduction in re@@ lap@@ se rat@@ e@@ , 34@@ % in ari@@ pi@@ pra@@ z@@ ole group and 57@@ % in pla@@ c@@ ebo@@ .
Wei@@ ght ga@@ in@@ : in clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight ga@@ in@@ .
In a 26@@ -@@ week@@ , ol@@ anz@@ ap@@ ine@@ -@@ contro@@ lle@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , multi@@ -@@ national study of sch@@ iz@@ op@@ hren@@ ia which included 3@@ 14 patients and where the primary end@@ -@@ point was weight ga@@ in@@ , significantly less patients had at least 7@@ % weight gain over bas@@ eline (@@ i@@ . e@@ . a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~@@ 8@@ 0.5 k@@ g@@ ) on ari@@ pi@@ pra@@ z@@ ole (@@ N@@ = 18@@ , or 13@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ , compared to ol@@ anz@@ ap@@ ine (@@ N@@ = 45@@ , or 33@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ .
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
In two 3@@ -@@ week@@ , flexi@@ ble@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o in reduction of man@@ ic symptoms over 3 wee@@ ks@@ .
These trials included patients with or without p@@ sycho@@ tic features and with or without a rap@@ id@@ -@@ cycling cour@@ se@@ .
In one 3@@ -@@ week@@ , fix@@ ed@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to pla@@ c@@ ebo@@ .
In two 12@@ -@@ week@@ , pla@@ c@@ ebo@@ - and ac@@ ti@@ ve@@ -@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o at week 3 and a maintenance of effect compar@@ able to li@@ thi@@ um or hal@@ operi@@ dol at week 12.
Ari@@ pi@@ pra@@ z@@ ole also demonstrated a compar@@ able proportion of patients in symp@@ tom@@ atic re@@ mission from man@@ ia as li@@ thi@@ um or hal@@ operi@@ dol at week 12.
In a 6@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , who were parti@@ ally non@@ -@@ respon@@ sive to li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeu@@ tic ser@@ um level@@ s@@ , the addition of ari@@ pi@@ pra@@ z@@ ole as ad@@ jun@@ ctive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therap@@ y@@ .
31 In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , followed by a 7@@ 4@@ -@@ week exten@@ sion@@ , in man@@ ic patients who achieved re@@ mission on ari@@ pi@@ pra@@ z@@ ole during a stabili@@ zation phase prior to rand@@ omi@@ z@@ ation@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ ren@@ ce@@ , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depres@@ sion@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ab@@ sor@@ p@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is well absor@@ bed@@ , with peak p@@ las@@ ma conc@@ ent@@ rations occ@@ urring within 3@@ -@@ 5 hours after d@@ os@@ ing@@ .
Ari@@ pi@@ pra@@ z@@ ole under@@ goes minimal pre@@ -@@ sy@@ ste@@ mic met@@ aboli@@ sm@@ .
The absolute oral bio@@ availability of the tab@@ let formu@@ lation is 8@@ 7@@ %@@ .
There is no effect of a high fat meal on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Distri@@ bu@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is widely distri@@ buted throughout the body with an apparent volume of distribution of 4.@@ 9 l@@ / k@@ g@@ , indic@@ ating extensive extra@@ v@@ as@@ cular distri@@ bu@@ tion@@ .
At therapeu@@ tic conc@@ entra@@ tions@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole are greater than 99@@ % bound to ser@@ um prot@@ ein@@ s@@ , bin@@ ding primarily to alb@@ umin@@ .
Met@@ aboli@@ sm@@ :
Ari@@ pi@@ pra@@ z@@ ole is exten@@ sively met@@ aboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ wa@@ ys@@ : de@@ hydro@@ gen@@ ation@@ , hydro@@ x@@ y@@ la@@ tion@@ , and N@@ -@@ deal@@ k@@ y@@ la@@ tion@@ .
Based on in vit@@ ro stu@@ dies@@ , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ ym@@ es are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ y@@ lation of ari@@ pi@@ pra@@ z@@ ole@@ , and N@@ -@@ deal@@ k@@ y@@ lation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A@@ 4.
Ari@@ pi@@ pra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ iety in sy@@ ste@@ mic circu@@ la@@ tion@@ .
At steady stat@@ e@@ , de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , represents about 40@@ % of ari@@ pi@@ pra@@ z@@ ole AU@@ C in p@@ las@@ ma@@ .
Eli@@ min@@ ation@@ :
The mean elim@@ ination half@@ -@@ lives for ari@@ pi@@ pra@@ z@@ ole are approximately 75 hours in extensive met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6.
The total body clear@@ ance of ari@@ pi@@ pra@@ z@@ ole is 0.@@ 7 m@@ l@@ / min@@ / k@@ g@@ , which is primarily he@@ pati@@ c.
Following a single oral dose of [@@ 14@@ C@@ ]@@ -@@ lab@@ elled ari@@ pi@@ pra@@ z@@ ole@@ , approximately 27@@ % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60@@ % in the fa@@ ec@@ es@@ .
L@@ ess than 1@@ % of un@@ changed ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18@@ % was recovered un@@ changed in the fa@@ ec@@ es@@ .
P@@ harm@@ ac@@ ok@@ ine@@ tics in special patient groups
El@@ der@@ ly@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy elderly and younger adult sub@@ jec@@ ts@@ , nor is there any dete@@ ct@@ able effect of age in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Gen@@ der@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy male and female subjects nor is there any dete@@ ct@@ able effect of gender in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Smo@@ king and Rac@@ e@@ :
Pop@@ ulation pharmac@@ ok@@ ine@@ tic ev@@ al@@ uation has revealed no evidence of clin@@ ically significant ra@@ ce@@ -@@ related differences or effects from smoking upon the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Ren@@ al Di@@ seas@@ e@@ :
The pharmac@@ ok@@ ine@@ tic characterist@@ ics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy sub@@ jec@@ ts@@ .
32 H@@ ep@@ atic Di@@ seas@@ e@@ :
A sing@@ le@@ -@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis (@@ Chil@@ d@@ -@@ Pu@@ gh Clas@@ ses A@@ , B@@ , and C@@ ) did not reveal a significant effect of he@@ pati@@ c im@@ pa@@ ir@@ ment on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ si@@ s@@ , which is in@@ sufficient to draw conclu@@ sions on their met@@ aboli@@ c cap@@ ac@@ it@@ y@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
Non@@ -@@ clinical safety data revealed no special ha@@ zard for humans based on conventional studies of safety pharmac@@ olog@@ y@@ , repe@@ at@@ -@@ dose tox@@ ic@@ it@@ y@@ , gen@@ oto@@ x@@ ic@@ it@@ y@@ , car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ , and tox@@ ic@@ ity to re@@ produc@@ tion@@ .
To@@ x@@ ic@@ ologi@@ cally significant effects were observed only at d@@ oses or exp@@ os@@ ures that were suff@@ ici@@ ently in excess of the maximum human dose or exp@@ os@@ ure@@ , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use@@ .
These inclu@@ de@@ d@@ : d@@ os@@ e@@ -@@ dependent ad@@ reno@@ cor@@ tical tox@@ ic@@ ity (@@ li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and@@ / or par@@ en@@ ch@@ y@@ mal cell los@@ s@@ ) in rats after 104 weeks at 20 to 60 m@@ g@@ / k@@ g@@ / day (@@ 3 to 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ ) and increased ad@@ reno@@ cor@@ tical car@@ cin@@ om@@ as and combined ad@@ reno@@ cor@@ tical aden@@ om@@ as@@ / car@@ cin@@ om@@ as in female rats at 60 m@@ g@@ / k@@ g@@ / day (@@ 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ )@@ .
The highest non@@ tum@@ ori@@ gen@@ ic exposure in female rats was 7 times the human exposure at the recommended d@@ os@@ e@@ .
An additional finding was chol@@ eli@@ thi@@ asi@@ s as a consequ@@ ence of pre@@ cip@@ itation of sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy met@@ aboli@@ tes of ari@@ pi@@ pra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 m@@ g@@ / k@@ g@@ / day (@@ 1 to 3 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on m@@ g@@ / m@@ 2@@ )@@ .
Ho@@ we@@ ver@@ , the conc@@ ent@@ rations of the sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy ari@@ pi@@ pra@@ z@@ ole in human b@@ ile at the highest dose propos@@ ed@@ , 30 mg per day@@ , were no more than 6@@ % of the b@@ ile conc@@ ent@@ rations found in the mon@@ keys in the 39@@ -@@ week study and are well below (@@ 6@@ %@@ ) their limits of in vit@@ ro sol@@ u@@ bili@@ ty@@ .
Based on results of a full range of standard gen@@ oto@@ x@@ ic@@ ity test@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was considered non@@ -@@ gen@@ oto@@ x@@ ic@@ .
Ari@@ pi@@ pra@@ z@@ ole did not im@@ pair fertili@@ ty in re@@ productive tox@@ ic@@ ity stu@@ dies@@ .
Develop@@ mental tox@@ ic@@ it@@ y@@ , including d@@ os@@ e@@ -@@ dependent delayed fo@@ et@@ al ossi@@ fication and possible ter@@ at@@ o@@ gen@@ ic effec@@ ts@@ , were observed in rats at d@@ oses resulting in sub@@ therapeu@@ tic exp@@ os@@ ures (@@ based on AU@@ C@@ ) and in ra@@ bb@@ its at d@@ oses resulting in exp@@ os@@ ures 3 and 11 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical d@@ os@@ e@@ .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ it@@ y@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
L@@ act@@ ose mon@@ oh@@ y@@ dr@@ ate Mai@@ ze star@@ ch Mic@@ ro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ ose Hy@@ dro@@ x@@ y@@ prop@@ yl cell@@ ul@@ ose Mag@@ ne@@ si@@ um ste@@ ar@@ ate
Y@@ ellow iron oxide (@@ E@@ 17@@ 2@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
Not applic@@ ab@@ le@@ .
6.@@ 3 Shel@@ f life
3 years
33 6.@@ 4 Special prec@@ au@@ tions for storage
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
6.5 Nature and cont@@ ents of container
Al@@ uminium per@@ for@@ ated unit dose bli@@ sters in car@@ tons of 14 x 1@@ , 28 x 1@@ , 49 x 1@@ , 56 x 1@@ , 98 x 1 tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 11@@ -@@ 0@@ 15
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
D@@ ate of first author@@ is@@ ation@@ :
4 June 2004
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
{@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
34 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 30 mg tab@@ lets
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each tab@@ let contains 30 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
Ex@@ cip@@ i@@ ent@@ :
18@@ 6.@@ 54 mg la@@ ct@@ ose per tab@@ let
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Tablet Round and p@@ ink@@ , en@@ gra@@ ved with "@@ A@@ -@@ 0@@ 11@@ " and "@@ 30@@ " on one si@@ de.
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hren@@ i@@ a.
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the pre@@ vention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pi@@ pra@@ z@@ ole treatment (@@ see section 5.@@ 1@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
O@@ ral use@@ .
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 10 or 15 m@@ g@@ / day with a maintenance dose of 15 m@@ g@@ / day administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to me@@ al@@ s.
AB@@ IL@@ I@@ F@@ Y is effective in a dose range of 10 to 30 m@@ g@@ / day@@ .
En@@ h@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
M@@ anic epis@@ o@@ des@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 15 mg administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy (@@ see section 5.@@ 1@@ )@@ .
Some patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
Rec@@ ur@@ r@@ ence pre@@ vention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pi@@ pra@@ z@@ ole@@ , continue therapy at the same d@@ os@@ e@@ .
Ad@@ ju@@ st@@ ments of daily d@@ os@@ age@@ , including dose reduction should be considered on the basis of clinical stat@@ us@@ .
Children and adol@@ es@@ cent@@ s@@ : there is no experience in children and adol@@ es@@ cents under 18 years of age@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required for patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
In patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ , the data available are in@@ sufficient to establish recommend@@ ations@@ .
Ho@@ we@@ ver@@ , the
35 maximum daily dose of 30 mg should be used with caution in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required in patients with ren@@ al im@@ pa@@ ir@@ ment@@ .
El@@ der@@ ly@@ : the effec@@ tiveness of AB@@ IL@@ I@@ F@@ Y in the treatment of sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been establi@@ sh@@ ed@@ .
O@@ wing to the greater sensi@@ tivity of this pop@@ ula@@ tion@@ , a lower starting dose should be considered when clinical factors warrant (@@ see section 4.@@ 4@@ )@@ .
Gen@@ der@@ : no d@@ os@@ age adju@@ st@@ ment is required for female patients as compared to male patients (@@ see section 5.@@ 2@@ )@@ .
Smo@@ king stat@@ us@@ : according to the met@@ aboli@@ c path@@ way of AB@@ IL@@ I@@ F@@ Y no d@@ os@@ age adju@@ st@@ ment is required for smo@@ kers (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ ors with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be re@@ duc@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ or is with@@ drawn from the combination therap@@ y@@ , ari@@ pi@@ pra@@ z@@ ole dose should then be increased (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be increas@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therap@@ y@@ , the ari@@ pi@@ pra@@ z@@ ole dose should then be reduced to the recommended dose (@@ see section 4.@@ 5@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
During anti@@ p@@ sycho@@ tic treat@@ ment@@ , improvement in the pati@@ ent@@ '@@ s clinical condition may take several days to some wee@@ ks@@ .
Pati@@ ents should be closely monit@@ ored throughout this peri@@ od@@ .
The occ@@ ur@@ r@@ ence of suici@@ dal behaviour is inher@@ ent in p@@ sycho@@ tic ill@@ nesses and mood disor@@ ders and in some cases has been reported early after initi@@ ation or switch of anti@@ p@@ sycho@@ tic therap@@ y@@ , including treatment with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
C@@ lose super@@ vision of high@@ -@@ risk patients should ac@@ company anti@@ p@@ sycho@@ tic therap@@ y@@ .
Res@@ ults of an epide@@ mi@@ ological study found that there was no increased risk of suici@@ d@@ ality with ari@@ pi@@ pra@@ z@@ ole compared to other anti@@ p@@ sycho@@ tics among patients with bi@@ pol@@ ar disor@@ der@@ .
Cardi@@ ov@@ as@@ cular disor@@ der@@ s@@ :
Ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with known cardi@@ ov@@ as@@ cular disease (@@ history of m@@ yo@@ cardi@@ al inf@@ ar@@ ction or i@@ scha@@ e@@ mic heart dise@@ as@@ e@@ , heart fail@@ ure@@ , or conduc@@ tion ab@@ nor@@ mali@@ ti@@ es@@ )@@ , cer@@ eb@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ ension (@@ de@@ hy@@ dra@@ tion@@ , hypo@@ vol@@ emi@@ a@@ , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations@@ ) or hyper@@ ten@@ sion@@ , including acceler@@ ated or mal@@ ign@@ ant@@ .
Con@@ duction ab@@ nor@@ mali@@ ti@@ es@@ :
In clinical trials of ari@@ pi@@ pra@@ z@@ ole@@ , the inci@@ dence of Q@@ T pro@@ long@@ ation was compar@@ able to pla@@ c@@ ebo@@ .
As with other anti@@ p@@ sycho@@ tic@@ s@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with a family history of Q@@ T pro@@ long@@ ation@@ .
T@@ ardi@@ ve Dy@@ sk@@ ine@@ si@@ a@@ : in clinical trials of one year or less dur@@ ation@@ , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ ine@@ sia during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
If signs and symptoms of tar@@ di@@ ve dy@@ sk@@ ine@@ sia appear in a patient on AB@@ IL@@ I@@ F@@ Y@@ , dose reduction or dis@@ continu@@ ation should be consider@@ ed@@ .
These symptoms can tempor@@ ally deterior@@ ate or can even ari@@ se after dis@@ continu@@ ation of treat@@ ment@@ .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ :
N@@ MS is a potentially fatal symp@@ tom complex associated with anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ .
In clinical tri@@ al@@ s@@ , rare cases of N@@ MS were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
36 mental status and evidence of auton@@ omic inst@@ ability (@@ ir@@ regular pul@@ se or blood pressu@@ re@@ , ta@@ ch@@ y@@ cardi@@ a@@ , di@@ aph@@ ore@@ sis and cardi@@ ac dys@@ rhyth@@ mi@@ a@@ )@@ .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ as@@ e@@ , m@@ yo@@ glob@@ in@@ uri@@ a (@@ r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ )@@ , and ac@@ ute ren@@ al fail@@ ure@@ .
Ho@@ we@@ ver@@ , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , not necessarily in association with N@@ M@@ S@@ , have also been repor@@ te@@ d.
If a patient develop@@ s signs and symptoms indic@@ ative of N@@ M@@ S@@ , or presents with un@@ explained high fe@@ ver without additional clinical manifest@@ ations of N@@ M@@ S@@ , all anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ , including AB@@ IL@@ I@@ F@@ Y@@ , must be dis@@ continu@@ ed@@ .
Sei@@ zu@@ re@@ : in clinical tri@@ al@@ s@@ , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Ther@@ e@@ fore@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients who have a history of sei@@ z@@ ure disorder or have conditions associated with sei@@ zu@@ res@@ .
El@@ derly patients with demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s@@ :
In@@ cre@@ ased mort@@ al@@ it@@ y@@ : in three pla@@ c@@ ebo@@ -@@ controlled trials (@@ n@@ = 9@@ 38@@ ; mean age@@ :
8@@ 2.@@ 4 ye@@ ar@@ s@@ ; ran@@ ge@@ :
56@@ -@@ 99 ye@@ ar@@ s@@ ) of ari@@ pi@@ pra@@ z@@ ole in elderly patients with p@@ sycho@@ sis associated with Al@@ z@@ hei@@ mer@@ '@@ s dise@@ as@@ e@@ , patients treated with ari@@ pi@@ pra@@ z@@ ole were at increased risk of death compared to pla@@ c@@ ebo@@ .
The rate of death in ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients was 3.@@ 5@@ % compared to 1.@@ 7@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
Although the causes of deaths were var@@ ie@@ d@@ , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular (@@ e@@ . g. heart fail@@ ure@@ , sudden de@@ ath@@ ) or inf@@ ec@@ tious (@@ e@@ . g. p@@ ne@@ um@@ oni@@ a@@ ) in nat@@ ure@@ .
Cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse event@@ s@@ : in the same tri@@ al@@ s@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events (@@ e@@ . g. stro@@ ke@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ )@@ , including fat@@ ali@@ ti@@ es@@ , were reported in patients (@@ mean age@@ :
84 ye@@ ar@@ s@@ ; ran@@ ge@@ :
78@@ -@@ 88 ye@@ ar@@ s@@ )@@ .
Over@@ all@@ , 1.@@ 3@@ % of ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients reported cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events compared with 0.@@ 6@@ % of pla@@ c@@ ebo@@ -@@ treated patients in these tri@@ al@@ s.
This difference was not stati@@ st@@ ically signific@@ ant@@ .
Ho@@ we@@ ver@@ , in one of these tri@@ al@@ s@@ , a fix@@ ed@@ -@@ dose tri@@ al@@ , there was a significant dose response relationship for cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events in patients treated with ari@@ pi@@ pra@@ z@@ ole@@ .
AB@@ IL@@ I@@ F@@ Y is not approved for the treatment of demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s.
Hy@@ per@@ g@@ ly@@ ca@@ emi@@ a and Diabetes Mel@@ li@@ t@@ us@@ : hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , in some cases extreme and associated with ket@@ o@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or de@@ ath@@ , has been reported in patients treated with at@@ yp@@ ical anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ris@@ k factors that may pre@@ disp@@ ose patients to severe complic@@ ations include obesity and family history of di@@ abet@@ es@@ .
In clinical trials with ari@@ pi@@ pra@@ z@@ ole@@ , there were no significant differences in the inci@@ dence rates of hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events (@@ including di@@ abet@@ es@@ ) or in ab@@ normal g@@ ly@@ ca@@ emi@@ a lab@@ oratory values compared to pla@@ c@@ ebo@@ .
Pre@@ cise risk estimates for hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events in patients treated with AB@@ IL@@ I@@ F@@ Y and with other at@@ yp@@ ical anti@@ p@@ sycho@@ tic agents are not available to allow direct compar@@ is@@ ons@@ .
Pati@@ ents treated with any anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ , should be observed for signs and symptoms of hyper@@ g@@ ly@@ ca@@ emi@@ a (@@ such as poly@@ di@@ p@@ si@@ a@@ , poly@@ uri@@ a@@ , poly@@ ph@@ ag@@ ia and weak@@ ness@@ ) and patients with diabetes mel@@ li@@ tus or with risk factors for diabetes mel@@ li@@ tus should be monit@@ ored regularly for wor@@ sen@@ ing of glu@@ c@@ ose contro@@ l.
Wei@@ ght ga@@ in@@ : weight gain is commonly seen in sch@@ iz@@ op@@ hren@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ti@@ es@@ , use of anti@@ p@@ sycho@@ tics known to cause weight ga@@ in@@ , poor@@ ly managed li@@ fe@@ -@@ sty@@ le@@ , and might lead to severe complic@@ ations@@ .
Wei@@ ght gain has been reported post@@ -@@ marketing among patients prescri@@ bed AB@@ IL@@ I@@ F@@ Y@@ .
When se@@ en@@ , it is usually in those with significant risk factors such as history of di@@ abet@@ es@@ , th@@ y@@ ro@@ id disorder or pit@@ u@@ it@@ ary aden@@ om@@ a.
In clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight gain (@@ see section 5.@@ 1@@ )@@ .
Dy@@ sph@@ ag@@ i@@ a@@ : o@@ es@@ op@@ ha@@ ge@@ al dy@@ smo@@ tili@@ ty and aspi@@ ration have been associated with anti@@ p@@ sycho@@ tic drug use@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ari@@ pi@@ pra@@ z@@ ole and other anti@@ p@@ sycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for aspi@@ ration p@@ ne@@ um@@ oni@@ a.
L@@ act@@ os@@ e@@ : patients with rare her@@ edi@@ tary problems of gal@@ act@@ ose int@@ oler@@ anc@@ e@@ , the l@@ app la@@ ct@@ ase def@@ ici@@ ency or glu@@ cos@@ e@@ -@@ gal@@ act@@ ose mal@@ absor@@ ption should not take this medic@@ inal produc@@ t.
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ : as with other medic@@ ations hyper@@ sensi@@ tivity re@@ ac@@ tions@@ , character@@ ised by aller@@ gic symp@@ tom@@ s@@ , may occur with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
37 4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
D@@ ue to its α 1@@ -@@ ad@@ ren@@ er@@ gic rec@@ ep@@ tor ant@@ agon@@ is@@ m@@ , ari@@ pi@@ pra@@ z@@ ole has the potential to enh@@ ance the effect of certain anti@@ hyper@@ ten@@ sive ag@@ ent@@ s.
Given the primary CN@@ S effects of ari@@ pi@@ pra@@ z@@ ole@@ , caution should be used when ari@@ pi@@ pra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping un@@ desi@@ rable effects such as se@@ dation (@@ see section 4.@@ 8@@ )@@ .
If ari@@ pi@@ pra@@ z@@ ole is administ@@ ered con@@ co@@ mit@@ antly with medic@@ ines known to cause Q@@ T pro@@ long@@ ation or elec@@ tro@@ ly@@ te im@@ bal@@ anc@@ e@@ , caution should be use@@ d.
Pot@@ ential for other medic@@ inal products to affect AB@@ IL@@ I@@ F@@ Y@@ :
A ga@@ stri@@ c acid blo@@ cker@@ , the H@@ 2 ant@@ agon@@ ist f@@ amo@@ ti@@ d@@ ine@@ , redu@@ ces ari@@ pi@@ pra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relev@@ ant@@ .
Ari@@ pi@@ pra@@ z@@ ole is met@@ aboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ ym@@ es but not C@@ Y@@ P@@ 1@@ A enz@@ ym@@ es@@ .
Th@@ us@@ , no d@@ os@@ age adju@@ st@@ ment is required for smo@@ ker@@ s.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ qu@@ ini@@ d@@ ine@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C by 10@@ 7@@ %@@ , while C@@ max was un@@ ch@@ ange@@ d.
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , decre@@ ased by 32@@ % and 47@@ %@@ .
AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed dose when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y with qu@@ ini@@ dine occ@@ urs@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 2@@ D@@ 6@@ , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 3@@ A4 (@@ ket@@ o@@ con@@ az@@ ole@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C and C@@ max by 6@@ 3@@ % and 37@@ %@@ , respec@@ ti@@ vel@@ y@@ .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole increased by 77@@ % and 43@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor met@@ aboli@@ ser@@ s@@ , con@@ co@@ mit@@ ant use of pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 may result in higher p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive met@@ aboli@@ zer@@ s.
When considering con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors with AB@@ IL@@ I@@ F@@ Y@@ , potential benefits should out@@ weigh the potential risks to the pati@@ ent@@ .
When con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ o@@ z@@ ole with AB@@ IL@@ I@@ F@@ Y occ@@ urs@@ , AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed d@@ os@@ e@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A@@ 4@@ , such as it@@ ra@@ con@@ az@@ ole and HIV prot@@ ease in@@ hi@@ bit@@ or@@ s@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hi@@ bit@@ or@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be increased to the level prior to the initi@@ ation of the con@@ co@@ mit@@ ant therap@@ y@@ .
When weak in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 (@@ e@@ . g@@ .@@ , dil@@ ti@@ az@@ em or esc@@ ital@@ op@@ ra@@ m@@ ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ co@@ mit@@ antly with AB@@ IL@@ I@@ F@@ Y@@ , modest increases in ari@@ pi@@ pra@@ z@@ ole conc@@ ent@@ rations might be expec@@ te@@ d.
Following con@@ co@@ mit@@ ant administration of car@@ b@@ amaz@@ ep@@ ine@@ , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A@@ 4@@ , the ge@@ omet@@ ric means of C@@ max and AU@@ C for ari@@ pi@@ pra@@ z@@ ole were 68@@ % and 7@@ 3@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , compared to when ari@@ pi@@ pra@@ z@@ ole (@@ 30 m@@ g@@ ) was administ@@ ered al@@ one@@ .
Simi@@ lar@@ ly@@ , for de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole the ge@@ omet@@ ric means of C@@ max and AU@@ C after car@@ b@@ amaz@@ ep@@ ine co@@ -@@ administration were 69@@ % and 7@@ 1@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , than those following treatment with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
AB@@ IL@@ I@@ F@@ Y dose should be doubled when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y occ@@ urs with car@@ b@@ amaz@@ ep@@ ine@@ .
John@@ '@@ s Wort@@ ) may be expected to have similar effects and similar dose increases should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be reduced to the recommended d@@ os@@ e@@ .
38 When either val@@ pro@@ ate or li@@ thi@@ um were administ@@ ered con@@ co@@ mit@@ antly with ari@@ pi@@ pra@@ z@@ ole@@ , there was no clin@@ ically significant change in ari@@ pi@@ pra@@ z@@ ole conc@@ entra@@ tions@@ .
Pot@@ ential for AB@@ IL@@ I@@ F@@ Y to affect other medic@@ inal produc@@ ts@@ :
In clinical stu@@ dies@@ , 10@@ -@@ 30 m@@ g@@ / day d@@ oses of ari@@ pi@@ pra@@ z@@ ole had no significant effect on the met@@ aboli@@ sm of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ / 3@@ -@@ metho@@ x@@ y@@ mor@@ ph@@ in@@ an rati@@ o@@ )@@ , 2@@ C@@ 9 (@@ war@@ far@@ in@@ )@@ , 2@@ C@@ 19 (@@ om@@ ep@@ raz@@ ole@@ )@@ , and 3@@ A4 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ )@@ .
Addi@@ tion@@ all@@ y@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole did not show potential for al@@ tering C@@ Y@@ P@@ 1@@ A@@ 2@@ -@@ medi@@ ated met@@ aboli@@ sm in vit@@ ro@@ .
Th@@ us@@ , ari@@ pi@@ pra@@ z@@ ole is unlikely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ ym@@ es@@ .
When ari@@ pi@@ pra@@ z@@ ole was administ@@ ered con@@ co@@ mit@@ antly with either val@@ pro@@ ate or li@@ thi@@ um@@ , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ thi@@ um conc@@ entra@@ tions@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled trials of ari@@ pi@@ pra@@ z@@ ole in pregnant wom@@ en@@ .
Ani@@ mal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
D@@ ue to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive stu@@ dies@@ , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ et@@ us@@ .
Ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during la@@ ct@@ ation@@ .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pi@@ pra@@ z@@ ole@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been per@@ for@@ med@@ .
Ho@@ we@@ ver@@ , as with other anti@@ p@@ sycho@@ tic@@ s@@ , patients should be cau@@ tioned about operating ha@@ z@@ ard@@ ous mach@@ in@@ es@@ , including motor v@@ ehic@@ les@@ , until they are reas@@ onably certain that ari@@ pi@@ pra@@ z@@ ole does not affect them adver@@ sel@@ y@@ .
4.@@ 8 Un@@ desi@@ rable effects
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ )@@ :
The frequ@@ ency listed below is defined using the following conven@@ tion@@ : common (@@ > 1@@ / 100 ,@@ < 1@@ /@@ 10@@ ) and un@@ common (@@ > 1@@ /@@ 1 ,@@ 00@@ 0@@ , < 1@@ /@@ 100@@ )@@ .
Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous System disor@@ ders Common@@ : ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disor@@ der@@ , ak@@ ath@@ isi@@ a@@ , tre@@ mor@@ , di@@ zz@@ in@@ ess@@ , som@@ n@@ ol@@ en@@ ce@@ , se@@ d@@ ation@@ , hea@@ da@@ che E@@ ye disor@@ ders Common@@ : bl@@ urred vision Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : dy@@ sp@@ ep@@ si@@ a@@ , vo@@ mit@@ ing@@ , nau@@ se@@ a@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ * General disor@@ ders and administration site conditions Common@@ : f@@ ati@@ gue P@@ sychiatri@@ c disor@@ ders Common@@ : rest@@ less@@ ness@@ , ins@@ om@@ ni@@ a@@ , anxiety Un@@ common@@ : depres@@ sion@@ *
39 Ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symptoms (@@ EP@@ S@@ )@@ :
Sch@@ iz@@ op@@ hren@@ ia - in a long term 5@@ 2@@ -@@ week controlled tri@@ al@@ , ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients had an over@@ all@@ -@@ lower inci@@ dence (@@ 25.@@ 8@@ %@@ ) of E@@ PS including par@@ kin@@ son@@ is@@ m@@ , ak@@ ath@@ isi@@ a@@ , dy@@ st@@ onia and dy@@ sk@@ ine@@ sia compared with those treated with hal@@ operi@@ dol (@@ 5@@ 7.@@ 3@@ %@@ )@@ .
In a long term 26@@ -@@ week pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 19@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 13.@@ 1@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In another long@@ -@@ term 26@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 14.@@ 8@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 1@@ % for ol@@ anz@@ ap@@ ine@@ -@@ treated pati@@ ent@@ s.
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 23.@@ 5@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 5@@ 3.@@ 3@@ % for hal@@ operi@@ dol@@ -@@ treated pati@@ ent@@ s.
In another 12@@ -@@ week tri@@ al@@ , the inci@@ dence of E@@ PS was 26.@@ 6@@ % for patients treated with ari@@ pi@@ pra@@ z@@ ole and 17.@@ 6@@ % for those treated with li@@ thi@@ um@@ .
In the long term 26@@ -@@ week maintenance phase of a pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 18.@@ 2@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 7@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ s@@ , the inci@@ dence of ak@@ ath@@ i@@ sia in bi@@ pol@@ ar patients was 12.@@ 1@@ % with ari@@ pi@@ pra@@ z@@ ole and 3.@@ 2@@ % with pla@@ c@@ ebo@@ .
In sch@@ iz@@ op@@ hren@@ ia patients the inci@@ dence of ak@@ ath@@ i@@ sia was 6.@@ 2@@ % with ari@@ pi@@ pra@@ z@@ ole and 3@@ .0@@ % with pla@@ c@@ ebo@@ .
Com@@ par@@ is@@ ons between ari@@ pi@@ pra@@ z@@ ole and pla@@ c@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine lab@@ oratory par@@ ame@@ ters revealed no medi@@ cally important differ@@ en@@ c@@ es@@ .
Ele@@ v@@ ations of C@@ P@@ K (@@ Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ )@@ , generally tran@@ si@@ ent and as@@ ymp@@ tom@@ ati@@ c@@ , were observed in 3.@@ 5@@ % of ari@@ pi@@ pra@@ z@@ ole treated patients as compared to 2@@ .0@@ % of patients who received pla@@ c@@ ebo@@ .
Other fin@@ d@@ ings@@ :
Un@@ desi@@ rable effects known to be associated with anti@@ p@@ sycho@@ tic therapy and also reported during treatment with ari@@ pi@@ pra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ dro@@ me@@ , tar@@ di@@ ve dy@@ sk@@ ine@@ si@@ a@@ , sei@@ zu@@ re@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly de@@ mented pati@@ ent@@ s@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ tus (@@ see section 4.@@ 4@@ )@@ .
Post@@ -@@ Market@@ ing@@ :
The following ad@@ verse events have been reported during post@@ -@@ marketing sur@@ veil@@ lan@@ ce@@ .
The frequ@@ ency of these events is considered not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Investig@@ ations@@ :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ , blood glu@@ c@@ ose increas@@ ed@@ , blood glu@@ c@@ ose flu@@ ctu@@ ation@@ , g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in increased
Cardi@@ ac disor@@ der@@ s@@ :
Q@@ T pro@@ long@@ ation@@ , vent@@ ri@@ cular arr@@ hyth@@ mi@@ as@@ , sudden un@@ explained de@@ ath@@ , cardi@@ ac ar@@ rest@@ , tor@@ sa@@ des de poin@@ tes@@ , bra@@ dy@@ car@@ dia
Bloo@@ d and the lymp@@ h@@ atic system disor@@ der@@ s@@ :
leu@@ kop@@ eni@@ a@@ , neut@@ rop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia
Ner@@ v@@ ous system disor@@ der@@ s@@ :
speech disor@@ der@@ , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ , grand mal con@@ vul@@ sion
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ s@@ :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m@@ , lar@@ yn@@ g@@ os@@ pas@@ m@@ , aspi@@ ration p@@ ne@@ um@@ onia
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
pan@@ cre@@ ati@@ tis@@ , dy@@ sph@@ ag@@ i@@ a@@ , ab@@ dom@@ inal dis@@ comfort@@ , stomach dis@@ comfort@@ , di@@ arr@@ ho@@ ea
Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
ur@@ inary in@@ contin@@ en@@ ce@@ , ur@@ inary re@@ tention
Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
ra@@ sh@@ , ph@@ otos@@ en@@ si@@ tivity re@@ ac@@ tion@@ , al@@ op@@ eci@@ a@@ , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , my@@ al@@ gi@@ a@@ , sti@@ ff@@ ness
En@@ do@@ cr@@ ine disor@@ der@@ s@@ :
hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , diabetes mel@@ li@@ t@@ us@@ , di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s@@ , di@@ abe@@ tic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
weight ga@@ in@@ , weight decre@@ as@@ ed@@ , an@@ or@@ ex@@ i@@ a@@ , h@@ yp@@ on@@ at@@ re@@ mia
V@@ as@@ cular disor@@ der@@ s@@ :
syn@@ cop@@ e@@ , hyper@@ ten@@ sion@@ , thro@@ mbo@@ em@@ bo@@ lic events
General disor@@ ders and administration site condi@@ tions@@ :
temperature regulation disorder (@@ e@@ . g. hypo@@ ther@@ mi@@ a@@ , py@@ re@@ xi@@ a@@ )@@ , chest pain@@ , peri@@ pher@@ al oe@@ de@@ ma
Immun@@ e system disor@@ der@@ s@@ :
aller@@ gic reaction (@@ e@@ . g. an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ , an@@ gi@@ oe@@ de@@ ma including s@@ wollen ton@@ gu@@ e@@ , ton@@ gue oe@@ de@@ ma@@ , face oe@@ de@@ ma@@ , p@@ ru@@ rit@@ us@@ , or ur@@ tic@@ ari@@ a@@ )
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ der@@ s@@ :
ja@@ un@@ di@@ ce@@ , he@@ pati@@ tis@@ , increased A@@ lan@@ ine A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ AL@@ T@@ )@@ , increased A@@ spar@@ tate A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ A@@ ST@@ )@@ , increased G@@ amm@@ a Gl@@ ut@@ am@@ yl Transfer@@ ase (@@ G@@ GT@@ )@@ , increased al@@ kal@@ ine ph@@ osp@@ hat@@ ase
Re@@ productive system and breast disor@@ der@@ s@@ :
pri@@ ap@@ ism
P@@ sychiatri@@ c disor@@ der@@ s@@ :
ag@@ it@@ ation@@ , nerv@@ ous@@ ness@@ ; suicide attemp@@ t@@ , suici@@ dal ide@@ ation@@ , and completed suicide (@@ see section 4.@@ 4@@ )
4.@@ 9 Over@@ dose
In clinical trials and post@@ -@@ marketing experi@@ en@@ ce@@ , acci@@ dental or inten@@ tional ac@@ ute over@@ d@@ os@@ age of ari@@ pi@@ pra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy@@ , increased blood pressu@@ re@@ , som@@ n@@ ol@@ en@@ ce@@ , ta@@ ch@@ y@@ cardi@@ a@@ , nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ e@@ a.
In addi@@ tion@@ , reports of acci@@ dental over@@ dose with ari@@ pi@@ pra@@ z@@ ole alone (@@ up to 19@@ 5 m@@ g@@ ) in children have been received with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ en@@ ce@@ , tran@@ si@@ ent loss of consci@@ ousness and ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symp@@ tom@@ s.
Management of over@@ dose should concentrate on supportive therap@@ y@@ , maintaining an adequate air@@ wa@@ y@@ , oxy@@ gen@@ ation and v@@ enti@@ la@@ tion@@ , and management of symp@@ tom@@ s.
The possibility of multiple medic@@ inal product involvement should be consider@@ ed@@ .
Ther@@ efore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continu@@ ous elec@@ tro@@ cardi@@ o@@ graphic monitoring to dete@@ ct possible arr@@ hyth@@ mi@@ as@@ .
Following any confirmed or suspected over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , close medical super@@ vision and monitoring should continue until the patient reco@@ vers@@ .
Ac@@ tiv@@ ated char@@ coal (@@ 50 g@@ )@@ , administ@@ ered one hour after ari@@ pi@@ pra@@ z@@ ole@@ , decre@@ ased ari@@ pi@@ pra@@ z@@ ole C@@ max by about 4@@ 1@@ % and AU@@ C by about 5@@ 1@@ %@@ , suggesting that char@@ coal may be effective in the treatment of over@@ d@@ os@@ e@@ .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in treating an over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , ha@@ emo@@ di@@ aly@@ sis is unlikely to be useful in over@@ dose management since ari@@ pi@@ pra@@ z@@ ole is highly bound to p@@ las@@ ma prot@@ ein@@ s.
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ p@@ sycho@@ tic@@ s@@ , AT@@ C co@@ de@@ :
N@@ 05@@ A@@ X@@ 12
41 It has been proposed that ari@@ pi@@ pra@@ z@@ ole@@ ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ amine D@@ 2 and ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a rec@@ ep@@ tors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hypo@@ activ@@ it@@ y@@ .
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited high bin@@ ding aff@@ in@@ ity in vit@@ ro for d@@ op@@ amine D@@ 2 and D@@ 3@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a and 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tors and moderate aff@@ in@@ ity for d@@ op@@ amine D@@ 4@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ c and 5@@ H@@ T@@ 7@@ , alp@@ ha@@ -@@ 1 ad@@ ren@@ er@@ gic and hist@@ amine H@@ 1 rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole also exhi@@ bited moderate bin@@ ding aff@@ in@@ ity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ in@@ ity for mus@@ car@@ ini@@ c rec@@ ep@@ tor@@ s.
Inter@@ action with rec@@ ep@@ tors other than d@@ op@@ amine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pi@@ pra@@ z@@ ole@@ .
Ari@@ pi@@ pra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a d@@ os@@ e@@ -@@ dependent reduction in the bin@@ ding of 11@@ C@@ -@@ ra@@ clo@@ pri@@ de@@ , a D@@ 2@@ / D@@ 3 rec@@ ep@@ tor lig@@ and@@ , to the cau@@ date and put@@ amen dete@@ cted by posi@@ tr@@ on e@@ mission tom@@ o@@ grap@@ hy@@ .
Further information on clinical tri@@ al@@ s@@ :
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
In three short@@ -@@ term (@@ 4 to 6 wee@@ ks@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 1,@@ 228 sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s@@ , presenting with positive or negative symp@@ tom@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was associated with stati@@ st@@ ically significantly greater improvements in p@@ sycho@@ tic symptoms compared to pla@@ c@@ ebo@@ .
AB@@ IL@@ I@@ F@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment respon@@ se@@ .
In a hal@@ operi@@ dol@@ -@@ controlled tri@@ al@@ , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2@@ -@@ weeks was similar in both groups (@@ ari@@ pi@@ pra@@ z@@ ole 77@@ % and hal@@ operi@@ dol 7@@ 3@@ %@@ )@@ .
The overall comple@@ tion rate was significantly higher for patients on ari@@ pi@@ pra@@ z@@ ole (@@ 43@@ %@@ ) than for hal@@ operi@@ dol (@@ 30@@ %@@ )@@ .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ poin@@ ts@@ , including P@@ AN@@ SS and the Montgom@@ er@@ y@@ -@@ As@@ berg Depression R@@ ating Sc@@ ale showed a significant improvement over hal@@ operi@@ dol@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hren@@ i@@ a@@ , ari@@ pi@@ pra@@ z@@ ole had significantly greater reduction in re@@ lap@@ se rat@@ e@@ , 34@@ % in ari@@ pi@@ pra@@ z@@ ole group and 57@@ % in pla@@ c@@ ebo@@ .
Wei@@ ght ga@@ in@@ : in clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight ga@@ in@@ .
In a 26@@ -@@ week@@ , ol@@ anz@@ ap@@ ine@@ -@@ contro@@ lle@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , multi@@ -@@ national study of sch@@ iz@@ op@@ hren@@ ia which included 3@@ 14 patients and where the primary end@@ -@@ point was weight ga@@ in@@ , significantly less patients had at least 7@@ % weight gain over bas@@ eline (@@ i@@ . e@@ . a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~@@ 8@@ 0.5 k@@ g@@ ) on ari@@ pi@@ pra@@ z@@ ole (@@ N@@ = 18@@ , or 13@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ , compared to ol@@ anz@@ ap@@ ine (@@ N@@ = 45@@ , or 33@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ .
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
In two 3@@ -@@ week@@ , flexi@@ ble@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o in reduction of man@@ ic symptoms over 3 wee@@ ks@@ .
These trials included patients with or without p@@ sycho@@ tic features and with or without a rap@@ id@@ -@@ cycling cour@@ se@@ .
In one 3@@ -@@ week@@ , fix@@ ed@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to pla@@ c@@ ebo@@ .
In two 12@@ -@@ week@@ , pla@@ c@@ ebo@@ - and ac@@ ti@@ ve@@ -@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o at week 3 and a maintenance of effect compar@@ able to li@@ thi@@ um or hal@@ operi@@ dol at week 12.
Ari@@ pi@@ pra@@ z@@ ole also demonstrated a compar@@ able proportion of patients in symp@@ tom@@ atic re@@ mission from man@@ ia as li@@ thi@@ um or hal@@ operi@@ dol at week 12.
In a 6@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , who were parti@@ ally non@@ -@@ respon@@ sive to li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeu@@ tic ser@@ um level@@ s@@ , the addition of ari@@ pi@@ pra@@ z@@ ole as ad@@ jun@@ ctive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therap@@ y@@ .
42 In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , followed by a 7@@ 4@@ -@@ week exten@@ sion@@ , in man@@ ic patients who achieved re@@ mission on ari@@ pi@@ pra@@ z@@ ole during a stabili@@ zation phase prior to rand@@ omi@@ z@@ ation@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ ren@@ ce@@ , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depres@@ sion@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ab@@ sor@@ p@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is well absor@@ bed@@ , with peak p@@ las@@ ma conc@@ ent@@ rations occ@@ urring within 3@@ -@@ 5 hours after d@@ os@@ ing@@ .
Ari@@ pi@@ pra@@ z@@ ole under@@ goes minimal pre@@ -@@ sy@@ ste@@ mic met@@ aboli@@ sm@@ .
The absolute oral bio@@ availability of the tab@@ let formu@@ lation is 8@@ 7@@ %@@ .
There is no effect of a high fat meal on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Distri@@ bu@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is widely distri@@ buted throughout the body with an apparent volume of distribution of 4.@@ 9 l@@ / k@@ g@@ , indic@@ ating extensive extra@@ v@@ as@@ cular distri@@ bu@@ tion@@ .
At therapeu@@ tic conc@@ entra@@ tions@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole are greater than 99@@ % bound to ser@@ um prot@@ ein@@ s@@ , bin@@ ding primarily to alb@@ umin@@ .
Met@@ aboli@@ sm@@ :
Ari@@ pi@@ pra@@ z@@ ole is exten@@ sively met@@ aboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ wa@@ ys@@ : de@@ hydro@@ gen@@ ation@@ , hydro@@ x@@ y@@ la@@ tion@@ , and N@@ -@@ deal@@ k@@ y@@ la@@ tion@@ .
Based on in vit@@ ro stu@@ dies@@ , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ ym@@ es are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ y@@ lation of ari@@ pi@@ pra@@ z@@ ole@@ , and N@@ -@@ deal@@ k@@ y@@ lation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A@@ 4.
Ari@@ pi@@ pra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ iety in sy@@ ste@@ mic circu@@ la@@ tion@@ .
At steady stat@@ e@@ , de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , represents about 40@@ % of ari@@ pi@@ pra@@ z@@ ole AU@@ C in p@@ las@@ ma@@ .
Eli@@ min@@ ation@@ :
The mean elim@@ ination half@@ -@@ lives for ari@@ pi@@ pra@@ z@@ ole are approximately 75 hours in extensive met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6.
The total body clear@@ ance of ari@@ pi@@ pra@@ z@@ ole is 0.@@ 7 m@@ l@@ / min@@ / k@@ g@@ , which is primarily he@@ pati@@ c.
Following a single oral dose of [@@ 14@@ C@@ ]@@ -@@ lab@@ elled ari@@ pi@@ pra@@ z@@ ole@@ , approximately 27@@ % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60@@ % in the fa@@ ec@@ es@@ .
L@@ ess than 1@@ % of un@@ changed ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18@@ % was recovered un@@ changed in the fa@@ ec@@ es@@ .
P@@ harm@@ ac@@ ok@@ ine@@ tics in special patient groups
El@@ der@@ ly@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy elderly and younger adult sub@@ jec@@ ts@@ , nor is there any dete@@ ct@@ able effect of age in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Gen@@ der@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy male and female subjects nor is there any dete@@ ct@@ able effect of gender in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Smo@@ king and Rac@@ e@@ :
Pop@@ ulation pharmac@@ ok@@ ine@@ tic ev@@ al@@ uation has revealed no evidence of clin@@ ically significant ra@@ ce@@ -@@ related differences or effects from smoking upon the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Ren@@ al Di@@ seas@@ e@@ :
The pharmac@@ ok@@ ine@@ tic characterist@@ ics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy sub@@ jec@@ ts@@ .
43 H@@ ep@@ atic Di@@ seas@@ e@@ :
A sing@@ le@@ -@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis (@@ Chil@@ d@@ -@@ Pu@@ gh Clas@@ ses A@@ , B@@ , and C@@ ) did not reveal a significant effect of he@@ pati@@ c im@@ pa@@ ir@@ ment on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ si@@ s@@ , which is in@@ sufficient to draw conclu@@ sions on their met@@ aboli@@ c cap@@ ac@@ it@@ y@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
Non@@ -@@ clinical safety data revealed no special ha@@ zard for humans based on conventional studies of safety pharmac@@ olog@@ y@@ , repe@@ at@@ -@@ dose tox@@ ic@@ it@@ y@@ , gen@@ oto@@ x@@ ic@@ it@@ y@@ , car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ , and tox@@ ic@@ ity to re@@ produc@@ tion@@ .
To@@ x@@ ic@@ ologi@@ cally significant effects were observed only at d@@ oses or exp@@ os@@ ures that were suff@@ ici@@ ently in excess of the maximum human dose or exp@@ os@@ ure@@ , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use@@ .
These inclu@@ de@@ d@@ : d@@ os@@ e@@ -@@ dependent ad@@ reno@@ cor@@ tical tox@@ ic@@ ity (@@ li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and@@ / or par@@ en@@ ch@@ y@@ mal cell los@@ s@@ ) in rats after 104 weeks at 20 to 60 m@@ g@@ / k@@ g@@ / day (@@ 3 to 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ ) and increased ad@@ reno@@ cor@@ tical car@@ cin@@ om@@ as and combined ad@@ reno@@ cor@@ tical aden@@ om@@ as@@ / car@@ cin@@ om@@ as in female rats at 60 m@@ g@@ / k@@ g@@ / day (@@ 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ )@@ .
The highest non@@ tum@@ ori@@ gen@@ ic exposure in female rats was 7 times the human exposure at the recommended d@@ os@@ e@@ .
An additional finding was chol@@ eli@@ thi@@ asi@@ s as a consequ@@ ence of pre@@ cip@@ itation of sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy met@@ aboli@@ tes of ari@@ pi@@ pra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 m@@ g@@ / k@@ g@@ / day (@@ 1 to 3 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on m@@ g@@ / m@@ 2@@ )@@ .
Ho@@ we@@ ver@@ , the conc@@ ent@@ rations of the sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy ari@@ pi@@ pra@@ z@@ ole in human b@@ ile at the highest dose propos@@ ed@@ , 30 mg per day@@ , were no more than 6@@ % of the b@@ ile conc@@ ent@@ rations found in the mon@@ keys in the 39@@ -@@ week study and are well below (@@ 6@@ %@@ ) their limits of in vit@@ ro sol@@ u@@ bili@@ ty@@ .
Based on results of a full range of standard gen@@ oto@@ x@@ ic@@ ity test@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was considered non@@ -@@ gen@@ oto@@ x@@ ic@@ .
Ari@@ pi@@ pra@@ z@@ ole did not im@@ pair fertili@@ ty in re@@ productive tox@@ ic@@ ity stu@@ dies@@ .
Develop@@ mental tox@@ ic@@ it@@ y@@ , including d@@ os@@ e@@ -@@ dependent delayed fo@@ et@@ al ossi@@ fication and possible ter@@ at@@ o@@ gen@@ ic effec@@ ts@@ , were observed in rats at d@@ oses resulting in sub@@ therapeu@@ tic exp@@ os@@ ures (@@ based on AU@@ C@@ ) and in ra@@ bb@@ its at d@@ oses resulting in exp@@ os@@ ures 3 and 11 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical d@@ os@@ e@@ .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ it@@ y@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
L@@ act@@ ose mon@@ oh@@ y@@ dr@@ ate Mai@@ ze star@@ ch Mic@@ ro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ ose Hy@@ dro@@ x@@ y@@ prop@@ yl cell@@ ul@@ ose Mag@@ ne@@ si@@ um ste@@ ar@@ ate
Red iron oxide (@@ E@@ 17@@ 2@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
Not applic@@ ab@@ le@@ .
6.@@ 3 Shel@@ f life
3 years
44 6.@@ 4 Special prec@@ au@@ tions for storage
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
6.5 Nature and cont@@ ents of container
Al@@ uminium per@@ for@@ ated unit dose bli@@ sters in car@@ tons of 14 x 1@@ , 28 x 1@@ , 49 x 1@@ , 56 x 1@@ , 98 x 1 tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 16@@ -@@ 0@@ 20
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
D@@ ate of first author@@ is@@ ation@@ :
4 June 2004
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
{@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
45 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 10 mg or@@ o@@ disp@@ er@@ sible tab@@ lets
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each or@@ o@@ disp@@ er@@ sible tab@@ let contains 10 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
Ex@@ cip@@ i@@ ent@@ :
2 mg as@@ part@@ ame (@@ E@@ 9@@ 5@@ 1@@ ) per or@@ o@@ disp@@ er@@ sible tab@@ let
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
O@@ ro@@ disp@@ er@@ sible tab@@ let Round and p@@ ink@@ , marked with "@@ A@@ " over "@@ 6@@ 40@@ " on one side and "@@ 10@@ " on the o@@ ther@@ .
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hren@@ i@@ a.
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the pre@@ vention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pi@@ pra@@ z@@ ole treatment (@@ see section 5.@@ 1@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
O@@ ral use@@ .
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 10 or 15 m@@ g@@ / day with a maintenance dose of 15 m@@ g@@ / day administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to me@@ al@@ s.
AB@@ IL@@ I@@ F@@ Y is effective in a dose range of 10 to 30 m@@ g@@ / day@@ .
En@@ h@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
M@@ anic epis@@ o@@ des@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 15 mg administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy (@@ see section 5.@@ 1@@ )@@ .
Some patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
Rec@@ ur@@ r@@ ence pre@@ vention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pi@@ pra@@ z@@ ole@@ , continue therapy at the same d@@ os@@ e@@ .
Ad@@ ju@@ st@@ ments of daily d@@ os@@ age@@ , including dose reduction should be considered on the basis of clinical stat@@ us@@ .
The or@@ o@@ disp@@ er@@ sible tab@@ let should be placed in the mouth on the ton@@ gu@@ e@@ , where it will rapidly disp@@ er@@ se in s@@ ali@@ v@@ a.
It can be taken with or without liqui@@ d.
R@@ emo@@ val of the int@@ act or@@ o@@ disp@@ er@@ sible tab@@ let from the mouth is difficul@@ t.
Since the or@@ o@@ disp@@ er@@ sible tab@@ let is fra@@ gi@@ le@@ , it should be taken immediately on opening the bli@@ ster@@ .
Altern@@ ati@@ vel@@ y@@ , disp@@ er@@ se the tab@@ let in water and drink the resulting susp@@ en@@ sion@@ .
46 The or@@ o@@ disp@@ er@@ sible tab@@ lets may be used as an alternative to AB@@ IL@@ I@@ F@@ Y tab@@ lets for patients who have difficulty to swal@@ low AB@@ IL@@ I@@ F@@ Y tab@@ lets (@@ see also section 5.@@ 2@@ )@@ .
Children and adol@@ es@@ cent@@ s@@ : there is no experience in children and adol@@ es@@ cents under 18 years of age@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required for patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
In patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ , the data available are in@@ sufficient to establish recommend@@ ations@@ .
In these patients d@@ osing should be managed cau@@ ti@@ ous@@ ly@@ .
Ho@@ we@@ ver@@ , the maximum daily dose of 30 mg should be used with caution in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required in patients with ren@@ al im@@ pa@@ ir@@ ment@@ .
El@@ der@@ ly@@ : the effec@@ tiveness of AB@@ IL@@ I@@ F@@ Y in the treatment of sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been establi@@ sh@@ ed@@ .
O@@ wing to the greater sensi@@ tivity of this pop@@ ula@@ tion@@ , a lower starting dose should be considered when clinical factors warrant (@@ see section 4.@@ 4@@ )@@ .
Gen@@ der@@ : no d@@ os@@ age adju@@ st@@ ment is required for female patients as compared to male patients (@@ see section 5.@@ 2@@ )@@ .
Smo@@ king stat@@ us@@ : according to the met@@ aboli@@ c path@@ way of ari@@ pi@@ pra@@ z@@ ole no d@@ os@@ age adju@@ st@@ ment is required for smo@@ kers (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ ors with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be re@@ duc@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ or is with@@ drawn from the combination therap@@ y@@ , ari@@ pi@@ pra@@ z@@ ole dose should then be increased (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be increas@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therap@@ y@@ , the ari@@ pi@@ pra@@ z@@ ole dose should then be reduced to the recommended dose (@@ see section 4.@@ 5@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
During anti@@ p@@ sycho@@ tic treat@@ ment@@ , improvement in the pati@@ ent@@ '@@ s clinical condition may take several days to some wee@@ ks@@ .
Pati@@ ents should be closely monit@@ ored throughout this peri@@ od@@ .
The occ@@ ur@@ r@@ ence of suici@@ dal behaviour is inher@@ ent in p@@ sycho@@ tic ill@@ nesses and mood disor@@ ders and in some cases has been reported early after initi@@ ation or switch of anti@@ p@@ sycho@@ tic therap@@ y@@ , including treatment with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
C@@ lose super@@ vision of high@@ -@@ risk patients should ac@@ company anti@@ p@@ sycho@@ tic therap@@ y@@ .
Res@@ ults of an epide@@ mi@@ ological study found that there was no increased risk of suici@@ d@@ ality with ari@@ pi@@ pra@@ z@@ ole compared to other anti@@ p@@ sycho@@ tics among patients with bi@@ pol@@ ar disor@@ der@@ .
Cardi@@ ov@@ as@@ cular disor@@ der@@ s@@ :
Ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with known cardi@@ ov@@ as@@ cular disease (@@ history of m@@ yo@@ cardi@@ al inf@@ ar@@ ction or i@@ scha@@ e@@ mic heart dise@@ as@@ e@@ , heart fail@@ ure@@ , or conduc@@ tion ab@@ nor@@ mali@@ ti@@ es@@ )@@ , cer@@ eb@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ ension (@@ de@@ hy@@ dra@@ tion@@ , hypo@@ vol@@ emi@@ a@@ , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations@@ ) or hyper@@ ten@@ sion@@ , including acceler@@ ated or mal@@ ign@@ ant@@ .
Con@@ duction ab@@ nor@@ mali@@ ti@@ es@@ :
In clinical trials of ari@@ pi@@ pra@@ z@@ ole@@ , the inci@@ dence of Q@@ T pro@@ long@@ ation was compar@@ able to pla@@ c@@ ebo@@ .
As with other anti@@ p@@ sycho@@ tic@@ s@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with a family history of Q@@ T pro@@ long@@ ation@@ .
47 T@@ ardi@@ ve Dy@@ sk@@ ine@@ si@@ a@@ : in clinical trials of one year or less dur@@ ation@@ , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ ine@@ sia during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
If signs and symptoms of tar@@ di@@ ve dy@@ sk@@ ine@@ sia appear in a patient on AB@@ IL@@ I@@ F@@ Y@@ , dose reduction or dis@@ continu@@ ation should be consider@@ ed@@ .
These symptoms can tempor@@ ally deterior@@ ate or can even ari@@ se after dis@@ continu@@ ation of treat@@ ment@@ .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ :
N@@ MS is a potentially fatal symp@@ tom complex associated with anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ .
In clinical tri@@ al@@ s@@ , rare cases of N@@ MS were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Clin@@ ical manifest@@ ations of N@@ MS are hyper@@ py@@ re@@ xi@@ a@@ , muscle rigi@@ di@@ ty@@ , al@@ tered mental status and evidence of auton@@ omic inst@@ ability (@@ ir@@ regular pul@@ se or blood pressu@@ re@@ , ta@@ ch@@ y@@ cardi@@ a@@ , di@@ aph@@ ore@@ sis and cardi@@ ac dys@@ rhyth@@ mi@@ a@@ )@@ .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ as@@ e@@ , m@@ yo@@ glob@@ in@@ uri@@ a (@@ r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ )@@ , and ac@@ ute ren@@ al fail@@ ure@@ .
Ho@@ we@@ ver@@ , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , not necessarily in association with N@@ M@@ S@@ , have also been repor@@ te@@ d.
If a patient develop@@ s signs and symptoms indic@@ ative of N@@ M@@ S@@ , or presents with un@@ explained high fe@@ ver without additional clinical manifest@@ ations of N@@ M@@ S@@ , all anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ , including AB@@ IL@@ I@@ F@@ Y@@ , must be dis@@ continu@@ ed@@ .
Sei@@ zu@@ re@@ : in clinical tri@@ al@@ s@@ , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Ther@@ e@@ fore@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients who have a history of sei@@ z@@ ure disorder or have conditions associated with sei@@ zu@@ res@@ .
El@@ derly patients with demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s@@ :
In@@ cre@@ ased mort@@ al@@ it@@ y@@ : in three pla@@ c@@ ebo@@ -@@ controlled trials (@@ n@@ = 9@@ 38@@ ; mean age@@ :
8@@ 2.@@ 4 ye@@ ar@@ s@@ ; ran@@ ge@@ :
56@@ -@@ 99 ye@@ ar@@ s@@ ) of ari@@ pi@@ pra@@ z@@ ole in elderly patients with p@@ sycho@@ sis associated with Al@@ z@@ hei@@ mer@@ '@@ s dise@@ as@@ e@@ , patients treated with ari@@ pi@@ pra@@ z@@ ole were at increased risk of death compared to pla@@ c@@ ebo@@ .
The rate of death in ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients was 3.@@ 5@@ % compared to 1.@@ 7@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
Although the causes of deaths were var@@ ie@@ d@@ , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular (@@ e@@ . g. heart fail@@ ure@@ , sudden de@@ ath@@ ) or inf@@ ec@@ tious (@@ e@@ . g. p@@ ne@@ um@@ oni@@ a@@ ) in nat@@ ure@@ .
Cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse event@@ s@@ : in the same tri@@ al@@ s@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events (@@ e@@ . g. stro@@ ke@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ )@@ , including fat@@ ali@@ ti@@ es@@ , were reported in patients (@@ mean age@@ :
84 ye@@ ar@@ s@@ ; ran@@ ge@@ :
78@@ -@@ 88 ye@@ ar@@ s@@ )@@ .
Over@@ all@@ , 1.@@ 3@@ % of ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients reported cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events compared with 0.@@ 6@@ % of pla@@ c@@ ebo@@ -@@ treated patients in these tri@@ al@@ s.
This difference was not stati@@ st@@ ically signific@@ ant@@ .
Ho@@ we@@ ver@@ , in one of these tri@@ al@@ s@@ , a fix@@ ed@@ -@@ dose tri@@ al@@ , there was a significant dose response relationship for cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events in patients treated with ari@@ pi@@ pra@@ z@@ ole@@ .
AB@@ IL@@ I@@ F@@ Y is not approved for the treatment of demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s.
Hy@@ per@@ g@@ ly@@ ca@@ emi@@ a and Diabetes Mel@@ li@@ t@@ us@@ : hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , in some cases extreme and associated with ket@@ o@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or de@@ ath@@ , has been reported in patients treated with at@@ yp@@ ical anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ris@@ k factors that may pre@@ disp@@ ose patients to severe complic@@ ations include obesity and family history of di@@ abet@@ es@@ .
In clinical trials with ari@@ pi@@ pra@@ z@@ ole@@ , there were no significant differences in the inci@@ dence rates of hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events (@@ including di@@ abet@@ es@@ ) or in ab@@ normal g@@ ly@@ ca@@ emi@@ a lab@@ oratory values compared to pla@@ c@@ ebo@@ .
Pre@@ cise risk estimates for hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events in patients treated with AB@@ IL@@ I@@ F@@ Y and with other at@@ yp@@ ical anti@@ p@@ sycho@@ tic agents are not available to allow direct compar@@ is@@ ons@@ .
Pati@@ ents treated with any anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ , should be observed for signs and symptoms of hyper@@ g@@ ly@@ ca@@ emi@@ a (@@ such as poly@@ di@@ p@@ si@@ a@@ , poly@@ uri@@ a@@ , poly@@ ph@@ ag@@ ia and weak@@ ness@@ ) and patients with diabetes mel@@ li@@ tus or with risk factors for diabetes mel@@ li@@ tus should be monit@@ ored regularly for wor@@ sen@@ ing of glu@@ c@@ ose contro@@ l.
Wei@@ ght ga@@ in@@ : weight gain is commonly seen in sch@@ iz@@ op@@ hren@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ti@@ es@@ , use of anti@@ p@@ sycho@@ tics known to cause weight ga@@ in@@ , poor@@ ly managed li@@ fe@@ -@@ sty@@ le@@ , and might lead to severe complic@@ ations@@ .
Wei@@ ght gain has been reported post@@ -@@ marketing among patients prescri@@ bed AB@@ IL@@ I@@ F@@ Y@@ .
When se@@ en@@ , it is usually in those with significant risk factors such as history of di@@ abet@@ es@@ , th@@ y@@ ro@@ id disorder or pit@@ u@@ it@@ ary aden@@ om@@ a.
In clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight gain (@@ see section 5.@@ 1@@ )@@ .
48 Dy@@ sph@@ ag@@ i@@ a@@ : o@@ es@@ op@@ ha@@ ge@@ al dy@@ smo@@ tili@@ ty and aspi@@ ration have been associated with anti@@ p@@ sycho@@ tic drug use@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ari@@ pi@@ pra@@ z@@ ole and other anti@@ p@@ sycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for aspi@@ ration p@@ ne@@ um@@ oni@@ a.
Ph@@ en@@ yl@@ ket@@ on@@ uri@@ c@@ s@@ :
AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets contain as@@ part@@ ame@@ , a source of phen@@ yl@@ al@@ an@@ ine which may be harm@@ ful for people with phen@@ yl@@ ket@@ on@@ uri@@ a.
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ : as with other medic@@ ations hyper@@ sensi@@ tivity re@@ ac@@ tions@@ , character@@ ised by aller@@ gic symp@@ tom@@ s@@ , may occur with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
D@@ ue to its α 1@@ -@@ ad@@ ren@@ er@@ gic rec@@ ep@@ tor ant@@ agon@@ is@@ m@@ , ari@@ pi@@ pra@@ z@@ ole has the potential to enh@@ ance the effect of certain anti@@ hyper@@ ten@@ sive ag@@ ent@@ s.
Given the primary CN@@ S effects of ari@@ pi@@ pra@@ z@@ ole@@ , caution should be used when ari@@ pi@@ pra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping un@@ desi@@ rable effects such as se@@ dation (@@ see section 4.@@ 8@@ )@@ .
If ari@@ pi@@ pra@@ z@@ ole is administ@@ ered con@@ co@@ mit@@ antly with medic@@ ines known to cause Q@@ T pro@@ long@@ ation or elec@@ tro@@ ly@@ te im@@ bal@@ anc@@ e@@ , caution should be use@@ d.
Pot@@ ential for other medic@@ inal products to affect AB@@ IL@@ I@@ F@@ Y@@ :
A ga@@ stri@@ c acid blo@@ cker@@ , the H@@ 2 ant@@ agon@@ ist f@@ amo@@ ti@@ d@@ ine@@ , redu@@ ces ari@@ pi@@ pra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relev@@ ant@@ .
Ari@@ pi@@ pra@@ z@@ ole is met@@ aboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ ym@@ es but not C@@ Y@@ P@@ 1@@ A enz@@ ym@@ es@@ .
Th@@ us@@ , no d@@ os@@ age adju@@ st@@ ment is required for smo@@ ker@@ s.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ qu@@ ini@@ d@@ ine@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C by 10@@ 7@@ %@@ , while C@@ max was un@@ ch@@ ange@@ d.
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , decre@@ ased by 32@@ % and 47@@ %@@ .
AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed dose when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y with qu@@ ini@@ dine occ@@ urs@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 2@@ D@@ 6@@ , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 3@@ A4 (@@ ket@@ o@@ con@@ az@@ ole@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C and C@@ max by 6@@ 3@@ % and 37@@ %@@ , respec@@ ti@@ vel@@ y@@ .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole increased by 77@@ % and 43@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor met@@ aboli@@ ser@@ s@@ , con@@ co@@ mit@@ ant use of pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 may result in higher p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive met@@ aboli@@ zer@@ s.
When considering con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors with AB@@ IL@@ I@@ F@@ Y@@ , potential benefits should out@@ weigh the potential risks to the pati@@ ent@@ .
When con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ o@@ z@@ ole with AB@@ IL@@ I@@ F@@ Y occ@@ urs@@ , AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed d@@ os@@ e@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A@@ 4@@ , such as it@@ ra@@ con@@ az@@ ole and HIV prot@@ ease in@@ hi@@ bit@@ or@@ s@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hi@@ bit@@ or@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be increased to the level prior to the initi@@ ation of the con@@ co@@ mit@@ ant therap@@ y@@ .
When weak in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 (@@ e@@ . g@@ .@@ , dil@@ ti@@ az@@ em or esc@@ ital@@ op@@ ra@@ m@@ ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ co@@ mit@@ antly with AB@@ IL@@ I@@ F@@ Y@@ , modest increases in ari@@ pi@@ pra@@ z@@ ole conc@@ ent@@ rations might be expec@@ te@@ d.
Following con@@ co@@ mit@@ ant administration of car@@ b@@ amaz@@ ep@@ ine@@ , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A@@ 4@@ , the ge@@ omet@@ ric means of C@@ max and AU@@ C for ari@@ pi@@ pra@@ z@@ ole were 68@@ % and 7@@ 3@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , compared to when ari@@ pi@@ pra@@ z@@ ole (@@ 30 m@@ g@@ ) was administ@@ ered al@@ one@@ .
Simi@@ lar@@ ly@@ , for de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole the ge@@ omet@@ ric means
49 of C@@ max and AU@@ C after car@@ b@@ amaz@@ ep@@ ine co@@ -@@ administration were 69@@ % and 7@@ 1@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , than those following treatment with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
AB@@ IL@@ I@@ F@@ Y dose should be doubled when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y occ@@ urs with car@@ b@@ amaz@@ ep@@ ine@@ .
John@@ '@@ s Wort@@ ) may be expected to have similar effects and similar dose increases should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be reduced to the recommended d@@ os@@ e@@ .
When either val@@ pro@@ ate or li@@ thi@@ um were administ@@ ered con@@ co@@ mit@@ antly with ari@@ pi@@ pra@@ z@@ ole@@ , there was no clin@@ ically significant change in ari@@ pi@@ pra@@ z@@ ole conc@@ entra@@ tions@@ .
Pot@@ ential for AB@@ IL@@ I@@ F@@ Y to affect other medic@@ inal produc@@ ts@@ :
In clinical stu@@ dies@@ , 10@@ -@@ 30 m@@ g@@ / day d@@ oses of ari@@ pi@@ pra@@ z@@ ole had no significant effect on the met@@ aboli@@ sm of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ / 3@@ -@@ metho@@ x@@ y@@ mor@@ ph@@ in@@ an rati@@ o@@ )@@ , 2@@ C@@ 9 (@@ war@@ far@@ in@@ )@@ , 2@@ C@@ 19 (@@ om@@ ep@@ raz@@ ole@@ )@@ , and 3@@ A4 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ )@@ .
Addi@@ tion@@ all@@ y@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole did not show potential for al@@ tering C@@ Y@@ P@@ 1@@ A@@ 2@@ -@@ medi@@ ated met@@ aboli@@ sm in vit@@ ro@@ .
Th@@ us@@ , ari@@ pi@@ pra@@ z@@ ole is unlikely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ ym@@ es@@ .
When ari@@ pi@@ pra@@ z@@ ole was administ@@ ered con@@ co@@ mit@@ antly with either val@@ pro@@ ate or li@@ thi@@ um@@ , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ thi@@ um conc@@ entra@@ tions@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled trials of ari@@ pi@@ pra@@ z@@ ole in pregnant wom@@ en@@ .
Ani@@ mal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
D@@ ue to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive stu@@ dies@@ , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ et@@ us@@ .
Ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during la@@ ct@@ ation@@ .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pi@@ pra@@ z@@ ole@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been per@@ for@@ med@@ .
Ho@@ we@@ ver@@ , as with other anti@@ p@@ sycho@@ tic@@ s@@ , patients should be cau@@ tioned about operating ha@@ z@@ ard@@ ous mach@@ in@@ es@@ , including motor v@@ ehic@@ les@@ , until they are reas@@ onably certain that ari@@ pi@@ pra@@ z@@ ole does not affect them adver@@ sel@@ y@@ .
4.@@ 8 Un@@ desi@@ rable effects
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ )@@ :
The frequ@@ ency listed below is defined using the following conven@@ tion@@ : common (@@ > 1@@ / 100 ,@@ < 1@@ /@@ 10@@ ) and un@@ common (@@ > 1@@ /@@ 1 ,@@ 00@@ 0@@ , < 1@@ /@@ 100@@ )@@ .
50 Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous System disor@@ ders Common@@ : ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disor@@ der@@ , ak@@ ath@@ isi@@ a@@ , tre@@ mor@@ , di@@ zz@@ in@@ ess@@ , som@@ n@@ ol@@ en@@ ce@@ , se@@ d@@ ation@@ , hea@@ da@@ che E@@ ye disor@@ ders Common@@ : bl@@ urred vision Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : dy@@ sp@@ ep@@ si@@ a@@ , vo@@ mit@@ ing@@ , nau@@ se@@ a@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ * General disor@@ ders and administration site conditions Common@@ : f@@ ati@@ gue P@@ sychiatri@@ c disor@@ ders Common@@ : rest@@ less@@ ness@@ , ins@@ om@@ ni@@ a@@ , anxiety Un@@ common@@ : depres@@ sion@@ *
Ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symptoms (@@ EP@@ S@@ )@@ :
Sch@@ iz@@ op@@ hren@@ ia - in a long term 5@@ 2@@ -@@ week controlled tri@@ al@@ , ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients had an over@@ all@@ -@@ lower inci@@ dence (@@ 25.@@ 8@@ %@@ ) of E@@ PS including par@@ kin@@ son@@ is@@ m@@ , ak@@ ath@@ isi@@ a@@ , dy@@ st@@ onia and dy@@ sk@@ ine@@ sia compared with those treated with hal@@ operi@@ dol (@@ 5@@ 7.@@ 3@@ %@@ )@@ .
In a long term 26@@ -@@ week pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 19@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 13.@@ 1@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In another long@@ -@@ term 26@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 14.@@ 8@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 1@@ % for ol@@ anz@@ ap@@ ine@@ -@@ treated pati@@ ent@@ s.
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 23.@@ 5@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 5@@ 3.@@ 3@@ % for hal@@ operi@@ dol@@ -@@ treated pati@@ ent@@ s.
In another 12@@ -@@ week tri@@ al@@ , the inci@@ dence of E@@ PS was 26.@@ 6@@ % for patients treated with ari@@ pi@@ pra@@ z@@ ole and 17.@@ 6@@ % for those treated with li@@ thi@@ um@@ .
In the long term 26@@ -@@ week maintenance phase of a pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 18.@@ 2@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 7@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ s@@ , the inci@@ dence of ak@@ ath@@ i@@ sia in bi@@ pol@@ ar patients was 12.@@ 1@@ % with ari@@ pi@@ pra@@ z@@ ole and 3.@@ 2@@ % with pla@@ c@@ ebo@@ .
In sch@@ iz@@ op@@ hren@@ ia patients the inci@@ dence of ak@@ ath@@ i@@ sia was 6.@@ 2@@ % with ari@@ pi@@ pra@@ z@@ ole and 3@@ .0@@ % with pla@@ c@@ ebo@@ .
Com@@ par@@ is@@ ons between ari@@ pi@@ pra@@ z@@ ole and pla@@ c@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine lab@@ oratory par@@ ame@@ ters revealed no medi@@ cally important differ@@ en@@ c@@ es@@ .
Ele@@ v@@ ations of C@@ P@@ K (@@ Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ )@@ , generally tran@@ si@@ ent and as@@ ymp@@ tom@@ ati@@ c@@ , were observed in 3.@@ 5@@ % of ari@@ pi@@ pra@@ z@@ ole treated patients as compared to 2@@ .0@@ % of patients who received pla@@ c@@ ebo@@ .
Other fin@@ d@@ ings@@ :
Un@@ desi@@ rable effects known to be associated with anti@@ p@@ sycho@@ tic therapy and also reported during treatment with ari@@ pi@@ pra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ dro@@ me@@ , tar@@ di@@ ve dy@@ sk@@ ine@@ si@@ a@@ , sei@@ zu@@ re@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly de@@ mented pati@@ ent@@ s@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ tus (@@ see section 4.@@ 4@@ )@@ .
Post@@ -@@ Market@@ ing@@ :
The following ad@@ verse events have been reported during post@@ -@@ marketing sur@@ veil@@ lan@@ ce@@ .
The frequ@@ ency of these events is considered not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Investig@@ ations@@ :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ , blood glu@@ c@@ ose increas@@ ed@@ , blood glu@@ c@@ ose flu@@ ctu@@ ation@@ , g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in increased
Cardi@@ ac disor@@ der@@ s@@ :
Q@@ T pro@@ long@@ ation@@ , vent@@ ri@@ cular arr@@ hyth@@ mi@@ as@@ , sudden un@@ explained de@@ ath@@ , cardi@@ ac ar@@ rest@@ , tor@@ sa@@ des de poin@@ tes@@ , bra@@ dy@@ car@@ dia
Bloo@@ d and the lymp@@ h@@ atic system disor@@ der@@ s@@ :
leu@@ kop@@ eni@@ a@@ , neut@@ rop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia
51 Ner@@ v@@ ous system disor@@ der@@ s@@ :
speech disor@@ der@@ , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ , grand mal con@@ vul@@ sion
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ s@@ :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m@@ , lar@@ yn@@ g@@ os@@ pas@@ m@@ , aspi@@ ration p@@ ne@@ um@@ onia
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
pan@@ cre@@ ati@@ tis@@ , dy@@ sph@@ ag@@ i@@ a@@ , ab@@ dom@@ inal dis@@ comfort@@ , stomach dis@@ comfort@@ , di@@ arr@@ ho@@ ea
Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
ur@@ inary in@@ contin@@ en@@ ce@@ , ur@@ inary re@@ tention
Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
ra@@ sh@@ , ph@@ otos@@ en@@ si@@ tivity re@@ ac@@ tion@@ , al@@ op@@ eci@@ a@@ , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , my@@ al@@ gi@@ a@@ , sti@@ ff@@ ness
En@@ do@@ cr@@ ine disor@@ der@@ s@@ :
hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , diabetes mel@@ li@@ t@@ us@@ , di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s@@ , di@@ abe@@ tic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
weight ga@@ in@@ , weight decre@@ as@@ ed@@ , an@@ or@@ ex@@ i@@ a@@ , h@@ yp@@ on@@ at@@ re@@ mia
V@@ as@@ cular disor@@ der@@ s@@ :
syn@@ cop@@ e@@ , hyper@@ ten@@ sion@@ , thro@@ mbo@@ em@@ bo@@ lic events
General disor@@ ders and administration site condi@@ tions@@ :
temperature regulation disorder (@@ e@@ . g. hypo@@ ther@@ mi@@ a@@ , py@@ re@@ xi@@ a@@ )@@ , chest pain@@ , peri@@ pher@@ al oe@@ de@@ ma
Immun@@ e system disor@@ der@@ s@@ :
aller@@ gic reaction (@@ e@@ . g. an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ , an@@ gi@@ oe@@ de@@ ma including s@@ wollen ton@@ gu@@ e@@ , ton@@ gue oe@@ de@@ ma@@ , face oe@@ de@@ ma@@ , p@@ ru@@ rit@@ us@@ , or ur@@ tic@@ ari@@ a@@ )
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ der@@ s@@ :
ja@@ un@@ di@@ ce@@ , he@@ pati@@ tis@@ , increased A@@ lan@@ ine A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ AL@@ T@@ )@@ , increased A@@ spar@@ tate A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ A@@ ST@@ )@@ , increased G@@ amm@@ a Gl@@ ut@@ am@@ yl Transfer@@ ase (@@ G@@ GT@@ )@@ , increased al@@ kal@@ ine ph@@ osp@@ hat@@ ase
Re@@ productive system and breast disor@@ der@@ s@@ :
pri@@ ap@@ ism
P@@ sychiatri@@ c disor@@ der@@ s@@ :
ag@@ it@@ ation@@ , nerv@@ ous@@ ness@@ ; suicide attemp@@ t@@ , suici@@ dal ide@@ ation@@ , and completed suicide (@@ see section 4.@@ 4@@ )
4.@@ 9 Over@@ dose
In clinical trials and post@@ -@@ marketing experi@@ en@@ ce@@ , acci@@ dental or inten@@ tional ac@@ ute over@@ d@@ os@@ age of ari@@ pi@@ pra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy@@ , increased blood pressu@@ re@@ , som@@ n@@ ol@@ en@@ ce@@ , ta@@ ch@@ y@@ cardi@@ a@@ , nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ e@@ a.
In addi@@ tion@@ , reports of acci@@ dental over@@ dose with ari@@ pi@@ pra@@ z@@ ole alone (@@ up to 19@@ 5 m@@ g@@ ) in children have been received with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ en@@ ce@@ , tran@@ si@@ ent loss of consci@@ ousness and ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symp@@ tom@@ s.
Management of over@@ dose should concentrate on supportive therap@@ y@@ , maintaining an adequate air@@ wa@@ y@@ , oxy@@ gen@@ ation and v@@ enti@@ la@@ tion@@ , and management of symp@@ tom@@ s.
The possibility of multiple medic@@ inal product involvement should be consider@@ ed@@ .
Ther@@ efore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continu@@ ous elec@@ tro@@ cardi@@ o@@ graphic monitoring to dete@@ ct possible arr@@ hyth@@ mi@@ as@@ .
Following any confirmed or suspected over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , close medical super@@ vision and monitoring should continue until the patient reco@@ vers@@ .
52 Ac@@ tiv@@ ated char@@ coal (@@ 50 g@@ )@@ , administ@@ ered one hour after ari@@ pi@@ pra@@ z@@ ole@@ , decre@@ ased ari@@ pi@@ pra@@ z@@ ole C@@ max by about 4@@ 1@@ % and AU@@ C by about 5@@ 1@@ %@@ , suggesting that char@@ coal may be effective in the treatment of over@@ d@@ os@@ e@@ .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in treating an over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , ha@@ emo@@ di@@ aly@@ sis is unlikely to be useful in over@@ dose management since ari@@ pi@@ pra@@ z@@ ole is highly bound to p@@ las@@ ma prot@@ ein@@ s.
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ p@@ sycho@@ tic@@ s@@ , AT@@ C co@@ de@@ :
N@@ 05@@ A@@ X@@ 12
It has been proposed that ari@@ pi@@ pra@@ z@@ ole@@ ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ amine D@@ 2 and ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a rec@@ ep@@ tors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hypo@@ activ@@ it@@ y@@ .
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited high bin@@ ding aff@@ in@@ ity in vit@@ ro for d@@ op@@ amine D@@ 2 and D@@ 3@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a and 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tors and moderate aff@@ in@@ ity for d@@ op@@ amine D@@ 4@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ c and 5@@ H@@ T@@ 7@@ , alp@@ ha@@ -@@ 1 ad@@ ren@@ er@@ gic and hist@@ amine H@@ 1 rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole also exhi@@ bited moderate bin@@ ding aff@@ in@@ ity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ in@@ ity for mus@@ car@@ ini@@ c rec@@ ep@@ tor@@ s.
Inter@@ action with rec@@ ep@@ tors other than d@@ op@@ amine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pi@@ pra@@ z@@ ole@@ .
Ari@@ pi@@ pra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a d@@ os@@ e@@ -@@ dependent reduction in the bin@@ ding of 11@@ C@@ -@@ ra@@ clo@@ pri@@ de@@ , a D@@ 2@@ / D@@ 3 rec@@ ep@@ tor lig@@ and@@ , to the cau@@ date and put@@ amen dete@@ cted by posi@@ tr@@ on e@@ mission tom@@ o@@ grap@@ hy@@ .
Further information on clinical tri@@ al@@ s@@ :
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
In three short@@ -@@ term (@@ 4 to 6 wee@@ ks@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 1,@@ 228 sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s@@ , presenting with positive or negative symp@@ tom@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was associated with stati@@ st@@ ically significantly greater improvements in p@@ sycho@@ tic symptoms compared to pla@@ c@@ ebo@@ .
AB@@ IL@@ I@@ F@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment respon@@ se@@ .
In a hal@@ operi@@ dol@@ -@@ controlled tri@@ al@@ , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2@@ -@@ weeks was similar in both groups (@@ ari@@ pi@@ pra@@ z@@ ole 77@@ % and hal@@ operi@@ dol 7@@ 3@@ %@@ )@@ .
The overall comple@@ tion rate was significantly higher for patients on ari@@ pi@@ pra@@ z@@ ole (@@ 43@@ %@@ ) than for hal@@ operi@@ dol (@@ 30@@ %@@ )@@ .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ poin@@ ts@@ , including P@@ AN@@ SS and the Montgom@@ er@@ y@@ -@@ As@@ berg Depression R@@ ating Sc@@ ale showed a significant improvement over hal@@ operi@@ dol@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hren@@ i@@ a@@ , ari@@ pi@@ pra@@ z@@ ole had significantly greater reduction in re@@ lap@@ se rat@@ e@@ , 34@@ % in ari@@ pi@@ pra@@ z@@ ole group and 57@@ % in pla@@ c@@ ebo@@ .
Wei@@ ght ga@@ in@@ : in clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight ga@@ in@@ .
In a 26@@ -@@ week@@ , ol@@ anz@@ ap@@ ine@@ -@@ contro@@ lle@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , multi@@ -@@ national study of sch@@ iz@@ op@@ hren@@ ia which included 3@@ 14 patients and where the primary end@@ -@@ point was weight ga@@ in@@ , significantly less patients had at least 7@@ % weight gain over bas@@ eline (@@ i@@ . e@@ . a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~@@ 8@@ 0.5 k@@ g@@ ) on ari@@ pi@@ pra@@ z@@ ole (@@ N@@ = 18@@ , or 13@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ , compared to ol@@ anz@@ ap@@ ine (@@ N@@ = 45@@ , or 33@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ .
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
In two 3@@ -@@ week@@ , flexi@@ ble@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o in
These trials included patients with or without p@@ sycho@@ tic features and with or without a rap@@ id@@ -@@ cycling cour@@ se@@ .
In one 3@@ -@@ week@@ , fix@@ ed@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to pla@@ c@@ ebo@@ .
In two 12@@ -@@ week@@ , pla@@ c@@ ebo@@ - and ac@@ ti@@ ve@@ -@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o at week 3 and a maintenance of effect compar@@ able to li@@ thi@@ um or hal@@ operi@@ dol at week 12.
Ari@@ pi@@ pra@@ z@@ ole also demonstrated a compar@@ able proportion of patients in symp@@ tom@@ atic re@@ mission from man@@ ia as li@@ thi@@ um or hal@@ operi@@ dol at week 12.
In a 6@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , who were parti@@ ally non@@ -@@ respon@@ sive to li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeu@@ tic ser@@ um level@@ s@@ , the addition of ari@@ pi@@ pra@@ z@@ ole as ad@@ jun@@ ctive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therap@@ y@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , followed by a 7@@ 4@@ -@@ week exten@@ sion@@ , in man@@ ic patients who achieved re@@ mission on ari@@ pi@@ pra@@ z@@ ole during a stabili@@ zation phase prior to rand@@ omi@@ z@@ ation@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ ren@@ ce@@ , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depres@@ sion@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ari@@ pi@@ pra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tab@@ let is bio@@ equivalent to ari@@ pi@@ pra@@ z@@ ole tab@@ le@@ ts@@ , with a similar rate and extent of absor@@ p@@ tion@@ .
Ari@@ pi@@ pra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tab@@ lets may be used as an alternative to ari@@ pi@@ pra@@ z@@ ole tab@@ le@@ ts@@ .
Ab@@ sor@@ p@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is well absor@@ bed@@ , with peak p@@ las@@ ma conc@@ ent@@ rations occ@@ urring within 3@@ -@@ 5 hours after d@@ os@@ ing@@ .
Ari@@ pi@@ pra@@ z@@ ole under@@ goes minimal pre@@ -@@ sy@@ ste@@ mic met@@ aboli@@ sm@@ .
The absolute oral bio@@ availability of the tab@@ let formu@@ lation is 8@@ 7@@ %@@ .
There is no effect of a high fat meal on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Distri@@ bu@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is widely distri@@ buted throughout the body with an apparent volume of distribution of 4.@@ 9 l@@ / k@@ g@@ , indic@@ ating extensive extra@@ v@@ as@@ cular distri@@ bu@@ tion@@ .
At therapeu@@ tic conc@@ entra@@ tions@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole are greater than 99@@ % bound to ser@@ um prot@@ ein@@ s@@ , bin@@ ding primarily to alb@@ umin@@ .
Met@@ aboli@@ sm@@ :
Ari@@ pi@@ pra@@ z@@ ole is exten@@ sively met@@ aboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ wa@@ ys@@ : de@@ hydro@@ gen@@ ation@@ , hydro@@ x@@ y@@ la@@ tion@@ , and N@@ -@@ deal@@ k@@ y@@ la@@ tion@@ .
Based on in vit@@ ro stu@@ dies@@ , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ ym@@ es are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ y@@ lation of ari@@ pi@@ pra@@ z@@ ole@@ , and N@@ -@@ deal@@ k@@ y@@ lation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A@@ 4.
Ari@@ pi@@ pra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ iety in sy@@ ste@@ mic circu@@ la@@ tion@@ .
At steady stat@@ e@@ , de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , represents about 40@@ % of ari@@ pi@@ pra@@ z@@ ole AU@@ C in p@@ las@@ ma@@ .
Eli@@ min@@ ation@@ :
The mean elim@@ ination half@@ -@@ lives for ari@@ pi@@ pra@@ z@@ ole are approximately 75 hours in extensive met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6.
The total body clear@@ ance of ari@@ pi@@ pra@@ z@@ ole is 0.@@ 7 m@@ l@@ / min@@ / k@@ g@@ , which is primarily he@@ pati@@ c.
Following a single oral dose of [@@ 14@@ C@@ ]@@ -@@ lab@@ elled ari@@ pi@@ pra@@ z@@ ole@@ , approximately 27@@ % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60@@ % in the fa@@ ec@@ es@@ .
L@@ ess than 1@@ % of un@@ changed ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18@@ % was recovered un@@ changed in the fa@@ ec@@ es@@ .
54 P@@ harm@@ ac@@ ok@@ ine@@ tics in special patient groups
El@@ der@@ ly@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy elderly and younger adult sub@@ jec@@ ts@@ , nor is there any dete@@ ct@@ able effect of age in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Gen@@ der@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy male and female subjects nor is there any dete@@ ct@@ able effect of gender in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Smo@@ king and Rac@@ e@@ :
Pop@@ ulation pharmac@@ ok@@ ine@@ tic ev@@ al@@ uation has revealed no evidence of clin@@ ically significant ra@@ ce@@ -@@ related differences or effects from smoking upon the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Ren@@ al Di@@ seas@@ e@@ :
The pharmac@@ ok@@ ine@@ tic characterist@@ ics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy sub@@ jec@@ ts@@ .
H@@ ep@@ atic Di@@ seas@@ e@@ :
A sing@@ le@@ -@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis (@@ Chil@@ d@@ -@@ Pu@@ gh Clas@@ ses A@@ , B@@ , and C@@ ) did not reveal a significant effect of he@@ pati@@ c im@@ pa@@ ir@@ ment on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ si@@ s@@ , which is in@@ sufficient to draw conclu@@ sions on their met@@ aboli@@ c cap@@ ac@@ it@@ y@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
Non@@ -@@ clinical safety data revealed no special ha@@ zard for humans based on conventional studies of safety pharmac@@ olog@@ y@@ , repe@@ at@@ -@@ dose tox@@ ic@@ it@@ y@@ , gen@@ oto@@ x@@ ic@@ it@@ y@@ , car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ , and tox@@ ic@@ ity to re@@ produc@@ tion@@ .
To@@ x@@ ic@@ ologi@@ cally significant effects were observed only at d@@ oses or exp@@ os@@ ures that were suff@@ ici@@ ently in excess of the maximum human dose or exp@@ os@@ ure@@ , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use@@ .
These inclu@@ de@@ d@@ : d@@ os@@ e@@ -@@ dependent ad@@ reno@@ cor@@ tical tox@@ ic@@ ity (@@ li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and@@ / or par@@ en@@ ch@@ y@@ mal cell los@@ s@@ ) in rats after 104 weeks at 20 to 60 m@@ g@@ / k@@ g@@ / day (@@ 3 to 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ ) and increased ad@@ reno@@ cor@@ tical car@@ cin@@ om@@ as and combined ad@@ reno@@ cor@@ tical aden@@ om@@ as@@ / car@@ cin@@ om@@ as in female rats at 60 m@@ g@@ / k@@ g@@ / day (@@ 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ )@@ .
The highest non@@ tum@@ ori@@ gen@@ ic exposure in female rats was 7 times the human exposure at the recommended d@@ os@@ e@@ .
An additional finding was chol@@ eli@@ thi@@ asi@@ s as a consequ@@ ence of pre@@ cip@@ itation of sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy met@@ aboli@@ tes of ari@@ pi@@ pra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 m@@ g@@ / k@@ g@@ / day (@@ 1 to 3 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on m@@ g@@ / m@@ 2@@ )@@ .
Ho@@ we@@ ver@@ , the conc@@ ent@@ rations of the sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy ari@@ pi@@ pra@@ z@@ ole in human b@@ ile at the highest dose propos@@ ed@@ , 30 mg per day@@ , were no more than 6@@ % of the b@@ ile conc@@ ent@@ rations found in the mon@@ keys in the 39@@ -@@ week study and are well below (@@ 6@@ %@@ ) their limits of in vit@@ ro sol@@ u@@ bili@@ ty@@ .
Based on results of a full range of standard gen@@ oto@@ x@@ ic@@ ity test@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was considered non@@ -@@ gen@@ oto@@ x@@ ic@@ .
Ari@@ pi@@ pra@@ z@@ ole did not im@@ pair fertili@@ ty in re@@ productive tox@@ ic@@ ity stu@@ dies@@ .
Develop@@ mental tox@@ ic@@ it@@ y@@ , including d@@ os@@ e@@ -@@ dependent delayed fo@@ et@@ al ossi@@ fication and possible ter@@ at@@ o@@ gen@@ ic effec@@ ts@@ , were observed in rats at d@@ oses resulting in sub@@ therapeu@@ tic exp@@ os@@ ures (@@ based on AU@@ C@@ ) and in ra@@ bb@@ its at d@@ oses resulting in exp@@ os@@ ures 3 and 11 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical d@@ os@@ e@@ .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ it@@ y@@ .
55 6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Cal@@ ci@@ um si@@ lic@@ ate Cros@@ car@@ m@@ ell@@ ose so@@ dium Cros@@ po@@ vi@@ done Sili@@ con di@@ oxide X@@ y@@ li@@ to@@ l Mic@@ ro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ ose A@@ spart@@ ame (@@ E@@ 9@@ 5@@ 1@@ ) Ac@@ es@@ ul@@ fame pot@@ assi@@ um Van@@ illa fla@@ vour (@@ including van@@ ill@@ in and eth@@ yl van@@ il@@ lin@@ ) T@@ art@@ ari@@ c acid Mag@@ ne@@ si@@ um ste@@ ar@@ ate
Red iron oxide (@@ E@@ 17@@ 2@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
Not applic@@ ab@@ le@@ .
6.@@ 3 Shel@@ f life
3 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
6.5 Nature and cont@@ ents of container
Car@@ ton of 14 x 1 tab@@ lets in col@@ d@@ -@@ formed al@@ uminium per@@ for@@ ated unit dose bli@@ ster@@ s.
Car@@ ton of 28 x 1 tab@@ lets in col@@ d@@ -@@ formed al@@ uminium per@@ for@@ ated unit dose bli@@ ster@@ s.
Car@@ ton of 49 x 1 tab@@ lets in col@@ d@@ -@@ formed al@@ uminium per@@ for@@ ated unit dose bli@@ ster@@ s.
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 24@@ -@@ 0@@ 26
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
56 D@@ ate of first author@@ is@@ ation@@ :
4 June 2004
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
{@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
57 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 15 mg or@@ o@@ disp@@ er@@ sible tab@@ lets
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each or@@ o@@ disp@@ er@@ sible tab@@ let contains 15 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
Ex@@ cip@@ i@@ ent@@ :
3 mg as@@ part@@ ame (@@ E@@ 9@@ 5@@ 1@@ ) per or@@ o@@ disp@@ er@@ sible tab@@ let
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
O@@ ro@@ disp@@ er@@ sible tab@@ let Round and y@@ el@@ low@@ , marked with "@@ A@@ " over "@@ 64@@ 1@@ " on one side and "@@ 15@@ " on the o@@ ther@@ .
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hren@@ i@@ a.
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the pre@@ vention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pi@@ pra@@ z@@ ole treatment (@@ see section 5.@@ 1@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
O@@ ral use@@ .
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 10 or 15 m@@ g@@ / day with a maintenance dose of 15 m@@ g@@ / day administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to me@@ al@@ s.
AB@@ IL@@ I@@ F@@ Y is effective in a dose range of 10 to 30 m@@ g@@ / day@@ .
En@@ h@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
M@@ anic epis@@ o@@ des@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 15 mg administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy (@@ see section 5.@@ 1@@ )@@ .
Some patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
Rec@@ ur@@ r@@ ence pre@@ vention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pi@@ pra@@ z@@ ole@@ , continue therapy at the same d@@ os@@ e@@ .
Ad@@ ju@@ st@@ ments of daily d@@ os@@ age@@ , including dose reduction should be considered on the basis of clinical stat@@ us@@ .
The or@@ o@@ disp@@ er@@ sible tab@@ let should be placed in the mouth on the ton@@ gu@@ e@@ , where it will rapidly disp@@ er@@ se in s@@ ali@@ v@@ a.
It can be taken with or without liqui@@ d.
R@@ emo@@ val of the int@@ act or@@ o@@ disp@@ er@@ sible tab@@ let from the mouth is difficul@@ t.
Since the or@@ o@@ disp@@ er@@ sible tab@@ let is fra@@ gi@@ le@@ , it should be taken immediately on opening the bli@@ ster@@ .
Altern@@ ati@@ vel@@ y@@ , disp@@ er@@ se the tab@@ let in water and drink the resulting susp@@ en@@ sion@@ .
58 The or@@ o@@ disp@@ er@@ sible tab@@ lets may be used as an alternative to AB@@ IL@@ I@@ F@@ Y tab@@ lets for patients who have difficulty to swal@@ low AB@@ IL@@ I@@ F@@ Y tab@@ lets (@@ see also section 5.@@ 2@@ )@@ .
Children and adol@@ es@@ cent@@ s@@ : there is no experience in children and adol@@ es@@ cents under 18 years of age@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required for patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
In patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ , the data available are in@@ sufficient to establish recommend@@ ations@@ .
In these patients d@@ osing should be managed cau@@ ti@@ ous@@ ly@@ .
Ho@@ we@@ ver@@ , the maximum daily dose of 30 mg should be used with caution in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required in patients with ren@@ al im@@ pa@@ ir@@ ment@@ .
El@@ der@@ ly@@ : the effec@@ tiveness of AB@@ IL@@ I@@ F@@ Y in the treatment of sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been establi@@ sh@@ ed@@ .
O@@ wing to the greater sensi@@ tivity of this pop@@ ula@@ tion@@ , a lower starting dose should be considered when clinical factors warrant (@@ see section 4.@@ 4@@ )@@ .
Gen@@ der@@ : no d@@ os@@ age adju@@ st@@ ment is required for female patients as compared to male patients (@@ see section 5.@@ 2@@ )@@ .
Smo@@ king stat@@ us@@ : according to the met@@ aboli@@ c path@@ way of ari@@ pi@@ pra@@ z@@ ole no d@@ os@@ age adju@@ st@@ ment is required for smo@@ kers (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ ors with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be re@@ duc@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ or is with@@ drawn from the combination therap@@ y@@ , ari@@ pi@@ pra@@ z@@ ole dose should then be increased (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be increas@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therap@@ y@@ , the ari@@ pi@@ pra@@ z@@ ole dose should then be reduced to the recommended dose (@@ see section 4.@@ 5@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
During anti@@ p@@ sycho@@ tic treat@@ ment@@ , improvement in the pati@@ ent@@ '@@ s clinical condition may take several days to some wee@@ ks@@ .
Pati@@ ents should be closely monit@@ ored throughout this peri@@ od@@ .
The occ@@ ur@@ r@@ ence of suici@@ dal behaviour is inher@@ ent in p@@ sycho@@ tic ill@@ nesses and mood disor@@ ders and in some cases has been reported early after initi@@ ation or switch of anti@@ p@@ sycho@@ tic therap@@ y@@ , including treatment with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
C@@ lose super@@ vision of high@@ -@@ risk patients should ac@@ company anti@@ p@@ sycho@@ tic therap@@ y@@ .
Res@@ ults of an epide@@ mi@@ ological study found that there was no increased risk of suici@@ d@@ ality with ari@@ pi@@ pra@@ z@@ ole compared to other anti@@ p@@ sycho@@ tics among patients with bi@@ pol@@ ar disor@@ der@@ .
Cardi@@ ov@@ as@@ cular disor@@ der@@ s@@ :
Ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with known cardi@@ ov@@ as@@ cular disease (@@ history of m@@ yo@@ cardi@@ al inf@@ ar@@ ction or i@@ scha@@ e@@ mic heart dise@@ as@@ e@@ , heart fail@@ ure@@ , or conduc@@ tion ab@@ nor@@ mali@@ ti@@ es@@ )@@ , cer@@ eb@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ ension (@@ de@@ hy@@ dra@@ tion@@ , hypo@@ vol@@ emi@@ a@@ , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations@@ ) or hyper@@ ten@@ sion@@ , including acceler@@ ated or mal@@ ign@@ ant@@ .
Con@@ duction ab@@ nor@@ mali@@ ti@@ es@@ :
In clinical trials of ari@@ pi@@ pra@@ z@@ ole@@ , the inci@@ dence of Q@@ T pro@@ long@@ ation was compar@@ able to pla@@ c@@ ebo@@ .
As with other anti@@ p@@ sycho@@ tic@@ s@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with a family history of Q@@ T pro@@ long@@ ation@@ .
59 T@@ ardi@@ ve Dy@@ sk@@ ine@@ si@@ a@@ : in clinical trials of one year or less dur@@ ation@@ , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ ine@@ sia during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
If signs and symptoms of tar@@ di@@ ve dy@@ sk@@ ine@@ sia appear in a patient on AB@@ IL@@ I@@ F@@ Y@@ , dose reduction or dis@@ continu@@ ation should be consider@@ ed@@ .
These symptoms can tempor@@ ally deterior@@ ate or can even ari@@ se after dis@@ continu@@ ation of treat@@ ment@@ .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ :
N@@ MS is a potentially fatal symp@@ tom complex associated with anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ .
In clinical tri@@ al@@ s@@ , rare cases of N@@ MS were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Clin@@ ical manifest@@ ations of N@@ MS are hyper@@ py@@ re@@ xi@@ a@@ , muscle rigi@@ di@@ ty@@ , al@@ tered mental status and evidence of auton@@ omic inst@@ ability (@@ ir@@ regular pul@@ se or blood pressu@@ re@@ , ta@@ ch@@ y@@ cardi@@ a@@ , di@@ aph@@ ore@@ sis and cardi@@ ac dys@@ rhyth@@ mi@@ a@@ )@@ .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ as@@ e@@ , m@@ yo@@ glob@@ in@@ uri@@ a (@@ r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ )@@ , and ac@@ ute ren@@ al fail@@ ure@@ .
Ho@@ we@@ ver@@ , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , not necessarily in association with N@@ M@@ S@@ , have also been repor@@ te@@ d.
If a patient develop@@ s signs and symptoms indic@@ ative of N@@ M@@ S@@ , or presents with un@@ explained high fe@@ ver without additional clinical manifest@@ ations of N@@ M@@ S@@ , all anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ , including AB@@ IL@@ I@@ F@@ Y@@ , must be dis@@ continu@@ ed@@ .
Sei@@ zu@@ re@@ : in clinical tri@@ al@@ s@@ , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Ther@@ e@@ fore@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients who have a history of sei@@ z@@ ure disorder or have conditions associated with sei@@ zu@@ res@@ .
El@@ derly patients with demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s@@ :
In@@ cre@@ ased mort@@ al@@ it@@ y@@ : in three pla@@ c@@ ebo@@ -@@ controlled trials (@@ n@@ = 9@@ 38@@ ; mean age@@ :
8@@ 2.@@ 4 ye@@ ar@@ s@@ ; ran@@ ge@@ :
56@@ -@@ 99 ye@@ ar@@ s@@ ) of ari@@ pi@@ pra@@ z@@ ole in elderly patients with p@@ sycho@@ sis associated with Al@@ z@@ hei@@ mer@@ '@@ s dise@@ as@@ e@@ , patients treated with ari@@ pi@@ pra@@ z@@ ole were at increased risk of death compared to pla@@ c@@ ebo@@ .
The rate of death in ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients was 3.@@ 5@@ % compared to 1.@@ 7@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
Although the causes of deaths were var@@ ie@@ d@@ , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular (@@ e@@ . g. heart fail@@ ure@@ , sudden de@@ ath@@ ) or inf@@ ec@@ tious (@@ e@@ . g. p@@ ne@@ um@@ oni@@ a@@ ) in nat@@ ure@@ .
Cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse event@@ s@@ : in the same tri@@ al@@ s@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events (@@ e@@ . g. stro@@ ke@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ )@@ , including fat@@ ali@@ ti@@ es@@ , were reported in patients (@@ mean age@@ :
84 ye@@ ar@@ s@@ ; ran@@ ge@@ :
78@@ -@@ 88 ye@@ ar@@ s@@ )@@ .
Over@@ all@@ , 1.@@ 3@@ % of ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients reported cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events compared with 0.@@ 6@@ % of pla@@ c@@ ebo@@ -@@ treated patients in these tri@@ al@@ s.
This difference was not stati@@ st@@ ically signific@@ ant@@ .
Ho@@ we@@ ver@@ , in one of these tri@@ al@@ s@@ , a fix@@ ed@@ -@@ dose tri@@ al@@ , there was a significant dose response relationship for cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events in patients treated with ari@@ pi@@ pra@@ z@@ ole@@ .
AB@@ IL@@ I@@ F@@ Y is not approved for the treatment of demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s.
Hy@@ per@@ g@@ ly@@ ca@@ emi@@ a and Diabetes Mel@@ li@@ t@@ us@@ : hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , in some cases extreme and associated with ket@@ o@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or de@@ ath@@ , has been reported in patients treated with at@@ yp@@ ical anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ris@@ k factors that may pre@@ disp@@ ose patients to severe complic@@ ations include obesity and family history of di@@ abet@@ es@@ .
In clinical trials with ari@@ pi@@ pra@@ z@@ ole@@ , there were no significant differences in the inci@@ dence rates of hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events (@@ including di@@ abet@@ es@@ ) or in ab@@ normal g@@ ly@@ ca@@ emi@@ a lab@@ oratory values compared to pla@@ c@@ ebo@@ .
Pre@@ cise risk estimates for hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events in patients treated with AB@@ IL@@ I@@ F@@ Y and with other at@@ yp@@ ical anti@@ p@@ sycho@@ tic agents are not available to allow direct compar@@ is@@ ons@@ .
Pati@@ ents treated with any anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ , should be observed for signs and symptoms of hyper@@ g@@ ly@@ ca@@ emi@@ a (@@ such as poly@@ di@@ p@@ si@@ a@@ , poly@@ uri@@ a@@ , poly@@ ph@@ ag@@ ia and weak@@ ness@@ ) and patients with diabetes mel@@ li@@ tus or with risk factors for diabetes mel@@ li@@ tus should be monit@@ ored regularly for wor@@ sen@@ ing of glu@@ c@@ ose contro@@ l.
Wei@@ ght ga@@ in@@ : weight gain is commonly seen in sch@@ iz@@ op@@ hren@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ti@@ es@@ , use of anti@@ p@@ sycho@@ tics known to cause weight ga@@ in@@ , poor@@ ly managed li@@ fe@@ -@@ sty@@ le@@ , and might lead to severe complic@@ ations@@ .
Wei@@ ght gain has been reported post@@ -@@ marketing among patients prescri@@ bed AB@@ IL@@ I@@ F@@ Y@@ .
When se@@ en@@ , it is usually in those with significant risk factors such as history of di@@ abet@@ es@@ , th@@ y@@ ro@@ id disorder or pit@@ u@@ it@@ ary aden@@ om@@ a.
In clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight gain (@@ see section 5.@@ 1@@ )@@ .
60 Dy@@ sph@@ ag@@ i@@ a@@ : o@@ es@@ op@@ ha@@ ge@@ al dy@@ smo@@ tili@@ ty and aspi@@ ration have been associated with anti@@ p@@ sycho@@ tic drug use@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ari@@ pi@@ pra@@ z@@ ole and other anti@@ p@@ sycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for aspi@@ ration p@@ ne@@ um@@ oni@@ a.
Ph@@ en@@ yl@@ ket@@ on@@ uri@@ c@@ s@@ :
AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets contain as@@ part@@ ame@@ , a source of phen@@ yl@@ al@@ an@@ ine which may be harm@@ ful for people with phen@@ yl@@ ket@@ on@@ uri@@ a.
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ : as with other medic@@ ations hyper@@ sensi@@ tivity re@@ ac@@ tions@@ , character@@ ised by aller@@ gic symp@@ tom@@ s@@ , may occur with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
D@@ ue to its α 1@@ -@@ ad@@ ren@@ er@@ gic rec@@ ep@@ tor ant@@ agon@@ is@@ m@@ , ari@@ pi@@ pra@@ z@@ ole has the potential to enh@@ ance the effect of certain anti@@ hyper@@ ten@@ sive ag@@ ent@@ s.
Given the primary CN@@ S effects of ari@@ pi@@ pra@@ z@@ ole@@ , caution should be used when ari@@ pi@@ pra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping un@@ desi@@ rable effects such as se@@ dation (@@ see section 4.@@ 8@@ )@@ .
If ari@@ pi@@ pra@@ z@@ ole is administ@@ ered con@@ co@@ mit@@ antly with medic@@ ines known to cause Q@@ T pro@@ long@@ ation or elec@@ tro@@ ly@@ te im@@ bal@@ anc@@ e@@ , caution should be use@@ d.
Pot@@ ential for other medic@@ inal products to affect AB@@ IL@@ I@@ F@@ Y@@ :
A ga@@ stri@@ c acid blo@@ cker@@ , the H@@ 2 ant@@ agon@@ ist f@@ amo@@ ti@@ d@@ ine@@ , redu@@ ces ari@@ pi@@ pra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relev@@ ant@@ .
Ari@@ pi@@ pra@@ z@@ ole is met@@ aboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ ym@@ es but not C@@ Y@@ P@@ 1@@ A enz@@ ym@@ es@@ .
Th@@ us@@ , no d@@ os@@ age adju@@ st@@ ment is required for smo@@ ker@@ s.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ qu@@ ini@@ d@@ ine@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C by 10@@ 7@@ %@@ , while C@@ max was un@@ ch@@ ange@@ d.
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , decre@@ ased by 32@@ % and 47@@ %@@ .
AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed dose when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y with qu@@ ini@@ dine occ@@ urs@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 2@@ D@@ 6@@ , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 3@@ A4 (@@ ket@@ o@@ con@@ az@@ ole@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C and C@@ max by 6@@ 3@@ % and 37@@ %@@ , respec@@ ti@@ vel@@ y@@ .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole increased by 77@@ % and 43@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor met@@ aboli@@ ser@@ s@@ , con@@ co@@ mit@@ ant use of pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 may result in higher p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive met@@ aboli@@ zer@@ s.
When considering con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors with AB@@ IL@@ I@@ F@@ Y@@ , potential benefits should out@@ weigh the potential risks to the pati@@ ent@@ .
When con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ o@@ z@@ ole with AB@@ IL@@ I@@ F@@ Y occ@@ urs@@ , AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed d@@ os@@ e@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A@@ 4@@ , such as it@@ ra@@ con@@ az@@ ole and HIV prot@@ ease in@@ hi@@ bit@@ or@@ s@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hi@@ bit@@ or@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be increased to the level prior to the initi@@ ation of the con@@ co@@ mit@@ ant therap@@ y@@ .
When weak in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 (@@ e@@ . g@@ .@@ , dil@@ ti@@ az@@ em or esc@@ ital@@ op@@ ra@@ m@@ ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ co@@ mit@@ antly with AB@@ IL@@ I@@ F@@ Y@@ , modest increases in ari@@ pi@@ pra@@ z@@ ole conc@@ ent@@ rations might be expec@@ te@@ d.
Following con@@ co@@ mit@@ ant administration of car@@ b@@ amaz@@ ep@@ ine@@ , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A@@ 4@@ , the ge@@ omet@@ ric means of C@@ max and AU@@ C for ari@@ pi@@ pra@@ z@@ ole were 68@@ % and 7@@ 3@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , compared to when ari@@ pi@@ pra@@ z@@ ole (@@ 30 m@@ g@@ ) was administ@@ ered al@@ one@@ .
Simi@@ lar@@ ly@@ , for de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole the ge@@ omet@@ ric means
61 of C@@ max and AU@@ C after car@@ b@@ amaz@@ ep@@ ine co@@ -@@ administration were 69@@ % and 7@@ 1@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , than those following treatment with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
AB@@ IL@@ I@@ F@@ Y dose should be doubled when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y occ@@ urs with car@@ b@@ amaz@@ ep@@ ine@@ .
John@@ '@@ s Wort@@ ) may be expected to have similar effects and similar dose increases should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be reduced to the recommended d@@ os@@ e@@ .
When either val@@ pro@@ ate or li@@ thi@@ um were administ@@ ered con@@ co@@ mit@@ antly with ari@@ pi@@ pra@@ z@@ ole@@ , there was no clin@@ ically significant change in ari@@ pi@@ pra@@ z@@ ole conc@@ entra@@ tions@@ .
Pot@@ ential for AB@@ IL@@ I@@ F@@ Y to affect other medic@@ inal produc@@ ts@@ :
In clinical stu@@ dies@@ , 10@@ -@@ 30 m@@ g@@ / day d@@ oses of ari@@ pi@@ pra@@ z@@ ole had no significant effect on the met@@ aboli@@ sm of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ / 3@@ -@@ metho@@ x@@ y@@ mor@@ ph@@ in@@ an rati@@ o@@ )@@ , 2@@ C@@ 9 (@@ war@@ far@@ in@@ )@@ , 2@@ C@@ 19 (@@ om@@ ep@@ raz@@ ole@@ )@@ , and 3@@ A4 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ )@@ .
Addi@@ tion@@ all@@ y@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole did not show potential for al@@ tering C@@ Y@@ P@@ 1@@ A@@ 2@@ -@@ medi@@ ated met@@ aboli@@ sm in vit@@ ro@@ .
Th@@ us@@ , ari@@ pi@@ pra@@ z@@ ole is unlikely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ ym@@ es@@ .
When ari@@ pi@@ pra@@ z@@ ole was administ@@ ered con@@ co@@ mit@@ antly with either val@@ pro@@ ate or li@@ thi@@ um@@ , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ thi@@ um conc@@ entra@@ tions@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled trials of ari@@ pi@@ pra@@ z@@ ole in pregnant wom@@ en@@ .
Ani@@ mal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
D@@ ue to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive stu@@ dies@@ , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ et@@ us@@ .
Ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during la@@ ct@@ ation@@ .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pi@@ pra@@ z@@ ole@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been per@@ for@@ med@@ .
Ho@@ we@@ ver@@ , as with other anti@@ p@@ sycho@@ tic@@ s@@ , patients should be cau@@ tioned about operating ha@@ z@@ ard@@ ous mach@@ in@@ es@@ , including motor v@@ ehic@@ les@@ , until they are reas@@ onably certain that ari@@ pi@@ pra@@ z@@ ole does not affect them adver@@ sel@@ y@@ .
4.@@ 8 Un@@ desi@@ rable effects
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ )@@ :
The frequ@@ ency listed below is defined using the following conven@@ tion@@ : common (@@ > 1@@ / 100 ,@@ < 1@@ /@@ 10@@ ) and un@@ common (@@ > 1@@ /@@ 1 ,@@ 00@@ 0@@ , < 1@@ /@@ 100@@ )@@ .
62 Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous System disor@@ ders Common@@ : ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disor@@ der@@ , ak@@ ath@@ isi@@ a@@ , tre@@ mor@@ , di@@ zz@@ in@@ ess@@ , som@@ n@@ ol@@ en@@ ce@@ , se@@ d@@ ation@@ , hea@@ da@@ che E@@ ye disor@@ ders Common@@ : bl@@ urred vision Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : dy@@ sp@@ ep@@ si@@ a@@ , vo@@ mit@@ ing@@ , nau@@ se@@ a@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ * General disor@@ ders and administration site conditions Common@@ : f@@ ati@@ gue P@@ sychiatri@@ c disor@@ ders Common@@ : rest@@ less@@ ness@@ , ins@@ om@@ ni@@ a@@ , anxiety Un@@ common@@ : depres@@ sion@@ *
Ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symptoms (@@ EP@@ S@@ )@@ :
Sch@@ iz@@ op@@ hren@@ ia - in a long term 5@@ 2@@ -@@ week controlled tri@@ al@@ , ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients had an over@@ all@@ -@@ lower inci@@ dence (@@ 25.@@ 8@@ %@@ ) of E@@ PS including par@@ kin@@ son@@ is@@ m@@ , ak@@ ath@@ isi@@ a@@ , dy@@ st@@ onia and dy@@ sk@@ ine@@ sia compared with those treated with hal@@ operi@@ dol (@@ 5@@ 7.@@ 3@@ %@@ )@@ .
In a long term 26@@ -@@ week pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 19@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 13.@@ 1@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In another long@@ -@@ term 26@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 14.@@ 8@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 1@@ % for ol@@ anz@@ ap@@ ine@@ -@@ treated pati@@ ent@@ s.
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 23.@@ 5@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 5@@ 3.@@ 3@@ % for hal@@ operi@@ dol@@ -@@ treated pati@@ ent@@ s.
In another 12@@ -@@ week tri@@ al@@ , the inci@@ dence of E@@ PS was 26.@@ 6@@ % for patients treated with ari@@ pi@@ pra@@ z@@ ole and 17.@@ 6@@ % for those treated with li@@ thi@@ um@@ .
In the long term 26@@ -@@ week maintenance phase of a pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 18.@@ 2@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 7@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ s@@ , the inci@@ dence of ak@@ ath@@ i@@ sia in bi@@ pol@@ ar patients was 12.@@ 1@@ % with ari@@ pi@@ pra@@ z@@ ole and 3.@@ 2@@ % with pla@@ c@@ ebo@@ .
In sch@@ iz@@ op@@ hren@@ ia patients the inci@@ dence of ak@@ ath@@ i@@ sia was 6.@@ 2@@ % with ari@@ pi@@ pra@@ z@@ ole and 3@@ .0@@ % with pla@@ c@@ ebo@@ .
Com@@ par@@ is@@ ons between ari@@ pi@@ pra@@ z@@ ole and pla@@ c@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine lab@@ oratory par@@ ame@@ ters revealed no medi@@ cally important differ@@ en@@ c@@ es@@ .
Ele@@ v@@ ations of C@@ P@@ K (@@ Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ )@@ , generally tran@@ si@@ ent and as@@ ymp@@ tom@@ ati@@ c@@ , were observed in 3.@@ 5@@ % of ari@@ pi@@ pra@@ z@@ ole treated patients as compared to 2@@ .0@@ % of patients who received pla@@ c@@ ebo@@ .
Other fin@@ d@@ ings@@ :
Un@@ desi@@ rable effects known to be associated with anti@@ p@@ sycho@@ tic therapy and also reported during treatment with ari@@ pi@@ pra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ dro@@ me@@ , tar@@ di@@ ve dy@@ sk@@ ine@@ si@@ a@@ , sei@@ zu@@ re@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly de@@ mented pati@@ ent@@ s@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ tus (@@ see section 4.@@ 4@@ )@@ .
Post@@ -@@ Market@@ ing@@ :
The following ad@@ verse events have been reported during post@@ -@@ marketing sur@@ veil@@ lan@@ ce@@ .
The frequ@@ ency of these events is considered not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Investig@@ ations@@ :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ , blood glu@@ c@@ ose increas@@ ed@@ , blood glu@@ c@@ ose flu@@ ctu@@ ation@@ , g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in increased
Cardi@@ ac disor@@ der@@ s@@ :
Q@@ T pro@@ long@@ ation@@ , vent@@ ri@@ cular arr@@ hyth@@ mi@@ as@@ , sudden un@@ explained de@@ ath@@ , cardi@@ ac ar@@ rest@@ , tor@@ sa@@ des de poin@@ tes@@ , bra@@ dy@@ car@@ dia
Bloo@@ d and the lymp@@ h@@ atic system disor@@ der@@ s@@ :
leu@@ kop@@ eni@@ a@@ , neut@@ rop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia
63 Ner@@ v@@ ous system disor@@ der@@ s@@ :
speech disor@@ der@@ , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ , grand mal con@@ vul@@ sion
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ s@@ :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m@@ , lar@@ yn@@ g@@ os@@ pas@@ m@@ , aspi@@ ration p@@ ne@@ um@@ onia
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
pan@@ cre@@ ati@@ tis@@ , dy@@ sph@@ ag@@ i@@ a@@ , ab@@ dom@@ inal dis@@ comfort@@ , stomach dis@@ comfort@@ , di@@ arr@@ ho@@ ea
Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
ur@@ inary in@@ contin@@ en@@ ce@@ , ur@@ inary re@@ tention
Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
ra@@ sh@@ , ph@@ otos@@ en@@ si@@ tivity re@@ ac@@ tion@@ , al@@ op@@ eci@@ a@@ , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , my@@ al@@ gi@@ a@@ , sti@@ ff@@ ness
En@@ do@@ cr@@ ine disor@@ der@@ s@@ :
hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , diabetes mel@@ li@@ t@@ us@@ , di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s@@ , di@@ abe@@ tic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
weight ga@@ in@@ , weight decre@@ as@@ ed@@ , an@@ or@@ ex@@ i@@ a@@ , h@@ yp@@ on@@ at@@ re@@ mia
V@@ as@@ cular disor@@ der@@ s@@ :
syn@@ cop@@ e@@ , hyper@@ ten@@ sion@@ , thro@@ mbo@@ em@@ bo@@ lic events
General disor@@ ders and administration site condi@@ tions@@ :
temperature regulation disorder (@@ e@@ . g. hypo@@ ther@@ mi@@ a@@ , py@@ re@@ xi@@ a@@ )@@ , chest pain@@ , peri@@ pher@@ al oe@@ de@@ ma
Immun@@ e system disor@@ der@@ s@@ :
aller@@ gic reaction (@@ e@@ . g. an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ , an@@ gi@@ oe@@ de@@ ma including s@@ wollen ton@@ gu@@ e@@ , ton@@ gue oe@@ de@@ ma@@ , face oe@@ de@@ ma@@ , p@@ ru@@ rit@@ us@@ , or ur@@ tic@@ ari@@ a@@ )
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ der@@ s@@ :
ja@@ un@@ di@@ ce@@ , he@@ pati@@ tis@@ , increased A@@ lan@@ ine A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ AL@@ T@@ )@@ , increased A@@ spar@@ tate A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ A@@ ST@@ )@@ , increased G@@ amm@@ a Gl@@ ut@@ am@@ yl Transfer@@ ase (@@ G@@ GT@@ )@@ , increased al@@ kal@@ ine ph@@ osp@@ hat@@ ase
Re@@ productive system and breast disor@@ der@@ s@@ :
pri@@ ap@@ ism
P@@ sychiatri@@ c disor@@ der@@ s@@ :
ag@@ it@@ ation@@ , nerv@@ ous@@ ness@@ ; suicide attemp@@ t@@ , suici@@ dal ide@@ ation@@ , and completed suicide (@@ see section 4.@@ 4@@ )
4.@@ 9 Over@@ dose
In clinical trials and post@@ -@@ marketing experi@@ en@@ ce@@ , acci@@ dental or inten@@ tional ac@@ ute over@@ d@@ os@@ age of ari@@ pi@@ pra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy@@ , increased blood pressu@@ re@@ , som@@ n@@ ol@@ en@@ ce@@ , ta@@ ch@@ y@@ cardi@@ a@@ , nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ e@@ a.
In addi@@ tion@@ , reports of acci@@ dental over@@ dose with ari@@ pi@@ pra@@ z@@ ole alone (@@ up to 19@@ 5 m@@ g@@ ) in children have been received with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ en@@ ce@@ , tran@@ si@@ ent loss of consci@@ ousness and ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symp@@ tom@@ s.
Management of over@@ dose should concentrate on supportive therap@@ y@@ , maintaining an adequate air@@ wa@@ y@@ , oxy@@ gen@@ ation and v@@ enti@@ la@@ tion@@ , and management of symp@@ tom@@ s.
The possibility of multiple medic@@ inal product involvement should be consider@@ ed@@ .
Ther@@ efore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continu@@ ous elec@@ tro@@ cardi@@ o@@ graphic monitoring to dete@@ ct possible arr@@ hyth@@ mi@@ as@@ .
Following any confirmed or suspected over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , close medical super@@ vision and monitoring should continue until the patient reco@@ vers@@ .
64 Ac@@ tiv@@ ated char@@ coal (@@ 50 g@@ )@@ , administ@@ ered one hour after ari@@ pi@@ pra@@ z@@ ole@@ , decre@@ ased ari@@ pi@@ pra@@ z@@ ole C@@ max by about 4@@ 1@@ % and AU@@ C by about 5@@ 1@@ %@@ , suggesting that char@@ coal may be effective in the treatment of over@@ d@@ os@@ e@@ .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in treating an over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , ha@@ emo@@ di@@ aly@@ sis is unlikely to be useful in over@@ dose management since ari@@ pi@@ pra@@ z@@ ole is highly bound to p@@ las@@ ma prot@@ ein@@ s.
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ p@@ sycho@@ tic@@ s@@ , AT@@ C co@@ de@@ :
N@@ 05@@ A@@ X@@ 12
It has been proposed that ari@@ pi@@ pra@@ z@@ ole@@ ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ amine D@@ 2 and ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a rec@@ ep@@ tors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hypo@@ activ@@ it@@ y@@ .
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited high bin@@ ding aff@@ in@@ ity in vit@@ ro for d@@ op@@ amine D@@ 2 and D@@ 3@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a and 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tors and moderate aff@@ in@@ ity for d@@ op@@ amine D@@ 4@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ c and 5@@ H@@ T@@ 7@@ , alp@@ ha@@ -@@ 1 ad@@ ren@@ er@@ gic and hist@@ amine H@@ 1 rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole also exhi@@ bited moderate bin@@ ding aff@@ in@@ ity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ in@@ ity for mus@@ car@@ ini@@ c rec@@ ep@@ tor@@ s.
Inter@@ action with rec@@ ep@@ tors other than d@@ op@@ amine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pi@@ pra@@ z@@ ole@@ .
Ari@@ pi@@ pra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a d@@ os@@ e@@ -@@ dependent reduction in the bin@@ ding of 11@@ C@@ -@@ ra@@ clo@@ pri@@ de@@ , a D@@ 2@@ / D@@ 3 rec@@ ep@@ tor lig@@ and@@ , to the cau@@ date and put@@ amen dete@@ cted by posi@@ tr@@ on e@@ mission tom@@ o@@ grap@@ hy@@ .
Further information on clinical tri@@ al@@ s@@ :
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
In three short@@ -@@ term (@@ 4 to 6 wee@@ ks@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 1,@@ 228 sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s@@ , presenting with positive or negative symp@@ tom@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was associated with stati@@ st@@ ically significantly greater improvements in p@@ sycho@@ tic symptoms compared to pla@@ c@@ ebo@@ .
AB@@ IL@@ I@@ F@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment respon@@ se@@ .
In a hal@@ operi@@ dol@@ -@@ controlled tri@@ al@@ , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2@@ -@@ weeks was similar in both groups (@@ ari@@ pi@@ pra@@ z@@ ole 77@@ % and hal@@ operi@@ dol 7@@ 3@@ %@@ )@@ .
The overall comple@@ tion rate was significantly higher for patients on ari@@ pi@@ pra@@ z@@ ole (@@ 43@@ %@@ ) than for hal@@ operi@@ dol (@@ 30@@ %@@ )@@ .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ poin@@ ts@@ , including P@@ AN@@ SS and the Montgom@@ er@@ y@@ -@@ As@@ berg Depression R@@ ating Sc@@ ale showed a significant improvement over hal@@ operi@@ dol@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hren@@ i@@ a@@ , ari@@ pi@@ pra@@ z@@ ole had significantly greater reduction in re@@ lap@@ se rat@@ e@@ , 34@@ % in ari@@ pi@@ pra@@ z@@ ole group and 57@@ % in pla@@ c@@ ebo@@ .
Wei@@ ght ga@@ in@@ : in clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight ga@@ in@@ .
In a 26@@ -@@ week@@ , ol@@ anz@@ ap@@ ine@@ -@@ contro@@ lle@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , multi@@ -@@ national study of sch@@ iz@@ op@@ hren@@ ia which included 3@@ 14 patients and where the primary end@@ -@@ point was weight ga@@ in@@ , significantly less patients had at least 7@@ % weight gain over bas@@ eline (@@ i@@ . e@@ . a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~@@ 8@@ 0.5 k@@ g@@ ) on ari@@ pi@@ pra@@ z@@ ole (@@ N@@ = 18@@ , or 13@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ , compared to ol@@ anz@@ ap@@ ine (@@ N@@ = 45@@ , or 33@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ .
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
In two 3@@ -@@ week@@ , flexi@@ ble@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o in
These trials included patients with or without p@@ sycho@@ tic features and with or without a rap@@ id@@ -@@ cycling cour@@ se@@ .
In one 3@@ -@@ week@@ , fix@@ ed@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to pla@@ c@@ ebo@@ .
In two 12@@ -@@ week@@ , pla@@ c@@ ebo@@ - and ac@@ ti@@ ve@@ -@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o at week 3 and a maintenance of effect compar@@ able to li@@ thi@@ um or hal@@ operi@@ dol at week 12.
Ari@@ pi@@ pra@@ z@@ ole also demonstrated a compar@@ able proportion of patients in symp@@ tom@@ atic re@@ mission from man@@ ia as li@@ thi@@ um or hal@@ operi@@ dol at week 12.
In a 6@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , who were parti@@ ally non@@ -@@ respon@@ sive to li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeu@@ tic ser@@ um level@@ s@@ , the addition of ari@@ pi@@ pra@@ z@@ ole as ad@@ jun@@ ctive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therap@@ y@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , followed by a 7@@ 4@@ -@@ week exten@@ sion@@ , in man@@ ic patients who achieved re@@ mission on ari@@ pi@@ pra@@ z@@ ole during a stabili@@ zation phase prior to rand@@ omi@@ z@@ ation@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ ren@@ ce@@ , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depres@@ sion@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ari@@ pi@@ pra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tab@@ let is bio@@ equivalent to ari@@ pi@@ pra@@ z@@ ole tab@@ le@@ ts@@ , with a similar rate and extent of absor@@ p@@ tion@@ .
Ari@@ pi@@ pra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tab@@ lets may be used as an alternative to ari@@ pi@@ pra@@ z@@ ole tab@@ le@@ ts@@ .
Ab@@ sor@@ p@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is well absor@@ bed@@ , with peak p@@ las@@ ma conc@@ ent@@ rations occ@@ urring within 3@@ -@@ 5 hours after d@@ os@@ ing@@ .
Ari@@ pi@@ pra@@ z@@ ole under@@ goes minimal pre@@ -@@ sy@@ ste@@ mic met@@ aboli@@ sm@@ .
The absolute oral bio@@ availability of the tab@@ let formu@@ lation is 8@@ 7@@ %@@ .
There is no effect of a high fat meal on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Distri@@ bu@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is widely distri@@ buted throughout the body with an apparent volume of distribution of 4.@@ 9 l@@ / k@@ g@@ , indic@@ ating extensive extra@@ v@@ as@@ cular distri@@ bu@@ tion@@ .
At therapeu@@ tic conc@@ entra@@ tions@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole are greater than 99@@ % bound to ser@@ um prot@@ ein@@ s@@ , bin@@ ding primarily to alb@@ umin@@ .
Met@@ aboli@@ sm@@ :
Ari@@ pi@@ pra@@ z@@ ole is exten@@ sively met@@ aboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ wa@@ ys@@ : de@@ hydro@@ gen@@ ation@@ , hydro@@ x@@ y@@ la@@ tion@@ , and N@@ -@@ deal@@ k@@ y@@ la@@ tion@@ .
Based on in vit@@ ro stu@@ dies@@ , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ ym@@ es are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ y@@ lation of ari@@ pi@@ pra@@ z@@ ole@@ , and N@@ -@@ deal@@ k@@ y@@ lation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A@@ 4.
Ari@@ pi@@ pra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ iety in sy@@ ste@@ mic circu@@ la@@ tion@@ .
At steady stat@@ e@@ , de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , represents about 40@@ % of ari@@ pi@@ pra@@ z@@ ole AU@@ C in p@@ las@@ ma@@ .
Eli@@ min@@ ation@@ :
The mean elim@@ ination half@@ -@@ lives for ari@@ pi@@ pra@@ z@@ ole are approximately 75 hours in extensive met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6.
The total body clear@@ ance of ari@@ pi@@ pra@@ z@@ ole is 0.@@ 7 m@@ l@@ / min@@ / k@@ g@@ , which is primarily he@@ pati@@ c.
Following a single oral dose of [@@ 14@@ C@@ ]@@ -@@ lab@@ elled ari@@ pi@@ pra@@ z@@ ole@@ , approximately 27@@ % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60@@ % in the fa@@ ec@@ es@@ .
L@@ ess than 1@@ % of un@@ changed ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18@@ % was recovered un@@ changed in the fa@@ ec@@ es@@ .
66 P@@ harm@@ ac@@ ok@@ ine@@ tics in special patient groups
El@@ der@@ ly@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy elderly and younger adult sub@@ jec@@ ts@@ , nor is there any dete@@ ct@@ able effect of age in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Gen@@ der@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy male and female subjects nor is there any dete@@ ct@@ able effect of gender in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Smo@@ king and Rac@@ e@@ :
Pop@@ ulation pharmac@@ ok@@ ine@@ tic ev@@ al@@ uation has revealed no evidence of clin@@ ically significant ra@@ ce@@ -@@ related differences or effects from smoking upon the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Ren@@ al Di@@ seas@@ e@@ :
The pharmac@@ ok@@ ine@@ tic characterist@@ ics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy sub@@ jec@@ ts@@ .
H@@ ep@@ atic Di@@ seas@@ e@@ :
A sing@@ le@@ -@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis (@@ Chil@@ d@@ -@@ Pu@@ gh Clas@@ ses A@@ , B@@ , and C@@ ) did not reveal a significant effect of he@@ pati@@ c im@@ pa@@ ir@@ ment on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ si@@ s@@ , which is in@@ sufficient to draw conclu@@ sions on their met@@ aboli@@ c cap@@ ac@@ it@@ y@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
Non@@ -@@ clinical safety data revealed no special ha@@ zard for humans based on conventional studies of safety pharmac@@ olog@@ y@@ , repe@@ at@@ -@@ dose tox@@ ic@@ it@@ y@@ , gen@@ oto@@ x@@ ic@@ it@@ y@@ , car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ , and tox@@ ic@@ ity to re@@ produc@@ tion@@ .
To@@ x@@ ic@@ ologi@@ cally significant effects were observed only at d@@ oses or exp@@ os@@ ures that were suff@@ ici@@ ently in excess of the maximum human dose or exp@@ os@@ ure@@ , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use@@ .
These inclu@@ de@@ d@@ : d@@ os@@ e@@ -@@ dependent ad@@ reno@@ cor@@ tical tox@@ ic@@ ity (@@ li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and@@ / or par@@ en@@ ch@@ y@@ mal cell los@@ s@@ ) in rats after 104 weeks at 20 to 60 m@@ g@@ / k@@ g@@ / day (@@ 3 to 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ ) and increased ad@@ reno@@ cor@@ tical car@@ cin@@ om@@ as and combined ad@@ reno@@ cor@@ tical aden@@ om@@ as@@ / car@@ cin@@ om@@ as in female rats at 60 m@@ g@@ / k@@ g@@ / day (@@ 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ )@@ .
The highest non@@ tum@@ ori@@ gen@@ ic exposure in female rats was 7 times the human exposure at the recommended d@@ os@@ e@@ .
An additional finding was chol@@ eli@@ thi@@ asi@@ s as a consequ@@ ence of pre@@ cip@@ itation of sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy met@@ aboli@@ tes of ari@@ pi@@ pra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 m@@ g@@ / k@@ g@@ / day (@@ 1 to 3 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on m@@ g@@ / m@@ 2@@ )@@ .
Ho@@ we@@ ver@@ , the conc@@ ent@@ rations of the sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy ari@@ pi@@ pra@@ z@@ ole in human b@@ ile at the highest dose propos@@ ed@@ , 30 mg per day@@ , were no more than 6@@ % of the b@@ ile conc@@ ent@@ rations found in the mon@@ keys in the 39@@ -@@ week study and are well below (@@ 6@@ %@@ ) their limits of in vit@@ ro sol@@ u@@ bili@@ ty@@ .
Based on results of a full range of standard gen@@ oto@@ x@@ ic@@ ity test@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was considered non@@ -@@ gen@@ oto@@ x@@ ic@@ .
Ari@@ pi@@ pra@@ z@@ ole did not im@@ pair fertili@@ ty in re@@ productive tox@@ ic@@ ity stu@@ dies@@ .
Develop@@ mental tox@@ ic@@ it@@ y@@ , including d@@ os@@ e@@ -@@ dependent delayed fo@@ et@@ al ossi@@ fication and possible ter@@ at@@ o@@ gen@@ ic effec@@ ts@@ , were observed in rats at d@@ oses resulting in sub@@ therapeu@@ tic exp@@ os@@ ures (@@ based on AU@@ C@@ ) and in ra@@ bb@@ its at d@@ oses resulting in exp@@ os@@ ures 3 and 11 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical d@@ os@@ e@@ .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ it@@ y@@ .
67 6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Cal@@ ci@@ um si@@ lic@@ ate Cros@@ car@@ m@@ ell@@ ose so@@ dium Cros@@ po@@ vi@@ done Sili@@ con di@@ oxide X@@ y@@ li@@ to@@ l Mic@@ ro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ ose A@@ spart@@ ame (@@ E@@ 9@@ 5@@ 1@@ ) Ac@@ es@@ ul@@ fame pot@@ assi@@ um Van@@ illa fla@@ vour (@@ including van@@ ill@@ in and eth@@ yl van@@ il@@ lin@@ ) T@@ art@@ ari@@ c acid Mag@@ ne@@ si@@ um ste@@ ar@@ ate
Y@@ ellow iron oxide (@@ E@@ 17@@ 2@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
Not applic@@ ab@@ le@@ .
6.@@ 3 Shel@@ f life
3 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
6.5 Nature and cont@@ ents of container
Car@@ ton of 14 x 1 tab@@ lets in col@@ d@@ -@@ formed al@@ uminium per@@ for@@ ated unit dose bli@@ ster@@ s.
Car@@ ton of 28 x 1 tab@@ lets in col@@ d@@ -@@ formed al@@ uminium per@@ for@@ ated unit dose bli@@ ster@@ s.
Car@@ ton of 49 x 1 tab@@ lets in col@@ d@@ -@@ formed al@@ uminium per@@ for@@ ated unit dose bli@@ ster@@ s.
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 27@@ -@@ 0@@ 29
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
68 D@@ ate of first author@@ is@@ ation@@ :
4 June 2004
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
{@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
69 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 30 mg or@@ o@@ disp@@ er@@ sible tab@@ lets
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each or@@ o@@ disp@@ er@@ sible tab@@ let contains 30 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
Ex@@ cip@@ i@@ ent@@ :
6 mg as@@ part@@ ame (@@ E@@ 9@@ 5@@ 1@@ ) per or@@ o@@ disp@@ er@@ sible tab@@ let
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
O@@ ro@@ disp@@ er@@ sible tab@@ let Round and p@@ ink@@ , marked with "@@ A@@ " over "@@ 6@@ 43@@ " on one side and "@@ 30@@ " on the o@@ ther@@ .
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hren@@ i@@ a.
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the pre@@ vention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pi@@ pra@@ z@@ ole treatment (@@ see section 5.@@ 1@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
O@@ ral use@@ .
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 10 or 15 m@@ g@@ / day with a maintenance dose of 15 m@@ g@@ / day administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to me@@ al@@ s.
AB@@ IL@@ I@@ F@@ Y is effective in a dose range of 10 to 30 m@@ g@@ / day@@ .
En@@ h@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
M@@ anic epis@@ o@@ des@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 15 mg administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy (@@ see section 5.@@ 1@@ )@@ .
Some patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
Rec@@ ur@@ r@@ ence pre@@ vention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pi@@ pra@@ z@@ ole@@ , continue therapy at the same d@@ os@@ e@@ .
Ad@@ ju@@ st@@ ments of daily d@@ os@@ age@@ , including dose reduction should be considered on the basis of clinical stat@@ us@@ .
The or@@ o@@ disp@@ er@@ sible tab@@ let should be placed in the mouth on the ton@@ gu@@ e@@ , where it will rapidly disp@@ er@@ se in s@@ ali@@ v@@ a.
It can be taken with or without liqui@@ d.
R@@ emo@@ val of the int@@ act or@@ o@@ disp@@ er@@ sible tab@@ let from the mouth is difficul@@ t.
Since the or@@ o@@ disp@@ er@@ sible tab@@ let is fra@@ gi@@ le@@ , it should be taken immediately on opening the bli@@ ster@@ .
Altern@@ ati@@ vel@@ y@@ , disp@@ er@@ se the tab@@ let in water and drink the resulting susp@@ en@@ sion@@ .
70 The or@@ o@@ disp@@ er@@ sible tab@@ lets may be used as an alternative to AB@@ IL@@ I@@ F@@ Y tab@@ lets for patients who have difficulty to swal@@ low AB@@ IL@@ I@@ F@@ Y tab@@ lets (@@ see also section 5.@@ 2@@ )@@ .
Children and adol@@ es@@ cent@@ s@@ : there is no experience in children and adol@@ es@@ cents under 18 years of age@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required for patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
In patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ , the data available are in@@ sufficient to establish recommend@@ ations@@ .
In these patients d@@ osing should be managed cau@@ ti@@ ous@@ ly@@ .
Ho@@ we@@ ver@@ , the maximum daily dose of 30 mg should be used with caution in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required in patients with ren@@ al im@@ pa@@ ir@@ ment@@ .
El@@ der@@ ly@@ : the effec@@ tiveness of AB@@ IL@@ I@@ F@@ Y in the treatment of sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been establi@@ sh@@ ed@@ .
O@@ wing to the greater sensi@@ tivity of this pop@@ ula@@ tion@@ , a lower starting dose should be considered when clinical factors warrant (@@ see section 4.@@ 4@@ )@@ .
Gen@@ der@@ : no d@@ os@@ age adju@@ st@@ ment is required for female patients as compared to male patients (@@ see section 5.@@ 2@@ )@@ .
Smo@@ king stat@@ us@@ : according to the met@@ aboli@@ c path@@ way of ari@@ pi@@ pra@@ z@@ ole no d@@ os@@ age adju@@ st@@ ment is required for smo@@ kers (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ ors with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be re@@ duc@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ or is with@@ drawn from the combination therap@@ y@@ , ari@@ pi@@ pra@@ z@@ ole dose should then be increased (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be increas@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therap@@ y@@ , the ari@@ pi@@ pra@@ z@@ ole dose should then be reduced to the recommended dose (@@ see section 4.@@ 5@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
During anti@@ p@@ sycho@@ tic treat@@ ment@@ , improvement in the pati@@ ent@@ '@@ s clinical condition may take several days to some wee@@ ks@@ .
Pati@@ ents should be closely monit@@ ored throughout this peri@@ od@@ .
The occ@@ ur@@ r@@ ence of suici@@ dal behaviour is inher@@ ent in p@@ sycho@@ tic ill@@ nesses and mood disor@@ ders and in some cases has been reported early after initi@@ ation or switch of anti@@ p@@ sycho@@ tic therap@@ y@@ , including treatment with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
C@@ lose super@@ vision of high@@ -@@ risk patients should ac@@ company anti@@ p@@ sycho@@ tic therap@@ y@@ .
Res@@ ults of an epide@@ mi@@ ological study found that there was no increased risk of suici@@ d@@ ality with ari@@ pi@@ pra@@ z@@ ole compared to other anti@@ p@@ sycho@@ tics among patients with bi@@ pol@@ ar disor@@ der@@ .
Cardi@@ ov@@ as@@ cular disor@@ der@@ s@@ :
Ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with known cardi@@ ov@@ as@@ cular disease (@@ history of m@@ yo@@ cardi@@ al inf@@ ar@@ ction or i@@ scha@@ e@@ mic heart dise@@ as@@ e@@ , heart fail@@ ure@@ , or conduc@@ tion ab@@ nor@@ mali@@ ti@@ es@@ )@@ , cer@@ eb@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ ension (@@ de@@ hy@@ dra@@ tion@@ , hypo@@ vol@@ emi@@ a@@ , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations@@ ) or hyper@@ ten@@ sion@@ , including acceler@@ ated or mal@@ ign@@ ant@@ .
Con@@ duction ab@@ nor@@ mali@@ ti@@ es@@ :
In clinical trials of ari@@ pi@@ pra@@ z@@ ole@@ , the inci@@ dence of Q@@ T pro@@ long@@ ation was compar@@ able to pla@@ c@@ ebo@@ .
As with other anti@@ p@@ sycho@@ tic@@ s@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with a family history of Q@@ T pro@@ long@@ ation@@ .
71 T@@ ardi@@ ve Dy@@ sk@@ ine@@ si@@ a@@ : in clinical trials of one year or less dur@@ ation@@ , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ ine@@ sia during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
If signs and symptoms of tar@@ di@@ ve dy@@ sk@@ ine@@ sia appear in a patient on AB@@ IL@@ I@@ F@@ Y@@ , dose reduction or dis@@ continu@@ ation should be consider@@ ed@@ .
These symptoms can tempor@@ ally deterior@@ ate or can even ari@@ se after dis@@ continu@@ ation of treat@@ ment@@ .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ :
N@@ MS is a potentially fatal symp@@ tom complex associated with anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ .
In clinical tri@@ al@@ s@@ , rare cases of N@@ MS were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Clin@@ ical manifest@@ ations of N@@ MS are hyper@@ py@@ re@@ xi@@ a@@ , muscle rigi@@ di@@ ty@@ , al@@ tered mental status and evidence of auton@@ omic inst@@ ability (@@ ir@@ regular pul@@ se or blood pressu@@ re@@ , ta@@ ch@@ y@@ cardi@@ a@@ , di@@ aph@@ ore@@ sis and cardi@@ ac dys@@ rhyth@@ mi@@ a@@ )@@ .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ as@@ e@@ , m@@ yo@@ glob@@ in@@ uri@@ a (@@ r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ )@@ , and ac@@ ute ren@@ al fail@@ ure@@ .
Ho@@ we@@ ver@@ , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , not necessarily in association with N@@ M@@ S@@ , have also been repor@@ te@@ d.
If a patient develop@@ s signs and symptoms indic@@ ative of N@@ M@@ S@@ , or presents with un@@ explained high fe@@ ver without additional clinical manifest@@ ations of N@@ M@@ S@@ , all anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ , including AB@@ IL@@ I@@ F@@ Y@@ , must be dis@@ continu@@ ed@@ .
Sei@@ zu@@ re@@ : in clinical tri@@ al@@ s@@ , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Ther@@ e@@ fore@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients who have a history of sei@@ z@@ ure disorder or have conditions associated with sei@@ zu@@ res@@ .
El@@ derly patients with demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s@@ :
In@@ cre@@ ased mort@@ al@@ it@@ y@@ : in three pla@@ c@@ ebo@@ -@@ controlled trials (@@ n@@ = 9@@ 38@@ ; mean age@@ :
8@@ 2.@@ 4 ye@@ ar@@ s@@ ; ran@@ ge@@ :
56@@ -@@ 99 ye@@ ar@@ s@@ ) of ari@@ pi@@ pra@@ z@@ ole in elderly patients with p@@ sycho@@ sis associated with Al@@ z@@ hei@@ mer@@ '@@ s dise@@ as@@ e@@ , patients treated with ari@@ pi@@ pra@@ z@@ ole were at increased risk of death compared to pla@@ c@@ ebo@@ .
The rate of death in ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients was 3.@@ 5@@ % compared to 1.@@ 7@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
Although the causes of deaths were var@@ ie@@ d@@ , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular (@@ e@@ . g. heart fail@@ ure@@ , sudden de@@ ath@@ ) or inf@@ ec@@ tious (@@ e@@ . g. p@@ ne@@ um@@ oni@@ a@@ ) in nat@@ ure@@ .
Cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse event@@ s@@ : in the same tri@@ al@@ s@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events (@@ e@@ . g. stro@@ ke@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ )@@ , including fat@@ ali@@ ti@@ es@@ , were reported in patients (@@ mean age@@ :
84 ye@@ ar@@ s@@ ; ran@@ ge@@ :
78@@ -@@ 88 ye@@ ar@@ s@@ )@@ .
Over@@ all@@ , 1.@@ 3@@ % of ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients reported cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events compared with 0.@@ 6@@ % of pla@@ c@@ ebo@@ -@@ treated patients in these tri@@ al@@ s.
This difference was not stati@@ st@@ ically signific@@ ant@@ .
Ho@@ we@@ ver@@ , in one of these tri@@ al@@ s@@ , a fix@@ ed@@ -@@ dose tri@@ al@@ , there was a significant dose response relationship for cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events in patients treated with ari@@ pi@@ pra@@ z@@ ole@@ .
AB@@ IL@@ I@@ F@@ Y is not approved for the treatment of demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s.
Hy@@ per@@ g@@ ly@@ ca@@ emi@@ a and Diabetes Mel@@ li@@ t@@ us@@ : hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , in some cases extreme and associated with ket@@ o@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or de@@ ath@@ , has been reported in patients treated with at@@ yp@@ ical anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ris@@ k factors that may pre@@ disp@@ ose patients to severe complic@@ ations include obesity and family history of di@@ abet@@ es@@ .
In clinical trials with ari@@ pi@@ pra@@ z@@ ole@@ , there were no significant differences in the inci@@ dence rates of hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events (@@ including di@@ abet@@ es@@ ) or in ab@@ normal g@@ ly@@ ca@@ emi@@ a lab@@ oratory values compared to pla@@ c@@ ebo@@ .
Pre@@ cise risk estimates for hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events in patients treated with AB@@ IL@@ I@@ F@@ Y and with other at@@ yp@@ ical anti@@ p@@ sycho@@ tic agents are not available to allow direct compar@@ is@@ ons@@ .
Pati@@ ents treated with any anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ , should be observed for signs and symptoms of hyper@@ g@@ ly@@ ca@@ emi@@ a (@@ such as poly@@ di@@ p@@ si@@ a@@ , poly@@ uri@@ a@@ , poly@@ ph@@ ag@@ ia and weak@@ ness@@ ) and patients with diabetes mel@@ li@@ tus or with risk factors for diabetes mel@@ li@@ tus should be monit@@ ored regularly for wor@@ sen@@ ing of glu@@ c@@ ose contro@@ l.
Wei@@ ght ga@@ in@@ : weight gain is commonly seen in sch@@ iz@@ op@@ hren@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ti@@ es@@ , use of anti@@ p@@ sycho@@ tics known to cause weight ga@@ in@@ , poor@@ ly managed li@@ fe@@ -@@ sty@@ le@@ , and might lead to severe complic@@ ations@@ .
Wei@@ ght gain has been reported post@@ -@@ marketing among patients prescri@@ bed AB@@ IL@@ I@@ F@@ Y@@ .
When se@@ en@@ , it is usually in those with significant risk factors such as history of di@@ abet@@ es@@ , th@@ y@@ ro@@ id disorder or pit@@ u@@ it@@ ary aden@@ om@@ a.
In clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight gain (@@ see section 5.@@ 1@@ )@@ .
72 Dy@@ sph@@ ag@@ i@@ a@@ : o@@ es@@ op@@ ha@@ ge@@ al dy@@ smo@@ tili@@ ty and aspi@@ ration have been associated with anti@@ p@@ sycho@@ tic drug use@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ari@@ pi@@ pra@@ z@@ ole and other anti@@ p@@ sycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for aspi@@ ration p@@ ne@@ um@@ oni@@ a.
Ph@@ en@@ yl@@ ket@@ on@@ uri@@ c@@ s@@ :
AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets contain as@@ part@@ ame@@ , a source of phen@@ yl@@ al@@ an@@ ine which may be harm@@ ful for people with phen@@ yl@@ ket@@ on@@ uri@@ a.
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ : as with other medic@@ ations hyper@@ sensi@@ tivity re@@ ac@@ tions@@ , character@@ ised by aller@@ gic symp@@ tom@@ s@@ , may occur with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
D@@ ue to its α 1@@ -@@ ad@@ ren@@ er@@ gic rec@@ ep@@ tor ant@@ agon@@ is@@ m@@ , ari@@ pi@@ pra@@ z@@ ole has the potential to enh@@ ance the effect of certain anti@@ hyper@@ ten@@ sive ag@@ ent@@ s.
Given the primary CN@@ S effects of ari@@ pi@@ pra@@ z@@ ole@@ , caution should be used when ari@@ pi@@ pra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping un@@ desi@@ rable effects such as se@@ dation (@@ see section 4.@@ 8@@ )@@ .
If ari@@ pi@@ pra@@ z@@ ole is administ@@ ered con@@ co@@ mit@@ antly with medic@@ ines known to cause Q@@ T pro@@ long@@ ation or elec@@ tro@@ ly@@ te im@@ bal@@ anc@@ e@@ , caution should be use@@ d.
Pot@@ ential for other medic@@ inal products to affect AB@@ IL@@ I@@ F@@ Y@@ :
A ga@@ stri@@ c acid blo@@ cker@@ , the H@@ 2 ant@@ agon@@ ist f@@ amo@@ ti@@ d@@ ine@@ , redu@@ ces ari@@ pi@@ pra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relev@@ ant@@ .
Ari@@ pi@@ pra@@ z@@ ole is met@@ aboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ ym@@ es but not C@@ Y@@ P@@ 1@@ A enz@@ ym@@ es@@ .
Th@@ us@@ , no d@@ os@@ age adju@@ st@@ ment is required for smo@@ ker@@ s.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ qu@@ ini@@ d@@ ine@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C by 10@@ 7@@ %@@ , while C@@ max was un@@ ch@@ ange@@ d.
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , decre@@ ased by 32@@ % and 47@@ %@@ .
AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed dose when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y with qu@@ ini@@ dine occ@@ urs@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 2@@ D@@ 6@@ , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 3@@ A4 (@@ ket@@ o@@ con@@ az@@ ole@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C and C@@ max by 6@@ 3@@ % and 37@@ %@@ , respec@@ ti@@ vel@@ y@@ .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole increased by 77@@ % and 43@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor met@@ aboli@@ ser@@ s@@ , con@@ co@@ mit@@ ant use of pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 may result in higher p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive met@@ aboli@@ zer@@ s.
When considering con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors with AB@@ IL@@ I@@ F@@ Y@@ , potential benefits should out@@ weigh the potential risks to the pati@@ ent@@ .
When con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ o@@ z@@ ole with AB@@ IL@@ I@@ F@@ Y occ@@ urs@@ , AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed d@@ os@@ e@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A@@ 4@@ , such as it@@ ra@@ con@@ az@@ ole and HIV prot@@ ease in@@ hi@@ bit@@ or@@ s@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hi@@ bit@@ or@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be increased to the level prior to the initi@@ ation of the con@@ co@@ mit@@ ant therap@@ y@@ .
When weak in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 (@@ e@@ . g@@ .@@ , dil@@ ti@@ az@@ em or esc@@ ital@@ op@@ ra@@ m@@ ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ co@@ mit@@ antly with AB@@ IL@@ I@@ F@@ Y@@ , modest increases in ari@@ pi@@ pra@@ z@@ ole conc@@ ent@@ rations might be expec@@ te@@ d.
Following con@@ co@@ mit@@ ant administration of car@@ b@@ amaz@@ ep@@ ine@@ , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A@@ 4@@ , the ge@@ omet@@ ric means of C@@ max and AU@@ C for ari@@ pi@@ pra@@ z@@ ole were 68@@ % and 7@@ 3@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , compared to when ari@@ pi@@ pra@@ z@@ ole (@@ 30 m@@ g@@ ) was administ@@ ered al@@ one@@ .
Simi@@ lar@@ ly@@ , for de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole the ge@@ omet@@ ric means
73 of C@@ max and AU@@ C after car@@ b@@ amaz@@ ep@@ ine co@@ -@@ administration were 69@@ % and 7@@ 1@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , than those following treatment with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
AB@@ IL@@ I@@ F@@ Y dose should be doubled when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y occ@@ urs with car@@ b@@ amaz@@ ep@@ ine@@ .
John@@ '@@ s Wort@@ ) may be expected to have similar effects and similar dose increases should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be reduced to the recommended d@@ os@@ e@@ .
When either val@@ pro@@ ate or li@@ thi@@ um were administ@@ ered con@@ co@@ mit@@ antly with ari@@ pi@@ pra@@ z@@ ole@@ , there was no clin@@ ically significant change in ari@@ pi@@ pra@@ z@@ ole conc@@ entra@@ tions@@ .
Pot@@ ential for AB@@ IL@@ I@@ F@@ Y to affect other medic@@ inal produc@@ ts@@ :
In clinical stu@@ dies@@ , 10@@ -@@ 30 m@@ g@@ / day d@@ oses of ari@@ pi@@ pra@@ z@@ ole had no significant effect on the met@@ aboli@@ sm of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ / 3@@ -@@ metho@@ x@@ y@@ mor@@ ph@@ in@@ an rati@@ o@@ )@@ , 2@@ C@@ 9 (@@ war@@ far@@ in@@ )@@ , 2@@ C@@ 19 (@@ om@@ ep@@ raz@@ ole@@ )@@ , and 3@@ A4 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ )@@ .
Addi@@ tion@@ all@@ y@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole did not show potential for al@@ tering C@@ Y@@ P@@ 1@@ A@@ 2@@ -@@ medi@@ ated met@@ aboli@@ sm in vit@@ ro@@ .
Th@@ us@@ , ari@@ pi@@ pra@@ z@@ ole is unlikely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ ym@@ es@@ .
When ari@@ pi@@ pra@@ z@@ ole was administ@@ ered con@@ co@@ mit@@ antly with either val@@ pro@@ ate or li@@ thi@@ um@@ , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ thi@@ um conc@@ entra@@ tions@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled trials of ari@@ pi@@ pra@@ z@@ ole in pregnant wom@@ en@@ .
Ani@@ mal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
D@@ ue to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive stu@@ dies@@ , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ et@@ us@@ .
Ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during la@@ ct@@ ation@@ .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pi@@ pra@@ z@@ ole@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been per@@ for@@ med@@ .
Ho@@ we@@ ver@@ , as with other anti@@ p@@ sycho@@ tic@@ s@@ , patients should be cau@@ tioned about operating ha@@ z@@ ard@@ ous mach@@ in@@ es@@ , including motor v@@ ehic@@ les@@ , until they are reas@@ onably certain that ari@@ pi@@ pra@@ z@@ ole does not affect them adver@@ sel@@ y@@ .
4.@@ 8 Un@@ desi@@ rable effects
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ )@@ :
The frequ@@ ency listed below is defined using the following conven@@ tion@@ : common (@@ > 1@@ / 100 ,@@ < 1@@ /@@ 10@@ ) and un@@ common (@@ > 1@@ /@@ 1 ,@@ 00@@ 0@@ , < 1@@ /@@ 100@@ )@@ .
74 Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous System disor@@ ders Common@@ : ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disor@@ der@@ , ak@@ ath@@ isi@@ a@@ , tre@@ mor@@ , di@@ zz@@ in@@ ess@@ , som@@ n@@ ol@@ en@@ ce@@ , se@@ d@@ ation@@ , hea@@ da@@ che E@@ ye disor@@ ders Common@@ : bl@@ urred vision Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : dy@@ sp@@ ep@@ si@@ a@@ , vo@@ mit@@ ing@@ , nau@@ se@@ a@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ * General disor@@ ders and administration site conditions Common@@ : f@@ ati@@ gue P@@ sychiatri@@ c disor@@ ders Common@@ : rest@@ less@@ ness@@ , ins@@ om@@ ni@@ a@@ , anxiety Un@@ common@@ : depres@@ sion@@ *
Ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symptoms (@@ EP@@ S@@ )@@ :
Sch@@ iz@@ op@@ hren@@ ia - in a long term 5@@ 2@@ -@@ week controlled tri@@ al@@ , ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients had an over@@ all@@ -@@ lower inci@@ dence (@@ 25.@@ 8@@ %@@ ) of E@@ PS including par@@ kin@@ son@@ is@@ m@@ , ak@@ ath@@ isi@@ a@@ , dy@@ st@@ onia and dy@@ sk@@ ine@@ sia compared with those treated with hal@@ operi@@ dol (@@ 5@@ 7.@@ 3@@ %@@ )@@ .
In a long term 26@@ -@@ week pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 19@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 13.@@ 1@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In another long@@ -@@ term 26@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 14.@@ 8@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 1@@ % for ol@@ anz@@ ap@@ ine@@ -@@ treated pati@@ ent@@ s.
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 23.@@ 5@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 5@@ 3.@@ 3@@ % for hal@@ operi@@ dol@@ -@@ treated pati@@ ent@@ s.
In another 12@@ -@@ week tri@@ al@@ , the inci@@ dence of E@@ PS was 26.@@ 6@@ % for patients treated with ari@@ pi@@ pra@@ z@@ ole and 17.@@ 6@@ % for those treated with li@@ thi@@ um@@ .
In the long term 26@@ -@@ week maintenance phase of a pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 18.@@ 2@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 7@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ s@@ , the inci@@ dence of ak@@ ath@@ i@@ sia in bi@@ pol@@ ar patients was 12.@@ 1@@ % with ari@@ pi@@ pra@@ z@@ ole and 3.@@ 2@@ % with pla@@ c@@ ebo@@ .
In sch@@ iz@@ op@@ hren@@ ia patients the inci@@ dence of ak@@ ath@@ i@@ sia was 6.@@ 2@@ % with ari@@ pi@@ pra@@ z@@ ole and 3@@ .0@@ % with pla@@ c@@ ebo@@ .
Com@@ par@@ is@@ ons between ari@@ pi@@ pra@@ z@@ ole and pla@@ c@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine lab@@ oratory par@@ ame@@ ters revealed no medi@@ cally important differ@@ en@@ c@@ es@@ .
Ele@@ v@@ ations of C@@ P@@ K (@@ Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ )@@ , generally tran@@ si@@ ent and as@@ ymp@@ tom@@ ati@@ c@@ , were observed in 3.@@ 5@@ % of ari@@ pi@@ pra@@ z@@ ole treated patients as compared to 2@@ .0@@ % of patients who received pla@@ c@@ ebo@@ .
Other fin@@ d@@ ings@@ :
Un@@ desi@@ rable effects known to be associated with anti@@ p@@ sycho@@ tic therapy and also reported during treatment with ari@@ pi@@ pra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ dro@@ me@@ , tar@@ di@@ ve dy@@ sk@@ ine@@ si@@ a@@ , sei@@ zu@@ re@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly de@@ mented pati@@ ent@@ s@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ tus (@@ see section 4.@@ 4@@ )@@ .
Post@@ -@@ Market@@ ing@@ :
The following ad@@ verse events have been reported during post@@ -@@ marketing sur@@ veil@@ lan@@ ce@@ .
The frequ@@ ency of these events is considered not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Investig@@ ations@@ :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ , blood glu@@ c@@ ose increas@@ ed@@ , blood glu@@ c@@ ose flu@@ ctu@@ ation@@ , g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in increased
Cardi@@ ac disor@@ der@@ s@@ :
Q@@ T pro@@ long@@ ation@@ , vent@@ ri@@ cular arr@@ hyth@@ mi@@ as@@ , sudden un@@ explained de@@ ath@@ , cardi@@ ac ar@@ rest@@ , tor@@ sa@@ des de poin@@ tes@@ , bra@@ dy@@ car@@ dia
Bloo@@ d and the lymp@@ h@@ atic system disor@@ der@@ s@@ :
leu@@ kop@@ eni@@ a@@ , neut@@ rop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia
75 Ner@@ v@@ ous system disor@@ der@@ s@@ :
speech disor@@ der@@ , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ , grand mal con@@ vul@@ sion
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ s@@ :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m@@ , lar@@ yn@@ g@@ os@@ pas@@ m@@ , aspi@@ ration p@@ ne@@ um@@ onia
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
pan@@ cre@@ ati@@ tis@@ , dy@@ sph@@ ag@@ i@@ a@@ , ab@@ dom@@ inal dis@@ comfort@@ , stomach dis@@ comfort@@ , di@@ arr@@ ho@@ ea
Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
ur@@ inary in@@ contin@@ en@@ ce@@ , ur@@ inary re@@ tention
Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
ra@@ sh@@ , ph@@ otos@@ en@@ si@@ tivity re@@ ac@@ tion@@ , al@@ op@@ eci@@ a@@ , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , my@@ al@@ gi@@ a@@ , sti@@ ff@@ ness
En@@ do@@ cr@@ ine disor@@ der@@ s@@ :
hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , diabetes mel@@ li@@ t@@ us@@ , di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s@@ , di@@ abe@@ tic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
weight ga@@ in@@ , weight decre@@ as@@ ed@@ , an@@ or@@ ex@@ i@@ a@@ , h@@ yp@@ on@@ at@@ re@@ mia
V@@ as@@ cular disor@@ der@@ s@@ :
syn@@ cop@@ e@@ , hyper@@ ten@@ sion@@ , thro@@ mbo@@ em@@ bo@@ lic events
General disor@@ ders and administration site condi@@ tions@@ :
temperature regulation disorder (@@ e@@ . g. hypo@@ ther@@ mi@@ a@@ , py@@ re@@ xi@@ a@@ )@@ , chest pain@@ , peri@@ pher@@ al oe@@ de@@ ma
Immun@@ e system disor@@ der@@ s@@ :
aller@@ gic reaction (@@ e@@ . g. an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ , an@@ gi@@ oe@@ de@@ ma including s@@ wollen ton@@ gu@@ e@@ , ton@@ gue oe@@ de@@ ma@@ , face oe@@ de@@ ma@@ , p@@ ru@@ rit@@ us@@ , or ur@@ tic@@ ari@@ a@@ )
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ der@@ s@@ :
ja@@ un@@ di@@ ce@@ , he@@ pati@@ tis@@ , increased A@@ lan@@ ine A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ AL@@ T@@ )@@ , increased A@@ spar@@ tate A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ A@@ ST@@ )@@ , increased G@@ amm@@ a Gl@@ ut@@ am@@ yl Transfer@@ ase (@@ G@@ GT@@ )@@ , increased al@@ kal@@ ine ph@@ osp@@ hat@@ ase
Re@@ productive system and breast disor@@ der@@ s@@ :
pri@@ ap@@ ism
P@@ sychiatri@@ c disor@@ der@@ s@@ :
ag@@ it@@ ation@@ , nerv@@ ous@@ ness@@ ; suicide attemp@@ t@@ , suici@@ dal ide@@ ation@@ , and completed suicide (@@ see section 4.@@ 4@@ )
4.@@ 9 Over@@ dose
In clinical trials and post@@ -@@ marketing experi@@ en@@ ce@@ , acci@@ dental or inten@@ tional ac@@ ute over@@ d@@ os@@ age of ari@@ pi@@ pra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy@@ , increased blood pressu@@ re@@ , som@@ n@@ ol@@ en@@ ce@@ , ta@@ ch@@ y@@ cardi@@ a@@ , nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ e@@ a.
In addi@@ tion@@ , reports of acci@@ dental over@@ dose with ari@@ pi@@ pra@@ z@@ ole alone (@@ up to 19@@ 5 m@@ g@@ ) in children have been received with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ en@@ ce@@ , tran@@ si@@ ent loss of consci@@ ousness and ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symp@@ tom@@ s.
Management of over@@ dose should concentrate on supportive therap@@ y@@ , maintaining an adequate air@@ wa@@ y@@ , oxy@@ gen@@ ation and v@@ enti@@ la@@ tion@@ , and management of symp@@ tom@@ s.
The possibility of multiple medic@@ inal product involvement should be consider@@ ed@@ .
Ther@@ efore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continu@@ ous elec@@ tro@@ cardi@@ o@@ graphic monitoring to dete@@ ct possible arr@@ hyth@@ mi@@ as@@ .
Following any confirmed or suspected over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , close medical super@@ vision and monitoring should continue until the patient reco@@ vers@@ .
76 Ac@@ tiv@@ ated char@@ coal (@@ 50 g@@ )@@ , administ@@ ered one hour after ari@@ pi@@ pra@@ z@@ ole@@ , decre@@ ased ari@@ pi@@ pra@@ z@@ ole C@@ max by about 4@@ 1@@ % and AU@@ C by about 5@@ 1@@ %@@ , suggesting that char@@ coal may be effective in the treatment of over@@ d@@ os@@ e@@ .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in treating an over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , ha@@ emo@@ di@@ aly@@ sis is unlikely to be useful in over@@ dose management since ari@@ pi@@ pra@@ z@@ ole is highly bound to p@@ las@@ ma prot@@ ein@@ s.
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ p@@ sycho@@ tic@@ s@@ , AT@@ C co@@ de@@ :
N@@ 05@@ A@@ X@@ 12
It has been proposed that ari@@ pi@@ pra@@ z@@ ole@@ ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ amine D@@ 2 and ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a rec@@ ep@@ tors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hypo@@ activ@@ it@@ y@@ .
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited high bin@@ ding aff@@ in@@ ity in vit@@ ro for d@@ op@@ amine D@@ 2 and D@@ 3@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a and 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tors and moderate aff@@ in@@ ity for d@@ op@@ amine D@@ 4@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ c and 5@@ H@@ T@@ 7@@ , alp@@ ha@@ -@@ 1 ad@@ ren@@ er@@ gic and hist@@ amine H@@ 1 rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole also exhi@@ bited moderate bin@@ ding aff@@ in@@ ity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ in@@ ity for mus@@ car@@ ini@@ c rec@@ ep@@ tor@@ s.
Inter@@ action with rec@@ ep@@ tors other than d@@ op@@ amine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pi@@ pra@@ z@@ ole@@ .
Ari@@ pi@@ pra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a d@@ os@@ e@@ -@@ dependent reduction in the bin@@ ding of 11@@ C@@ -@@ ra@@ clo@@ pri@@ de@@ , a D@@ 2@@ / D@@ 3 rec@@ ep@@ tor lig@@ and@@ , to the cau@@ date and put@@ amen dete@@ cted by posi@@ tr@@ on e@@ mission tom@@ o@@ grap@@ hy@@ .
Further information on clinical tri@@ al@@ s@@ :
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
In three short@@ -@@ term (@@ 4 to 6 wee@@ ks@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 1,@@ 228 sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s@@ , presenting with positive or negative symp@@ tom@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was associated with stati@@ st@@ ically significantly greater improvements in p@@ sycho@@ tic symptoms compared to pla@@ c@@ ebo@@ .
AB@@ IL@@ I@@ F@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment respon@@ se@@ .
In a hal@@ operi@@ dol@@ -@@ controlled tri@@ al@@ , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2@@ -@@ weeks was similar in both groups (@@ ari@@ pi@@ pra@@ z@@ ole 77@@ % and hal@@ operi@@ dol 7@@ 3@@ %@@ )@@ .
The overall comple@@ tion rate was significantly higher for patients on ari@@ pi@@ pra@@ z@@ ole (@@ 43@@ %@@ ) than for hal@@ operi@@ dol (@@ 30@@ %@@ )@@ .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ poin@@ ts@@ , including P@@ AN@@ SS and the Montgom@@ er@@ y@@ -@@ As@@ berg Depression R@@ ating Sc@@ ale showed a significant improvement over hal@@ operi@@ dol@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hren@@ i@@ a@@ , ari@@ pi@@ pra@@ z@@ ole had significantly greater reduction in re@@ lap@@ se rat@@ e@@ , 34@@ % in ari@@ pi@@ pra@@ z@@ ole group and 57@@ % in pla@@ c@@ ebo@@ .
Wei@@ ght ga@@ in@@ : in clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight ga@@ in@@ .
In a 26@@ -@@ week@@ , ol@@ anz@@ ap@@ ine@@ -@@ contro@@ lle@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , multi@@ -@@ national study of sch@@ iz@@ op@@ hren@@ ia which included 3@@ 14 patients and where the primary end@@ -@@ point was weight ga@@ in@@ , significantly less patients had at least 7@@ % weight gain over bas@@ eline (@@ i@@ . e@@ . a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~@@ 8@@ 0.5 k@@ g@@ ) on ari@@ pi@@ pra@@ z@@ ole (@@ N@@ = 18@@ , or 13@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ , compared to ol@@ anz@@ ap@@ ine (@@ N@@ = 45@@ , or 33@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ .
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
In two 3@@ -@@ week@@ , flexi@@ ble@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o in
These trials included patients with or without p@@ sycho@@ tic features and with or without a rap@@ id@@ -@@ cycling cour@@ se@@ .
In one 3@@ -@@ week@@ , fix@@ ed@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to pla@@ c@@ ebo@@ .
In two 12@@ -@@ week@@ , pla@@ c@@ ebo@@ - and ac@@ ti@@ ve@@ -@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o at week 3 and a maintenance of effect compar@@ able to li@@ thi@@ um or hal@@ operi@@ dol at week 12.
Ari@@ pi@@ pra@@ z@@ ole also demonstrated a compar@@ able proportion of patients in symp@@ tom@@ atic re@@ mission from man@@ ia as li@@ thi@@ um or hal@@ operi@@ dol at week 12.
In a 6@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , who were parti@@ ally non@@ -@@ respon@@ sive to li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeu@@ tic ser@@ um level@@ s@@ , the addition of ari@@ pi@@ pra@@ z@@ ole as ad@@ jun@@ ctive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therap@@ y@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , followed by a 7@@ 4@@ -@@ week exten@@ sion@@ , in man@@ ic patients who achieved re@@ mission on ari@@ pi@@ pra@@ z@@ ole during a stabili@@ zation phase prior to rand@@ omi@@ z@@ ation@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ ren@@ ce@@ , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depres@@ sion@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ari@@ pi@@ pra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tab@@ let is bio@@ equivalent to ari@@ pi@@ pra@@ z@@ ole tab@@ le@@ ts@@ , with a similar rate and extent of absor@@ p@@ tion@@ .
Ari@@ pi@@ pra@@ z@@ ole or@@ o@@ disp@@ er@@ sible tab@@ lets may be used as an alternative to ari@@ pi@@ pra@@ z@@ ole tab@@ le@@ ts@@ .
Ab@@ sor@@ p@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is well absor@@ bed@@ , with peak p@@ las@@ ma conc@@ ent@@ rations occ@@ urring within 3@@ -@@ 5 hours after d@@ os@@ ing@@ .
Ari@@ pi@@ pra@@ z@@ ole under@@ goes minimal pre@@ -@@ sy@@ ste@@ mic met@@ aboli@@ sm@@ .
The absolute oral bio@@ availability of the tab@@ let formu@@ lation is 8@@ 7@@ %@@ .
There is no effect of a high fat meal on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Distri@@ bu@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is widely distri@@ buted throughout the body with an apparent volume of distribution of 4.@@ 9 l@@ / k@@ g@@ , indic@@ ating extensive extra@@ v@@ as@@ cular distri@@ bu@@ tion@@ .
At therapeu@@ tic conc@@ entra@@ tions@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole are greater than 99@@ % bound to ser@@ um prot@@ ein@@ s@@ , bin@@ ding primarily to alb@@ umin@@ .
Met@@ aboli@@ sm@@ :
Ari@@ pi@@ pra@@ z@@ ole is exten@@ sively met@@ aboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ wa@@ ys@@ : de@@ hydro@@ gen@@ ation@@ , hydro@@ x@@ y@@ la@@ tion@@ , and N@@ -@@ deal@@ k@@ y@@ la@@ tion@@ .
Based on in vit@@ ro stu@@ dies@@ , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ ym@@ es are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ y@@ lation of ari@@ pi@@ pra@@ z@@ ole@@ , and N@@ -@@ deal@@ k@@ y@@ lation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A@@ 4.
Ari@@ pi@@ pra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ iety in sy@@ ste@@ mic circu@@ la@@ tion@@ .
At steady stat@@ e@@ , de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , represents about 40@@ % of ari@@ pi@@ pra@@ z@@ ole AU@@ C in p@@ las@@ ma@@ .
Eli@@ min@@ ation@@ :
The mean elim@@ ination half@@ -@@ lives for ari@@ pi@@ pra@@ z@@ ole are approximately 75 hours in extensive met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6.
The total body clear@@ ance of ari@@ pi@@ pra@@ z@@ ole is 0.@@ 7 m@@ l@@ / min@@ / k@@ g@@ , which is primarily he@@ pati@@ c.
Following a single oral dose of [@@ 14@@ C@@ ]@@ -@@ lab@@ elled ari@@ pi@@ pra@@ z@@ ole@@ , approximately 27@@ % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60@@ % in the fa@@ ec@@ es@@ .
L@@ ess than 1@@ % of un@@ changed ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18@@ % was recovered un@@ changed in the fa@@ ec@@ es@@ .
78 P@@ harm@@ ac@@ ok@@ ine@@ tics in special patient groups
El@@ der@@ ly@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy elderly and younger adult sub@@ jec@@ ts@@ , nor is there any dete@@ ct@@ able effect of age in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Gen@@ der@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy male and female subjects nor is there any dete@@ ct@@ able effect of gender in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Smo@@ king and Rac@@ e@@ :
Pop@@ ulation pharmac@@ ok@@ ine@@ tic ev@@ al@@ uation has revealed no evidence of clin@@ ically significant ra@@ ce@@ -@@ related differences or effects from smoking upon the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Ren@@ al Di@@ seas@@ e@@ :
The pharmac@@ ok@@ ine@@ tic characterist@@ ics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy sub@@ jec@@ ts@@ .
H@@ ep@@ atic Di@@ seas@@ e@@ :
A sing@@ le@@ -@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis (@@ Chil@@ d@@ -@@ Pu@@ gh Clas@@ ses A@@ , B@@ , and C@@ ) did not reveal a significant effect of he@@ pati@@ c im@@ pa@@ ir@@ ment on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ si@@ s@@ , which is in@@ sufficient to draw conclu@@ sions on their met@@ aboli@@ c cap@@ ac@@ it@@ y@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
Non@@ -@@ clinical safety data revealed no special ha@@ zard for humans based on conventional studies of safety pharmac@@ olog@@ y@@ , repe@@ at@@ -@@ dose tox@@ ic@@ it@@ y@@ , gen@@ oto@@ x@@ ic@@ it@@ y@@ , car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ , and tox@@ ic@@ ity to re@@ produc@@ tion@@ .
To@@ x@@ ic@@ ologi@@ cally significant effects were observed only at d@@ oses or exp@@ os@@ ures that were suff@@ ici@@ ently in excess of the maximum human dose or exp@@ os@@ ure@@ , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use@@ .
These inclu@@ de@@ d@@ : d@@ os@@ e@@ -@@ dependent ad@@ reno@@ cor@@ tical tox@@ ic@@ ity (@@ li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and@@ / or par@@ en@@ ch@@ y@@ mal cell los@@ s@@ ) in rats after 104 weeks at 20 to 60 m@@ g@@ / k@@ g@@ / day (@@ 3 to 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ ) and increased ad@@ reno@@ cor@@ tical car@@ cin@@ om@@ as and combined ad@@ reno@@ cor@@ tical aden@@ om@@ as@@ / car@@ cin@@ om@@ as in female rats at 60 m@@ g@@ / k@@ g@@ / day (@@ 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ )@@ .
The highest non@@ tum@@ ori@@ gen@@ ic exposure in female rats was 7 times the human exposure at the recommended d@@ os@@ e@@ .
An additional finding was chol@@ eli@@ thi@@ asi@@ s as a consequ@@ ence of pre@@ cip@@ itation of sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy met@@ aboli@@ tes of ari@@ pi@@ pra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 m@@ g@@ / k@@ g@@ / day (@@ 1 to 3 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on m@@ g@@ / m@@ 2@@ )@@ .
Ho@@ we@@ ver@@ , the conc@@ ent@@ rations of the sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy ari@@ pi@@ pra@@ z@@ ole in human b@@ ile at the highest dose propos@@ ed@@ , 30 mg per day@@ , were no more than 6@@ % of the b@@ ile conc@@ ent@@ rations found in the mon@@ keys in the 39@@ -@@ week study and are well below (@@ 6@@ %@@ ) their limits of in vit@@ ro sol@@ u@@ bili@@ ty@@ .
Based on results of a full range of standard gen@@ oto@@ x@@ ic@@ ity test@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was considered non@@ -@@ gen@@ oto@@ x@@ ic@@ .
Ari@@ pi@@ pra@@ z@@ ole did not im@@ pair fertili@@ ty in re@@ productive tox@@ ic@@ ity stu@@ dies@@ .
Develop@@ mental tox@@ ic@@ it@@ y@@ , including d@@ os@@ e@@ -@@ dependent delayed fo@@ et@@ al ossi@@ fication and possible ter@@ at@@ o@@ gen@@ ic effec@@ ts@@ , were observed in rats at d@@ oses resulting in sub@@ therapeu@@ tic exp@@ os@@ ures (@@ based on AU@@ C@@ ) and in ra@@ bb@@ its at d@@ oses resulting in exp@@ os@@ ures 3 and 11 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical d@@ os@@ e@@ .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ it@@ y@@ .
79 6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Cal@@ ci@@ um si@@ lic@@ ate Cros@@ car@@ m@@ ell@@ ose so@@ dium Cros@@ po@@ vi@@ done Sili@@ con di@@ oxide X@@ y@@ li@@ to@@ l Mic@@ ro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ ose A@@ spart@@ ame (@@ E@@ 9@@ 5@@ 1@@ ) Ac@@ es@@ ul@@ fame pot@@ assi@@ um Van@@ illa fla@@ vour (@@ including van@@ ill@@ in and eth@@ yl van@@ il@@ lin@@ ) T@@ art@@ ari@@ c acid Mag@@ ne@@ si@@ um ste@@ ar@@ ate
Red iron oxide (@@ E@@ 17@@ 2@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
Not applic@@ ab@@ le@@ .
6.@@ 3 Shel@@ f life
3 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
6.5 Nature and cont@@ ents of container
Car@@ ton of 14 x 1 tab@@ lets in col@@ d@@ -@@ formed al@@ uminium per@@ for@@ ated unit dose bli@@ ster@@ s.
Car@@ ton of 28 x 1 tab@@ lets in col@@ d@@ -@@ formed al@@ uminium per@@ for@@ ated unit dose bli@@ ster@@ s.
Car@@ ton of 49 x 1 tab@@ lets in col@@ d@@ -@@ formed al@@ uminium per@@ for@@ ated unit dose bli@@ ster@@ s.
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 30@@ -@@ 0@@ 32
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
80 D@@ ate of first author@@ is@@ ation@@ :
4 June 2004
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
{@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
81 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 1 m@@ g@@ / ml oral solution
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml contains 1 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
Ex@@ cip@@ i@@ ent@@ s@@ :
200 mg fru@@ ct@@ ose per ml 400 mg su@@ cr@@ ose per ml 1.@@ 8 mg meth@@ yl par@@ ah@@ y@@ dro@@ x@@ y@@ ben@@ zo@@ ate (@@ E@@ 2@@ 18@@ ) per ml 0.@@ 2 mg prop@@ yl par@@ ah@@ y@@ dro@@ x@@ y@@ ben@@ zo@@ ate (@@ E@@ 2@@ 16@@ ) per ml
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
O@@ ral solution C@@ lear@@ , colo@@ ur@@ less to light yellow liqui@@ d.
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of sch@@ iz@@ op@@ hren@@ i@@ a.
AB@@ IL@@ I@@ F@@ Y is indicated for the treatment of moderate to severe man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ order and for the pre@@ vention of a new man@@ ic episode in patients who experienced pre@@ domin@@ antly man@@ ic episodes and whose man@@ ic episodes responded to ari@@ pi@@ pra@@ z@@ ole treatment (@@ see section 5.@@ 1@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
O@@ ral use@@ .
AB@@ IL@@ I@@ F@@ Y oral solution may be used as an alternative to AB@@ IL@@ I@@ F@@ Y tab@@ lets for patients who have difficulty swal@@ lowing AB@@ IL@@ I@@ F@@ Y tab@@ lets (@@ see section 5.@@ 2@@ )@@ .
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
The recommended starting dose for AB@@ IL@@ I@@ F@@ Y is 10 or 15 m@@ g@@ / day (@@ i@@ . e@@ .
10 or 15 ml sol@@ u@@ tion@@ / day@@ ) with a maintenance dose of 15 m@@ g@@ / day administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to me@@ al@@ s.
A cali@@ br@@ ated meas@@ uring cup and a 2 ml cali@@ br@@ ated dro@@ pper are included in the car@@ ton@@ .
AB@@ IL@@ I@@ F@@ Y is effective in a dose range of 10 to 30 m@@ g@@ / day (@@ i@@ . e@@ .
10 to 30 ml sol@@ u@@ tion@@ / day@@ )@@ .
En@@ h@@ anced eff@@ ic@@ acy at d@@ oses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher d@@ os@@ e@@ .
The maximum daily dose should not exce@@ ed 30 m@@ g.
M@@ anic epis@@ o@@ des@@ :
15 ml sol@@ u@@ tion@@ / day@@ ) administ@@ ered on a on@@ ce@@ -@@ a@@ -@@ day schedule without regard to meals as mon@@ o@@ therapy or combination therapy (@@ see section 5.@@ 1@@ )@@ .
Some patients may benefit from a higher d@@ os@@ e@@ .
30 ml sol@@ u@@ tion@@ / day@@ )@@ .
Rec@@ ur@@ r@@ ence pre@@ vention of man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
82 For preventing rec@@ ur@@ r@@ ence of man@@ ic episodes in patients who have been receiving ari@@ pi@@ pra@@ z@@ ole@@ , continue therapy at the same d@@ os@@ e@@ .
Ad@@ ju@@ st@@ ments of daily d@@ os@@ age@@ , including dose reduction should be considered on the basis of clinical stat@@ us@@ .
Children and adol@@ es@@ cent@@ s@@ : there is no experience in children and adol@@ es@@ cents under 18 years of age@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required for patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
In patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ , the data available are in@@ sufficient to establish recommend@@ ations@@ .
In these patients d@@ osing should be managed cau@@ ti@@ ous@@ ly@@ .
Ho@@ we@@ ver@@ , the maximum daily dose of 30 mg should be used with caution in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required in patients with ren@@ al im@@ pa@@ ir@@ ment@@ .
El@@ der@@ ly@@ : the effec@@ tiveness of AB@@ IL@@ I@@ F@@ Y in the treatment of sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order in patients 65 years of age or older has not been establi@@ sh@@ ed@@ .
O@@ wing to the greater sensi@@ tivity of this pop@@ ula@@ tion@@ , a lower starting dose should be considered when clinical factors warrant (@@ see section 4.@@ 4@@ )@@ .
Gen@@ der@@ : no d@@ os@@ age adju@@ st@@ ment is required for female patients as compared to male patients (@@ see sections 4.@@ 4 and 5.@@ 2@@ )@@ .
Smo@@ king stat@@ us@@ : according to the met@@ aboli@@ c path@@ way of AB@@ IL@@ I@@ F@@ Y no d@@ os@@ age adju@@ st@@ ment is required for smo@@ kers (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ ors with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be re@@ duc@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ or is with@@ drawn from the combination therap@@ y@@ , ari@@ pi@@ pra@@ z@@ ole dose should then be increased (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be increas@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therap@@ y@@ , the ari@@ pi@@ pra@@ z@@ ole dose should then be reduced to the recommended dose (@@ see section 4.@@ 5@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
During anti@@ p@@ sycho@@ tic treat@@ ment@@ , improvement in the pati@@ ent@@ '@@ s clinical condition may take several days to some wee@@ ks@@ .
Pati@@ ents should be closely monit@@ ored throughout this peri@@ od@@ .
The occ@@ ur@@ r@@ ence of suici@@ dal behaviour is inher@@ ent in p@@ sycho@@ tic ill@@ nesses and mood disor@@ ders and in some cases has been reported early after initi@@ ation or switch of anti@@ p@@ sycho@@ tic therap@@ y@@ , including treatment with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
C@@ lose super@@ vision of high@@ -@@ risk patients should ac@@ company anti@@ p@@ sycho@@ tic therap@@ y@@ .
Res@@ ults of an epide@@ mi@@ ological study found that there was no increased risk of suici@@ d@@ ality with ari@@ pi@@ pra@@ z@@ ole compared to other anti@@ p@@ sycho@@ tics among patients with bi@@ pol@@ ar disor@@ der@@ .
Cardi@@ ov@@ as@@ cular disor@@ der@@ s@@ :
Ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with known cardi@@ ov@@ as@@ cular disease (@@ history of m@@ yo@@ cardi@@ al inf@@ ar@@ ction or i@@ scha@@ e@@ mic heart dise@@ as@@ e@@ , heart fail@@ ure@@ , or conduc@@ tion ab@@ nor@@ mali@@ ti@@ es@@ )@@ , cer@@ eb@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ ension (@@ de@@ hy@@ dra@@ tion@@ , hypo@@ vol@@ emi@@ a@@ , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations@@ ) or hyper@@ ten@@ sion@@ , including acceler@@ ated or mal@@ ign@@ ant@@ .
Con@@ duction ab@@ nor@@ mali@@ ti@@ es@@ :
In clinical trials of ari@@ pi@@ pra@@ z@@ ole@@ , the inci@@ dence of Q@@ T pro@@ long@@ ation was compar@@ able to pla@@ c@@ ebo@@ .
As with other anti@@ p@@ sycho@@ tic@@ s@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with a family history of Q@@ T pro@@ long@@ ation@@ .
83 T@@ ardi@@ ve dy@@ sk@@ ine@@ si@@ a@@ : in clinical trials of one year or less dur@@ ation@@ , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ ine@@ sia during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
If signs and symptoms of tar@@ di@@ ve dy@@ sk@@ ine@@ sia appear in a patient on AB@@ IL@@ I@@ F@@ Y@@ , dose reduction or dis@@ continu@@ ation should be consider@@ ed@@ .
These symptoms can tempor@@ ally deterior@@ ate or can even ari@@ se after dis@@ continu@@ ation of treat@@ ment@@ .
Neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ drome (@@ N@@ M@@ S@@ )@@ :
N@@ MS is a potentially fatal symp@@ tom complex associated with anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ .
In clinical tri@@ al@@ s@@ , rare cases of N@@ MS were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Clin@@ ical manifest@@ ations of N@@ MS are hyper@@ py@@ re@@ xi@@ a@@ , muscle rigi@@ di@@ ty@@ , al@@ tered mental status and evidence of auton@@ omic inst@@ ability (@@ ir@@ regular pul@@ se or blood pressu@@ re@@ , ta@@ ch@@ y@@ cardi@@ a@@ , di@@ aph@@ ore@@ sis and cardi@@ ac dys@@ rhyth@@ mi@@ a@@ )@@ .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ as@@ e@@ , m@@ yo@@ glob@@ in@@ uri@@ a (@@ r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ )@@ , and ac@@ ute ren@@ al fail@@ ure@@ .
Ho@@ we@@ ver@@ , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , not necessarily in association with N@@ M@@ S@@ , have also been repor@@ te@@ d.
If a patient develop@@ s signs and symptoms indic@@ ative of N@@ M@@ S@@ , or presents with un@@ explained high fe@@ ver without additional clinical manifest@@ ations of N@@ M@@ S@@ , all anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ , including AB@@ IL@@ I@@ F@@ Y@@ , must be dis@@ continu@@ ed@@ .
Sei@@ zu@@ re@@ : in clinical tri@@ al@@ s@@ , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Ther@@ e@@ fore@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients who have a history of sei@@ z@@ ure disorder or have conditions associated with sei@@ zu@@ res@@ .
El@@ derly patients with demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s@@ :
In@@ cre@@ ased mort@@ al@@ it@@ y@@ : in three pla@@ c@@ ebo@@ -@@ controlled trials (@@ n@@ = 9@@ 38@@ ; mean age@@ :
8@@ 2.@@ 4 ye@@ ar@@ s@@ ; ran@@ ge@@ :
56@@ -@@ 99 ye@@ ar@@ s@@ ) of ari@@ pi@@ pra@@ z@@ ole in elderly patients with p@@ sycho@@ sis associated with Al@@ z@@ hei@@ mer@@ '@@ s dise@@ as@@ e@@ , patients treated with ari@@ pi@@ pra@@ z@@ ole were at increased risk of death compared to pla@@ c@@ ebo@@ .
The rate of death in ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients was 3.@@ 5@@ % compared to 1.@@ 7@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
Although the causes of deaths were var@@ ie@@ d@@ , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular (@@ e@@ . g. heart fail@@ ure@@ , sudden de@@ ath@@ ) or inf@@ ec@@ tious (@@ e@@ . g. p@@ ne@@ um@@ oni@@ a@@ ) in nat@@ ure@@ .
Cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse event@@ s@@ : in the same tri@@ al@@ s@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events (@@ e@@ . g. stro@@ ke@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ )@@ , including fat@@ ali@@ ti@@ es@@ , were reported in patients (@@ mean age@@ :
84 ye@@ ar@@ s@@ ; ran@@ ge@@ :
78@@ -@@ 88 ye@@ ar@@ s@@ )@@ .
Over@@ all@@ , 1.@@ 3@@ % of ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients reported cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events compared with 0.@@ 6@@ % of pla@@ c@@ ebo@@ -@@ treated patients in these tri@@ al@@ s.
This difference was not stati@@ st@@ ically signific@@ ant@@ .
Ho@@ we@@ ver@@ , in one of these tri@@ al@@ s@@ , a fix@@ ed@@ -@@ dose tri@@ al@@ , there was a significant dose response relationship for cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events in patients treated with ari@@ pi@@ pra@@ z@@ ole@@ .
AB@@ IL@@ I@@ F@@ Y is not approved for the treatment of demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s.
Hy@@ per@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ t@@ us@@ : hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , in some cases extreme and associated with ket@@ o@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or de@@ ath@@ , has been reported in patients treated with at@@ yp@@ ical anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ris@@ k factors that may pre@@ disp@@ ose patients to severe complic@@ ations include obesity and family history of di@@ abet@@ es@@ .
In clinical trials with ari@@ pi@@ pra@@ z@@ ole@@ , there were no significant differences in the inci@@ dence rates of hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events (@@ including di@@ abet@@ es@@ ) or in ab@@ normal g@@ ly@@ ca@@ emi@@ a lab@@ oratory values compared to pla@@ c@@ ebo@@ .
Pre@@ cise risk estimates for hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events in patients treated with AB@@ IL@@ I@@ F@@ Y and with other at@@ yp@@ ical anti@@ p@@ sycho@@ tic agents are not available to allow direct compar@@ is@@ ons@@ .
Pati@@ ents treated with any anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ , should be observed for signs and symptoms of hyper@@ g@@ ly@@ ca@@ emi@@ a (@@ such as poly@@ di@@ p@@ si@@ a@@ , poly@@ uri@@ a@@ , poly@@ ph@@ ag@@ ia and weak@@ ness@@ ) and patients with diabetes mel@@ li@@ tus or with risk factors for diabetes mel@@ li@@ tus should be monit@@ ored regularly for wor@@ sen@@ ing of glu@@ c@@ ose contro@@ l.
Wei@@ ght ga@@ in@@ : weight gain is commonly seen in sch@@ iz@@ op@@ hren@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ti@@ es@@ , use of anti@@ p@@ sycho@@ tics known to cause weight ga@@ in@@ , poor@@ ly managed li@@ fe@@ -@@ sty@@ le@@ , and might lead to severe complic@@ ations@@ .
Wei@@ ght gain has been reported post@@ -@@ marketing among patients prescri@@ bed AB@@ IL@@ I@@ F@@ Y@@ .
When se@@ en@@ , it is usually in those with significant risk factors such as history of di@@ abet@@ es@@ , th@@ y@@ ro@@ id disorder or pit@@ u@@ it@@ ary aden@@ om@@ a.
In clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight gain (@@ see section 5.@@ 1@@ )@@ .
84 Dy@@ sph@@ ag@@ i@@ a@@ : o@@ es@@ op@@ ha@@ ge@@ al dy@@ smo@@ tili@@ ty and aspi@@ ration have been associated with anti@@ p@@ sycho@@ tic drug use@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ari@@ pi@@ pra@@ z@@ ole and other anti@@ p@@ sycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for aspi@@ ration p@@ ne@@ um@@ oni@@ a.
In@@ toler@@ anc@@ e@@ :
The oral solution contains fru@@ ct@@ os@@ e@@ .
Pati@@ ents with rare her@@ edi@@ tary problems of fru@@ ct@@ ose int@@ oler@@ ance should not take this medic@@ inal produc@@ t.
The oral solution contains meth@@ yl par@@ ah@@ y@@ dro@@ x@@ y@@ ben@@ zo@@ ate and prop@@ yl par@@ ah@@ y@@ dro@@ x@@ y@@ ben@@ zo@@ ate which may cause aller@@ gic re@@ actions (@@ possibly dela@@ ye@@ d@@ )@@ .
The oral solution contains su@@ cros@@ e@@ .
Pati@@ ents with rare her@@ edi@@ tary problems of fru@@ ct@@ ose int@@ oler@@ anc@@ e@@ , glu@@ cos@@ e@@ -@@ gal@@ act@@ ose mal@@ absor@@ ption or su@@ cra@@ se@@ -@@ is@@ om@@ alt@@ ase in@@ suff@@ ici@@ ency should not take the oral sol@@ u@@ tion@@ .
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ : as with other medic@@ ations hyper@@ sensi@@ tivity re@@ ac@@ tions@@ , character@@ ised by aller@@ gic symp@@ tom@@ s@@ , may occur with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
D@@ ue to its α 1@@ -@@ ad@@ ren@@ er@@ gic rec@@ ep@@ tor ant@@ agon@@ is@@ m@@ , ari@@ pi@@ pra@@ z@@ ole has the potential to enh@@ ance the effect of certain anti@@ hyper@@ ten@@ sive ag@@ ent@@ s.
Given the primary CN@@ S effects of ari@@ pi@@ pra@@ z@@ ole@@ , caution should be used when ari@@ pi@@ pra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping un@@ desi@@ rable effects such as se@@ dation (@@ see section 4.@@ 8@@ )@@ .
If ari@@ pi@@ pra@@ z@@ ole is administ@@ ered con@@ co@@ mit@@ antly with medic@@ ines known to cause Q@@ T pro@@ long@@ ation or elec@@ tro@@ ly@@ te im@@ bal@@ anc@@ e@@ , caution should be use@@ d.
Pot@@ ential for other medic@@ inal products to affect AB@@ IL@@ I@@ F@@ Y@@ :
A ga@@ stri@@ c acid blo@@ cker@@ , the H@@ 2 ant@@ agon@@ ist f@@ amo@@ ti@@ d@@ ine@@ , redu@@ ces ari@@ pi@@ pra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relev@@ ant@@ .
Ari@@ pi@@ pra@@ z@@ ole is met@@ aboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ ym@@ es but not C@@ Y@@ P@@ 1@@ A enz@@ ym@@ es@@ .
Th@@ us@@ , no d@@ os@@ age adju@@ st@@ ment is required for smo@@ ker@@ s.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ qu@@ ini@@ d@@ ine@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C by 10@@ 7@@ %@@ , while C@@ max was un@@ ch@@ ange@@ d.
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , decre@@ ased by 32@@ % and 47@@ %@@ .
AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed dose when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y with qu@@ ini@@ dine occ@@ urs@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 2@@ D@@ 6@@ , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 3@@ A4 (@@ ket@@ o@@ con@@ az@@ ole@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C and C@@ max by 6@@ 3@@ % and 37@@ %@@ , respec@@ ti@@ vel@@ y@@ .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole increased by 77@@ % and 43@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor met@@ aboli@@ ser@@ s@@ , con@@ co@@ mit@@ ant use of pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 may result in higher p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive met@@ aboli@@ zer@@ s.
When considering con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors with AB@@ IL@@ I@@ F@@ Y@@ , potential benefits should out@@ weigh the potential risks to the pati@@ ent@@ .
When con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ o@@ z@@ ole with AB@@ IL@@ I@@ F@@ Y occ@@ urs@@ , AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed d@@ os@@ e@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A@@ 4@@ , such as it@@ ra@@ con@@ az@@ ole and HIV prot@@ ease in@@ hi@@ bit@@ or@@ s@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hi@@ bit@@ or@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be increased to the level prior to the initi@@ ation of the con@@ co@@ mit@@ ant therap@@ y@@ .
85 When weak in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 (@@ e@@ . g@@ .@@ , dil@@ ti@@ az@@ em or esc@@ ital@@ op@@ ra@@ m@@ ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ co@@ mit@@ antly with AB@@ IL@@ I@@ F@@ Y@@ , modest increases in ari@@ pi@@ pra@@ z@@ ole conc@@ ent@@ rations might be expec@@ te@@ d.
Following con@@ co@@ mit@@ ant administration of car@@ b@@ amaz@@ ep@@ ine@@ , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A@@ 4@@ , the ge@@ omet@@ ric means of C@@ max and AU@@ C for ari@@ pi@@ pra@@ z@@ ole were 68@@ % and 7@@ 3@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , compared to when ari@@ pi@@ pra@@ z@@ ole (@@ 30 m@@ g@@ ) was administ@@ ered al@@ one@@ .
Simi@@ lar@@ ly@@ , for de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole the ge@@ omet@@ ric means of C@@ max and AU@@ C after car@@ b@@ amaz@@ ep@@ ine co@@ -@@ administration were 69@@ % and 7@@ 1@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , than those following treatment with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
AB@@ IL@@ I@@ F@@ Y dose should be doubled when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y occ@@ urs with car@@ b@@ amaz@@ ep@@ ine@@ .
John@@ '@@ s Wort@@ ) may be expected to have similar effects and similar dose increases should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be reduced to the recommended d@@ os@@ e@@ .
When either val@@ pro@@ ate or li@@ thi@@ um were administ@@ ered con@@ co@@ mit@@ antly with ari@@ pi@@ pra@@ z@@ ole@@ , there was no clin@@ ically significant change in ari@@ pi@@ pra@@ z@@ ole conc@@ entra@@ tions@@ .
Pot@@ ential for AB@@ IL@@ I@@ F@@ Y to affect other medic@@ inal produc@@ ts@@ :
In clinical stu@@ dies@@ , 10@@ -@@ 30 m@@ g@@ / day d@@ oses of ari@@ pi@@ pra@@ z@@ ole had no significant effect on the met@@ aboli@@ sm of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ / 3@@ -@@ metho@@ x@@ y@@ mor@@ ph@@ in@@ an rati@@ o@@ )@@ , 2@@ C@@ 9 (@@ war@@ far@@ in@@ )@@ , 2@@ C@@ 19 (@@ om@@ ep@@ raz@@ ole@@ )@@ , and 3@@ A4 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ )@@ .
Addi@@ tion@@ all@@ y@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole did not show potential for al@@ tering C@@ Y@@ P@@ 1@@ A@@ 2@@ -@@ medi@@ ated met@@ aboli@@ sm in vit@@ ro@@ .
Th@@ us@@ , ari@@ pi@@ pra@@ z@@ ole is unlikely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ ym@@ es@@ .
When ari@@ pi@@ pra@@ z@@ ole was administ@@ ered con@@ co@@ mit@@ antly with either val@@ pro@@ ate or li@@ thi@@ um@@ , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ thi@@ um conc@@ entra@@ tions@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled trials of ari@@ pi@@ pra@@ z@@ ole in pregnant wom@@ en@@ .
Ani@@ mal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
D@@ ue to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive stu@@ dies@@ , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ et@@ us@@ .
Ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during la@@ ct@@ ation@@ .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pi@@ pra@@ z@@ ole@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been per@@ for@@ med@@ .
Ho@@ we@@ ver@@ , as with other anti@@ p@@ sycho@@ tic@@ s@@ , patients should be cau@@ tioned about operating ha@@ z@@ ard@@ ous mach@@ in@@ es@@ , including motor v@@ ehic@@ les@@ , until they are reas@@ onably certain that ari@@ pi@@ pra@@ z@@ ole does not affect them adver@@ sel@@ y@@ .
4.@@ 8 Un@@ desi@@ rable effects
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ )@@ :
The frequ@@ ency listed below is defined using the following conven@@ tion@@ : common (@@ > 1@@ / 100 ,@@ < 1@@ /@@ 10@@ ) and un@@ common (@@ > 1@@ /@@ 1 ,@@ 00@@ 0@@ , < 1@@ /@@ 100@@ )@@ .
86 Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous System disor@@ ders Common@@ : ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disor@@ der@@ , ak@@ ath@@ isi@@ a@@ , tre@@ mor@@ , di@@ zz@@ in@@ ess@@ , som@@ n@@ ol@@ en@@ ce@@ , se@@ d@@ ation@@ , hea@@ da@@ che E@@ ye disor@@ ders Common@@ : bl@@ urred vision Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : dy@@ sp@@ ep@@ si@@ a@@ , vo@@ mit@@ ing@@ , nau@@ se@@ a@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ * General disor@@ ders and administration site conditions Common@@ : f@@ ati@@ gue P@@ sychiatri@@ c disor@@ ders Common@@ : rest@@ less@@ ness@@ , ins@@ om@@ ni@@ a@@ , anxiety Un@@ common@@ : depres@@ sion@@ *
Ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symptoms (@@ EP@@ S@@ )@@ :
Sch@@ iz@@ op@@ hren@@ ia - in a long term 5@@ 2@@ -@@ week controlled tri@@ al@@ , ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients had an over@@ all@@ -@@ lower inci@@ dence (@@ 25.@@ 8@@ %@@ ) of E@@ PS including par@@ kin@@ son@@ is@@ m@@ , ak@@ ath@@ isi@@ a@@ , dy@@ st@@ onia and dy@@ sk@@ ine@@ sia compared with those treated with hal@@ operi@@ dol (@@ 5@@ 7.@@ 3@@ %@@ )@@ .
In a long term 26@@ -@@ week pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 19@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 13.@@ 1@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In another long@@ -@@ term 26@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 14.@@ 8@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 1@@ % for ol@@ anz@@ ap@@ ine@@ -@@ treated pati@@ ent@@ s.
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 23.@@ 5@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 5@@ 3.@@ 3@@ % for hal@@ operi@@ dol@@ -@@ treated pati@@ ent@@ s.
In another 12@@ -@@ week tri@@ al@@ , the inci@@ dence of E@@ PS was 26.@@ 6@@ % for patients treated with ari@@ pi@@ pra@@ z@@ ole and 17.@@ 6@@ % for those treated with li@@ thi@@ um@@ .
In the long term 26@@ -@@ week maintenance phase of a pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 18.@@ 2@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 7@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ s@@ , the inci@@ dence of ak@@ ath@@ i@@ sia in bi@@ pol@@ ar patients was 12.@@ 1@@ % with ari@@ pi@@ pra@@ z@@ ole and 3.@@ 2@@ % with pla@@ c@@ ebo@@ .
In sch@@ iz@@ op@@ hren@@ ia patients the inci@@ dence of ak@@ ath@@ i@@ sia was 6.@@ 2@@ % with ari@@ pi@@ pra@@ z@@ ole and 3@@ .0@@ % with pla@@ c@@ ebo@@ .
Com@@ par@@ is@@ ons between ari@@ pi@@ pra@@ z@@ ole and pla@@ c@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine lab@@ oratory par@@ ame@@ ters revealed no medi@@ cally important differ@@ en@@ c@@ es@@ .
Ele@@ v@@ ations of C@@ P@@ K (@@ Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ )@@ , generally tran@@ si@@ ent and as@@ ymp@@ tom@@ ati@@ c@@ , were observed in 3.@@ 5@@ % of ari@@ pi@@ pra@@ z@@ ole treated patients as compared to 2@@ .0@@ % of patients who received pla@@ c@@ ebo@@ .
Other fin@@ d@@ ings@@ :
Un@@ desi@@ rable effects known to be associated with anti@@ p@@ sycho@@ tic therapy and also reported during treatment with ari@@ pi@@ pra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ dro@@ me@@ , tar@@ di@@ ve dy@@ sk@@ ine@@ si@@ a@@ , sei@@ zu@@ re@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly de@@ mented pati@@ ent@@ s@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ tus (@@ see section 4.@@ 4@@ )@@ .
Post@@ -@@ Market@@ ing@@ :
The frequ@@ ency of these events is considered not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Investig@@ ations@@ :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ , blood glu@@ c@@ ose increas@@ ed@@ , blood glu@@ c@@ ose flu@@ ctu@@ ation@@ , g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in increased
Cardi@@ ac disor@@ der@@ s@@ :
Q@@ T pro@@ long@@ ation@@ , vent@@ ri@@ cular arr@@ hyth@@ mi@@ as@@ , sudden un@@ explained de@@ ath@@ , cardi@@ ac ar@@ rest@@ , tor@@ sa@@ des de poin@@ tes@@ , bra@@ dy@@ car@@ dia
Bloo@@ d and the lymp@@ h@@ atic system disor@@ der@@ s@@ :
leu@@ kop@@ eni@@ a@@ , neut@@ rop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia
87 Ner@@ v@@ ous system disor@@ der@@ s@@ :
speech disor@@ der@@ , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ , grand mal con@@ vul@@ sion
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ s@@ :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m@@ , lar@@ yn@@ g@@ os@@ pas@@ m@@ , aspi@@ ration p@@ ne@@ um@@ onia
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
pan@@ cre@@ ati@@ tis@@ , dy@@ sph@@ ag@@ i@@ a@@ , ab@@ dom@@ inal dis@@ comfort@@ , stomach dis@@ comfort@@ , di@@ arr@@ ho@@ ea
Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
ur@@ inary in@@ contin@@ en@@ ce@@ , ur@@ inary re@@ tention
Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
ra@@ sh@@ , ph@@ otos@@ en@@ si@@ tivity re@@ ac@@ tion@@ , al@@ op@@ eci@@ a@@ , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , my@@ al@@ gi@@ a@@ , sti@@ ff@@ ness
En@@ do@@ cr@@ ine disor@@ der@@ s@@ :
hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , diabetes mel@@ li@@ t@@ us@@ , di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s@@ , di@@ abe@@ tic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
weight ga@@ in@@ , weight decre@@ as@@ ed@@ , an@@ or@@ ex@@ i@@ a@@ , h@@ yp@@ on@@ at@@ re@@ mia
V@@ as@@ cular disor@@ der@@ s@@ :
syn@@ cop@@ e@@ , hyper@@ ten@@ sion@@ , thro@@ mbo@@ em@@ bo@@ lic events
General disor@@ ders and administration site condi@@ tions@@ :
temperature regulation disorder (@@ e@@ . g. hypo@@ ther@@ mi@@ a@@ , py@@ re@@ xi@@ a@@ )@@ , chest pain@@ , peri@@ pher@@ al oe@@ de@@ ma
Immun@@ e system disor@@ der@@ s@@ :
aller@@ gic reaction (@@ e@@ . g. an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ , an@@ gi@@ oe@@ de@@ ma including s@@ wollen ton@@ gu@@ e@@ , ton@@ gue oe@@ de@@ ma@@ , face oe@@ de@@ ma@@ , p@@ ru@@ rit@@ us@@ , or ur@@ tic@@ ari@@ a@@ )
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ der@@ s@@ :
ja@@ un@@ di@@ ce@@ , he@@ pati@@ tis@@ , increased A@@ lan@@ ine A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ AL@@ T@@ )@@ , increased A@@ spar@@ tate A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ A@@ ST@@ )@@ , increased G@@ amm@@ a Gl@@ ut@@ am@@ yl Transfer@@ ase (@@ G@@ GT@@ )@@ , increased al@@ kal@@ ine ph@@ osp@@ hat@@ ase
Re@@ productive system and breast disor@@ der@@ s@@ :
pri@@ ap@@ ism
P@@ sychiatri@@ c disor@@ der@@ s@@ :
ag@@ it@@ ation@@ , nerv@@ ous@@ ness@@ ; suicide attemp@@ t@@ , suici@@ dal ide@@ ation@@ , and completed suicide (@@ see section 4.@@ 4@@ )
4.@@ 9 Over@@ dose
In clinical trials and post@@ -@@ marketing experi@@ en@@ ce@@ , acci@@ dental or inten@@ tional ac@@ ute over@@ d@@ os@@ age of ari@@ pi@@ pra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy@@ , increased blood pressu@@ re@@ , som@@ n@@ ol@@ en@@ ce@@ , ta@@ ch@@ y@@ cardi@@ a@@ , nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ e@@ a.
In addi@@ tion@@ , reports of acci@@ dental over@@ dose with ari@@ pi@@ pra@@ z@@ ole alone (@@ up to 19@@ 5 m@@ g@@ ) in children have been received with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ en@@ ce@@ , tran@@ si@@ ent loss of consci@@ ousness and ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symp@@ tom@@ s.
Management of over@@ dose should concentrate on supportive therap@@ y@@ , maintaining an adequate air@@ wa@@ y@@ , oxy@@ gen@@ ation and v@@ enti@@ la@@ tion@@ , and management of symp@@ tom@@ s.
The possibility of multiple medic@@ inal product involvement should be consider@@ ed@@ .
Ther@@ efore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continu@@ ous elec@@ tro@@ cardi@@ o@@ graphic monitoring to dete@@ ct possible arr@@ hyth@@ mi@@ as@@ .
Following any confirmed or suspected over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , close medical super@@ vision and monitoring should continue until the patient reco@@ vers@@ .
88 Ac@@ tiv@@ ated char@@ coal (@@ 50 g@@ )@@ , administ@@ ered one hour after ari@@ pi@@ pra@@ z@@ ole@@ , decre@@ ased ari@@ pi@@ pra@@ z@@ ole C@@ max by about 4@@ 1@@ % and AU@@ C by about 5@@ 1@@ %@@ , suggesting that char@@ coal may be effective in the treatment of over@@ d@@ os@@ e@@ .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in treating an over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , ha@@ emo@@ di@@ aly@@ sis is unlikely to be useful in over@@ dose management since ari@@ pi@@ pra@@ z@@ ole is highly bound to p@@ las@@ ma prot@@ ein@@ s.
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ p@@ sycho@@ tic@@ s@@ , AT@@ C co@@ de@@ :
N@@ 05@@ A@@ X@@ 12
It has been proposed that ari@@ pi@@ pra@@ z@@ ole@@ ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ amine D@@ 2 and ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a rec@@ ep@@ tors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hypo@@ activ@@ it@@ y@@ .
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited high bin@@ ding aff@@ in@@ ity in vit@@ ro for d@@ op@@ amine D@@ 2 and D@@ 3@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a and 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tors and moderate aff@@ in@@ ity for d@@ op@@ amine D@@ 4@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ c and 5@@ H@@ T@@ 7@@ , alp@@ ha@@ -@@ 1 ad@@ ren@@ er@@ gic and hist@@ amine H@@ 1 rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole also exhi@@ bited moderate bin@@ ding aff@@ in@@ ity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ in@@ ity for mus@@ car@@ ini@@ c rec@@ ep@@ tor@@ s.
Inter@@ action with rec@@ ep@@ tors other than d@@ op@@ amine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pi@@ pra@@ z@@ ole@@ .
Ari@@ pi@@ pra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a d@@ os@@ e@@ -@@ dependent reduction in the bin@@ ding of 11@@ C@@ -@@ ra@@ clo@@ pri@@ de@@ , a D@@ 2@@ / D@@ 3 rec@@ ep@@ tor lig@@ and@@ , to the cau@@ date and put@@ amen dete@@ cted by posi@@ tr@@ on e@@ mission tom@@ o@@ grap@@ hy@@ .
Further information on clinical tri@@ al@@ s@@ :
Sch@@ iz@@ op@@ hren@@ i@@ a@@ :
In three short@@ -@@ term (@@ 4 to 6 wee@@ ks@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 1,@@ 228 sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s@@ , presenting with positive or negative symp@@ tom@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was associated with stati@@ st@@ ically significantly greater improvements in p@@ sycho@@ tic symptoms compared to pla@@ c@@ ebo@@ .
AB@@ IL@@ I@@ F@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment respon@@ se@@ .
In a hal@@ operi@@ dol@@ -@@ controlled tri@@ al@@ , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2@@ -@@ weeks was similar in both groups (@@ ari@@ pi@@ pra@@ z@@ ole 77@@ % and hal@@ operi@@ dol 7@@ 3@@ %@@ )@@ .
The overall comple@@ tion rate was significantly higher for patients on ari@@ pi@@ pra@@ z@@ ole (@@ 43@@ %@@ ) than for hal@@ operi@@ dol (@@ 30@@ %@@ )@@ .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ poin@@ ts@@ , including P@@ AN@@ SS and the Montgom@@ er@@ y@@ -@@ As@@ berg Depression R@@ ating Sc@@ ale showed a significant improvement over hal@@ operi@@ dol@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hren@@ i@@ a@@ , ari@@ pi@@ pra@@ z@@ ole had significantly greater reduction in re@@ lap@@ se rat@@ e@@ , 34@@ % in ari@@ pi@@ pra@@ z@@ ole group and 57@@ % in pla@@ c@@ ebo@@ .
Wei@@ ght ga@@ in@@ : in clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight ga@@ in@@ .
In a 26@@ -@@ week@@ , ol@@ anz@@ ap@@ ine@@ -@@ contro@@ lle@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , multi@@ -@@ national study of sch@@ iz@@ op@@ hren@@ ia which included 3@@ 14 patients and where the primary end@@ -@@ point was weight ga@@ in@@ , significantly less patients had at least 7@@ % weight gain over bas@@ eline (@@ i@@ . e@@ . a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~@@ 8@@ 0.5 k@@ g@@ ) on ari@@ pi@@ pra@@ z@@ ole (@@ N = 18@@ , or 13@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ , compared to ol@@ anz@@ ap@@ ine (@@ N = 45@@ , or 33@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ .
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ :
In two 3@@ -@@ week@@ , flexi@@ ble@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o in
These trials included patients with or without p@@ sycho@@ tic features and with or without a rap@@ id@@ -@@ cycling cour@@ se@@ .
In one 3@@ -@@ week@@ , fix@@ ed@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to pla@@ c@@ ebo@@ .
In two 12@@ -@@ week@@ , pla@@ c@@ ebo@@ - and ac@@ ti@@ ve@@ -@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o at week 3 and a maintenance of effect compar@@ able to li@@ thi@@ um or hal@@ operi@@ dol at week 12.
Ari@@ pi@@ pra@@ z@@ ole also demonstrated a compar@@ able proportion of patients in symp@@ tom@@ atic re@@ mission from man@@ ia as li@@ thi@@ um or hal@@ operi@@ dol at week 12.
In a 6@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , who were parti@@ ally non@@ -@@ respon@@ sive to li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeu@@ tic ser@@ um level@@ s@@ , the addition of ari@@ pi@@ pra@@ z@@ ole as ad@@ jun@@ ctive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therap@@ y@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , followed by a 7@@ 4@@ -@@ week exten@@ sion@@ , in man@@ ic patients who achieved re@@ mission on ari@@ pi@@ pra@@ z@@ ole during a stabili@@ zation phase prior to rand@@ omi@@ z@@ ation@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ ren@@ ce@@ , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depres@@ sion@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ab@@ sor@@ p@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is well absor@@ bed@@ , with peak p@@ las@@ ma conc@@ ent@@ rations occ@@ urring within 3@@ -@@ 5 hours after d@@ os@@ ing@@ .
Ari@@ pi@@ pra@@ z@@ ole under@@ goes minimal pre@@ -@@ sy@@ ste@@ mic met@@ aboli@@ sm@@ .
The absolute oral bio@@ availability of the tab@@ let formu@@ lation is 8@@ 7@@ %@@ .
There is no effect of a high fat meal on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Distri@@ bu@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is widely distri@@ buted throughout the body with an apparent volume of distribution of 4.@@ 9 l@@ / k@@ g@@ , indic@@ ating extensive extra@@ v@@ as@@ cular distri@@ bu@@ tion@@ .
At therapeu@@ tic conc@@ entra@@ tions@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole are greater than 99@@ % bound to ser@@ um prot@@ ein@@ s@@ , bin@@ ding primarily to alb@@ umin@@ .
Met@@ aboli@@ sm@@ :
Ari@@ pi@@ pra@@ z@@ ole is exten@@ sively met@@ aboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ wa@@ ys@@ : de@@ hydro@@ gen@@ ation@@ , hydro@@ x@@ y@@ la@@ tion@@ , and N@@ -@@ deal@@ k@@ y@@ la@@ tion@@ .
Based on in vit@@ ro stu@@ dies@@ , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ ym@@ es are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ y@@ lation of ari@@ pi@@ pra@@ z@@ ole@@ , and N@@ -@@ deal@@ k@@ y@@ lation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A@@ 4.
Ari@@ pi@@ pra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ iety in sy@@ ste@@ mic circu@@ la@@ tion@@ .
At steady stat@@ e@@ , de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , represents about 40@@ % of ari@@ pi@@ pra@@ z@@ ole AU@@ C in p@@ las@@ ma@@ .
Eli@@ min@@ ation@@ :
The mean elim@@ ination half@@ -@@ lives for ari@@ pi@@ pra@@ z@@ ole are approximately 75 hours in extensive met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6.
The total body clear@@ ance of ari@@ pi@@ pra@@ z@@ ole is 0.@@ 7 m@@ l@@ / min@@ / k@@ g@@ , which is primarily he@@ pati@@ c.
Following a single oral dose of [@@ 14@@ C@@ ]@@ -@@ lab@@ elled ari@@ pi@@ pra@@ z@@ ole@@ , approximately 27@@ % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60@@ % in the fa@@ ec@@ es@@ .
L@@ ess than 1@@ % of un@@ changed ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18@@ % was recovered un@@ changed in the fa@@ ec@@ es@@ .
Ari@@ pi@@ pra@@ z@@ ole is well absor@@ bed when administ@@ ered or@@ ally as the sol@@ u@@ tion@@ .
At equivalent d@@ os@@ es@@ , the peak p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole (@@ C@@ ma@@ x@@ ) from the solution were somewhat higher but the sy@@ ste@@ mic
90 exposure (@@ AU@@ C@@ ) was equivalent to tab@@ le@@ ts@@ .
In a relative bio@@ availability study compar@@ ing the pharmac@@ ok@@ ine@@ tics of 30 mg ari@@ pi@@ pra@@ z@@ ole as the oral solution to 30 mg ari@@ pi@@ pra@@ z@@ ole tab@@ lets in healthy sub@@ jec@@ ts@@ , the solution to the tab@@ let ratio of ge@@ omet@@ ric mean C@@ max values was 12@@ 2@@ % (@@ N = 30@@ )@@ .
The sing@@ le@@ - dose pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole were line@@ ar and d@@ os@@ e@@ -@@ propor@@ tion@@ al@@ .
P@@ harm@@ ac@@ ok@@ ine@@ tics in special patient groups
El@@ der@@ ly@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy elderly and younger adult sub@@ jec@@ ts@@ , nor is there any dete@@ ct@@ able effect of age in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Gen@@ der@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy male and female subjects nor is there any dete@@ ct@@ able effect of gender in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Smo@@ king and Rac@@ e@@ :
Pop@@ ulation pharmac@@ ok@@ ine@@ tic ev@@ al@@ uation has revealed no evidence of clin@@ ically significant ra@@ ce@@ -@@ related differences or effects from smoking upon the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
Ren@@ al Di@@ seas@@ e@@ :
The pharmac@@ ok@@ ine@@ tic characterist@@ ics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy sub@@ jec@@ ts@@ .
H@@ ep@@ atic Di@@ seas@@ e@@ :
A sing@@ le@@ -@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis (@@ Chil@@ d@@ -@@ Pu@@ gh Clas@@ ses A@@ , B@@ , and C@@ ) did not reveal a significant effect of he@@ pati@@ c im@@ pa@@ ir@@ ment on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ si@@ s@@ , which is in@@ sufficient to draw conclu@@ sions on their met@@ aboli@@ c cap@@ ac@@ it@@ y@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
Non@@ -@@ clinical safety data revealed no special ha@@ zard for humans based on conventional studies of safety pharmac@@ olog@@ y@@ , repe@@ at@@ -@@ dose tox@@ ic@@ it@@ y@@ , gen@@ oto@@ x@@ ic@@ it@@ y@@ , car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ , and tox@@ ic@@ ity to re@@ produc@@ tion@@ .
To@@ x@@ ic@@ ologi@@ cally significant effects were observed only at d@@ oses or exp@@ os@@ ures that were suff@@ ici@@ ently in excess of the maximum human dose or exp@@ os@@ ure@@ , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use@@ .
These inclu@@ de@@ d@@ : d@@ os@@ e@@ -@@ dependent ad@@ reno@@ cor@@ tical tox@@ ic@@ ity (@@ li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and@@ / or par@@ en@@ ch@@ y@@ mal cell los@@ s@@ ) in rats after 104 weeks at 20 to 60 m@@ g@@ / k@@ g@@ / day (@@ 3 to 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ ) and increased ad@@ reno@@ cor@@ tical car@@ cin@@ om@@ as and combined ad@@ reno@@ cor@@ tical aden@@ om@@ as@@ / car@@ cin@@ om@@ as in female rats at 60 m@@ g@@ / k@@ g@@ / day (@@ 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ )@@ .
The highest non@@ tum@@ ori@@ gen@@ ic exposure in female rats was 7 times the human exposure at the recommended d@@ os@@ e@@ .
An additional finding was chol@@ eli@@ thi@@ asi@@ s as a consequ@@ ence of pre@@ cip@@ itation of sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy met@@ aboli@@ tes of ari@@ pi@@ pra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 m@@ g@@ / k@@ g@@ / day (@@ 1 to 3 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on m@@ g@@ / m@@ 2@@ )@@ .
Ho@@ we@@ ver@@ , the conc@@ ent@@ rations of the sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy ari@@ pi@@ pra@@ z@@ ole in human b@@ ile at the highest dose propos@@ ed@@ , 30 mg per day@@ , were no more than 6@@ % of the b@@ ile conc@@ ent@@ rations found in the mon@@ keys in the 39@@ -@@ week study and are well below (@@ 6@@ %@@ ) their limits of in vit@@ ro sol@@ u@@ bili@@ ty@@ .
Based on results of a full range of standard gen@@ oto@@ x@@ ic@@ ity test@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was considered non@@ -@@ gen@@ oto@@ x@@ ic@@ .
Ari@@ pi@@ pra@@ z@@ ole did not im@@ pair fertili@@ ty in re@@ productive tox@@ ic@@ ity stu@@ dies@@ .
Develop@@ mental tox@@ ic@@ it@@ y@@ , including d@@ os@@ e@@ -@@ dependent delayed fo@@ et@@ al ossi@@ fication and possible ter@@ at@@ o@@ gen@@ ic effec@@ ts@@ , were
91 observed in rats at d@@ oses resulting in sub@@ therapeu@@ tic exp@@ os@@ ures (@@ based on AU@@ C@@ ) and in ra@@ bb@@ its at d@@ oses resulting in exp@@ os@@ ures 3 and 11 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical d@@ os@@ e@@ .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ it@@ y@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Dis@@ o@@ dium e@@ de@@ tate Fru@@ ct@@ ose G@@ ly@@ c@@ erin Lac@@ tic acid Me@@ th@@ yl par@@ ah@@ y@@ dro@@ x@@ y@@ ben@@ zo@@ ate (@@ E@@ 2@@ 18@@ ) Prop@@ yl@@ ene g@@ ly@@ co@@ l Prop@@ yl par@@ ah@@ y@@ dro@@ x@@ y@@ ben@@ zo@@ ate (@@ E@@ 2@@ 16@@ ) So@@ dium hydro@@ xi@@ de Su@@ cr@@ ose Pu@@ ri@@ fied water
Natural orange cream with other natural fla@@ vo@@ urs
6.@@ 2 In@@ comp@@ ati@@ bilities
The oral solution should not be dil@@ uted with other liqui@@ ds or mixed with any food prior to administ@@ ration@@ .
6.@@ 3 Shel@@ f life
3 years After first op@@ en@@ ing@@ :
6 mon@@ th@@ s.
6.@@ 4 Special prec@@ au@@ tions for storage
This medic@@ inal product does not require any special storage condi@@ tions@@ .
6.5 Nature and cont@@ ents of container
P@@ ET@@ -@@ bottles with poly@@ prop@@ yl@@ ene child@@ -@@ resi@@ stant closure containing 50@@ , 150 or 4@@ 80 ml per bot@@ t@@ le@@ .
Each car@@ ton contains 1 bottle and both a cali@@ br@@ ated poly@@ prop@@ yl@@ ene meas@@ uring cup and a cali@@ br@@ ated poly@@ prop@@ yl@@ ene low@@ -@@ den@@ sity pol@@ ye@@ th@@ yl@@ ene d@@ rop@@ per@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
92 8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 33@@ -@@ 0@@ 35
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
D@@ ate of first author@@ is@@ ation@@ :
4 June 2004
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
{@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
93 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 7.5 m@@ g@@ / ml solution for in@@ jection
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml contains 7.5 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
A vi@@ al contains 9.@@ 75 mg ari@@ pi@@ pra@@ z@@ ole@@ .
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection C@@ lear@@ , colo@@ ur@@ less@@ , aqu@@ e@@ ous sol@@ u@@ tion@@ .
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
AB@@ IL@@ I@@ F@@ Y solution for in@@ jection is indicated for the rapid control of ag@@ itation and distur@@ bed behavi@@ ours in patients with sch@@ iz@@ op@@ hren@@ ia or in patients with man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ , when oral therapy is not appropri@@ ate@@ .
Tre@@ at@@ ment with ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection should be dis@@ continued as soon as clin@@ ically appropriate and the use of oral ari@@ pi@@ pra@@ z@@ ole should be initi@@ at@@ ed@@ .
4.@@ 2 Pos@@ ology and method of administration
For in@@ tra@@ mus@@ cular use@@ .
To enh@@ ance absor@@ ption and mini@@ mise vari@@ abili@@ ty@@ , in@@ jection into the del@@ to@@ id or deep within the glu@@ te@@ us maxim@@ us mus@@ cle@@ , avoiding adi@@ pose regi@@ ons@@ , is recommen@@ de@@ d.
AB@@ IL@@ I@@ F@@ Y solution for in@@ jection should not be administ@@ ered in@@ tra@@ ven@@ ously or sub@@ cut@@ an@@ e@@ ous@@ ly@@ .
AB@@ IL@@ I@@ F@@ Y solution for in@@ jection is ready to use and intended for short@@ -@@ term use only (@@ see section 5.@@ 1@@ )@@ .
The recommended initial dose for ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection is 9.@@ 75 mg (@@ 1.3 m@@ l@@ )@@ , administ@@ ered as a single in@@ tra@@ mus@@ cular in@@ jec@@ tion@@ .
The effective dose range of ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection is 5.@@ 25@@ -@@ 15 mg as a single in@@ jec@@ tion@@ .
A lower dose of 5.@@ 25 mg (@@ 0.@@ 7 m@@ l@@ ) may be gi@@ ven@@ , on the basis of individual clinical stat@@ us@@ , which should also include consideration of medic@@ inal products already administ@@ ered either for maintenance or ac@@ ute treatment (@@ see section 4.@@ 5@@ )@@ .
A second in@@ jection may be administ@@ ered 2 hours after the first in@@ jec@@ tion@@ , on the basis of individual clinical status and no more than three in@@ jections should be given in any 24@@ -@@ hour peri@@ od@@ .
The maximum daily dose of ari@@ pi@@ pra@@ z@@ ole is 30 mg (@@ including all formu@@ lations of ari@@ pi@@ pra@@ z@@ ole@@ )@@ .
If continued treatment is indicated with oral ari@@ pi@@ pra@@ z@@ ole@@ , see the Sum@@ mary of Product Char@@ ac@@ ter@@ ist@@ ics for AB@@ IL@@ I@@ F@@ Y tab@@ le@@ ts@@ , AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ le@@ ts@@ , or AB@@ IL@@ I@@ F@@ Y oral sol@@ u@@ tion@@ .
Children and adol@@ es@@ cent@@ s@@ : there is no experience in children and adol@@ es@@ cents under 18 years of age@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required for patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
In patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ , the data available are in@@ sufficient to
94 establish recommend@@ ations@@ .
In these patients d@@ osing should be managed cau@@ ti@@ ous@@ ly@@ .
Ho@@ we@@ ver@@ , the maximum daily dose of 30 mg should be used with caution in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ : no d@@ os@@ age adju@@ st@@ ment is required in patients with ren@@ al im@@ pa@@ ir@@ ment@@ .
El@@ der@@ ly@@ : the effec@@ tiveness of AB@@ IL@@ I@@ F@@ Y solution for in@@ jection in patients who are 65 years of age or older has not been establi@@ sh@@ ed@@ .
O@@ wing to the greater sensi@@ tivity of this pop@@ ula@@ tion@@ , a lower starting dose should be considered when clinical factors warrant (@@ see section 4.@@ 4@@ )@@ .
Gen@@ der@@ : no d@@ os@@ age adju@@ st@@ ment is required for female patients as compared to male patients (@@ see section 5.@@ 2@@ )@@ .
Smo@@ king stat@@ us@@ : according to the met@@ aboli@@ c path@@ way of AB@@ IL@@ I@@ F@@ Y no d@@ os@@ age adju@@ st@@ ment is required for smo@@ kers (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ ors with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be re@@ duc@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 or C@@ Y@@ P@@ 2@@ D@@ 6 in@@ hi@@ bit@@ or is with@@ drawn from the combination therap@@ y@@ , ari@@ pi@@ pra@@ z@@ ole dose should then be increased (@@ see section 4.@@ 5@@ )@@ .
When con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers with ari@@ pi@@ pra@@ z@@ ole occ@@ urs@@ , the ari@@ pi@@ pra@@ z@@ ole dose should be increas@@ ed@@ .
When the C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ er is with@@ drawn from the combination therap@@ y@@ , the ari@@ pi@@ pra@@ z@@ ole dose should then be reduced to the recommended dose (@@ see section 4.@@ 5@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
The eff@@ ic@@ acy of ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection in patients with ag@@ itation and distur@@ bed behavi@@ ours has not been established related to conditions other than sch@@ iz@@ op@@ hren@@ ia and man@@ ic episodes in Bi@@ pol@@ ar I Dis@@ or@@ der@@ .
Sim@@ ul@@ tane@@ ous administration of in@@ jec@@ table anti@@ p@@ sycho@@ tics and par@@ enter@@ al ben@@ zo@@ di@@ az@@ ep@@ ine may be associated with excessive se@@ dation and cardi@@ or@@ esp@@ ir@@ atory depres@@ sion@@ .
If par@@ enter@@ al ben@@ zo@@ di@@ az@@ ep@@ ine therapy is deemed necessary in addition to ari@@ pi@@ pra@@ z@@ ole solution for in@@ jec@@ tion@@ , patients should be monit@@ ored for excessive se@@ dation and for or@@ tho@@ st@@ atic h@@ yp@@ ot@@ ension (@@ see section 4.@@ 5@@ )@@ .
Pati@@ ents receiving ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection should be observed for or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ .
Bloo@@ d pressu@@ re@@ , pul@@ se@@ , resp@@ ir@@ atory rate and level of consci@@ ousness should be monit@@ ored regul@@ ar@@ ly@@ .
The safety and eff@@ ic@@ acy of ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection has not been evalu@@ ated in patients with alcohol or medic@@ inal product in@@ tox@@ ic@@ ation (@@ either with prescri@@ bed or illi@@ c@@ it medic@@ inal produc@@ ts@@ )@@ .
During anti@@ p@@ sycho@@ tic treat@@ ment@@ , improvement in the pati@@ ent@@ '@@ s clinical condition may take several days to some wee@@ ks@@ .
Pati@@ ents should be closely monit@@ ored throughout this peri@@ od@@ .
The occ@@ ur@@ r@@ ence of suici@@ dal behaviour is inher@@ ent in p@@ sycho@@ tic ill@@ nesses and mood disor@@ ders and in some cases has been reported early after initi@@ ation or switch of anti@@ p@@ sycho@@ tic therap@@ y@@ , including treatment with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
C@@ lose super@@ vision of high@@ -@@ risk patients should ac@@ company anti@@ p@@ sycho@@ tic therap@@ y@@ .
Res@@ ults of an epide@@ mi@@ ological study found that there was no increased risk of suici@@ d@@ ality with ari@@ pi@@ pra@@ z@@ ole compared to other anti@@ p@@ sycho@@ tics among patients with bi@@ pol@@ ar disor@@ der@@ .
Cardi@@ ov@@ as@@ cular disor@@ der@@ s@@ :
95 conduc@@ tion ab@@ nor@@ mali@@ ti@@ es@@ )@@ , cer@@ eb@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , conditions which would pre@@ disp@@ ose patients to h@@ yp@@ ot@@ ension (@@ de@@ hy@@ dra@@ tion@@ , hypo@@ vol@@ emi@@ a@@ , and treatment with anti@@ hyper@@ ten@@ sive medic@@ ations@@ ) or hyper@@ ten@@ sion@@ , including acceler@@ ated or mal@@ ign@@ ant@@ .
Con@@ duction ab@@ nor@@ mali@@ ti@@ es@@ :
In clinical trials of ari@@ pi@@ pra@@ z@@ ole@@ , the inci@@ dence of Q@@ T pro@@ long@@ ation was compar@@ able to pla@@ c@@ ebo@@ .
As with other anti@@ p@@ sycho@@ tic@@ s@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients with a family history of Q@@ T pro@@ long@@ ation@@ .
T@@ ardi@@ ve Dy@@ sk@@ ine@@ si@@ a@@ : in clinical trials of one year or less dur@@ ation@@ , there were un@@ common reports of treatment emerg@@ ent dy@@ sk@@ ine@@ sia during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
If signs and symptoms of tar@@ di@@ ve dy@@ sk@@ ine@@ sia appear in a patient on AB@@ IL@@ I@@ F@@ Y@@ , dose reduction or dis@@ continu@@ ation should be consider@@ ed@@ .
These symptoms can tempor@@ ally deterior@@ ate or can even ari@@ se after dis@@ continu@@ ation of treat@@ ment@@ .
Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ :
N@@ MS is a potentially fatal symp@@ tom complex associated with anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ .
In clinical tri@@ al@@ s@@ , rare cases of N@@ MS were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Clin@@ ical manifest@@ ations of N@@ MS are hyper@@ py@@ re@@ xi@@ a@@ , muscle rigi@@ di@@ ty@@ , al@@ tered mental status and evidence of auton@@ omic inst@@ ability (@@ ir@@ regular pul@@ se or blood pressu@@ re@@ , ta@@ ch@@ y@@ cardi@@ a@@ , di@@ aph@@ ore@@ sis and cardi@@ ac dys@@ rhyth@@ mi@@ a@@ )@@ .
Additional signs may include elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ as@@ e@@ , m@@ yo@@ glob@@ in@@ uri@@ a (@@ r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ )@@ , and ac@@ ute ren@@ al fail@@ ure@@ .
Ho@@ we@@ ver@@ , elev@@ ated cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase and r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , not necessarily in association with N@@ M@@ S@@ , have also been repor@@ te@@ d.
If a patient develop@@ s signs and symptoms indic@@ ative of N@@ M@@ S@@ , or presents with un@@ explained high fe@@ ver without additional clinical manifest@@ ations of N@@ M@@ S@@ , all anti@@ p@@ sycho@@ tic medic@@ inal produc@@ ts@@ , including AB@@ IL@@ I@@ F@@ Y@@ , must be dis@@ continu@@ ed@@ .
Sei@@ zu@@ re@@ : in clinical tri@@ al@@ s@@ , un@@ common cases of sei@@ z@@ ure were reported during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
Ther@@ e@@ fore@@ , ari@@ pi@@ pra@@ z@@ ole should be used with caution in patients who have a history of sei@@ z@@ ure disorder or have conditions associated with sei@@ zu@@ res@@ .
El@@ derly patients with demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s@@ :
In@@ cre@@ ased mort@@ al@@ it@@ y@@ : in three pla@@ c@@ ebo@@ -@@ controlled trials (@@ n@@ = 9@@ 38@@ ; mean age@@ :
8@@ 2.@@ 4 ye@@ ar@@ s@@ ; ran@@ ge@@ :
56@@ -@@ 99 ye@@ ar@@ s@@ ) of ari@@ pi@@ pra@@ z@@ ole in elderly patients with p@@ sycho@@ sis associated with Al@@ z@@ hei@@ mer@@ '@@ s dise@@ as@@ e@@ , patients treated with ari@@ pi@@ pra@@ z@@ ole were at increased risk of death compared to pla@@ c@@ ebo@@ .
The rate of death in ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients was 3.@@ 5@@ % compared to 1.@@ 7@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
Although the causes of deaths were var@@ ie@@ d@@ , most of the deaths appeared to be either cardi@@ ov@@ as@@ cular (@@ e@@ . g. heart fail@@ ure@@ , sudden de@@ ath@@ ) or inf@@ ec@@ tious (@@ e@@ . g. p@@ ne@@ um@@ oni@@ a@@ ) in nat@@ ure@@ .
Cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse event@@ s@@ : in the same tri@@ al@@ s@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events (@@ e@@ . g. stro@@ ke@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ )@@ , including fat@@ ali@@ ti@@ es@@ , were reported in patients (@@ mean age@@ :
84 ye@@ ar@@ s@@ ; ran@@ ge@@ :
78@@ -@@ 88 ye@@ ar@@ s@@ )@@ .
Over@@ all@@ , 1.@@ 3@@ % of ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients reported cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events compared with 0.@@ 6@@ % of pla@@ c@@ ebo@@ -@@ treated patients in these tri@@ al@@ s.
This difference was not stati@@ st@@ ically signific@@ ant@@ .
Ho@@ we@@ ver@@ , in one of these tri@@ al@@ s@@ , a fix@@ ed@@ -@@ dose tri@@ al@@ , there was a significant dose response relationship for cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events in patients treated with ari@@ pi@@ pra@@ z@@ ole@@ .
AB@@ IL@@ I@@ F@@ Y is not approved for the treatment of demen@@ ti@@ a@@ -@@ related p@@ sycho@@ si@@ s.
Hy@@ per@@ g@@ ly@@ ca@@ emi@@ a and Diabetes Mel@@ li@@ t@@ us@@ : hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , in some cases extreme and associated with ket@@ o@@ aci@@ do@@ sis or hyper@@ os@@ mol@@ ar com@@ a or de@@ ath@@ , has been reported in patients treated with at@@ yp@@ ical anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ris@@ k factors that may pre@@ disp@@ ose patients to severe complic@@ ations include obesity and family history of di@@ abet@@ es@@ .
In clinical trials with ari@@ pi@@ pra@@ z@@ ole@@ , there were no significant differences in the inci@@ dence rates of hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events (@@ including di@@ abet@@ es@@ ) or in ab@@ normal g@@ ly@@ ca@@ emi@@ a lab@@ oratory values compared to pla@@ c@@ ebo@@ .
Pre@@ cise risk estimates for hyper@@ g@@ ly@@ ca@@ emi@@ a@@ -@@ related ad@@ verse events in patients treated with AB@@ IL@@ I@@ F@@ Y and with other at@@ yp@@ ical anti@@ p@@ sycho@@ tic agents are not available to allow direct compar@@ is@@ ons@@ .
Pati@@ ents treated with any anti@@ p@@ sycho@@ tic ag@@ ent@@ s@@ , including AB@@ IL@@ I@@ F@@ Y@@ , should be observed for signs and symptoms of hyper@@ g@@ ly@@ ca@@ emi@@ a (@@ such as poly@@ di@@ p@@ si@@ a@@ , poly@@ uri@@ a@@ , poly@@ ph@@ ag@@ ia and weak@@ ness@@ ) and patients with diabetes mel@@ li@@ tus or with risk factors for diabetes mel@@ li@@ tus should be monit@@ ored regularly for wor@@ sen@@ ing of glu@@ c@@ ose contro@@ l.
96 Wei@@ ght ga@@ in@@ : weight gain is commonly seen in sch@@ iz@@ op@@ hren@@ ic and bi@@ pol@@ ar man@@ ia patients due to co@@ - mor@@ bi@@ di@@ ti@@ es@@ , use of anti@@ p@@ sycho@@ tics known to cause weight ga@@ in@@ , poor@@ ly managed li@@ fe@@ -@@ sty@@ le@@ , and might lead to severe complic@@ ations@@ .
Wei@@ ght gain has been reported post@@ -@@ marketing among patients prescri@@ bed AB@@ IL@@ I@@ F@@ Y@@ .
When se@@ en@@ , it is usually in those with significant risk factors such as history of di@@ abet@@ es@@ , th@@ y@@ ro@@ id disorder or pit@@ u@@ it@@ ary aden@@ om@@ a.
In clinical trials ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight gain (@@ see section 5.@@ 1@@ )@@ .
Dy@@ sph@@ ag@@ i@@ a@@ : o@@ es@@ op@@ ha@@ ge@@ al dy@@ smo@@ tili@@ ty and aspi@@ ration have been associated with anti@@ p@@ sycho@@ tic drug use@@ , including AB@@ IL@@ I@@ F@@ Y@@ .
Ari@@ pi@@ pra@@ z@@ ole and other anti@@ p@@ sycho@@ tic drugs should be used cau@@ ti@@ ously in patients at risk for aspi@@ ration p@@ ne@@ um@@ oni@@ a.
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ : as with other medic@@ ations hyper@@ sensi@@ tivity re@@ ac@@ tions@@ , character@@ ised by aller@@ gic symp@@ tom@@ s@@ , may occur with ari@@ pi@@ pra@@ z@@ ole (@@ see section 4.@@ 8@@ )@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
D@@ ue to its α 1@@ -@@ ad@@ ren@@ er@@ gic rec@@ ep@@ tor ant@@ agon@@ is@@ m@@ , ari@@ pi@@ pra@@ z@@ ole has the potential to enh@@ ance the effect of certain anti@@ hyper@@ ten@@ sive ag@@ ent@@ s.
Given the primary CN@@ S effects of ari@@ pi@@ pra@@ z@@ ole@@ , caution should be used when ari@@ pi@@ pra@@ z@@ ole is taken in combination with alcohol or other CN@@ S medic@@ inal products with over@@ l@@ apping un@@ desi@@ rable effects such as se@@ dation (@@ see section 4.@@ 8@@ )@@ .
If ari@@ pi@@ pra@@ z@@ ole is administ@@ ered con@@ co@@ mit@@ antly with medic@@ ines known to cause Q@@ T pro@@ long@@ ation or elec@@ tro@@ ly@@ te im@@ bal@@ anc@@ e@@ , caution should be use@@ d.
Pot@@ ential for other medic@@ inal products to affect AB@@ IL@@ I@@ F@@ Y@@ :
The administration of lor@@ az@@ ep@@ am solution for in@@ jection had no effect on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection when administ@@ ered con@@ co@@ mit@@ ant@@ ly@@ .
Ho@@ we@@ ver@@ , in a sing@@ le@@ -@@ d@@ os@@ e@@ , in@@ tra@@ mus@@ cular study of ari@@ pi@@ pra@@ z@@ ole (@@ dose 15 m@@ g@@ ) in healthy sub@@ jec@@ ts@@ , administ@@ ered simul@@ tane@@ ously with in@@ tra@@ mus@@ cular lor@@ az@@ ep@@ am (@@ dose 2 m@@ g@@ )@@ , the intensity of se@@ dation was greater with the combination as compared to that observed with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
A ga@@ stri@@ c acid blo@@ cker@@ , the H@@ 2 ant@@ agon@@ ist f@@ amo@@ ti@@ d@@ ine@@ , redu@@ ces ari@@ pi@@ pra@@ z@@ ole rate of absor@@ ption but this effect is deemed not clin@@ ically relev@@ ant@@ .
Ari@@ pi@@ pra@@ z@@ ole is met@@ aboli@@ sed by multiple path@@ ways involving the C@@ Y@@ P@@ 2@@ D@@ 6 and C@@ Y@@ P@@ 3@@ A4 enz@@ ym@@ es but not C@@ Y@@ P@@ 1@@ A enz@@ ym@@ es@@ .
Th@@ us@@ , no d@@ os@@ age adju@@ st@@ ment is required for smo@@ ker@@ s.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ qu@@ ini@@ d@@ ine@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C by 10@@ 7@@ %@@ , while C@@ max was un@@ ch@@ ange@@ d.
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , decre@@ ased by 32@@ % and 47@@ %@@ .
AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed dose when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y with qu@@ ini@@ dine occ@@ urs@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 2@@ D@@ 6@@ , such as flu@@ ox@@ et@@ ine and par@@ ox@@ et@@ ine@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
In a clinical trial in healthy sub@@ jec@@ ts@@ , a pot@@ ent in@@ hi@@ bit@@ or of C@@ Y@@ P@@ 3@@ A4 (@@ ket@@ o@@ con@@ az@@ ole@@ ) increased ari@@ pi@@ pra@@ z@@ ole AU@@ C and C@@ max by 6@@ 3@@ % and 37@@ %@@ , respec@@ ti@@ vel@@ y@@ .
The AU@@ C and C@@ max of de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole increased by 77@@ % and 43@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In C@@ Y@@ P@@ 2@@ D@@ 6 poor met@@ aboli@@ ser@@ s@@ , con@@ co@@ mit@@ ant use of pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 may result in higher p@@ las@@ ma conc@@ ent@@ rations of ari@@ pi@@ pra@@ z@@ ole compared to that in C@@ Y@@ P@@ 2@@ D@@ 6 extensive met@@ aboli@@ zer@@ s.
When considering con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole or other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors with AB@@ IL@@ I@@ F@@ Y@@ , potential benefits should out@@ weigh the potential risks to the pati@@ ent@@ .
When con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ o@@ z@@ ole with AB@@ IL@@ I@@ F@@ Y occ@@ urs@@ , AB@@ IL@@ I@@ F@@ Y dose should be reduced to approximately one@@ -@@ half of its prescri@@ bed d@@ os@@ e@@ .
Other pot@@ ent in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A@@ 4@@ , such as it@@ ra@@ con@@ az@@ ole and HIV prot@@ ease in@@ hi@@ bit@@ or@@ s@@ , may be expected to have similar effects and similar dose re@@ ductions should therefore be app@@ lie@@ d.
97 Up@@ on dis@@ continu@@ ation of the C@@ Y@@ P@@ 2@@ D@@ 6 or 3@@ A4 in@@ hi@@ bit@@ or@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be increased to the level prior to the initi@@ ation of the con@@ co@@ mit@@ ant therap@@ y@@ .
When weak in@@ hi@@ bit@@ ors of C@@ Y@@ P@@ 3@@ A4 (@@ e@@ . g@@ .@@ , dil@@ ti@@ az@@ em or esc@@ ital@@ op@@ ra@@ m@@ ) or C@@ Y@@ P@@ 2@@ D@@ 6 are used con@@ co@@ mit@@ antly with AB@@ IL@@ I@@ F@@ Y@@ , modest increases in ari@@ pi@@ pra@@ z@@ ole conc@@ ent@@ rations might be expec@@ te@@ d.
Following con@@ co@@ mit@@ ant administration of car@@ b@@ amaz@@ ep@@ ine@@ , a pot@@ ent in@@ duc@@ er of C@@ Y@@ P@@ 3@@ A@@ 4@@ , the ge@@ omet@@ ric means of C@@ max and AU@@ C for ari@@ pi@@ pra@@ z@@ ole were 68@@ % and 7@@ 3@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , compared to when ari@@ pi@@ pra@@ z@@ ole (@@ 30 m@@ g@@ ) was administ@@ ered al@@ one@@ .
Simi@@ lar@@ ly@@ , for de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole the ge@@ omet@@ ric means of C@@ max and AU@@ C after car@@ b@@ amaz@@ ep@@ ine co@@ -@@ administration were 69@@ % and 7@@ 1@@ % lo@@ wer@@ , respec@@ ti@@ vel@@ y@@ , than those following treatment with ari@@ pi@@ pra@@ z@@ ole al@@ one@@ .
AB@@ IL@@ I@@ F@@ Y dose should be doubled when con@@ co@@ mit@@ ant administration of AB@@ IL@@ I@@ F@@ Y occ@@ urs with car@@ b@@ amaz@@ ep@@ ine@@ .
John@@ '@@ s Wort@@ ) may be expected to have similar effects and similar dose increases should therefore be app@@ lie@@ d.
Up@@ on dis@@ continu@@ ation of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers@@ , the d@@ os@@ age of AB@@ IL@@ I@@ F@@ Y should be reduced to the recommended d@@ os@@ e@@ .
When either val@@ pro@@ ate or li@@ thi@@ um were administ@@ ered con@@ co@@ mit@@ antly with ari@@ pi@@ pra@@ z@@ ole@@ , there was no clin@@ ically significant change in ari@@ pi@@ pra@@ z@@ ole conc@@ entra@@ tions@@ .
Pot@@ ential for AB@@ IL@@ I@@ F@@ Y to affect other medic@@ inal produc@@ ts@@ :
The administration of ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection had no effect on the pharmac@@ ok@@ ine@@ tics of lor@@ az@@ ep@@ am solution for in@@ jection when administ@@ ered con@@ co@@ mit@@ ant@@ ly@@ .
Ho@@ we@@ ver@@ , in a sing@@ le@@ -@@ d@@ os@@ e@@ , in@@ tra@@ mus@@ cular study of ari@@ pi@@ pra@@ z@@ ole (@@ dose 15 m@@ g@@ ) in healthy sub@@ jec@@ ts@@ , administ@@ ered simul@@ tane@@ ously with in@@ tra@@ mus@@ cular lor@@ az@@ ep@@ am (@@ dose 2 m@@ g@@ )@@ , the or@@ tho@@ st@@ atic h@@ yp@@ ot@@ ension observed was greater with the combination as compared to that observed with lor@@ az@@ ep@@ am al@@ one@@ .
In clinical stu@@ dies@@ , 10@@ -@@ 30 m@@ g@@ / day d@@ oses of ari@@ pi@@ pra@@ z@@ ole had no significant effect on the met@@ aboli@@ sm of sub@@ str@@ ates of C@@ Y@@ P@@ 2@@ D@@ 6 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ / 3@@ -@@ metho@@ x@@ y@@ mor@@ ph@@ in@@ an rati@@ o@@ )@@ , 2@@ C@@ 9 (@@ war@@ far@@ in@@ )@@ , 2@@ C@@ 19 (@@ om@@ ep@@ raz@@ ole@@ )@@ , and 3@@ A4 (@@ de@@ x@@ tro@@ me@@ thor@@ ph@@ an@@ )@@ .
Addi@@ tion@@ all@@ y@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole did not show potential for al@@ tering C@@ Y@@ P@@ 1@@ A@@ 2@@ -@@ medi@@ ated met@@ aboli@@ sm in vit@@ ro@@ .
Th@@ us@@ , ari@@ pi@@ pra@@ z@@ ole is unlikely to cause clin@@ ically important medic@@ inal product inter@@ actions medi@@ ated by these enz@@ ym@@ es@@ .
When ari@@ pi@@ pra@@ z@@ ole was administ@@ ered con@@ co@@ mit@@ antly with either val@@ pro@@ ate or li@@ thi@@ um@@ , there was no clin@@ ically important change in val@@ pro@@ ate or li@@ thi@@ um conc@@ entra@@ tions@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled trials of ari@@ pi@@ pra@@ z@@ ole in pregnant wom@@ en@@ .
Ani@@ mal studies could not exclu@@ de potential develop@@ mental tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Pati@@ ents should be advised to noti@@ fy their physi@@ cian if they become pregnant or intend to become pregnant during treatment with ari@@ pi@@ pra@@ z@@ ole@@ .
D@@ ue to in@@ sufficient safety information in humans and concerns raised by animal re@@ productive stu@@ dies@@ , this medic@@ inal product should not be used in pregnancy unless the expected benefit clearly justi@@ fies the potential risk to the fo@@ et@@ us@@ .
Ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the milk of treated rats during la@@ ct@@ ation@@ .
Pati@@ ents should be advised not to breast feed if they are taking ari@@ pi@@ pra@@ z@@ ole@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been per@@ for@@ med@@ .
Ho@@ we@@ ver@@ , as with other anti@@ p@@ sycho@@ tic@@ s@@ , patients should be cau@@ tioned about operating ha@@ z@@ ard@@ ous mach@@ in@@ es@@ , including motor v@@ ehic@@ les@@ , until they are reas@@ onably certain that ari@@ pi@@ pra@@ z@@ ole does not affect them adver@@ sel@@ y@@ .
98 4.@@ 8 Un@@ desi@@ rable effects
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ ) in clinical trials with ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection (@@ see section 5.@@ 1@@ )@@ :
The frequ@@ ency listed below is defined using the following conven@@ tion@@ : common (@@ ≥ 1@@ / 100@@ , < 1@@ / 10@@ ) and un@@ common (@@ ≥ 1@@ / 1,@@ 00@@ 0@@ , < 1@@ / 100@@ )@@ .
Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous system disor@@ ders Common@@ : som@@ n@@ ol@@ en@@ ce@@ , di@@ zz@@ in@@ ess@@ , hea@@ da@@ che@@ , ak@@ ath@@ i@@ sia Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : nau@@ se@@ a@@ , vo@@ mi@@ ting Un@@ common@@ : dry mou@@ th@@ * V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ *@@ , increased di@@ ast@@ oli@@ c blood pressu@@ re@@ * General disor@@ ders and administration site conditions Un@@ common@@ : f@@ ati@@ gu@@ e@@ *
The following un@@ desi@@ rable effects occurred more often (@@ ≥ 1@@ / 100@@ ) than pla@@ c@@ ebo@@ , or were identified as possibly medi@@ cally relevant ad@@ verse re@@ actions (@@ *@@ ) in clinical trials with oral formu@@ lations of ari@@ pi@@ pra@@ z@@ ole (@@ see section 5.@@ 1@@ )@@ :
Cardi@@ ac disor@@ ders Un@@ common@@ : ta@@ ch@@ y@@ cardi@@ a@@ * Ner@@ v@@ ous system disor@@ ders Common@@ : ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al disor@@ der@@ , ak@@ ath@@ isi@@ a@@ , tre@@ mor@@ , di@@ zz@@ in@@ ess@@ , som@@ n@@ ol@@ en@@ ce@@ , se@@ d@@ ation@@ , hea@@ da@@ che E@@ ye disor@@ ders Common@@ : bl@@ urred vision Gast@@ ro@@ inte@@ st@@ inal disor@@ ders Common@@ : dy@@ sp@@ ep@@ si@@ a@@ , vo@@ mit@@ ing@@ , nau@@ se@@ a@@ , con@@ sti@@ p@@ ation@@ , s@@ ali@@ v@@ ary hyper@@ secre@@ tion V@@ as@@ cular disor@@ ders Un@@ common@@ : or@@ tho@@ st@@ atic h@@ yp@@ ot@@ en@@ sion@@ * General disor@@ ders and administration site conditions Common@@ : f@@ ati@@ gue P@@ sychiatri@@ c disor@@ ders Common@@ : rest@@ less@@ ness@@ , ins@@ om@@ ni@@ a@@ , anxiety Un@@ common@@ : depres@@ sion@@ *
Ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symptoms (@@ EP@@ S@@ )@@ :
Sch@@ iz@@ op@@ hren@@ ia - in a long term 5@@ 2@@ -@@ week controlled tri@@ al@@ , ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients had an over@@ all@@ -@@ lower inci@@ dence (@@ 25.@@ 8@@ %@@ ) of E@@ PS including par@@ kin@@ son@@ is@@ m@@ , ak@@ ath@@ isi@@ a@@ , dy@@ st@@ onia and dy@@ sk@@ ine@@ sia compared with those treated with hal@@ operi@@ dol (@@ 5@@ 7.@@ 3@@ %@@ )@@ .
In a long term 26@@ -@@ week pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 19@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 13.@@ 1@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In another long@@ -@@ term 26@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 14.@@ 8@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 1@@ % for ol@@ anz@@ ap@@ ine@@ -@@ treated pati@@ ent@@ s.
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order - in a 12@@ -@@ week controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 23.@@ 5@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 5@@ 3.@@ 3@@ % for hal@@ operi@@ dol@@ -@@ treated pati@@ ent@@ s.
In another 12@@ -@@ week tri@@ al@@ , the inci@@ dence of E@@ PS was 26.@@ 6@@ % for patients treated with ari@@ pi@@ pra@@ z@@ ole and 17.@@ 6@@ % for those treated with li@@ thi@@ um@@ .
In the long term 26@@ -@@ week maintenance phase of a pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , the inci@@ dence of E@@ PS was 18.@@ 2@@ % for ari@@ pi@@ pra@@ z@@ ole@@ -@@ treated patients and 15.@@ 7@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
In pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ s@@ , the inci@@ dence of ak@@ ath@@ i@@ sia in bi@@ pol@@ ar patients was 12.@@ 1@@ % with ari@@ pi@@ pra@@ z@@ ole and 3.@@ 2@@ % with pla@@ c@@ ebo@@ .
In sch@@ iz@@ op@@ hren@@ ia patients the inci@@ dence of ak@@ ath@@ i@@ sia was 6.@@ 2@@ % with ari@@ pi@@ pra@@ z@@ ole and 3@@ .0@@ % with pla@@ c@@ ebo@@ .
99 Com@@ par@@ is@@ ons between ari@@ pi@@ pra@@ z@@ ole and pla@@ c@@ eb@@ o in the propor@@ tions of patients experiencing potentially clin@@ ically significant changes in routine lab@@ oratory par@@ ame@@ ters revealed no medi@@ cally important differ@@ en@@ c@@ es@@ .
Ele@@ v@@ ations of C@@ P@@ K (@@ Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ )@@ , generally tran@@ si@@ ent and as@@ ymp@@ tom@@ ati@@ c@@ , were observed in 3.@@ 5@@ % of ari@@ pi@@ pra@@ z@@ ole treated patients as compared to 2@@ .0@@ % of patients who received pla@@ c@@ ebo@@ .
Other fin@@ d@@ ings@@ :
Un@@ desi@@ rable effects known to be associated with anti@@ p@@ sycho@@ tic therapy and also reported during treatment with ari@@ pi@@ pra@@ z@@ ole include neuro@@ le@@ p@@ tic mal@@ ign@@ ant syn@@ dro@@ me@@ , tar@@ di@@ ve dy@@ sk@@ ine@@ si@@ a@@ , sei@@ zu@@ re@@ , cer@@ eb@@ ro@@ v@@ as@@ cular ad@@ verse events and increased mort@@ ality in elderly de@@ mented pati@@ ent@@ s@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a and diabetes mel@@ li@@ tus (@@ see section 4.@@ 4@@ )@@ .
Post@@ -@@ Market@@ ing@@ :
The following ad@@ verse events have been reported during post@@ -@@ marketing sur@@ veil@@ lan@@ ce@@ .
The frequ@@ ency of these events is considered not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Investig@@ ations@@ :
increased Cre@@ at@@ ine Ph@@ osp@@ ho@@ kin@@ as@@ e@@ , blood glu@@ c@@ ose increas@@ ed@@ , blood glu@@ c@@ ose flu@@ ctu@@ ation@@ , g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in increased
Cardi@@ ac disor@@ der@@ s@@ :
Q@@ T pro@@ long@@ ation@@ , vent@@ ri@@ cular arr@@ hyth@@ mi@@ as@@ , sudden un@@ explained de@@ ath@@ , cardi@@ ac ar@@ rest@@ , tor@@ sa@@ des de poin@@ tes@@ , bra@@ dy@@ car@@ dia
Bloo@@ d and the lymp@@ h@@ atic system disor@@ der@@ s@@ :
leu@@ kop@@ eni@@ a@@ , neut@@ rop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia
Ner@@ v@@ ous system disor@@ der@@ s@@ :
speech disor@@ der@@ , Neuro@@ le@@ p@@ tic Mal@@ ign@@ ant Syn@@ drome (@@ N@@ M@@ S@@ )@@ , grand mal con@@ vul@@ sion
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ s@@ :
or@@ op@@ har@@ yn@@ ge@@ al sp@@ as@@ m@@ , lar@@ yn@@ g@@ os@@ pas@@ m@@ , aspi@@ ration p@@ ne@@ um@@ onia
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
pan@@ cre@@ ati@@ tis@@ , dy@@ sph@@ ag@@ i@@ a@@ , ab@@ dom@@ inal dis@@ comfort@@ , stomach dis@@ comfort@@ , di@@ arr@@ ho@@ ea
Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
ur@@ inary in@@ contin@@ en@@ ce@@ , ur@@ inary re@@ tention
Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
ra@@ sh@@ , ph@@ otos@@ en@@ si@@ tivity re@@ ac@@ tion@@ , al@@ op@@ eci@@ a@@ , hyper@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
r@@ hab@@ dom@@ y@@ ol@@ ysi@@ s@@ , my@@ al@@ gi@@ a@@ , sti@@ ff@@ ness
En@@ do@@ cr@@ ine disor@@ der@@ s@@ :
hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , diabetes mel@@ li@@ t@@ us@@ , di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s@@ , di@@ abe@@ tic hyper@@ os@@ mol@@ ar com@@ a
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
weight ga@@ in@@ , weight decre@@ as@@ ed@@ , an@@ or@@ ex@@ i@@ a@@ , h@@ yp@@ on@@ at@@ re@@ mia
V@@ as@@ cular disor@@ der@@ s@@ :
syn@@ cop@@ e@@ , hyper@@ ten@@ sion@@ , thro@@ mbo@@ em@@ bo@@ lic events
General disor@@ ders and administration site condi@@ tions@@ :
temperature regulation disorder (@@ e@@ . g. hypo@@ ther@@ mi@@ a@@ , py@@ re@@ xi@@ a@@ )@@ , chest pain@@ , peri@@ pher@@ al oe@@ de@@ ma
Immun@@ e system disor@@ der@@ s@@ :
aller@@ gic reaction (@@ e@@ . g. an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ , an@@ gi@@ oe@@ de@@ ma including s@@ wollen ton@@ gu@@ e@@ , ton@@ gue oe@@ de@@ ma@@ , face oe@@ de@@ ma@@ , p@@ ru@@ rit@@ us@@ , or ur@@ tic@@ ari@@ a@@ )
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ der@@ s@@ :
ja@@ un@@ di@@ ce@@ , he@@ pati@@ tis@@ , increased A@@ lan@@ ine A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ AL@@ T@@ )@@ , increased A@@ spar@@ tate A@@ min@@ ot@@ ran@@ s@@ fer@@ ase (@@ A@@ ST@@ )@@ , increased G@@ amm@@ a Gl@@ ut@@ am@@ yl Transfer@@ ase (@@ G@@ GT@@ )@@ , increased al@@ kal@@ ine ph@@ osp@@ hat@@ ase
Re@@ productive system and breast disor@@ der@@ s@@ :
pri@@ ap@@ ism
P@@ sychiatri@@ c disor@@ der@@ s@@ :
ag@@ it@@ ation@@ , nerv@@ ous@@ ness@@ ; suicide attemp@@ t@@ , suici@@ dal ide@@ ation@@ , and completed suicide (@@ see section 4.@@ 4@@ )
4.@@ 9 Over@@ dose
In clinical trials and post@@ -@@ marketing experi@@ en@@ ce@@ , acci@@ dental or inten@@ tional ac@@ ute over@@ d@@ os@@ age of ari@@ pi@@ pra@@ z@@ ole alone was identified in adult patients with reported estimated d@@ oses up to 1,@@ 260 mg with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally important signs and symptoms observed included le@@ th@@ ar@@ gy@@ , increased blood pressu@@ re@@ , som@@ n@@ ol@@ en@@ ce@@ , ta@@ ch@@ y@@ cardi@@ a@@ , nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ e@@ a.
In addi@@ tion@@ , reports of acci@@ dental over@@ dose with ari@@ pi@@ pra@@ z@@ ole alone (@@ up to 19@@ 5 m@@ g@@ ) in children have been received with no fat@@ ali@@ ti@@ es@@ .
The potentially medi@@ cally serious signs and symptoms reported included som@@ n@@ ol@@ en@@ ce@@ , tran@@ si@@ ent loss of consci@@ ousness and ex@@ tr@@ ap@@ y@@ ra@@ mid@@ al symp@@ tom@@ s.
Management of over@@ dose should concentrate on supportive therap@@ y@@ , maintaining an adequate air@@ wa@@ y@@ , oxy@@ gen@@ ation and v@@ enti@@ la@@ tion@@ , and management of symp@@ tom@@ s.
The possibility of multiple medic@@ inal product involvement should be consider@@ ed@@ .
Ther@@ efore cardi@@ ov@@ as@@ cular monitoring should be started immediately and should include continu@@ ous elec@@ tro@@ cardi@@ o@@ graphic monitoring to dete@@ ct possible arr@@ hyth@@ mi@@ as@@ .
Following any confirmed or suspected over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , close medical super@@ vision and monitoring should continue until the patient reco@@ vers@@ .
Ac@@ tiv@@ ated char@@ coal (@@ 50 g@@ )@@ , administ@@ ered one hour after ari@@ pi@@ pra@@ z@@ ole@@ , decre@@ ased ari@@ pi@@ pra@@ z@@ ole C@@ max by about 4@@ 1@@ % and AU@@ C by about 5@@ 1@@ %@@ , suggesting that char@@ coal may be effective in the treatment of over@@ d@@ os@@ e@@ .
Although there is no information on the effect of ha@@ emo@@ di@@ aly@@ sis in treating an over@@ dose with ari@@ pi@@ pra@@ z@@ ole@@ , ha@@ emo@@ di@@ aly@@ sis is unlikely to be useful in over@@ dose management since ari@@ pi@@ pra@@ z@@ ole is highly bound to p@@ las@@ ma prot@@ ein@@ s.
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ p@@ sycho@@ tic@@ s@@ , AT@@ C co@@ de@@ :
N@@ 05@@ A@@ X@@ 12
It has been proposed that ari@@ pi@@ pra@@ z@@ ole@@ ’ s eff@@ ic@@ acy in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order is medi@@ ated through a combination of partial agon@@ ism at d@@ op@@ amine D@@ 2 and ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a rec@@ ep@@ tors and ant@@ agon@@ ism of ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited ant@@ agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hyper@@ activity and agon@@ ist properties in animal models of d@@ op@@ am@@ in@@ er@@ gic hypo@@ activ@@ it@@ y@@ .
Ari@@ pi@@ pra@@ z@@ ole exhi@@ bited high bin@@ ding aff@@ in@@ ity in vit@@ ro for d@@ op@@ amine D@@ 2 and D@@ 3@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 1@@ a and 5@@ H@@ T@@ 2@@ a rec@@ ep@@ tors and moderate aff@@ in@@ ity for d@@ op@@ amine D@@ 4@@ , ser@@ ot@@ on@@ in 5@@ H@@ T@@ 2@@ c and 5@@ H@@ T@@ 7@@ , alp@@ ha@@ -@@ 1 ad@@ ren@@ er@@ gic and hist@@ amine H@@ 1 rec@@ ep@@ tor@@ s.
Ari@@ pi@@ pra@@ z@@ ole also exhi@@ bited moderate bin@@ ding aff@@ in@@ ity for the ser@@ ot@@ on@@ in re@@ up@@ take site and no appreci@@ able aff@@ in@@ ity for mus@@ car@@ ini@@ c rec@@ ep@@ tor@@ s.
Inter@@ action with rec@@ ep@@ tors other than d@@ op@@ amine and ser@@ ot@@ on@@ in sub@@ types may explain some of the other clinical effects of ari@@ pi@@ pra@@ z@@ ole@@ .
Ari@@ pi@@ pra@@ z@@ ole d@@ oses ranging from 0.5 to 30 mg administ@@ ered once a day to healthy subjects for 2 weeks produced a d@@ os@@ e@@ -@@ dependent reduction in the bin@@ ding of 11@@ C@@ -@@ ra@@ clo@@ pri@@ de@@ , a D@@ 2@@ / D@@ 3 rec@@ ep@@ tor lig@@ and@@ , to the cau@@ date and put@@ amen dete@@ cted by posi@@ tr@@ on e@@ mission tom@@ o@@ grap@@ hy@@ .
101 Further information on clinical tri@@ al@@ s@@ :
A@@ git@@ ation in sch@@ iz@@ op@@ hren@@ ia and Bi@@ pol@@ ar I Dis@@ order with ari@@ pi@@ pra@@ z@@ ole solution for in@@ jec@@ tion@@ :
In two short@@ - term (@@ 24@@ -@@ ho@@ ur@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 5@@ 54 sch@@ iz@@ op@@ hren@@ ic patients presenting with ag@@ itation and distur@@ bed behavi@@ o@@ urs@@ , ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection was associated with stati@@ st@@ ically significant greater improvements in ag@@ it@@ ation@@ / behavi@@ our@@ al symptoms compared to pla@@ c@@ eb@@ o and was similar to hal@@ operi@@ dol@@ .
In one short@@ -@@ term (@@ 24@@ -@@ ho@@ ur@@ ) pla@@ c@@ ebo@@ -@@ controlled trial involving 29@@ 1 patients with bi@@ pol@@ ar disorder presenting with ag@@ itation and distur@@ bed behavi@@ o@@ urs@@ , ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection was associated with stati@@ st@@ ically significant greater improvements in ag@@ it@@ ation@@ / behavi@@ our@@ al symptoms compared to pla@@ c@@ eb@@ o and was similar to the reference arm lor@@ az@@ ep@@ am@@ .
The observed mean improvement from bas@@ eline on the P@@ AN@@ SS Ex@@ cit@@ ement Comp@@ on@@ ent score at the primary 2@@ -@@ hour end@@ point was 5.@@ 8 for pla@@ c@@ ebo@@ , 9.@@ 6 for lor@@ az@@ ep@@ am@@ , and 8.@@ 7 for ari@@ pi@@ pra@@ z@@ ole@@ .
In sub@@ population analy@@ ses on patients with mixed episodes or on patients with severe ag@@ it@@ ation@@ , a similar pattern of eff@@ ic@@ acy to the overall population was observed but stati@@ stical significance could not be established due to a reduced sample si@@ ze@@ .
Sch@@ iz@@ op@@ hren@@ ia with oral ari@@ pi@@ pra@@ z@@ ole@@ :
In three short@@ -@@ term (@@ 4 to 6 wee@@ ks@@ ) pla@@ c@@ ebo@@ -@@ controlled trials involving 1,@@ 228 sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s@@ , presenting with positive or negative symp@@ tom@@ s@@ , oral ari@@ pi@@ pra@@ z@@ ole was associated with stati@@ st@@ ically significantly greater improvements in p@@ sycho@@ tic symptoms compared to pla@@ c@@ ebo@@ .
AB@@ IL@@ I@@ F@@ Y is effective in maintaining the clinical improvement during continu@@ ation therapy in patients who have shown an initial treatment respon@@ se@@ .
In a hal@@ operi@@ dol@@ -@@ controlled tri@@ al@@ , the proportion of respon@@ der patients maintaining response to medic@@ inal product at 5@@ 2@@ -@@ weeks was similar in both groups (@@ oral ari@@ pi@@ pra@@ z@@ ole 77@@ % and hal@@ operi@@ dol 7@@ 3@@ %@@ )@@ .
The overall comple@@ tion rate was significantly higher for patients on oral ari@@ pi@@ pra@@ z@@ ole (@@ 43@@ %@@ ) than for oral hal@@ operi@@ dol (@@ 30@@ %@@ )@@ .
Ac@@ tual scores in rating sc@@ ales used as secondary end@@ poin@@ ts@@ , including P@@ AN@@ SS and the Montgom@@ er@@ y@@ -@@ As@@ berg Depression R@@ ating Sc@@ ale showed a significant improvement over hal@@ operi@@ dol@@ .
In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial in stabili@@ sed patients with chronic sch@@ iz@@ op@@ hren@@ i@@ a@@ , oral ari@@ pi@@ pra@@ z@@ ole had significantly greater reduction in re@@ lap@@ se rat@@ e@@ , 34@@ % in oral ari@@ pi@@ pra@@ z@@ ole group and 57@@ % in pla@@ c@@ ebo@@ .
Wei@@ ght ga@@ in@@ : in clinical trials oral ari@@ pi@@ pra@@ z@@ ole has not been shown to indu@@ ce clin@@ ically relevant weight ga@@ in@@ .
In a 26@@ -@@ week@@ , ol@@ anz@@ ap@@ ine@@ -@@ contro@@ lle@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , multi@@ -@@ national study of sch@@ iz@@ op@@ hren@@ ia which included 3@@ 14 patients and where the primary end@@ -@@ point was weight ga@@ in@@ , significantly less patients had at least 7@@ % weight gain over bas@@ eline (@@ i@@ . e@@ . a gain of at least 5.@@ 6 kg for a mean bas@@ eline weight of ~@@ 8@@ 0.5 k@@ g@@ ) on oral ari@@ pi@@ pra@@ z@@ ole (@@ N@@ = 18@@ , or 13@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ , compared to oral ol@@ anz@@ ap@@ ine (@@ N@@ = 45@@ , or 33@@ % of evalu@@ able pati@@ ent@@ s@@ )@@ .
M@@ anic episodes in Bi@@ pol@@ ar I Dis@@ order with oral ari@@ pi@@ pra@@ z@@ ole@@ :
In two 3@@ -@@ week@@ , flexi@@ ble@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trials involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o in reduction of man@@ ic symptoms over 3 wee@@ ks@@ .
These trials included patients with or without p@@ sycho@@ tic features and with or without a rap@@ id@@ -@@ cycling cour@@ se@@ .
In one 3@@ -@@ week@@ , fix@@ ed@@ -@@ d@@ os@@ e@@ , pla@@ c@@ ebo@@ -@@ controlled mon@@ o@@ therapy trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , ari@@ pi@@ pra@@ z@@ ole failed to demonstrate superior eff@@ ic@@ acy to pla@@ c@@ ebo@@ .
In two 12@@ -@@ week@@ , pla@@ c@@ ebo@@ - and ac@@ ti@@ ve@@ -@@ controlled mon@@ o@@ therapy trials in patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated superior eff@@ ic@@ acy to pla@@ c@@ eb@@ o at week 3 and a maintenance of effect compar@@ able to li@@ thi@@ um or hal@@ operi@@ dol at week 12.
Ari@@ pi@@ pra@@ z@@ ole also demonstrated a compar@@ able proportion of patients in symp@@ tom@@ atic re@@ mission from man@@ ia as li@@ thi@@ um or hal@@ operi@@ dol at week 12.
In a 6@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled trial involving patients with a man@@ ic or mixed episode of Bi@@ pol@@ ar I Dis@@ or@@ der@@ , with or without p@@ sycho@@ tic feat@@ u@@ res@@ , who were parti@@ ally non@@ -@@ respon@@ sive to li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therapy for 2 weeks at therapeu@@ tic ser@@ um level@@ s@@ , the addition of ari@@ pi@@ pra@@ z@@ ole as ad@@ jun@@ ctive therapy resulted in superior eff@@ ic@@ acy in reduction of man@@ ic symptoms than li@@ thi@@ um or val@@ pro@@ ate mon@@ o@@ therap@@ y@@ .
102 In a 26@@ -@@ week@@ , pla@@ c@@ ebo@@ -@@ controlled tri@@ al@@ , followed by a 7@@ 4@@ -@@ week exten@@ sion@@ , in man@@ ic patients who achieved re@@ mission on ari@@ pi@@ pra@@ z@@ ole during a stabili@@ zation phase prior to rand@@ omi@@ z@@ ation@@ , ari@@ pi@@ pra@@ z@@ ole demonstrated su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing bi@@ pol@@ ar rec@@ ur@@ ren@@ ce@@ , primarily in preventing rec@@ ur@@ r@@ ence into man@@ ia but failed to demonstrate su@@ peri@@ ority over pla@@ c@@ eb@@ o in preventing rec@@ ur@@ r@@ ence into depres@@ sion@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ab@@ sor@@ p@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection administ@@ ered in@@ tra@@ mus@@ cul@@ arly as a sing@@ le@@ -@@ dose to healthy subjects is well absor@@ bed and has an absolute bio@@ availability of 100@@ %@@ .
The ari@@ pi@@ pra@@ z@@ ole AU@@ C in the first 2 hours after an in@@ tra@@ mus@@ cular in@@ jection was 90@@ % greater than the AU@@ C after the same dose as a tab@@ let@@ ; sy@@ ste@@ mic exposure was generally similar between the 2 formu@@ la@@ tions@@ .
In 2 studies in healthy subjects the medi@@ an times to the peak p@@ las@@ ma conc@@ ent@@ rations were 1 and 3 hours after d@@ os@@ ing@@ .
Distri@@ bu@@ tion@@ :
Ari@@ pi@@ pra@@ z@@ ole is widely distri@@ buted throughout the body with an apparent volume of distribution of 4.@@ 9 l@@ / k@@ g@@ , indic@@ ating extensive extra@@ v@@ as@@ cular distri@@ bu@@ tion@@ .
At therapeu@@ tic conc@@ entra@@ tions@@ , ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole are greater than 99@@ % bound to ser@@ um prot@@ ein@@ s@@ , bin@@ ding primarily to alb@@ umin@@ .
Met@@ aboli@@ sm@@ :
Ari@@ pi@@ pra@@ z@@ ole is exten@@ sively met@@ aboli@@ sed by the liver primarily by three bi@@ ot@@ ran@@ s@@ formation path@@ wa@@ ys@@ : de@@ hydro@@ gen@@ ation@@ , hydro@@ x@@ y@@ la@@ tion@@ , and N@@ -@@ deal@@ k@@ y@@ la@@ tion@@ .
Based on in vit@@ ro stu@@ dies@@ , C@@ Y@@ P@@ 3@@ A4 and C@@ Y@@ P@@ 2@@ D@@ 6 enz@@ ym@@ es are responsible for de@@ hydro@@ gen@@ ation and hydro@@ x@@ y@@ lation of ari@@ pi@@ pra@@ z@@ ole@@ , and N@@ -@@ deal@@ k@@ y@@ lation is cat@@ aly@@ sed by C@@ Y@@ P@@ 3@@ A@@ 4.
Ari@@ pi@@ pra@@ z@@ ole is the pre@@ dominant medic@@ inal product mo@@ iety in sy@@ ste@@ mic circu@@ la@@ tion@@ .
At steady stat@@ e@@ , de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , the active met@@ aboli@@ te@@ , represents about 40@@ % of ari@@ pi@@ pra@@ z@@ ole AU@@ C in p@@ las@@ ma@@ .
Eli@@ min@@ ation@@ :
The mean elim@@ ination half@@ -@@ lives for ari@@ pi@@ pra@@ z@@ ole are approximately 75 hours in extensive met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6 and approximately 14@@ 6 hours in poor met@@ aboli@@ sers of C@@ Y@@ P@@ 2@@ D@@ 6.
The total body clear@@ ance of ari@@ pi@@ pra@@ z@@ ole is 0.@@ 7 m@@ l@@ / min@@ / k@@ g@@ , which is primarily he@@ pati@@ c.
Following a single oral dose of [@@ 14@@ C@@ ]@@ -@@ lab@@ elled ari@@ pi@@ pra@@ z@@ ole@@ , approximately 27@@ % of the administ@@ ered radio@@ activity was recovered in the ur@@ ine and approximately 60@@ % in the fa@@ ec@@ es@@ .
L@@ ess than 1@@ % of un@@ changed ari@@ pi@@ pra@@ z@@ ole was ex@@ cre@@ ted in the ur@@ ine and approximately 18@@ % was recovered un@@ changed in the fa@@ ec@@ es@@ .
P@@ harm@@ ac@@ ok@@ ine@@ tics in special patient groups
El@@ der@@ ly@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy elderly and younger adult sub@@ jec@@ ts@@ , nor is there any dete@@ ct@@ able effect of age in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Gen@@ der@@ :
There are no differences in the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole between healthy male and female subjects nor is there any dete@@ ct@@ able effect of gender in a population pharmac@@ ok@@ ine@@ tic analysis in sch@@ iz@@ op@@ hren@@ ic pati@@ ent@@ s.
Smo@@ king and Rac@@ e@@ :
Pop@@ ulation pharmac@@ ok@@ ine@@ tic ev@@ al@@ uation has revealed no evidence of clin@@ ically significant ra@@ ce@@ -@@ related differences or effects from smoking upon the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole@@ .
103 Ren@@ al Di@@ seas@@ e@@ :
The pharmac@@ ok@@ ine@@ tic characterist@@ ics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole were found to be similar in patients with severe ren@@ al disease compared to young healthy sub@@ jec@@ ts@@ .
H@@ ep@@ atic Di@@ seas@@ e@@ :
A sing@@ le@@ -@@ dose study in subjects with var@@ ying degrees of liver cir@@ r@@ ho@@ sis (@@ Chil@@ d@@ -@@ Pu@@ gh Clas@@ ses A@@ , B@@ , and C@@ ) did not reveal a significant effect of he@@ pati@@ c im@@ pa@@ ir@@ ment on the pharmac@@ ok@@ ine@@ tics of ari@@ pi@@ pra@@ z@@ ole and de@@ hydro@@ -@@ ari@@ pi@@ pra@@ z@@ ole@@ , but the study included only 3 patients with Class C liver cir@@ r@@ ho@@ si@@ s@@ , which is in@@ sufficient to draw conclu@@ sions on their met@@ aboli@@ c cap@@ ac@@ it@@ y@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
Administration of ari@@ pi@@ pra@@ z@@ ole solution for in@@ jection was well toler@@ ated and produced no direct target organ tox@@ ic@@ ity in rats or mon@@ keys after repeated d@@ osing at sy@@ ste@@ mic exp@@ os@@ ures (@@ AU@@ C@@ ) that were 15 and 5 tim@@ es@@ , respec@@ ti@@ vel@@ y@@ , human exposure at the maximum recommended human dose of 30 mg in@@ tra@@ mus@@ cul@@ ar@@ .
In in@@ tra@@ ven@@ ous re@@ productive tox@@ ic@@ ity stu@@ dies@@ , no new safety concerns were observed at mat@@ ern@@ al exp@@ os@@ ures up to 15 (@@ rat@@ ) and 29 (@@ rab@@ bit@@ ) times human exposure at 30 m@@ g.
Non@@ -@@ clinical safety data revealed no special ha@@ zard for humans based on conventional oral ari@@ pi@@ pra@@ z@@ ole studies of safety pharmac@@ olog@@ y@@ , repe@@ at@@ -@@ dose tox@@ ic@@ it@@ y@@ , gen@@ oto@@ x@@ ic@@ it@@ y@@ , car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ , and tox@@ ic@@ ity to re@@ produc@@ tion@@ .
To@@ x@@ ic@@ ologi@@ cally significant effects were observed only at d@@ oses or exp@@ os@@ ures that were suff@@ ici@@ ently in excess of the maximum human dose or exp@@ os@@ ure@@ , indic@@ ating that these effects were limited or of no relev@@ ance to clinical use@@ .
These inclu@@ de@@ d@@ : d@@ os@@ e@@ -@@ dependent ad@@ reno@@ cor@@ tical tox@@ ic@@ ity (@@ li@@ po@@ f@@ us@@ c@@ in pig@@ ment accum@@ ulation and@@ / or par@@ en@@ ch@@ y@@ mal cell los@@ s@@ ) in rats after 104 weeks at 20 to 60 m@@ g@@ / k@@ g@@ / day (@@ 3 to 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ ) and increased ad@@ reno@@ cor@@ tical car@@ cin@@ om@@ as and combined ad@@ reno@@ cor@@ tical aden@@ om@@ as@@ / car@@ cin@@ om@@ as in female rats at 60 m@@ g@@ / k@@ g@@ / day (@@ 10 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended human d@@ os@@ e@@ )@@ .
The highest non@@ tum@@ ori@@ gen@@ ic exposure in female rats was 7 times the human exposure at the recommended d@@ os@@ e@@ .
An additional finding was chol@@ eli@@ thi@@ asi@@ s as a consequ@@ ence of pre@@ cip@@ itation of sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy met@@ aboli@@ tes of ari@@ pi@@ pra@@ z@@ ole in the b@@ ile of mon@@ keys after repeated oral d@@ osing at 25 to 125 m@@ g@@ / k@@ g@@ / day (@@ 1 to 3 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical dose 2 or 16 to 81 times the maximum recommended human dose based on m@@ g@@ / m@@ )@@ .
Ho@@ we@@ ver@@ , the conc@@ ent@@ rations of the sul@@ ph@@ ate con@@ ju@@ gates of hydro@@ xy ari@@ pi@@ pra@@ z@@ ole in human b@@ ile at the highest dose propos@@ ed@@ , 30 mg per day@@ , were no more than 6@@ % of the b@@ ile conc@@ ent@@ rations found in the mon@@ keys in the 39@@ -@@ week study and are well below (@@ 6@@ %@@ ) their limits of in vit@@ ro sol@@ u@@ bili@@ ty@@ .
Based on results of a full range of standard gen@@ oto@@ x@@ ic@@ ity test@@ s@@ , ari@@ pi@@ pra@@ z@@ ole was considered non@@ -@@ gen@@ oto@@ x@@ ic@@ .
Ari@@ pi@@ pra@@ z@@ ole did not im@@ pair fertili@@ ty in re@@ productive tox@@ ic@@ ity stu@@ dies@@ .
Develop@@ mental tox@@ ic@@ it@@ y@@ , including d@@ os@@ e@@ -@@ dependent delayed fo@@ et@@ al ossi@@ fication and possible ter@@ at@@ o@@ gen@@ ic effec@@ ts@@ , were observed in rats at d@@ oses resulting in sub@@ therapeu@@ tic exp@@ os@@ ures (@@ based on AU@@ C@@ ) and in ra@@ bb@@ its at d@@ oses resulting in exp@@ os@@ ures 3 and 11 times the mean ste@@ ad@@ y@@ -@@ state AU@@ C at the maximum recommended clinical d@@ os@@ e@@ .
Mat@@ ern@@ al tox@@ ic@@ ity occurred at d@@ oses similar to those el@@ ic@@ iting develop@@ mental tox@@ ic@@ it@@ y@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Sul@@ f@@ ob@@ ut@@ y@@ le@@ ther β -@@ cy@@ clo@@ de@@ x@@ tr@@ in (@@ S@@ BE@@ CD@@ ) T@@ art@@ ari@@ c acid So@@ dium hydro@@ xi@@ de Water for in@@ jection
104 6.@@ 2 In@@ comp@@ ati@@ bilities
Not applic@@ able
6.@@ 3 Shel@@ f life
18 months Use product immediately after opening and disc@@ ard any un@@ used amoun@@ t.
6.@@ 4 Special prec@@ au@@ tions for storage
Keep the vi@@ al in the ou@@ ter car@@ ton in order to protect from light@@ .
6.5 Nature and cont@@ ents of container
Each car@@ ton contains one sing@@ le@@ -@@ use type I glass vi@@ al with a rubber but@@ yl stop@@ per and a "@@ fli@@ p@@ -@@ off@@ " al@@ uminium se@@ al@@ .
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 36
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
D@@ ate of first author@@ is@@ ation@@ :
4 June 2004
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
{@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
105 AN@@ NE@@ X II
A M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER RE@@ SP@@ ON@@ S@@ IB@@ LE FO@@ R B@@ AT@@ CH RE@@ LE@@ AS@@ E
B CON@@ D@@ IT@@ I@@ ON@@ S O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION
106 A M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER RE@@ SP@@ ON@@ S@@ IB@@ LE FO@@ R B@@ AT@@ CH RE@@ LE@@ AS@@ E
Name and address of the manufacturer responsible for bat@@ ch release
Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S@@ r@@ l Con@@ tra@@ da Fon@@ t@@ ana Del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one Italy
B CON@@ D@@ IT@@ I@@ ON@@ S O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION
• CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S RE@@ G@@ AR@@ D@@ ING SU@@ P@@ PL@@ Y AND US@@ E I@@ MP@@ O@@ SED ON THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
• CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE S@@ AF@@ E AND E@@ FF@@ EC@@ T@@ IV@@ E US@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Not applic@@ ab@@ le@@ .
• O@@ TH@@ ER CON@@ D@@ IT@@ I@@ ON@@ S
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe Ltd com@@ mits to provide a P@@ SU@@ R at 6 monthly inter@@ vals unless otherwise decided by the CH@@ MP@@ .
P@@ harm@@ ac@@ o@@ vig@@ il@@ ance system The MA@@ H must ensure that the system of pharmac@@ o@@ vig@@ il@@ anc@@ e@@ , as described in version 1.@@ 0 presented in Mo@@ dule 1.@@ 8.@@ 1. of the Marketing Auth@@ or@@ is@@ ation@@ , is in place and func@@ tioning before and whilst the product is on the market@@ .
Ris@@ k Management Plan The MA@@ H com@@ mits to performing the studies and additional pharmac@@ o@@ vig@@ il@@ ance activities detailed in the P@@ harm@@ ac@@ o@@ vig@@ il@@ ance Plan@@ , as agreed in version 3.@@ 0 of the Ris@@ k Management Plan (@@ R@@ MP@@ ) presented in Mo@@ dule 1.@@ 8.@@ 2. of the Marketing Auth@@ or@@ isation and any subsequent updates of the R@@ MP agreed by the CH@@ MP@@ .
As per the CH@@ MP Gui@@ del@@ ine on Ris@@ k Management Systems for medic@@ inal products for human use@@ , the updated R@@ MP should be submitted at the same time as the next Peri@@ o@@ dic Safety Update Report (@@ P@@ S@@ UR@@ )@@ .
In addi@@ tion@@ , an updated R@@ MP should be submitted When new information is received that may impact on the current Safety Speci@@ fic@@ ation@@ , P@@ harm@@ ac@@ o@@ vig@@ il@@ ance Plan or risk mini@@ mis@@ ation activities Within 60 days of an important (@@ pharmac@@ o@@ vig@@ il@@ ance or risk mini@@ mis@@ ation@@ ) mi@@ lestone being reached At the request of the E@@ ME@@ A
10@@ 7 AN@@ NE@@ X III
LA@@ B@@ EL@@ LIN@@ G AND P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T
108 A.
LA@@ B@@ EL@@ LIN@@ G
10@@ 9 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 5 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE
Each tab@@ let contains 5 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Also conta@@ ins@@ : la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ .
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
14 x 1 tab@@ lets 28 x 1 tab@@ lets 49 x 1 tab@@ lets 56 x 1 tab@@ lets 98 x 1 tab@@ lets
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
O@@ ral use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
110 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 1 14 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 2 28 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 3 49 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 4 56 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 5 98 x 1 tab@@ lets
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
AB@@ IL@@ I@@ F@@ Y 5 mg
111 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ TER@@ S
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 5 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
O@@ TH@@ ER
112 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 10 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE
Each tab@@ let contains 10 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Also conta@@ ins@@ : la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ .
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
14 x 1 tab@@ lets 28 x 1 tab@@ lets 49 x 1 tab@@ lets 56 x 1 tab@@ lets 98 x 1 tab@@ lets
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
O@@ ral use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
1@@ 13 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 6 14 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 7 28 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 8 49 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 00@@ 9 56 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 10 98 x 1 tab@@ lets
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
AB@@ IL@@ I@@ F@@ Y 10 mg
1@@ 14 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ TER@@ S
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 10 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
O@@ TH@@ ER
115 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 15 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE
Each tab@@ let contains 15 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Also conta@@ ins@@ : la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ .
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
14 x 1 tab@@ lets 28 x 1 tab@@ lets 49 x 1 tab@@ lets 56 x 1 tab@@ lets 98 x 1 tab@@ lets
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
O@@ ral use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
1@@ 16 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 11 14 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 12 28 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 13 49 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 14 56 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 15 98 x 1 tab@@ lets
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
AB@@ IL@@ I@@ F@@ Y 15 mg
1@@ 17 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ TER@@ S
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 15 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
O@@ TH@@ ER
1@@ 18 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 30 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE
Each tab@@ let contains 30 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Also conta@@ ins@@ : la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ .
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
14 x 1 tab@@ lets 28 x 1 tab@@ lets 49 x 1 tab@@ lets 56 x 1 tab@@ lets 98 x 1 tab@@ lets
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
O@@ ral use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
1@@ 19 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 16 14 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 17 28 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 18 49 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 19 56 x 1 tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 20 98 x 1 tab@@ lets
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
AB@@ IL@@ I@@ F@@ Y 30 mg
120 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ TER@@ S
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 30 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
O@@ TH@@ ER
12@@ 1 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 10 mg or@@ o@@ disp@@ er@@ sible tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE
Each tab@@ let contains 10 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
14 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets 28 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets 49 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
O@@ ral use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
Con@@ tains as@@ part@@ ame@@ .
See le@@ af@@ let for further inform@@ ation@@ .
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
12@@ 2 9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 24 14 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 25 28 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 26 49 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
AB@@ IL@@ I@@ F@@ Y 10 mg
123 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ TER@@ S
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 10 mg or@@ o@@ disp@@ er@@ sible tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
O@@ TH@@ ER
12@@ 4 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 15 mg or@@ o@@ disp@@ er@@ sible tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE
Each tab@@ let contains 15 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
14 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets 28 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets 49 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
O@@ ral use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
Con@@ tains as@@ part@@ ame@@ .
See le@@ af@@ let for further inform@@ ation@@ .
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
125 9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 27 14 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 28 28 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 29 49 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
AB@@ IL@@ I@@ F@@ Y 15 mg
12@@ 6 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ TER@@ S
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 15 mg or@@ o@@ disp@@ er@@ sible tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
O@@ TH@@ ER
12@@ 7 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 30 mg or@@ o@@ disp@@ er@@ sible tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE
Each tab@@ let contains 30 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
14 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets 28 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets 49 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
O@@ ral use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
Con@@ tains as@@ part@@ ame@@ .
See le@@ af@@ let for further inform@@ ation@@ .
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
12@@ 8 9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 30 14 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 31 28 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 32 49 x 1 or@@ o@@ disp@@ er@@ sible tab@@ lets
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
AB@@ IL@@ I@@ F@@ Y 30 mg
12@@ 9 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ TER@@ S
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 30 mg or@@ o@@ disp@@ er@@ sible tab@@ lets ari@@ pi@@ pra@@ z@@ ole
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
O@@ TH@@ ER
130 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING AND THE IM@@ ME@@ DI@@ AT@@ E P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON AND B@@ OT@@ T@@ LE LA@@ B@@ EL
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 1 m@@ g@@ / ml oral solution ari@@ pi@@ pra@@ z@@ ole
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE
Each ml contains 1 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Con@@ tains fru@@ ct@@ os@@ e@@ , su@@ cros@@ e@@ , E@@ 2@@ 18@@ , and E@@ 2@@ 16.
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
50 ml oral solution 150 ml oral solution 4@@ 80 ml oral solution
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
O@@ ral use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P Use within 6 months after first op@@ en@@ ing@@ .
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
13@@ 1 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
O@@ uter car@@ ton@@ :
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 33 - 50 ml bottle EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 34 - 150 ml bottle EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 35 - 4@@ 80 ml bottle
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
O@@ uter car@@ ton@@ :
AB@@ IL@@ I@@ F@@ Y 1 m@@ g@@ / ml
13@@ 2 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AB@@ IL@@ I@@ F@@ Y 7.5 m@@ g@@ / ml solution for in@@ jection ari@@ pi@@ pra@@ z@@ ole
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
Each ml contains 7.5 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
A vi@@ al provides 9.@@ 75 mg in 1.3 ml
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Also contains sul@@ f@@ ob@@ ut@@ y@@ le@@ ther b@@ -@@ cy@@ clo@@ de@@ x@@ tr@@ in@@ , t@@ art@@ ari@@ c aci@@ d@@ , so@@ dium hydro@@ x@@ ide@@ , and water for in@@ jec@@ tion@@ .
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
Sol@@ ution for in@@ jection 1 vi@@ al
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
In@@ tra@@ mus@@ cular use Read the package le@@ af@@ let before use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Keep the vi@@ al in the ou@@ ter car@@ ton in order to protect from light@@ .
13@@ 3 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 04@@ / 27@@ 6@@ / 0@@ 36
13.
M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ER@@ ’ S B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
As AB@@ IL@@ I@@ F@@ Y 7.5 m@@ g@@ / ml solution for in@@ jection is only intended for administration by health care professi@@ onal@@ s@@ , no information will be included in Bra@@ il@@ le@@ .
13@@ 4 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON SM@@ ALL IM@@ ME@@ DI@@ AT@@ E P@@ AC@@ K@@ AG@@ ING UN@@ IT@@ S
VI@@ AL LA@@ B@@ EL
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
AB@@ IL@@ I@@ F@@ Y 7.5 m@@ g@@ / ml solution for in@@ jection ari@@ pi@@ pra@@ z@@ ole In@@ tra@@ mus@@ cular use
2.
ME@@ TH@@ O@@ D O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
CON@@ T@@ EN@@ TS B@@ Y WE@@ IG@@ H@@ T@@ , B@@ Y V@@ OL@@ U@@ ME O@@ R B@@ Y UN@@ IT
9.@@ 75 mg (@@ 1.@@ 3@@ m@@ l@@ )
6.
O@@ TH@@ ER
135 B.
P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T
13@@ 6 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AB@@ IL@@ I@@ F@@ Y 5 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
This medicine has been prescri@@ bed for you@@ .
Do not pass it on to o@@ ther@@ s.
It may harm them@@ , even if their symptoms are the same as yo@@ urs@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
In this le@@ af@@ let@@ :
1.
What AB@@ IL@@ I@@ F@@ Y is and what it is used for 2.
Before you take AB@@ IL@@ I@@ F@@ Y 3.
How to take AB@@ IL@@ I@@ F@@ Y 4.
Pos@@ sible side effects 5 How to store AB@@ IL@@ I@@ F@@ Y 6.
Further information
1.
WH@@ AT AB@@ IL@@ I@@ F@@ Y IS AND WH@@ AT IT IS US@@ ED FO@@ R
AB@@ IL@@ I@@ F@@ Y is one of a group of medic@@ ines called anti@@ p@@ sycho@@ tic@@ s.
It is used to treat adults who suffer from a disease character@@ ised by symptoms such as hear@@ ing@@ , seeing or sen@@ sing things which are not ther@@ e@@ , suspici@@ ous@@ ness@@ , mistak@@ en belie@@ fs@@ , in@@ co@@ her@@ ent speech and behaviour and emotional flat@@ ness@@ .
People with this condition may also feel depres@@ se@@ d@@ , guil@@ ty@@ , anxious or ten@@ se@@ .
AB@@ IL@@ I@@ F@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling "@@ high@@ "@@ , having excessive amounts of energ@@ y@@ , nee@@ ding much less sleep than us@@ u@@ al@@ , talking very quickly with racing ideas and sometimes severe irrit@@ abili@@ ty@@ .
It also prev@@ ents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ I@@ F@@ Y@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Do not take AB@@ IL@@ I@@ F@@ Y if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ I@@ F@@ Y@@ .
Take special care with AB@@ IL@@ I@@ F@@ Y Before treatment with AB@@ IL@@ I@@ F@@ Y@@ , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ volun@@ tar@@ y@@ , ir@@ regular muscle mov@@ em@@ ent@@ s@@ , especially in the face Cardi@@ ov@@ as@@ cular dise@@ as@@ es@@ , family history of cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ , stroke or "@@ mini@@ " stro@@ ke@@ , ab@@ normal blood pressure
If you notice you are gaining wei@@ ght@@ , experience any difficulty in swal@@ lowing or aller@@ gic symp@@ tom@@ s@@ , please tell your do@@ ct@@ or@@ .
If you are an elderly patient suffering from dementia (@@ loss of memory and other mental abili@@ ti@@ es@@ )@@ , you or your car@@ er@@ / relative should tell your doctor if you have ever had a stroke or "@@ mini@@ " stro@@ ke@@ .
T@@ ell your doctor immediately if you are having any thoughts or feelings about hur@@ ting your@@ sel@@ f@@ .
Su@@ ici@@ dal thoughts and behavi@@ ours have been reported during ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
13@@ 7 T@@ ell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ le@@ xi@@ bility with high fe@@ ver@@ , swe@@ at@@ ing@@ , al@@ tered mental stat@@ us@@ , or very rapid or ir@@ regular heart be@@ at@@ .
Children and adol@@ es@@ cents AB@@ IL@@ I@@ F@@ Y is not for use in children and adol@@ es@@ cents as it has not been studied in patients under 18 ye@@ ar@@ s.
As@@ k your doctor or pharmac@@ ist for advice before taking AB@@ IL@@ I@@ F@@ Y@@ .
Taking other medic@@ ines Please tell your doctor or pharmac@@ ist if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
Bloo@@ d pressu@@ re@@ -@@ lo@@ wering medi@@ cin@@ es@@ :
AB@@ IL@@ I@@ F@@ Y may increase the effect of medic@@ ines used to lower the blood pressu@@ re@@ .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under contro@@ l.
Taking AB@@ IL@@ I@@ F@@ Y with some medic@@ ines may need to change your dose of AB@@ IL@@ I@@ F@@ Y@@ .
It is especially important to mention the following to your do@@ ct@@ or@@ :
Medic@@ ines to correct heart rhyth@@ m Anti@@ depres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and anxiety Anti@@ f@@ ung@@ al agents Cer@@ tain medic@@ ines to treat HIV infection Anti@@ con@@ vul@@ s@@ ants used to treat ep@@ ile@@ p@@ sy
Taking AB@@ IL@@ I@@ F@@ Y with food and drink AB@@ IL@@ I@@ F@@ Y can be taken regardless of me@@ al@@ s.
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ I@@ F@@ Y@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ I@@ F@@ Y if you are pregnant unless you have discussed this with your do@@ ct@@ or@@ .
Be sure to tell your doctor immediately if you are pregn@@ ant@@ , think you may be pregn@@ ant@@ , or if you are planning to become pregn@@ ant@@ .
Bre@@ ast@@ -@@ feeding mothers should not take AB@@ IL@@ I@@ F@@ Y@@ .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
Dri@@ ving and using machines Do not drive or use any tools or mach@@ in@@ es@@ , until you know how AB@@ IL@@ I@@ F@@ Y affects you@@ .
Imp@@ ort@@ ant information about some of the ingredients of AB@@ IL@@ I@@ F@@ Y If you have been told by your doctor that you have an int@@ oler@@ ance to some su@@ gar@@ s@@ , contact your doctor before taking this medic@@ ine@@ .
3.
HO@@ W TO T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Al@@ ways take AB@@ IL@@ I@@ F@@ Y exactly as your doctor has told you@@ .
You should check with your doctor or pharmac@@ ist if you are not su@@ re@@ .
The usual dose is 15 mg once a day@@ .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg once a day@@ .
If you have the impression that the effect of AB@@ IL@@ I@@ F@@ Y is too strong or too weak@@ , talk to your doctor or pharmac@@ ist@@ .
T@@ ry to take the AB@@ IL@@ I@@ F@@ Y tab@@ let at the same time each day@@ .
It does not matter whether you take it with or without f@@ ood@@ .
Al@@ ways take the tab@@ let with water and swal@@ low it whol@@ e@@ .
13@@ 8 Even if you feel bet@@ ter@@ , do not alter or dis@@ continue the daily dose of AB@@ IL@@ I@@ F@@ Y without first consul@@ ting your do@@ ct@@ or@@ .
If you take more AB@@ IL@@ I@@ F@@ Y than you should If you realise you have taken more AB@@ IL@@ I@@ F@@ Y tab@@ lets than your doctor has recommended (@@ or if someone else has taken some of your AB@@ IL@@ I@@ F@@ Y tab@@ le@@ ts@@ )@@ , contact your doctor right a@@ wa@@ y@@ .
If you cannot reach your do@@ ct@@ or@@ , go to the near@@ est hospital and take the pack with you@@ .
If you forget to take AB@@ IL@@ I@@ F@@ Y If you miss a d@@ os@@ e@@ , take the missed dose as soon as you remember but do not take two d@@ oses in one day@@ .
If you have any further questions on the use of this produc@@ t@@ , ask your doctor or pharmac@@ ist@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AB@@ IL@@ I@@ F@@ Y can cause side effec@@ ts@@ , although not everybody gets them@@ .
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) Un@@ contro@@ ll@@ able twi@@ t@@ ching or jer@@ king mov@@ em@@ ent@@ s@@ , hea@@ da@@ che@@ , ti@@ re@@ dn@@ ess@@ , nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , an uncomfortable feeling in the stom@@ ach@@ , con@@ sti@@ p@@ ation@@ , increased production of s@@ ali@@ v@@ a@@ , light@@ -@@ he@@ ade@@ dn@@ ess@@ , trouble sle@@ ep@@ ing@@ , rest@@ less@@ ness@@ , feeling an@@ xi@@ ous@@ , sle@@ ep@@ in@@ ess@@ , sha@@ king and bl@@ urred visi@@ on@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ .
Some people may feel depres@@ se@@ d.
Other in@@ frequently reported side effec@@ ts@@ :
Ch@@ ang@@ es in the levels of some blood cell@@ s@@ ; unusual heart be@@ at@@ , sudden un@@ explained de@@ ath@@ , heart attack@@ ; aller@@ gic reaction (@@ e@@ . g. sw@@ elling in the mou@@ th@@ , ton@@ gu@@ e@@ , face and thro@@ at@@ , it@@ ch@@ ing@@ , ra@@ sh@@ )@@ ; high blood su@@ gar@@ , on@@ set or wor@@ sen@@ ing of di@@ abet@@ es@@ , ket@@ o@@ aci@@ do@@ sis (@@ ket@@ ones in the blood and ur@@ ine@@ ) or com@@ a@@ , low so@@ dium level in the bloo@@ d@@ ; weight ga@@ in@@ , weight los@@ s@@ , an@@ or@@ ex@@ i@@ a@@ ; nerv@@ ous@@ ness@@ , ag@@ it@@ ation@@ , feeling an@@ xi@@ ous@@ ; thoughts of suici@@ de@@ , suicide attempt and suici@@ de@@ ; speech disor@@ der@@ , sei@@ zu@@ re@@ , combination of fe@@ ver@@ , muscle sti@@ ff@@ ness@@ , faster breath@@ ing@@ , swe@@ at@@ ing@@ , reduced consci@@ ousness and sudden changes in blood pressure and heart rat@@ e@@ ; fa@@ int@@ ing@@ , high blood pressu@@ re@@ , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body@@ ; sp@@ asm of the muscles around the voice bo@@ x@@ , acci@@ dental inhal@@ ation of food with risk of p@@ ne@@ um@@ oni@@ a@@ , difficulty in swal@@ low@@ ing@@ ; infl@@ amm@@ ation of the pan@@ cre@@ as@@ ; infl@@ amm@@ ation of the li@@ ver@@ , y@@ el@@ lowing of the skin and white part of ey@@ es@@ , reports of ab@@ normal liver test valu@@ es@@ , ab@@ dom@@ inal and stomach dis@@ comfort@@ , di@@ arr@@ ho@@ e@@ a@@ ; skin ra@@ sh and sensi@@ tivity to light@@ , unusual hair loss or th@@ inn@@ ing@@ , excessive swe@@ at@@ ing@@ ; sti@@ ff@@ ness or cra@@ mp@@ s@@ , muscle pain@@ , weak@@ ness@@ ; invol@@ un@@ tary loss of ur@@ ine@@ , difficulty in passing ur@@ ine@@ ; pro@@ lon@@ ged and@@ / or painful er@@ ec@@ tion@@ ; difficulty controlling core body temperature or over@@ he@@ at@@ ing@@ , chest pain@@ , and sw@@ elling of hand@@ s@@ , an@@ kles or fe@@ et@@ .
In elderly patients with demen@@ ti@@ a@@ , more fatal cases have been reported while taking ari@@ pi@@ pra@@ z@@ ole@@ .
In addi@@ tion@@ , cases of stroke or "@@ mini@@ " stroke have been repor@@ te@@ d.
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
5.
HO@@ W TO ST@@ ORE AB@@ IL@@ I@@ F@@ Y
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use AB@@ IL@@ I@@ F@@ Y after the exp@@ iry date which is stated on the bli@@ ster and on the car@@ ton@@ .
13@@ 9 Store in the original package in order to protect from mo@@ ist@@ ure@@ .
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
These measures will help to protect the environ@@ ment@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AB@@ IL@@ I@@ F@@ Y contains The active substance is ari@@ pi@@ pra@@ z@@ ole@@ .
Each tab@@ let contains 5 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
The other ingredients are la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ , ma@@ i@@ ze star@@ ch@@ , micro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ os@@ e@@ , hydro@@ x@@ y@@ prop@@ yl cell@@ ul@@ os@@ e@@ , magne@@ si@@ um ste@@ ar@@ ate@@ , indi@@ go car@@ mine al@@ uminium lake (@@ E@@ 13@@ 2@@ )@@ .
What AB@@ IL@@ I@@ F@@ Y looks like and cont@@ ents of the pack AB@@ IL@@ I@@ F@@ Y 5 mg tab@@ lets are rec@@ tan@@ gu@@ lar and blu@@ e@@ , marked with A@@ -@@ 00@@ 7 and 5 on one si@@ de.
They are supp@@ lied in per@@ for@@ ated unit dose bli@@ sters packed in car@@ tons containing 14@@ , 28@@ , 49@@ , 56@@ , or 98 tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manu@@ fac@@ tur@@ er Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S. r. l.
Con@@ tra@@ da Fon@@ t@@ ana del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one - Italy
For any information about this medic@@ ine@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ :
Belgi@@ qu@@ e@@ / Belgi@@ ë@@ / Belgien BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Luxem@@ bour@@ g@@ / Luxemburg BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Te@@ л@@ .@@ : + 3@@ 59 800 12 400
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ .@@ : + 36 1 30@@ 1 9@@ 700
Č es@@ k@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 20 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Dan@@ mark BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B T@@ l@@ f@@ : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ V Tel@@ : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B GM@@ B@@ H & CO@@ .
K@@ G@@ AA Tel@@ : + 49 89 12@@ 1 4@@ 2@@ -@@ 0
Nor@@ ge BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y L@@ T@@ D T@@ l@@ f@@ : + 47 67 55 53 50
140 E@@ est@@ i Österreich BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ ES@@ M@@ B@@ H Tel@@ : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ@@ : + 30 210 60@@ 7@@ 4@@ 300
Pol@@ ska BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B P@@ OL@@ S@@ KA SP@@ .
Z O@@ . O@@ .
Tel@@ .@@ : + 48 22 57@@ 9@@ 66@@ 66
E@@ spa@@ ñ@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B@@ , S. A.
Tel@@ : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ U@@ T@@ IC@@ A P@@ OR@@ TU@@ G@@ U@@ ES@@ A@@ , S. A.
Tel@@ : + 3@@ 51 21 4@@ 40 70 00
France BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l@@ : + 33 (@@ 0@@ )@@ 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 40 (@@ 0@@ )@@ 21 27@@ 2 16 00
Ireland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 3@@ 53 (@@ 1 800@@ ) 7@@ 49 7@@ 49
Slo@@ ven@@ i@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 38@@ 6 1 2@@ 36 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R H@@ F S@@ í@@ mi@@ : + 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 21 2 59@@ 29@@ 8@@ 4@@ 11
Itali@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Su@@ omi@@ / Fin@@ land O@@ Y BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B (@@ F@@ IN@@ L@@ AND@@ ) AB Pu@@ h@@ / Tel@@ : + 3@@ 58 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ & Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ@@ : + 3@@ 57 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B AB Tel@@ : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 44 (@@ 08@@ 00@@ ) 7@@ 31 17@@ 36
Lie@@ tu@@ va BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 370 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
14@@ 1 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AB@@ IL@@ I@@ F@@ Y 10 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
This medicine has been prescri@@ bed for you@@ .
Do not pass it on to o@@ ther@@ s.
It may harm them@@ , even if their symptoms are the same as yo@@ urs@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
In this le@@ af@@ let@@ :
1.
What AB@@ IL@@ I@@ F@@ Y is and what it is used for 2.
Before you take AB@@ IL@@ I@@ F@@ Y 3.
How to take AB@@ IL@@ I@@ F@@ Y 4.
Pos@@ sible side effects 5 How to store AB@@ IL@@ I@@ F@@ Y 6.
Further information
1.
WH@@ AT AB@@ IL@@ I@@ F@@ Y IS AND WH@@ AT IT IS US@@ ED FO@@ R
AB@@ IL@@ I@@ F@@ Y is one of a group of medic@@ ines called anti@@ p@@ sycho@@ tic@@ s.
It is used to treat adults who suffer from a disease character@@ ised by symptoms such as hear@@ ing@@ , seeing or sen@@ sing things which are not ther@@ e@@ , suspici@@ ous@@ ness@@ , mistak@@ en belie@@ fs@@ , in@@ co@@ her@@ ent speech and behaviour and emotional flat@@ ness@@ .
People with this condition may also feel depres@@ se@@ d@@ , guil@@ ty@@ , anxious or ten@@ se@@ .
AB@@ IL@@ I@@ F@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling "@@ high@@ "@@ , having excessive amounts of energ@@ y@@ , nee@@ ding much less sleep than us@@ u@@ al@@ , talking very quickly with racing ideas and sometimes severe irrit@@ abili@@ ty@@ .
It also prev@@ ents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ I@@ F@@ Y@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Do not take AB@@ IL@@ I@@ F@@ Y if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ I@@ F@@ Y@@ .
Take special care with AB@@ IL@@ I@@ F@@ Y Before treatment with AB@@ IL@@ I@@ F@@ Y@@ , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ volun@@ tar@@ y@@ , ir@@ regular muscle mov@@ em@@ ent@@ s@@ , especially in the face Cardi@@ ov@@ as@@ cular dise@@ as@@ es@@ , family history of cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ , stroke or "@@ mini@@ " stro@@ ke@@ , ab@@ normal blood pressure
If you notice you are gaining wei@@ ght@@ , experience any difficulty in swal@@ lowing or aller@@ gic symp@@ tom@@ s@@ , please tell your do@@ ct@@ or@@ .
If you are an elderly patient suffering from dementia (@@ loss of memory and other mental abili@@ ti@@ es@@ )@@ , you or your car@@ er@@ / relative should tell your doctor if you have ever had a stroke or "@@ mini@@ " stro@@ ke@@ .
T@@ ell your doctor immediately if you are having any thoughts or feelings about hur@@ ting your@@ sel@@ f@@ .
Su@@ ici@@ dal thoughts and behavi@@ ours have been reported during ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
14@@ 2 T@@ ell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ le@@ xi@@ bility with high fe@@ ver@@ , swe@@ at@@ ing@@ , al@@ tered mental stat@@ us@@ , or very rapid or ir@@ regular heart be@@ at@@ .
Children and adol@@ es@@ cents AB@@ IL@@ I@@ F@@ Y is not for use in children and adol@@ es@@ cents as it has not been studied in patients under 18 ye@@ ar@@ s.
As@@ k your doctor or pharmac@@ ist for advice before taking AB@@ IL@@ I@@ F@@ Y@@ .
Taking other medic@@ ines Please tell your doctor or pharmac@@ ist if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
Bloo@@ d pressu@@ re@@ -@@ lo@@ wering medi@@ cin@@ es@@ :
AB@@ IL@@ I@@ F@@ Y may increase the effect of medic@@ ines used to lower the blood pressu@@ re@@ .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under contro@@ l.
Taking AB@@ IL@@ I@@ F@@ Y with some medic@@ ines may need to change your dose of AB@@ IL@@ I@@ F@@ Y@@ .
It is especially important to mention the following to your do@@ ct@@ or@@ :
Medic@@ ines to correct heart rhyth@@ m Anti@@ depres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and anxiety Anti@@ f@@ ung@@ al agents Cer@@ tain medic@@ ines to treat HIV infection Anti@@ con@@ vul@@ s@@ ants used to treat ep@@ ile@@ p@@ sy
Taking AB@@ IL@@ I@@ F@@ Y with food and drink AB@@ IL@@ I@@ F@@ Y can be taken regardless of me@@ al@@ s.
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ I@@ F@@ Y@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ I@@ F@@ Y if you are pregnant unless you have discussed this with your do@@ ct@@ or@@ .
Be sure to tell your doctor immediately if you are pregn@@ ant@@ , think you may be pregn@@ ant@@ , or if you are planning to become pregn@@ ant@@ .
Bre@@ ast@@ -@@ feeding mothers should not take AB@@ IL@@ I@@ F@@ Y@@ .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
Dri@@ ving and using machines Do not drive or use any tools or mach@@ in@@ es@@ , until you know how AB@@ IL@@ I@@ F@@ Y affects you@@ .
Imp@@ ort@@ ant information about some of the ingredients of AB@@ IL@@ I@@ F@@ Y If you have been told by your doctor that you have an int@@ oler@@ ance to some su@@ gar@@ s@@ , contact your doctor before taking this medic@@ ine@@ .
3.
HO@@ W TO T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Al@@ ways take AB@@ IL@@ I@@ F@@ Y exactly as your doctor has told you@@ .
You should check with your doctor or pharmac@@ ist if you are not su@@ re@@ .
The usual dose is 15 mg once a day@@ .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg once a day@@ .
If you have the impression that the effect of AB@@ IL@@ I@@ F@@ Y is too strong or too weak@@ , talk to your doctor or pharmac@@ ist@@ .
T@@ ry to take the AB@@ IL@@ I@@ F@@ Y tab@@ let at the same time each day@@ .
It does not matter whether you take it with or without f@@ ood@@ .
Al@@ ways take the tab@@ let with water and swal@@ low it whol@@ e@@ .
14@@ 3 Even if you feel bet@@ ter@@ , do not alter or dis@@ continue the daily dose of AB@@ IL@@ I@@ F@@ Y without first consul@@ ting your do@@ ct@@ or@@ .
If you take more AB@@ IL@@ I@@ F@@ Y than you should If you realise you have taken more AB@@ IL@@ I@@ F@@ Y tab@@ lets than your doctor has recommended (@@ or if someone else has taken some of your AB@@ IL@@ I@@ F@@ Y tab@@ le@@ ts@@ )@@ , contact your doctor right a@@ wa@@ y@@ .
If you cannot reach your do@@ ct@@ or@@ , go to the near@@ est hospital and take the pack with you@@ .
If you forget to take AB@@ IL@@ I@@ F@@ Y If you miss a d@@ os@@ e@@ , take the missed dose as soon as you remember but do not take two d@@ oses in one day@@ .
If you have any further questions on the use of this produc@@ t@@ , ask your doctor or pharmac@@ ist@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AB@@ IL@@ I@@ F@@ Y can cause side effec@@ ts@@ , although not everybody gets them@@ .
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) Un@@ contro@@ ll@@ able twi@@ t@@ ching or jer@@ king mov@@ em@@ ent@@ s@@ , hea@@ da@@ che@@ , ti@@ re@@ dn@@ ess@@ , nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , an uncomfortable feeling in the stom@@ ach@@ , con@@ sti@@ p@@ ation@@ , increased production of s@@ ali@@ v@@ a@@ , light@@ -@@ he@@ ade@@ dn@@ ess@@ , trouble sle@@ ep@@ ing@@ , rest@@ less@@ ness@@ , feeling an@@ xi@@ ous@@ , sle@@ ep@@ in@@ ess@@ , sha@@ king and bl@@ urred visi@@ on@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ .
Some people may feel depres@@ se@@ d.
Other in@@ frequently reported side effec@@ ts@@ :
Ch@@ ang@@ es in the levels of some blood cell@@ s@@ ; unusual heart be@@ at@@ , sudden un@@ explained de@@ ath@@ , heart attack@@ ; aller@@ gic reaction (@@ e@@ . g. sw@@ elling in the mou@@ th@@ , ton@@ gu@@ e@@ , face and thro@@ at@@ , it@@ ch@@ ing@@ , ra@@ sh@@ )@@ ; high blood su@@ gar@@ , on@@ set or wor@@ sen@@ ing of di@@ abet@@ es@@ , ket@@ o@@ aci@@ do@@ sis (@@ ket@@ ones in the blood and ur@@ ine@@ ) or com@@ a@@ , low so@@ dium level in the bloo@@ d@@ ; weight ga@@ in@@ , weight los@@ s@@ , an@@ or@@ ex@@ i@@ a@@ ; nerv@@ ous@@ ness@@ , ag@@ it@@ ation@@ , feeling an@@ xi@@ ous@@ ; thoughts of suici@@ de@@ , suicide attempt and suici@@ de@@ ; speech disor@@ der@@ , sei@@ zu@@ re@@ , combination of fe@@ ver@@ , muscle sti@@ ff@@ ness@@ , faster breath@@ ing@@ , swe@@ at@@ ing@@ , reduced consci@@ ousness and sudden changes in blood pressure and heart rat@@ e@@ ; fa@@ int@@ ing@@ , high blood pressu@@ re@@ , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body@@ ; sp@@ asm of the muscles around the voice bo@@ x@@ , acci@@ dental inhal@@ ation of food with risk of p@@ ne@@ um@@ oni@@ a@@ , difficulty in swal@@ low@@ ing@@ ; infl@@ amm@@ ation of the pan@@ cre@@ as@@ ; infl@@ amm@@ ation of the li@@ ver@@ , y@@ el@@ lowing of the skin and white part of ey@@ es@@ , reports of ab@@ normal liver test valu@@ es@@ , ab@@ dom@@ inal and stomach dis@@ comfort@@ , di@@ arr@@ ho@@ e@@ a@@ ; skin ra@@ sh and sensi@@ tivity to light@@ , unusual hair loss or th@@ inn@@ ing@@ , excessive swe@@ at@@ ing@@ ; sti@@ ff@@ ness or cra@@ mp@@ s@@ , muscle pain@@ , weak@@ ness@@ ; invol@@ un@@ tary loss of ur@@ ine@@ , difficulty in passing ur@@ ine@@ ; pro@@ lon@@ ged and@@ / or painful er@@ ec@@ tion@@ ; difficulty controlling core body temperature or over@@ he@@ at@@ ing@@ , chest pain@@ , and sw@@ elling of hand@@ s@@ , an@@ kles or fe@@ et@@ .
In elderly patients with demen@@ ti@@ a@@ , more fatal cases have been reported while taking ari@@ pi@@ pra@@ z@@ ole@@ .
In addi@@ tion@@ , cases of stroke or "@@ mini@@ " stroke have been repor@@ te@@ d.
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
5.
HO@@ W TO ST@@ ORE AB@@ IL@@ I@@ F@@ Y
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use AB@@ IL@@ I@@ F@@ Y after the exp@@ iry date which is stated on the bli@@ ster and on the car@@ ton@@ .
14@@ 4 Store in the original package in order to protect from mo@@ ist@@ ure@@ .
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
These measures will help to protect the environ@@ ment@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AB@@ IL@@ I@@ F@@ Y contains The active substance is ari@@ pi@@ pra@@ z@@ ole@@ .
Each tab@@ let contains 10 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
The other ingredients are la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ , ma@@ i@@ ze star@@ ch@@ , micro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ os@@ e@@ , hydro@@ x@@ y@@ prop@@ yl cell@@ ul@@ os@@ e@@ , magne@@ si@@ um ste@@ ar@@ ate@@ , red iron oxide (@@ E@@ 17@@ 2@@ )@@ .
What AB@@ IL@@ I@@ F@@ Y looks like and cont@@ ents of the pack AB@@ IL@@ I@@ F@@ Y 10 mg tab@@ lets are rec@@ tan@@ gu@@ lar and p@@ ink@@ , marked with A@@ -@@ 00@@ 8 and 10 on one si@@ de.
They are supp@@ lied in per@@ for@@ ated unit dose bli@@ sters packed in car@@ tons containing 14@@ , 28@@ , 49@@ , 56@@ , or 98 tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manu@@ fac@@ tur@@ er Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S. r. l.
Con@@ tra@@ da Fon@@ t@@ ana del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one - Italy
For any information about this medic@@ ine@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ :
Belgi@@ qu@@ e@@ / Belgi@@ ë@@ / Belgien BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Luxem@@ bour@@ g@@ / Luxemburg BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Te@@ л@@ .@@ : + 3@@ 59 800 12 400
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ .@@ : + 36 1 30@@ 1 9@@ 700
Č es@@ k@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 20 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Dan@@ mark BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B T@@ l@@ f@@ : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ V Tel@@ : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B GM@@ B@@ H & CO@@ .
K@@ G@@ AA Tel@@ : + 49 89 12@@ 1 4@@ 2@@ -@@ 0
Nor@@ ge BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y L@@ T@@ D T@@ l@@ f@@ : + 47 67 55 53 50
14@@ 5 E@@ est@@ i Österreich BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ ES@@ M@@ B@@ H Tel@@ : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ@@ : + 30 210 60@@ 7@@ 4@@ 300
Pol@@ ska BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B P@@ OL@@ S@@ KA SP@@ .
Z O@@ . O@@ .
Tel@@ .@@ : + 48 22 57@@ 9@@ 66@@ 66
E@@ spa@@ ñ@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B@@ , S. A.
Tel@@ : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ U@@ T@@ IC@@ A P@@ OR@@ TU@@ G@@ U@@ ES@@ A@@ , S. A.
Tel@@ : + 3@@ 51 21 4@@ 40 70 00
France BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l@@ : + 33 (@@ 0@@ )@@ 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 40 (@@ 0@@ )@@ 21 27@@ 2 16 00
Ireland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 3@@ 53 (@@ 1 800@@ ) 7@@ 49 7@@ 49
Slo@@ ven@@ i@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 38@@ 6 1 2@@ 36 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R H@@ F S@@ í@@ mi@@ : + 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 21 2 59@@ 29@@ 8@@ 4@@ 11
Itali@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Su@@ omi@@ / Fin@@ land O@@ Y BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B (@@ F@@ IN@@ L@@ AND@@ ) AB Pu@@ h@@ / Tel@@ : + 3@@ 58 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ & Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ@@ : + 3@@ 57 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B AB Tel@@ : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 44 (@@ 08@@ 00@@ ) 7@@ 31 17@@ 36
Lie@@ tu@@ va BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 370 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
14@@ 6 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AB@@ IL@@ I@@ F@@ Y 15 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
This medicine has been prescri@@ bed for you@@ .
Do not pass it on to o@@ ther@@ s.
It may harm them@@ , even if their symptoms are the same as yo@@ urs@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
In this le@@ af@@ let@@ :
1.
What AB@@ IL@@ I@@ F@@ Y is and what it is used for 2.
Before you take AB@@ IL@@ I@@ F@@ Y 3.
How to take AB@@ IL@@ I@@ F@@ Y 4.
Pos@@ sible side effects 5 How to store AB@@ IL@@ I@@ F@@ Y 6.
Further information
1.
WH@@ AT AB@@ IL@@ I@@ F@@ Y IS AND WH@@ AT IT IS US@@ ED FO@@ R
AB@@ IL@@ I@@ F@@ Y is one of a group of medic@@ ines called anti@@ p@@ sycho@@ tic@@ s.
It is used to treat adults who suffer from a disease character@@ ised by symptoms such as hear@@ ing@@ , seeing or sen@@ sing things which are not ther@@ e@@ , suspici@@ ous@@ ness@@ , mistak@@ en belie@@ fs@@ , in@@ co@@ her@@ ent speech and behaviour and emotional flat@@ ness@@ .
People with this condition may also feel depres@@ se@@ d@@ , guil@@ ty@@ , anxious or ten@@ se@@ .
AB@@ IL@@ I@@ F@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling "@@ high@@ "@@ , having excessive amounts of energ@@ y@@ , nee@@ ding much less sleep than us@@ u@@ al@@ , talking very quickly with racing ideas and sometimes severe irrit@@ abili@@ ty@@ .
It also prev@@ ents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ I@@ F@@ Y@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Do not take AB@@ IL@@ I@@ F@@ Y if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ I@@ F@@ Y@@ .
Take special care with AB@@ IL@@ I@@ F@@ Y Before treatment with AB@@ IL@@ I@@ F@@ Y@@ , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ volun@@ tar@@ y@@ , ir@@ regular muscle mov@@ em@@ ent@@ s@@ , especially in the face Cardi@@ ov@@ as@@ cular dise@@ as@@ es@@ , family history of cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ , stroke or "@@ mini@@ " stro@@ ke@@ , ab@@ normal blood pressure
If you notice you are gaining wei@@ ght@@ , experience any difficulty in swal@@ lowing or aller@@ gic symp@@ tom@@ s@@ , please tell your do@@ ct@@ or@@ .
If you are an elderly patient suffering from dementia (@@ loss of memory and other mental abili@@ ti@@ es@@ )@@ , you or your car@@ er@@ / relative should tell your doctor if you have ever had a stroke or "@@ mini@@ " stro@@ ke@@ .
T@@ ell your doctor immediately if you are having any thoughts or feelings about hur@@ ting your@@ sel@@ f@@ .
Su@@ ici@@ dal thoughts and behavi@@ ours have been reported during ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
14@@ 7 T@@ ell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ le@@ xi@@ bility with high fe@@ ver@@ , swe@@ at@@ ing@@ , al@@ tered mental stat@@ us@@ , or very rapid or ir@@ regular heart be@@ at@@ .
Children and adol@@ es@@ cents AB@@ IL@@ I@@ F@@ Y is not for use in children and adol@@ es@@ cents as it has not been studied in patients under 18 ye@@ ar@@ s.
As@@ k your doctor or pharmac@@ ist for advice before taking AB@@ IL@@ I@@ F@@ Y@@ .
Taking other medic@@ ines Please tell your doctor or pharmac@@ ist if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
Bloo@@ d pressu@@ re@@ -@@ lo@@ wering medi@@ cin@@ es@@ :
AB@@ IL@@ I@@ F@@ Y may increase the effect of medic@@ ines used to lower the blood pressu@@ re@@ .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under contro@@ l.
Taking AB@@ IL@@ I@@ F@@ Y with some medic@@ ines may need to change your dose of AB@@ IL@@ I@@ F@@ Y@@ .
It is especially important to mention the following to your do@@ ct@@ or@@ :
Medic@@ ines to correct heart rhyth@@ m Anti@@ depres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and anxiety Anti@@ f@@ ung@@ al agents Cer@@ tain medic@@ ines to treat HIV infection Anti@@ con@@ vul@@ s@@ ants used to treat ep@@ ile@@ p@@ sy
Taking AB@@ IL@@ I@@ F@@ Y with food and drink AB@@ IL@@ I@@ F@@ Y can be taken regardless of me@@ al@@ s.
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ I@@ F@@ Y@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ I@@ F@@ Y if you are pregnant unless you have discussed this with your do@@ ct@@ or@@ .
Be sure to tell your doctor immediately if you are pregn@@ ant@@ , think you may be pregn@@ ant@@ , or if you are planning to become pregn@@ ant@@ .
Bre@@ ast@@ -@@ feeding mothers should not take AB@@ IL@@ I@@ F@@ Y@@ .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
Dri@@ ving and using machines Do not drive or use any tools or mach@@ in@@ es@@ , until you know how AB@@ IL@@ I@@ F@@ Y affects you@@ .
Imp@@ ort@@ ant information about some of the ingredients of AB@@ IL@@ I@@ F@@ Y If you have been told by your doctor that you have an int@@ oler@@ ance to some su@@ gar@@ s@@ , contact your doctor before taking this medic@@ ine@@ .
3.
HO@@ W TO T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Al@@ ways take AB@@ IL@@ I@@ F@@ Y exactly as your doctor has told you@@ .
You should check with your doctor or pharmac@@ ist if you are not su@@ re@@ .
The usual dose is 15 mg once a day@@ .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg once a day@@ .
If you have the impression that the effect of AB@@ IL@@ I@@ F@@ Y is too strong or too weak@@ , talk to your doctor or pharmac@@ ist@@ .
T@@ ry to take the AB@@ IL@@ I@@ F@@ Y tab@@ let at the same time each day@@ .
It does not matter whether you take it with or without f@@ ood@@ .
Al@@ ways take the tab@@ let with water and swal@@ low it whol@@ e@@ .
14@@ 8 Even if you feel bet@@ ter@@ , do not alter or dis@@ continue the daily dose of AB@@ IL@@ I@@ F@@ Y without first consul@@ ting your do@@ ct@@ or@@ .
If you take more AB@@ IL@@ I@@ F@@ Y than you should If you realise you have taken more AB@@ IL@@ I@@ F@@ Y tab@@ lets than your doctor has recommended (@@ or if someone else has taken some of your AB@@ IL@@ I@@ F@@ Y tab@@ le@@ ts@@ )@@ , contact your doctor right a@@ wa@@ y@@ .
If you cannot reach your do@@ ct@@ or@@ , go to the near@@ est hospital and take the pack with you@@ .
If you forget to take AB@@ IL@@ I@@ F@@ Y If you miss a d@@ os@@ e@@ , take the missed dose as soon as you remember but do not take two d@@ oses in one day@@ .
If you have any further questions on the use of this produc@@ t@@ , ask your doctor or pharmac@@ ist@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AB@@ IL@@ I@@ F@@ Y can cause side effec@@ ts@@ , although not everybody gets them@@ .
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) Un@@ contro@@ ll@@ able twi@@ t@@ ching or jer@@ king mov@@ em@@ ent@@ s@@ , hea@@ da@@ che@@ , ti@@ re@@ dn@@ ess@@ , nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , an uncomfortable feeling in the stom@@ ach@@ , con@@ sti@@ p@@ ation@@ , increased production of s@@ ali@@ v@@ a@@ , light@@ -@@ he@@ ade@@ dn@@ ess@@ , trouble sle@@ ep@@ ing@@ , rest@@ less@@ ness@@ , feeling an@@ xi@@ ous@@ , sle@@ ep@@ in@@ ess@@ , sha@@ king and bl@@ urred visi@@ on@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ .
Some people may feel depres@@ se@@ d.
Other in@@ frequently reported side effec@@ ts@@ :
Ch@@ ang@@ es in the levels of some blood cell@@ s@@ ; unusual heart be@@ at@@ , sudden un@@ explained de@@ ath@@ , heart attack@@ ; aller@@ gic reaction (@@ e@@ . g. sw@@ elling in the mou@@ th@@ , ton@@ gu@@ e@@ , face and thro@@ at@@ , it@@ ch@@ ing@@ , ra@@ sh@@ )@@ ; high blood su@@ gar@@ , on@@ set or wor@@ sen@@ ing of di@@ abet@@ es@@ , ket@@ o@@ aci@@ do@@ sis (@@ ket@@ ones in the blood and ur@@ ine@@ ) or com@@ a@@ , low so@@ dium level in the bloo@@ d@@ ; weight ga@@ in@@ , weight los@@ s@@ , an@@ or@@ ex@@ i@@ a@@ ; nerv@@ ous@@ ness@@ , ag@@ it@@ ation@@ , feeling an@@ xi@@ ous@@ ; thoughts of suici@@ de@@ , suicide attempt and suici@@ de@@ ; speech disor@@ der@@ , sei@@ zu@@ re@@ , combination of fe@@ ver@@ , muscle sti@@ ff@@ ness@@ , faster breath@@ ing@@ , swe@@ at@@ ing@@ , reduced consci@@ ousness and sudden changes in blood pressure and heart rat@@ e@@ ; fa@@ int@@ ing@@ , high blood pressu@@ re@@ , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body@@ ; sp@@ asm of the muscles around the voice bo@@ x@@ , acci@@ dental inhal@@ ation of food with risk of p@@ ne@@ um@@ oni@@ a@@ , difficulty in swal@@ low@@ ing@@ ; infl@@ amm@@ ation of the pan@@ cre@@ as@@ ; infl@@ amm@@ ation of the li@@ ver@@ , y@@ el@@ lowing of the skin and white part of ey@@ es@@ , reports of ab@@ normal liver test valu@@ es@@ , ab@@ dom@@ inal and stomach dis@@ comfort@@ , di@@ arr@@ ho@@ e@@ a@@ ; skin ra@@ sh and sensi@@ tivity to light@@ , unusual hair loss or th@@ inn@@ ing@@ , excessive swe@@ at@@ ing@@ ; sti@@ ff@@ ness or cra@@ mp@@ s@@ , muscle pain@@ , weak@@ ness@@ ; invol@@ un@@ tary loss of ur@@ ine@@ , difficulty in passing ur@@ ine@@ ; pro@@ lon@@ ged and@@ / or painful er@@ ec@@ tion@@ ; difficulty controlling core body temperature or over@@ he@@ at@@ ing@@ , chest pain@@ , and sw@@ elling of hand@@ s@@ , an@@ kles or fe@@ et@@ .
In elderly patients with demen@@ ti@@ a@@ , more fatal cases have been reported while taking ari@@ pi@@ pra@@ z@@ ole@@ .
In addi@@ tion@@ , cases of stroke or "@@ mini@@ " stroke have been repor@@ te@@ d.
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
5.
HO@@ W TO ST@@ ORE AB@@ IL@@ I@@ F@@ Y
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use AB@@ IL@@ I@@ F@@ Y after the exp@@ iry date which is stated on the bli@@ ster and on the car@@ ton@@ .
14@@ 9 Store in the original package in order to protect from mo@@ ist@@ ure@@ .
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
These measures will help to protect the environ@@ ment@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AB@@ IL@@ I@@ F@@ Y contains The active substance is ari@@ pi@@ pra@@ z@@ ole@@ .
Each tab@@ let contains 15 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
The other ingredients are la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ , ma@@ i@@ ze star@@ ch@@ , micro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ os@@ e@@ , hydro@@ x@@ y@@ prop@@ yl cell@@ ul@@ os@@ e@@ , magne@@ si@@ um ste@@ ar@@ ate@@ , yellow iron oxide (@@ E@@ 17@@ 2@@ )@@ .
What AB@@ IL@@ I@@ F@@ Y looks like and cont@@ ents of the pack AB@@ IL@@ I@@ F@@ Y 15 mg tab@@ lets are round and y@@ el@@ low@@ , marked with A@@ -@@ 00@@ 9 and 15 on one si@@ de.
They are supp@@ lied in per@@ for@@ ated unit dose bli@@ sters packed in car@@ tons containing 14@@ , 28@@ , 49@@ , 56@@ , or 98 tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manu@@ fac@@ tur@@ er Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S. r. l.
Con@@ tra@@ da Fon@@ t@@ ana del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one - Italy
For any information about this medic@@ ine@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ :
Belgi@@ qu@@ e@@ / Belgi@@ ë@@ / Belgien BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Luxem@@ bour@@ g@@ / Luxemburg BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Te@@ л@@ .@@ : + 3@@ 59 800 12 400
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ .@@ : + 36 1 30@@ 1 9@@ 700
Č es@@ k@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 20 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Dan@@ mark BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B T@@ l@@ f@@ : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ V Tel@@ : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B GM@@ B@@ H & CO@@ .
K@@ G@@ AA Tel@@ : + 49 89 12@@ 1 4@@ 2@@ -@@ 0
Nor@@ ge BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y L@@ T@@ D T@@ l@@ f@@ : + 47 67 55 53 50
150 E@@ est@@ i Österreich BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ ES@@ M@@ B@@ H Tel@@ : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ@@ : + 30 210 60@@ 7@@ 4@@ 300
Pol@@ ska BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B P@@ OL@@ S@@ KA SP@@ .
Z O@@ . O@@ .
Tel@@ .@@ : + 48 22 57@@ 9@@ 66@@ 66
E@@ spa@@ ñ@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B@@ , S. A.
Tel@@ : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ U@@ T@@ IC@@ A P@@ OR@@ TU@@ G@@ U@@ ES@@ A@@ , S. A.
Tel@@ : + 3@@ 51 21 4@@ 40 70 00
France BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l@@ : + 33 (@@ 0@@ )@@ 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 40 (@@ 0@@ )@@ 21 27@@ 2 16 00
Ireland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 3@@ 53 (@@ 1 800@@ ) 7@@ 49 7@@ 49
Slo@@ ven@@ i@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 38@@ 6 1 2@@ 36 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R H@@ F S@@ í@@ mi@@ : + 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 21 2 59@@ 29@@ 8@@ 4@@ 11
Itali@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Su@@ omi@@ / Fin@@ land O@@ Y BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B (@@ F@@ IN@@ L@@ AND@@ ) AB Pu@@ h@@ / Tel@@ : + 3@@ 58 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ & Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ@@ : + 3@@ 57 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B AB Tel@@ : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 44 (@@ 08@@ 00@@ ) 7@@ 31 17@@ 36
Lie@@ tu@@ va BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 370 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
15@@ 1 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AB@@ IL@@ I@@ F@@ Y 30 mg tab@@ lets ari@@ pi@@ pra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
This medicine has been prescri@@ bed for you@@ .
Do not pass it on to o@@ ther@@ s.
It may harm them@@ , even if their symptoms are the same as yo@@ urs@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
In this le@@ af@@ let@@ :
1.
What AB@@ IL@@ I@@ F@@ Y is and what it is used for 2.
Before you take AB@@ IL@@ I@@ F@@ Y 3.
How to take AB@@ IL@@ I@@ F@@ Y 4.
Pos@@ sible side effects 5 How to store AB@@ IL@@ I@@ F@@ Y 6.
Further information
1.
WH@@ AT AB@@ IL@@ I@@ F@@ Y IS AND WH@@ AT IT IS US@@ ED FO@@ R
AB@@ IL@@ I@@ F@@ Y is one of a group of medic@@ ines called anti@@ p@@ sycho@@ tic@@ s.
It is used to treat adults who suffer from a disease character@@ ised by symptoms such as hear@@ ing@@ , seeing or sen@@ sing things which are not ther@@ e@@ , suspici@@ ous@@ ness@@ , mistak@@ en belie@@ fs@@ , in@@ co@@ her@@ ent speech and behaviour and emotional flat@@ ness@@ .
People with this condition may also feel depres@@ se@@ d@@ , guil@@ ty@@ , anxious or ten@@ se@@ .
AB@@ IL@@ I@@ F@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling "@@ high@@ "@@ , having excessive amounts of energ@@ y@@ , nee@@ ding much less sleep than us@@ u@@ al@@ , talking very quickly with racing ideas and sometimes severe irrit@@ abili@@ ty@@ .
It also prev@@ ents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ I@@ F@@ Y@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Do not take AB@@ IL@@ I@@ F@@ Y if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ I@@ F@@ Y@@ .
Take special care with AB@@ IL@@ I@@ F@@ Y Before treatment with AB@@ IL@@ I@@ F@@ Y@@ , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ volun@@ tar@@ y@@ , ir@@ regular muscle mov@@ em@@ ent@@ s@@ , especially in the face Cardi@@ ov@@ as@@ cular dise@@ as@@ es@@ , family history of cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ , stroke or "@@ mini@@ " stro@@ ke@@ , ab@@ normal blood pressure
If you notice you are gaining wei@@ ght@@ , experience any difficulty in swal@@ lowing or aller@@ gic symp@@ tom@@ s@@ , please tell your do@@ ct@@ or@@ .
If you are an elderly patient suffering from dementia (@@ loss of memory and other mental abili@@ ti@@ es@@ )@@ , you or your car@@ er@@ / relative should tell your doctor if you have ever had a stroke or "@@ mini@@ " stro@@ ke@@ .
T@@ ell your doctor immediately if you are having any thoughts or feelings about hur@@ ting your@@ sel@@ f@@ .
Su@@ ici@@ dal thoughts and behavi@@ ours have been reported during ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
15@@ 2 T@@ ell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ le@@ xi@@ bility with high fe@@ ver@@ , swe@@ at@@ ing@@ , al@@ tered mental stat@@ us@@ , or very rapid or ir@@ regular heart be@@ at@@ .
Children and adol@@ es@@ cents AB@@ IL@@ I@@ F@@ Y is not for use in children and adol@@ es@@ cents as it has not been studied in patients under 18 ye@@ ar@@ s.
As@@ k your doctor or pharmac@@ ist for advice before taking AB@@ IL@@ I@@ F@@ Y@@ .
Taking other medic@@ ines Please tell your doctor or pharmac@@ ist if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
Bloo@@ d pressu@@ re@@ -@@ lo@@ wering medi@@ cin@@ es@@ :
AB@@ IL@@ I@@ F@@ Y may increase the effect of medic@@ ines used to lower the blood pressu@@ re@@ .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under contro@@ l.
Taking AB@@ IL@@ I@@ F@@ Y with some medic@@ ines may need to change your dose of AB@@ IL@@ I@@ F@@ Y@@ .
It is especially important to mention the following to your do@@ ct@@ or@@ :
Medic@@ ines to correct heart rhyth@@ m Anti@@ depres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and anxiety Anti@@ f@@ ung@@ al agents Cer@@ tain medic@@ ines to treat HIV infection Anti@@ con@@ vul@@ s@@ ants used to treat ep@@ ile@@ p@@ sy
Taking AB@@ IL@@ I@@ F@@ Y with food and drink AB@@ IL@@ I@@ F@@ Y can be taken regardless of me@@ al@@ s.
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ I@@ F@@ Y@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ I@@ F@@ Y if you are pregnant unless you have discussed this with your do@@ ct@@ or@@ .
Be sure to tell your doctor immediately if you are pregn@@ ant@@ , think you may be pregn@@ ant@@ , or if you are planning to become pregn@@ ant@@ .
Bre@@ ast@@ -@@ feeding mothers should not take AB@@ IL@@ I@@ F@@ Y@@ .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
Dri@@ ving and using machines Do not drive or use any tools or mach@@ in@@ es@@ , until you know how AB@@ IL@@ I@@ F@@ Y affects you@@ .
Imp@@ ort@@ ant information about some of the ingredients of AB@@ IL@@ I@@ F@@ Y If you have been told by your doctor that you have an int@@ oler@@ ance to some su@@ gar@@ s@@ , contact your doctor before taking this medic@@ ine@@ .
3.
HO@@ W TO T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Al@@ ways take AB@@ IL@@ I@@ F@@ Y exactly as your doctor has told you@@ .
You should check with your doctor or pharmac@@ ist if you are not su@@ re@@ .
The usual dose is 15 mg once a day@@ .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg once a day@@ .
If you have the impression that the effect of AB@@ IL@@ I@@ F@@ Y is too strong or too weak@@ , talk to your doctor or pharmac@@ ist@@ .
T@@ ry to take the AB@@ IL@@ I@@ F@@ Y tab@@ let at the same time each day@@ .
It does not matter whether you take it with or without f@@ ood@@ .
Al@@ ways take the tab@@ let with water and swal@@ low it whol@@ e@@ .
15@@ 3 Even if you feel bet@@ ter@@ , do not alter or dis@@ continue the daily dose of AB@@ IL@@ I@@ F@@ Y without first consul@@ ting your do@@ ct@@ or@@ .
If you take more AB@@ IL@@ I@@ F@@ Y than you should If you realise you have taken more AB@@ IL@@ I@@ F@@ Y tab@@ lets than your doctor has recommended (@@ or if someone else has taken some of your AB@@ IL@@ I@@ F@@ Y tab@@ le@@ ts@@ )@@ , contact your doctor right a@@ wa@@ y@@ .
If you cannot reach your do@@ ct@@ or@@ , go to the near@@ est hospital and take the pack with you@@ .
If you forget to take AB@@ IL@@ I@@ F@@ Y If you miss a d@@ os@@ e@@ , take the missed dose as soon as you remember but do not take two d@@ oses in one day@@ .
If you have any further questions on the use of this produc@@ t@@ , ask your doctor or pharmac@@ ist@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AB@@ IL@@ I@@ F@@ Y can cause side effec@@ ts@@ , although not everybody gets them@@ .
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) Un@@ contro@@ ll@@ able twi@@ t@@ ching or jer@@ king mov@@ em@@ ent@@ s@@ , hea@@ da@@ che@@ , ti@@ re@@ dn@@ ess@@ , nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , an uncomfortable feeling in the stom@@ ach@@ , con@@ sti@@ p@@ ation@@ , increased production of s@@ ali@@ v@@ a@@ , light@@ -@@ he@@ ade@@ dn@@ ess@@ , trouble sle@@ ep@@ ing@@ , rest@@ less@@ ness@@ , feeling an@@ xi@@ ous@@ , sle@@ ep@@ in@@ ess@@ , sha@@ king and bl@@ urred visi@@ on@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ .
Some people may feel depres@@ se@@ d.
Other in@@ frequently reported side effec@@ ts@@ :
Ch@@ ang@@ es in the levels of some blood cell@@ s@@ ; unusual heart be@@ at@@ , sudden un@@ explained de@@ ath@@ , heart attack@@ ; aller@@ gic reaction (@@ e@@ . g. sw@@ elling in the mou@@ th@@ , ton@@ gu@@ e@@ , face and thro@@ at@@ , it@@ ch@@ ing@@ , ra@@ sh@@ )@@ ; high blood su@@ gar@@ , on@@ set or wor@@ sen@@ ing of di@@ abet@@ es@@ , ket@@ o@@ aci@@ do@@ sis (@@ ket@@ ones in the blood and ur@@ ine@@ ) or com@@ a@@ , low so@@ dium level in the bloo@@ d@@ ; weight ga@@ in@@ , weight los@@ s@@ , an@@ or@@ ex@@ i@@ a@@ ; nerv@@ ous@@ ness@@ , ag@@ it@@ ation@@ , feeling an@@ xi@@ ous@@ ; thoughts of suici@@ de@@ , suicide attempt and suici@@ de@@ ; speech disor@@ der@@ , sei@@ zu@@ re@@ , combination of fe@@ ver@@ , muscle sti@@ ff@@ ness@@ , faster breath@@ ing@@ , swe@@ at@@ ing@@ , reduced consci@@ ousness and sudden changes in blood pressure and heart rat@@ e@@ ; fa@@ int@@ ing@@ , high blood pressu@@ re@@ , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body@@ ; sp@@ asm of the muscles around the voice bo@@ x@@ , acci@@ dental inhal@@ ation of food with risk of p@@ ne@@ um@@ oni@@ a@@ , difficulty in swal@@ low@@ ing@@ ; infl@@ amm@@ ation of the pan@@ cre@@ as@@ ; infl@@ amm@@ ation of the li@@ ver@@ , y@@ el@@ lowing of the skin and white part of ey@@ es@@ , reports of ab@@ normal liver test valu@@ es@@ , ab@@ dom@@ inal and stomach dis@@ comfort@@ , di@@ arr@@ ho@@ e@@ a@@ ; skin ra@@ sh and sensi@@ tivity to light@@ , unusual hair loss or th@@ inn@@ ing@@ , excessive swe@@ at@@ ing@@ ; sti@@ ff@@ ness or cra@@ mp@@ s@@ , muscle pain@@ , weak@@ ness@@ ; invol@@ un@@ tary loss of ur@@ ine@@ , difficulty in passing ur@@ ine@@ ; pro@@ lon@@ ged and@@ / or painful er@@ ec@@ tion@@ ; difficulty controlling core body temperature or over@@ he@@ at@@ ing@@ , chest pain@@ , and sw@@ elling of hand@@ s@@ , an@@ kles or fe@@ et@@ .
In elderly patients with demen@@ ti@@ a@@ , more fatal cases have been reported while taking ari@@ pi@@ pra@@ z@@ ole@@ .
In addi@@ tion@@ , cases of stroke or "@@ mini@@ " stroke have been repor@@ te@@ d.
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
5.
HO@@ W TO ST@@ ORE AB@@ IL@@ I@@ F@@ Y
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use AB@@ IL@@ I@@ F@@ Y after the exp@@ iry date which is stated on the bli@@ ster and on the car@@ ton@@ .
15@@ 4 Store in the original package in order to protect from mo@@ ist@@ ure@@ .
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
These measures will help to protect the environ@@ ment@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AB@@ IL@@ I@@ F@@ Y contains The active substance is ari@@ pi@@ pra@@ z@@ ole@@ .
Each tab@@ let contains 30 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
The other ingredients are la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ , ma@@ i@@ ze star@@ ch@@ , micro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ os@@ e@@ , hydro@@ x@@ y@@ prop@@ yl cell@@ ul@@ os@@ e@@ , magne@@ si@@ um ste@@ ar@@ ate@@ , red iron oxide (@@ E@@ 17@@ 2@@ )@@ .
What AB@@ IL@@ I@@ F@@ Y looks like and cont@@ ents of the pack AB@@ IL@@ I@@ F@@ Y 30 mg tab@@ lets are round and p@@ ink@@ , marked with A@@ -@@ 0@@ 11 and 30 on one si@@ de.
They are supp@@ lied in per@@ for@@ ated unit dose bli@@ sters packed in car@@ tons containing 14@@ , 28@@ , 49@@ , 56@@ , or 98 tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manu@@ fac@@ tur@@ er Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S. r. l.
Con@@ tra@@ da Fon@@ t@@ ana del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one - Italy
For any information about this medic@@ ine@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ :
Belgi@@ qu@@ e@@ / Belgi@@ ë@@ / Belgien BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Luxem@@ bour@@ g@@ / Luxemburg BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Te@@ л@@ .@@ : + 3@@ 59 800 12 400
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ .@@ : + 36 1 30@@ 1 9@@ 700
Č es@@ k@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 20 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Dan@@ mark BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B T@@ l@@ f@@ : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ V Tel@@ : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B GM@@ B@@ H & CO@@ .
K@@ G@@ AA Tel@@ : + 49 89 12@@ 1 4@@ 2@@ -@@ 0
Nor@@ ge BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y L@@ T@@ D T@@ l@@ f@@ : + 47 67 55 53 50
15@@ 5 E@@ est@@ i Österreich BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ ES@@ M@@ B@@ H Tel@@ : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ@@ : + 30 210 60@@ 7@@ 4@@ 300
Pol@@ ska BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B P@@ OL@@ S@@ KA SP@@ .
Z O@@ . O@@ .
Tel@@ .@@ : + 48 22 57@@ 9@@ 66@@ 66
E@@ spa@@ ñ@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B@@ , S. A.
Tel@@ : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ U@@ T@@ IC@@ A P@@ OR@@ TU@@ G@@ U@@ ES@@ A@@ , S. A.
Tel@@ : + 3@@ 51 21 4@@ 40 70 00
France BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l@@ : + 33 (@@ 0@@ )@@ 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 40 (@@ 0@@ )@@ 21 27@@ 2 16 00
Ireland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 3@@ 53 (@@ 1 800@@ ) 7@@ 49 7@@ 49
Slo@@ ven@@ i@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 38@@ 6 1 2@@ 36 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R H@@ F S@@ í@@ mi@@ : + 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 21 2 59@@ 29@@ 8@@ 4@@ 11
Itali@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Su@@ omi@@ / Fin@@ land O@@ Y BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B (@@ F@@ IN@@ L@@ AND@@ ) AB Pu@@ h@@ / Tel@@ : + 3@@ 58 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ & Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ@@ : + 3@@ 57 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B AB Tel@@ : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 44 (@@ 08@@ 00@@ ) 7@@ 31 17@@ 36
Lie@@ tu@@ va BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 370 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
15@@ 6 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AB@@ IL@@ I@@ F@@ Y 10 mg or@@ o@@ disp@@ er@@ sible tab@@ lets ari@@ pi@@ pra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
This medicine has been prescri@@ bed for you@@ .
Do not pass it on to o@@ ther@@ s.
It may harm them@@ , even if their symptoms are the same as yo@@ urs@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
In this le@@ af@@ let@@ :
1.
What AB@@ IL@@ I@@ F@@ Y is and what it is used for 2.
Before you take AB@@ IL@@ I@@ F@@ Y 3.
How to take AB@@ IL@@ I@@ F@@ Y 4.
Pos@@ sible side effects 5 How to store AB@@ IL@@ I@@ F@@ Y 6.
Further information
1.
WH@@ AT AB@@ IL@@ I@@ F@@ Y IS AND WH@@ AT IT IS US@@ ED FO@@ R
AB@@ IL@@ I@@ F@@ Y is one of a group of medic@@ ines called anti@@ p@@ sycho@@ tic@@ s.
It is used to treat adults who suffer from a disease character@@ ised by symptoms such as hear@@ ing@@ , seeing or sen@@ sing things which are not ther@@ e@@ , suspici@@ ous@@ ness@@ , mistak@@ en belie@@ fs@@ , in@@ co@@ her@@ ent speech and behaviour and emotional flat@@ ness@@ .
People with this condition may also feel depres@@ se@@ d@@ , guil@@ ty@@ , anxious or ten@@ se@@ .
AB@@ IL@@ I@@ F@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling "@@ high@@ "@@ , having excessive amounts of energ@@ y@@ , nee@@ ding much less sleep than us@@ u@@ al@@ , talking very quickly with racing ideas and sometimes severe irrit@@ abili@@ ty@@ .
It also prev@@ ents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ I@@ F@@ Y@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Do not take AB@@ IL@@ I@@ F@@ Y if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ I@@ F@@ Y@@ .
Take special care with AB@@ IL@@ I@@ F@@ Y Before treatment with AB@@ IL@@ I@@ F@@ Y@@ , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ volun@@ tar@@ y@@ , ir@@ regular muscle mov@@ em@@ ent@@ s@@ , especially in the face Cardi@@ ov@@ as@@ cular dise@@ as@@ es@@ , family history of cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ , stroke or "@@ mini@@ " stro@@ ke@@ , ab@@ normal blood pressure
If you notice you are gaining wei@@ ght@@ , experience any difficulty in swal@@ lowing or aller@@ gic symp@@ tom@@ s@@ , please tell your do@@ ct@@ or@@ .
If you are an elderly patient suffering from dementia (@@ loss of memory and other mental abili@@ ti@@ es@@ )@@ , you or your car@@ er@@ / relative should tell your doctor if you have ever had a stroke or "@@ mini@@ " stro@@ ke@@ .
T@@ ell your doctor immediately if you are having any thoughts or feelings about hur@@ ting your@@ sel@@ f@@ .
Su@@ ici@@ dal thoughts and behavi@@ ours have been reported during ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
15@@ 7 T@@ ell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ le@@ xi@@ bility with high fe@@ ver@@ , swe@@ at@@ ing@@ , al@@ tered mental stat@@ us@@ , or very rapid or ir@@ regular heart be@@ at@@ .
Children and adol@@ es@@ cents AB@@ IL@@ I@@ F@@ Y is not for use in children and adol@@ es@@ cents as it has not been studied in patients under 18 ye@@ ar@@ s.
As@@ k your doctor or pharmac@@ ist for advice before taking AB@@ IL@@ I@@ F@@ Y@@ .
Taking other medic@@ ines Please tell your doctor or pharmac@@ ist if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
Bloo@@ d pressu@@ re@@ -@@ lo@@ wering medi@@ cin@@ es@@ :
AB@@ IL@@ I@@ F@@ Y may increase the effect of medic@@ ines used to lower the blood pressu@@ re@@ .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under contro@@ l.
Taking AB@@ IL@@ I@@ F@@ Y with some medic@@ ines may need to change your dose of AB@@ IL@@ I@@ F@@ Y@@ .
It is especially important to mention the following to your do@@ ct@@ or@@ :
Medic@@ ines to correct heart rhyth@@ m Anti@@ depres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and anxiety Anti@@ f@@ ung@@ al agents Cer@@ tain medic@@ ines to treat HIV infection Anti@@ con@@ vul@@ s@@ ants used to treat ep@@ ile@@ p@@ sy
Taking AB@@ IL@@ I@@ F@@ Y with food and drink AB@@ IL@@ I@@ F@@ Y can be taken regardless of me@@ al@@ s.
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ I@@ F@@ Y@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ I@@ F@@ Y if you are pregnant unless you have discussed this with your do@@ ct@@ or@@ .
Be sure to tell your doctor immediately if you are pregn@@ ant@@ , think you may be pregn@@ ant@@ , or if you are planning to become pregn@@ ant@@ .
Bre@@ ast@@ -@@ feeding mothers should not take AB@@ IL@@ I@@ F@@ Y@@ .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
Dri@@ ving and using machines Do not drive or use any tools or mach@@ in@@ es@@ , until you know how AB@@ IL@@ I@@ F@@ Y affects you@@ .
Imp@@ ort@@ ant information about some of the ingredients of AB@@ IL@@ I@@ F@@ Y Pati@@ ents who cannot take phen@@ yl@@ al@@ an@@ ine should note that AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets contain as@@ part@@ ame@@ , which is a source of phen@@ yl@@ al@@ an@@ ine@@ .
May be harm@@ ful for people with phen@@ yl@@ ket@@ on@@ uri@@ a.
3.
HO@@ W TO T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Al@@ ways take AB@@ IL@@ I@@ F@@ Y exactly as your doctor has told you@@ .
You should check with your doctor or pharmac@@ ist if you are not su@@ re@@ .
The usual dose is 15 mg once a day@@ .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg once a day@@ .
If you have the impression that the effect of AB@@ IL@@ I@@ F@@ Y is too strong or too weak@@ , talk to your doctor or pharmac@@ ist@@ .
T@@ ry to take the AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ let at the same time each day@@ .
It does not matter whether you take it with or without f@@ ood@@ .
15@@ 8 Do not open the bli@@ ster until ready to administ@@ er@@ .
For single tab@@ let remo@@ val@@ , open the package and pe@@ el back the fo@@ il on the bli@@ ster to exp@@ ose the tab@@ let@@ .
Do not push the tab@@ let through the fo@@ il because this could damage the tab@@ let@@ .
Im@@ medi@@ ately upon opening the bli@@ ster@@ , using dry hand@@ s@@ , remove the tab@@ let and place the entire or@@ o@@ disp@@ er@@ sible tab@@ let on the ton@@ gu@@ e@@ .
Tablet dis@@ integration occ@@ urs rapidly in s@@ ali@@ v@@ a.
The or@@ o@@ disp@@ er@@ sible tab@@ let can be taken with or without liqui@@ d.
Altern@@ ati@@ vel@@ y@@ , disp@@ er@@ se the tab@@ let in water and drink the resulting susp@@ en@@ sion@@ .
Even if you feel bet@@ ter@@ , do not alter or dis@@ continue the daily dose of AB@@ IL@@ I@@ F@@ Y without first consul@@ ting your do@@ ct@@ or@@ .
If you take more AB@@ IL@@ I@@ F@@ Y than you should If you realise you have taken more AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets than your doctor has recommended (@@ or if someone else has taken some of your AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ le@@ ts@@ )@@ , contact your doctor right a@@ wa@@ y@@ .
If you cannot reach your do@@ ct@@ or@@ , go to the near@@ est hospital and take the pack with you@@ .
If you forget to take AB@@ IL@@ I@@ F@@ Y If you miss a d@@ os@@ e@@ , take the missed dose as soon as you remember but do not take two d@@ oses in one day@@ .
If you have any further questions on the use of this produc@@ t@@ , ask your doctor or pharmac@@ ist@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AB@@ IL@@ I@@ F@@ Y can cause side effec@@ ts@@ , although not everybody gets them@@ .
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) Un@@ contro@@ ll@@ able twi@@ t@@ ching or jer@@ king mov@@ em@@ ent@@ s@@ , hea@@ da@@ che@@ , ti@@ re@@ dn@@ ess@@ , nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , an uncomfortable feeling in the stom@@ ach@@ , con@@ sti@@ p@@ ation@@ , increased production of s@@ ali@@ v@@ a@@ , light@@ -@@ he@@ ade@@ dn@@ ess@@ , trouble sle@@ ep@@ ing@@ , rest@@ less@@ ness@@ , feeling an@@ xi@@ ous@@ , sle@@ ep@@ in@@ ess@@ , sha@@ king and bl@@ urred visi@@ on@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ .
Some people may feel depres@@ se@@ d.
Other in@@ frequently reported side effec@@ ts@@ :
Ch@@ ang@@ es in the levels of some blood cell@@ s@@ ; unusual heart be@@ at@@ , sudden un@@ explained de@@ ath@@ , heart attack@@ ; aller@@ gic reaction (@@ e@@ . g. sw@@ elling in the mou@@ th@@ , ton@@ gu@@ e@@ , face and thro@@ at@@ , it@@ ch@@ ing@@ , ra@@ sh@@ )@@ ; high blood su@@ gar@@ , on@@ set or wor@@ sen@@ ing of di@@ abet@@ es@@ , ket@@ o@@ aci@@ do@@ sis (@@ ket@@ ones in the blood and ur@@ ine@@ ) or com@@ a@@ , low so@@ dium level in the bloo@@ d@@ ; weight ga@@ in@@ , weight los@@ s@@ , an@@ or@@ ex@@ i@@ a@@ ; nerv@@ ous@@ ness@@ , ag@@ it@@ ation@@ , feeling an@@ xi@@ ous@@ ; thoughts of suici@@ de@@ , suicide attempt and suici@@ de@@ ; speech disor@@ der@@ , sei@@ zu@@ re@@ , combination of fe@@ ver@@ , muscle sti@@ ff@@ ness@@ , faster breath@@ ing@@ , swe@@ at@@ ing@@ , reduced consci@@ ousness and sudden changes in blood pressure and heart rat@@ e@@ ; fa@@ int@@ ing@@ , high blood pressu@@ re@@ , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body@@ ; sp@@ asm of the muscles around the voice bo@@ x@@ , acci@@ dental inhal@@ ation of food with risk of p@@ ne@@ um@@ oni@@ a@@ , difficulty in swal@@ low@@ ing@@ ; infl@@ amm@@ ation of the pan@@ cre@@ as@@ ; infl@@ amm@@ ation of the li@@ ver@@ , y@@ el@@ lowing of the skin and white part of ey@@ es@@ , reports of ab@@ normal liver test valu@@ es@@ , ab@@ dom@@ inal and stomach dis@@ comfort@@ , di@@ arr@@ ho@@ e@@ a@@ ; skin ra@@ sh and sensi@@ tivity to light@@ , unusual hair loss or th@@ inn@@ ing@@ , excessive swe@@ at@@ ing@@ ; sti@@ ff@@ ness or cra@@ mp@@ s@@ , muscle pain@@ , weak@@ ness@@ ; invol@@ un@@ tary loss of ur@@ ine@@ , difficulty in passing ur@@ ine@@ ; pro@@ lon@@ ged and@@ / or painful er@@ ec@@ tion@@ ; difficulty controlling core body temperature or over@@ he@@ at@@ ing@@ , chest pain@@ , and sw@@ elling of hand@@ s@@ , an@@ kles or fe@@ et@@ .
In elderly patients with demen@@ ti@@ a@@ , more fatal cases have been reported while taking ari@@ pi@@ pra@@ z@@ ole@@ .
In addi@@ tion@@ , cases of stroke or "@@ mini@@ " stroke have been repor@@ te@@ d.
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
15@@ 9 5.
HO@@ W TO ST@@ ORE AB@@ IL@@ I@@ F@@ Y
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use AB@@ IL@@ I@@ F@@ Y after the exp@@ iry date which is stated on the bli@@ ster and on the car@@ ton@@ .
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
These measures will help to protect the environ@@ ment@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AB@@ IL@@ I@@ F@@ Y contains The active substance is ari@@ pi@@ pra@@ z@@ ole@@ .
Each or@@ o@@ disp@@ er@@ sible tab@@ let contains 10 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
The other ingredients are cal@@ ci@@ um si@@ lic@@ ate@@ , cros@@ car@@ m@@ ell@@ ose so@@ di@@ um@@ , cros@@ po@@ vi@@ don@@ e@@ , si@@ lic@@ on di@@ ox@@ ide@@ , x@@ y@@ li@@ t@@ ol@@ , micro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ os@@ e@@ , as@@ part@@ ame@@ , ac@@ es@@ ul@@ fame pot@@ assi@@ um@@ , van@@ illa fla@@ vo@@ ur@@ , t@@ art@@ ari@@ c aci@@ d@@ , magne@@ si@@ um ste@@ ar@@ ate@@ , red iron oxide (@@ E@@ 17@@ 2@@ )@@ .
What AB@@ IL@@ I@@ F@@ Y looks like and cont@@ ents of the pack AB@@ IL@@ I@@ F@@ Y 10 mg or@@ o@@ disp@@ er@@ sible tab@@ lets are round and p@@ ink@@ , marked with "@@ A@@ " over "@@ 6@@ 40@@ " on one side and 10 on the o@@ ther@@ .
They are supp@@ lied in per@@ for@@ ated unit dose bli@@ sters packed in car@@ tons containing 14@@ , 28@@ , or 49 or@@ o@@ disp@@ er@@ sible tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manu@@ fac@@ tur@@ er Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S. r. l.
Con@@ tra@@ da Fon@@ t@@ ana del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one - Italy
For any information about this medic@@ ine@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ :
Belgi@@ qu@@ e@@ / Belgi@@ ë@@ / Belgien BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Luxem@@ bour@@ g@@ / Luxemburg BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Te@@ л@@ .@@ : + 3@@ 59 800 12 400
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ .@@ : + 36 1 30@@ 1 9@@ 700
Č es@@ k@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 20 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
160 Dan@@ mark BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B T@@ l@@ f@@ : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ V Tel@@ : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B GM@@ B@@ H & CO@@ .
K@@ G@@ AA Tel@@ : + 49 89 12@@ 1 4@@ 2@@ -@@ 0
Nor@@ ge BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y L@@ T@@ D T@@ l@@ f@@ : + 47 67 55 53 50
E@@ est@@ i Österreich BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ ES@@ M@@ B@@ H Tel@@ : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ@@ : + 30 210 60@@ 7@@ 4@@ 300
Pol@@ ska BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B P@@ OL@@ S@@ KA SP@@ .
Z O@@ . O@@ .
Tel@@ .@@ : + 48 22 57@@ 9@@ 66@@ 66
E@@ spa@@ ñ@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B@@ , S. A.
Tel@@ : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ U@@ T@@ IC@@ A P@@ OR@@ TU@@ G@@ U@@ ES@@ A@@ , S. A.
Tel@@ : + 3@@ 51 21 4@@ 40 70 00
France BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l@@ : + 33 (@@ 0@@ )@@ 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 40 (@@ 0@@ )@@ 21 27@@ 2 16 00
Ireland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 3@@ 53 (@@ 1 800@@ ) 7@@ 49 7@@ 49
Slo@@ ven@@ i@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 38@@ 6 1 2@@ 36 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R H@@ F S@@ í@@ mi@@ : + 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 21 2 59@@ 29@@ 8@@ 4@@ 11
Itali@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Su@@ omi@@ / Fin@@ land O@@ Y BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B (@@ F@@ IN@@ L@@ AND@@ ) AB Pu@@ h@@ / Tel@@ : + 3@@ 58 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ & Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ@@ : + 3@@ 57 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B AB Tel@@ : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 44 (@@ 08@@ 00@@ ) 7@@ 31 17@@ 36
Lie@@ tu@@ va BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 370 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
16@@ 1 Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
16@@ 2 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AB@@ IL@@ I@@ F@@ Y 15 mg or@@ o@@ disp@@ er@@ sible tab@@ lets ari@@ pi@@ pra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
This medicine has been prescri@@ bed for you@@ .
Do not pass it on to o@@ ther@@ s.
It may harm them@@ , even if their symptoms are the same as yo@@ urs@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
In this le@@ af@@ let@@ :
1.
What AB@@ IL@@ I@@ F@@ Y is and what it is used for 2.
Before you take AB@@ IL@@ I@@ F@@ Y 3.
How to take AB@@ IL@@ I@@ F@@ Y 4.
Pos@@ sible side effects 5 How to store AB@@ IL@@ I@@ F@@ Y 6.
Further information
1.
WH@@ AT AB@@ IL@@ I@@ F@@ Y IS AND WH@@ AT IT IS US@@ ED FO@@ R
AB@@ IL@@ I@@ F@@ Y is one of a group of medic@@ ines called anti@@ p@@ sycho@@ tic@@ s.
It is used to treat adults who suffer from a disease character@@ ised by symptoms such as hear@@ ing@@ , seeing or sen@@ sing things which are not ther@@ e@@ , suspici@@ ous@@ ness@@ , mistak@@ en belie@@ fs@@ , in@@ co@@ her@@ ent speech and behaviour and emotional flat@@ ness@@ .
People with this condition may also feel depres@@ se@@ d@@ , guil@@ ty@@ , anxious or ten@@ se@@ .
AB@@ IL@@ I@@ F@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling "@@ high@@ "@@ , having excessive amounts of energ@@ y@@ , nee@@ ding much less sleep than us@@ u@@ al@@ , talking very quickly with racing ideas and sometimes severe irrit@@ abili@@ ty@@ .
It also prev@@ ents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ I@@ F@@ Y@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Do not take AB@@ IL@@ I@@ F@@ Y if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ I@@ F@@ Y@@ .
Take special care with AB@@ IL@@ I@@ F@@ Y Before treatment with AB@@ IL@@ I@@ F@@ Y@@ , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ volun@@ tar@@ y@@ , ir@@ regular muscle mov@@ em@@ ent@@ s@@ , especially in the face Cardi@@ ov@@ as@@ cular dise@@ as@@ es@@ , family history of cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ , stroke or "@@ mini@@ " stro@@ ke@@ , ab@@ normal blood pressure
If you notice you are gaining wei@@ ght@@ , experience any difficulty in swal@@ lowing or aller@@ gic symp@@ tom@@ s@@ , please tell your do@@ ct@@ or@@ .
If you are an elderly patient suffering from dementia (@@ loss of memory and other mental abili@@ ti@@ es@@ )@@ , you or your car@@ er@@ / relative should tell your doctor if you have ever had a stroke or "@@ mini@@ " stro@@ ke@@ .
T@@ ell your doctor immediately if you are having any thoughts or feelings about hur@@ ting your@@ sel@@ f@@ .
Su@@ ici@@ dal thoughts and behavi@@ ours have been reported during ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
16@@ 3 T@@ ell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ le@@ xi@@ bility with high fe@@ ver@@ , swe@@ at@@ ing@@ , al@@ tered mental stat@@ us@@ , or very rapid or ir@@ regular heart be@@ at@@ .
Children and adol@@ es@@ cents AB@@ IL@@ I@@ F@@ Y is not for use in children and adol@@ es@@ cents as it has not been studied in patients under 18 ye@@ ar@@ s.
As@@ k your doctor or pharmac@@ ist for advice before taking AB@@ IL@@ I@@ F@@ Y@@ .
Taking other medic@@ ines Please tell your doctor or pharmac@@ ist if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
Bloo@@ d pressu@@ re@@ -@@ lo@@ wering medi@@ cin@@ es@@ :
AB@@ IL@@ I@@ F@@ Y may increase the effect of medic@@ ines used to lower the blood pressu@@ re@@ .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under contro@@ l.
Taking AB@@ IL@@ I@@ F@@ Y with some medic@@ ines may need to change your dose of AB@@ IL@@ I@@ F@@ Y@@ .
It is especially important to mention the following to your do@@ ct@@ or@@ :
Medic@@ ines to correct heart rhyth@@ m Anti@@ depres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and anxiety Anti@@ f@@ ung@@ al agents Cer@@ tain medic@@ ines to treat HIV infection Anti@@ con@@ vul@@ s@@ ants used to treat ep@@ ile@@ p@@ sy
Taking AB@@ IL@@ I@@ F@@ Y with food and drink AB@@ IL@@ I@@ F@@ Y can be taken regardless of me@@ al@@ s.
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ I@@ F@@ Y@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ I@@ F@@ Y if you are pregnant unless you have discussed this with your do@@ ct@@ or@@ .
Be sure to tell your doctor immediately if you are pregn@@ ant@@ , think you may be pregn@@ ant@@ , or if you are planning to become pregn@@ ant@@ .
Bre@@ ast@@ -@@ feeding mothers should not take AB@@ IL@@ I@@ F@@ Y@@ .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
Dri@@ ving and using machines Do not drive or use any tools or mach@@ in@@ es@@ , until you know how AB@@ IL@@ I@@ F@@ Y affects you@@ .
Imp@@ ort@@ ant information about some of the ingredients of AB@@ IL@@ I@@ F@@ Y Pati@@ ents who cannot take phen@@ yl@@ al@@ an@@ ine should note that AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets contain as@@ part@@ ame@@ , which is a source of phen@@ yl@@ al@@ an@@ ine@@ .
May be harm@@ ful for people with phen@@ yl@@ ket@@ on@@ uri@@ a.
3.
HO@@ W TO T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Al@@ ways take AB@@ IL@@ I@@ F@@ Y exactly as your doctor has told you@@ .
You should check with your doctor or pharmac@@ ist if you are not su@@ re@@ .
The usual dose is 15 mg once a day@@ .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg once a day@@ .
If you have the impression that the effect of AB@@ IL@@ I@@ F@@ Y is too strong or too weak@@ , talk to your doctor or pharmac@@ ist@@ .
T@@ ry to take the AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ let at the same time each day@@ .
It does not matter whether you take it with or without f@@ ood@@ .
16@@ 4 Do not open the bli@@ ster until ready to administ@@ er@@ .
For single tab@@ let remo@@ val@@ , open the package and pe@@ el back the fo@@ il on the bli@@ ster to exp@@ ose the tab@@ let@@ .
Do not push the tab@@ let through the fo@@ il because this could damage the tab@@ let@@ .
Im@@ medi@@ ately upon opening the bli@@ ster@@ , using dry hand@@ s@@ , remove the tab@@ let and place the entire or@@ o@@ disp@@ er@@ sible tab@@ let on the ton@@ gu@@ e@@ .
Tablet dis@@ integration occ@@ urs rapidly in s@@ ali@@ v@@ a.
The or@@ o@@ disp@@ er@@ sible tab@@ let can be taken with or without liqui@@ d.
Altern@@ ati@@ vel@@ y@@ , disp@@ er@@ se the tab@@ let in water and drink the resulting susp@@ en@@ sion@@ .
Even if you feel bet@@ ter@@ , do not alter or dis@@ continue the daily dose of AB@@ IL@@ I@@ F@@ Y without first consul@@ ting your do@@ ct@@ or@@ .
If you take more AB@@ IL@@ I@@ F@@ Y than you should If you realise you have taken more AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets than your doctor has recommended (@@ or if someone else has taken some of your AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ le@@ ts@@ )@@ , contact your doctor right a@@ wa@@ y@@ .
If you cannot reach your do@@ ct@@ or@@ , go to the near@@ est hospital and take the pack with you@@ .
If you forget to take AB@@ IL@@ I@@ F@@ Y If you miss a d@@ os@@ e@@ , take the missed dose as soon as you remember but do not take two d@@ oses in one day@@ .
If you have any further questions on the use of this produc@@ t@@ , ask your doctor or pharmac@@ ist@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AB@@ IL@@ I@@ F@@ Y can cause side effec@@ ts@@ , although not everybody gets them@@ .
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) Un@@ contro@@ ll@@ able twi@@ t@@ ching or jer@@ king mov@@ em@@ ent@@ s@@ , hea@@ da@@ che@@ , ti@@ re@@ dn@@ ess@@ , nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , an uncomfortable feeling in the stom@@ ach@@ , con@@ sti@@ p@@ ation@@ , increased production of s@@ ali@@ v@@ a@@ , light@@ -@@ he@@ ade@@ dn@@ ess@@ , trouble sle@@ ep@@ ing@@ , rest@@ less@@ ness@@ , feeling an@@ xi@@ ous@@ , sle@@ ep@@ in@@ ess@@ , sha@@ king and bl@@ urred visi@@ on@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ .
Some people may feel depres@@ se@@ d.
Other in@@ frequently reported side effec@@ ts@@ :
Ch@@ ang@@ es in the levels of some blood cell@@ s@@ ; unusual heart be@@ at@@ , sudden un@@ explained de@@ ath@@ , heart attack@@ ; aller@@ gic reaction (@@ e@@ . g. sw@@ elling in the mou@@ th@@ , ton@@ gu@@ e@@ , face and thro@@ at@@ , it@@ ch@@ ing@@ , ra@@ sh@@ )@@ ; high blood su@@ gar@@ , on@@ set or wor@@ sen@@ ing of di@@ abet@@ es@@ , ket@@ o@@ aci@@ do@@ sis (@@ ket@@ ones in the blood and ur@@ ine@@ ) or com@@ a@@ , low so@@ dium level in the bloo@@ d@@ ; weight ga@@ in@@ , weight los@@ s@@ , an@@ or@@ ex@@ i@@ a@@ ; nerv@@ ous@@ ness@@ , ag@@ it@@ ation@@ , feeling an@@ xi@@ ous@@ ; thoughts of suici@@ de@@ , suicide attempt and suici@@ de@@ ; speech disor@@ der@@ , sei@@ zu@@ re@@ , combination of fe@@ ver@@ , muscle sti@@ ff@@ ness@@ , faster breath@@ ing@@ , swe@@ at@@ ing@@ , reduced consci@@ ousness and sudden changes in blood pressure and heart rat@@ e@@ ; fa@@ int@@ ing@@ , high blood pressu@@ re@@ , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body@@ ; sp@@ asm of the muscles around the voice bo@@ x@@ , acci@@ dental inhal@@ ation of food with risk of p@@ ne@@ um@@ oni@@ a@@ , difficulty in swal@@ low@@ ing@@ ; infl@@ amm@@ ation of the pan@@ cre@@ as@@ ; infl@@ amm@@ ation of the li@@ ver@@ , y@@ el@@ lowing of the skin and white part of ey@@ es@@ , reports of ab@@ normal liver test valu@@ es@@ , ab@@ dom@@ inal and stomach dis@@ comfort@@ , di@@ arr@@ ho@@ e@@ a@@ ; skin ra@@ sh and sensi@@ tivity to light@@ , unusual hair loss or th@@ inn@@ ing@@ , excessive swe@@ at@@ ing@@ ; sti@@ ff@@ ness or cra@@ mp@@ s@@ , muscle pain@@ , weak@@ ness@@ ; invol@@ un@@ tary loss of ur@@ ine@@ , difficulty in passing ur@@ ine@@ ; pro@@ lon@@ ged and@@ / or painful er@@ ec@@ tion@@ ; difficulty controlling core body temperature or over@@ he@@ at@@ ing@@ , chest pain@@ , and sw@@ elling of hand@@ s@@ , an@@ kles or fe@@ et@@ .
In elderly patients with demen@@ ti@@ a@@ , more fatal cases have been reported while taking ari@@ pi@@ pra@@ z@@ ole@@ .
In addi@@ tion@@ , cases of stroke or "@@ mini@@ " stroke have been repor@@ te@@ d.
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
16@@ 5 5.
HO@@ W TO ST@@ ORE AB@@ IL@@ I@@ F@@ Y
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use AB@@ IL@@ I@@ F@@ Y after the exp@@ iry date which is stated on the bli@@ ster and on the car@@ ton@@ .
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
These measures will help to protect the environ@@ ment@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AB@@ IL@@ I@@ F@@ Y contains The active substance is ari@@ pi@@ pra@@ z@@ ole@@ .
Each or@@ o@@ disp@@ er@@ sible tab@@ let contains 15 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
The other ingredients are cal@@ ci@@ um si@@ lic@@ ate@@ , cros@@ car@@ m@@ ell@@ ose so@@ di@@ um@@ , cros@@ po@@ vi@@ don@@ e@@ , si@@ lic@@ on di@@ ox@@ ide@@ , x@@ y@@ li@@ t@@ ol@@ , micro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ os@@ e@@ , as@@ part@@ ame@@ , ac@@ es@@ ul@@ fame pot@@ assi@@ um@@ , van@@ illa fla@@ vo@@ ur@@ , t@@ art@@ ari@@ c aci@@ d@@ , magne@@ si@@ um ste@@ ar@@ ate@@ , yellow iron oxide (@@ E@@ 17@@ 2@@ )@@ .
What AB@@ IL@@ I@@ F@@ Y looks like and cont@@ ents of the pack AB@@ IL@@ I@@ F@@ Y 15 mg or@@ o@@ disp@@ er@@ sible tab@@ lets are round and y@@ el@@ low@@ , marked with "@@ A@@ " over "@@ 64@@ 1@@ " on one side and 15 on the o@@ ther@@ .
They are supp@@ lied in per@@ for@@ ated unit dose bli@@ sters packed in car@@ tons containing 14@@ , 28@@ , or 49 or@@ o@@ disp@@ er@@ sible tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manu@@ fac@@ tur@@ er Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S. r. l.
Con@@ tra@@ da Fon@@ t@@ ana del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one - Italy
For any information about this medic@@ ine@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ :
Belgi@@ qu@@ e@@ / Belgi@@ ë@@ / Belgien BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Luxem@@ bour@@ g@@ / Luxemburg BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Te@@ л@@ .@@ : + 3@@ 59 800 12 400
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ .@@ : + 36 1 30@@ 1 9@@ 700
Č es@@ k@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 20 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
16@@ 6 Dan@@ mark BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B T@@ l@@ f@@ : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ V Tel@@ : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B GM@@ B@@ H & CO@@ .
K@@ G@@ AA Tel@@ : + 49 89 12@@ 1 4@@ 2@@ -@@ 0
Nor@@ ge BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y L@@ T@@ D T@@ l@@ f@@ : + 47 67 55 53 50
E@@ est@@ i Österreich BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ ES@@ M@@ B@@ H Tel@@ : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ@@ : + 30 210 60@@ 7@@ 4@@ 300
Pol@@ ska BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B P@@ OL@@ S@@ KA SP@@ .
Z O@@ . O@@ .
Tel@@ .@@ : + 48 22 57@@ 9@@ 66@@ 66
E@@ spa@@ ñ@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B@@ , S. A.
Tel@@ : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ U@@ T@@ IC@@ A P@@ OR@@ TU@@ G@@ U@@ ES@@ A@@ , S. A.
Tel@@ : + 3@@ 51 21 4@@ 40 70 00
France BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l@@ : + 33 (@@ 0@@ )@@ 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 40 (@@ 0@@ )@@ 21 27@@ 2 16 00
Ireland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 3@@ 53 (@@ 1 800@@ ) 7@@ 49 7@@ 49
Slo@@ ven@@ i@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 38@@ 6 1 2@@ 36 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R H@@ F S@@ í@@ mi@@ : + 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 21 2 59@@ 29@@ 8@@ 4@@ 11
Itali@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Su@@ omi@@ / Fin@@ land O@@ Y BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B (@@ F@@ IN@@ L@@ AND@@ ) AB Pu@@ h@@ / Tel@@ : + 3@@ 58 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ & Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ@@ : + 3@@ 57 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B AB Tel@@ : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 44 (@@ 08@@ 00@@ ) 7@@ 31 17@@ 36
Lie@@ tu@@ va BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 370 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
16@@ 7 Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
16@@ 8 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AB@@ IL@@ I@@ F@@ Y 30 mg or@@ o@@ disp@@ er@@ sible tab@@ lets ari@@ pi@@ pra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
This medicine has been prescri@@ bed for you@@ .
Do not pass it on to o@@ ther@@ s.
It may harm them@@ , even if their symptoms are the same as yo@@ urs@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
In this le@@ af@@ let@@ :
1.
What AB@@ IL@@ I@@ F@@ Y is and what it is used for 2.
Before you take AB@@ IL@@ I@@ F@@ Y 3.
How to take AB@@ IL@@ I@@ F@@ Y 4.
Pos@@ sible side effects 5 How to store AB@@ IL@@ I@@ F@@ Y 6.
Further information
1.
WH@@ AT AB@@ IL@@ I@@ F@@ Y IS AND WH@@ AT IT IS US@@ ED FO@@ R
AB@@ IL@@ I@@ F@@ Y is one of a group of medic@@ ines called anti@@ p@@ sycho@@ tic@@ s.
It is used to treat adults who suffer from a disease character@@ ised by symptoms such as hear@@ ing@@ , seeing or sen@@ sing things which are not ther@@ e@@ , suspici@@ ous@@ ness@@ , mistak@@ en belie@@ fs@@ , in@@ co@@ her@@ ent speech and behaviour and emotional flat@@ ness@@ .
People with this condition may also feel depres@@ se@@ d@@ , guil@@ ty@@ , anxious or ten@@ se@@ .
AB@@ IL@@ I@@ F@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling "@@ high@@ "@@ , having excessive amounts of energ@@ y@@ , nee@@ ding much less sleep than us@@ u@@ al@@ , talking very quickly with racing ideas and sometimes severe irrit@@ abili@@ ty@@ .
It also prev@@ ents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ I@@ F@@ Y@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Do not take AB@@ IL@@ I@@ F@@ Y if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ I@@ F@@ Y@@ .
Take special care with AB@@ IL@@ I@@ F@@ Y Before treatment with AB@@ IL@@ I@@ F@@ Y@@ , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ volun@@ tar@@ y@@ , ir@@ regular muscle mov@@ em@@ ent@@ s@@ , especially in the face Cardi@@ ov@@ as@@ cular dise@@ as@@ es@@ , family history of cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ , stroke or "@@ mini@@ " stro@@ ke@@ , ab@@ normal blood pressure
If you notice you are gaining wei@@ ght@@ , experience any difficulty in swal@@ lowing or aller@@ gic symp@@ tom@@ s@@ , please tell your do@@ ct@@ or@@ .
If you are an elderly patient suffering from dementia (@@ loss of memory and other mental abili@@ ti@@ es@@ )@@ , you or your car@@ er@@ / relative should tell your doctor if you have ever had a stroke or "@@ mini@@ " stro@@ ke@@ .
T@@ ell your doctor immediately if you are having any thoughts or feelings about hur@@ ting your@@ sel@@ f@@ .
Su@@ ici@@ dal thoughts and behavi@@ ours have been reported during ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
16@@ 9 T@@ ell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ le@@ xi@@ bility with high fe@@ ver@@ , swe@@ at@@ ing@@ , al@@ tered mental stat@@ us@@ , or very rapid or ir@@ regular heart be@@ at@@ .
Children and adol@@ es@@ cents AB@@ IL@@ I@@ F@@ Y is not for use in children and adol@@ es@@ cents as it has not been studied in patients under 18 ye@@ ar@@ s.
As@@ k your doctor or pharmac@@ ist for advice before taking AB@@ IL@@ I@@ F@@ Y@@ .
Taking other medic@@ ines Please tell your doctor or pharmac@@ ist if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
Bloo@@ d pressu@@ re@@ -@@ lo@@ wering medi@@ cin@@ es@@ :
AB@@ IL@@ I@@ F@@ Y may increase the effect of medic@@ ines used to lower the blood pressu@@ re@@ .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under contro@@ l.
Taking AB@@ IL@@ I@@ F@@ Y with some medic@@ ines may need to change your dose of AB@@ IL@@ I@@ F@@ Y@@ .
It is especially important to mention the following to your do@@ ct@@ or@@ :
Medic@@ ines to correct heart rhyth@@ m Anti@@ depres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and anxiety Anti@@ f@@ ung@@ al agents Cer@@ tain medic@@ ines to treat HIV infection Anti@@ con@@ vul@@ s@@ ants used to treat ep@@ ile@@ p@@ sy
Taking AB@@ IL@@ I@@ F@@ Y with food and drink AB@@ IL@@ I@@ F@@ Y can be taken regardless of me@@ al@@ s.
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ I@@ F@@ Y@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ I@@ F@@ Y if you are pregnant unless you have discussed this with your do@@ ct@@ or@@ .
Be sure to tell your doctor immediately if you are pregn@@ ant@@ , think you may be pregn@@ ant@@ , or if you are planning to become pregn@@ ant@@ .
Bre@@ ast@@ -@@ feeding mothers should not take AB@@ IL@@ I@@ F@@ Y@@ .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
Dri@@ ving and using machines Do not drive or use any tools or mach@@ in@@ es@@ , until you know how AB@@ IL@@ I@@ F@@ Y affects you@@ .
Imp@@ ort@@ ant information about some of the ingredients of AB@@ IL@@ I@@ F@@ Y Pati@@ ents who cannot take phen@@ yl@@ al@@ an@@ ine should note that AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets contain as@@ part@@ ame@@ , which is a source of phen@@ yl@@ al@@ an@@ ine@@ .
May be harm@@ ful for people with phen@@ yl@@ ket@@ on@@ uri@@ a.
3.
HO@@ W TO T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Al@@ ways take AB@@ IL@@ I@@ F@@ Y exactly as your doctor has told you@@ .
You should check with your doctor or pharmac@@ ist if you are not su@@ re@@ .
The usual dose is 15 mg once a day@@ .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg once a day@@ .
If you have the impression that the effect of AB@@ IL@@ I@@ F@@ Y is too strong or too weak@@ , talk to your doctor or pharmac@@ ist@@ .
T@@ ry to take the AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ let at the same time each day@@ .
It does not matter whether you take it with or without f@@ ood@@ .
170 Do not open the bli@@ ster until ready to administ@@ er@@ .
For single tab@@ let remo@@ val@@ , open the package and pe@@ el back the fo@@ il on the bli@@ ster to exp@@ ose the tab@@ let@@ .
Do not push the tab@@ let through the fo@@ il because this could damage the tab@@ let@@ .
Im@@ medi@@ ately upon opening the bli@@ ster@@ , using dry hand@@ s@@ , remove the tab@@ let and place the entire or@@ o@@ disp@@ er@@ sible tab@@ let on the ton@@ gu@@ e@@ .
Tablet dis@@ integration occ@@ urs rapidly in s@@ ali@@ v@@ a.
The or@@ o@@ disp@@ er@@ sible tab@@ let can be taken with or without liqui@@ d.
Altern@@ ati@@ vel@@ y@@ , disp@@ er@@ se the tab@@ let in water and drink the resulting susp@@ en@@ sion@@ .
Even if you feel bet@@ ter@@ , do not alter or dis@@ continue the daily dose of AB@@ IL@@ I@@ F@@ Y without first consul@@ ting your do@@ ct@@ or@@ .
If you take more AB@@ IL@@ I@@ F@@ Y than you should If you realise you have taken more AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets than your doctor has recommended (@@ or if someone else has taken some of your AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ le@@ ts@@ )@@ , contact your doctor right a@@ wa@@ y@@ .
If you cannot reach your do@@ ct@@ or@@ , go to the near@@ est hospital and take the pack with you@@ .
If you forget to take AB@@ IL@@ I@@ F@@ Y If you miss a d@@ os@@ e@@ , take the missed dose as soon as you remember but do not take two d@@ oses in one day@@ .
If you have any further questions on the use of this produc@@ t@@ , ask your doctor or pharmac@@ ist@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AB@@ IL@@ I@@ F@@ Y can cause side effec@@ ts@@ , although not everybody gets them@@ .
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) Un@@ contro@@ ll@@ able twi@@ t@@ ching or jer@@ king mov@@ em@@ ent@@ s@@ , hea@@ da@@ che@@ , ti@@ re@@ dn@@ ess@@ , nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , an uncomfortable feeling in the stom@@ ach@@ , con@@ sti@@ p@@ ation@@ , increased production of s@@ ali@@ v@@ a@@ , light@@ -@@ he@@ ade@@ dn@@ ess@@ , trouble sle@@ ep@@ ing@@ , rest@@ less@@ ness@@ , feeling an@@ xi@@ ous@@ , sle@@ ep@@ in@@ ess@@ , sha@@ king and bl@@ urred visi@@ on@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ .
Some people may feel depres@@ se@@ d.
Other in@@ frequently reported side effec@@ ts@@ :
Ch@@ ang@@ es in the levels of some blood cell@@ s@@ ; unusual heart be@@ at@@ , sudden un@@ explained de@@ ath@@ , heart attack@@ ; aller@@ gic reaction (@@ e@@ . g. sw@@ elling in the mou@@ th@@ , ton@@ gu@@ e@@ , face and thro@@ at@@ , it@@ ch@@ ing@@ , ra@@ sh@@ )@@ ; high blood su@@ gar@@ , on@@ set or wor@@ sen@@ ing of di@@ abet@@ es@@ , ket@@ o@@ aci@@ do@@ sis (@@ ket@@ ones in the blood and ur@@ ine@@ ) or com@@ a@@ , low so@@ dium level in the bloo@@ d@@ ; weight ga@@ in@@ , weight los@@ s@@ , an@@ or@@ ex@@ i@@ a@@ ; nerv@@ ous@@ ness@@ , ag@@ it@@ ation@@ , feeling an@@ xi@@ ous@@ ; thoughts of suici@@ de@@ , suicide attempt and suici@@ de@@ ; speech disor@@ der@@ , sei@@ zu@@ re@@ , combination of fe@@ ver@@ , muscle sti@@ ff@@ ness@@ , faster breath@@ ing@@ , swe@@ at@@ ing@@ , reduced consci@@ ousness and sudden changes in blood pressure and heart rat@@ e@@ ; fa@@ int@@ ing@@ , high blood pressu@@ re@@ , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body@@ ; sp@@ asm of the muscles around the voice bo@@ x@@ , acci@@ dental inhal@@ ation of food with risk of p@@ ne@@ um@@ oni@@ a@@ , difficulty in swal@@ low@@ ing@@ ; infl@@ amm@@ ation of the pan@@ cre@@ as@@ ; infl@@ amm@@ ation of the li@@ ver@@ , y@@ el@@ lowing of the skin and white part of ey@@ es@@ , reports of ab@@ normal liver test valu@@ es@@ , ab@@ dom@@ inal and stomach dis@@ comfort@@ , di@@ arr@@ ho@@ e@@ a@@ ; skin ra@@ sh and sensi@@ tivity to light@@ , unusual hair loss or th@@ inn@@ ing@@ , excessive swe@@ at@@ ing@@ ; sti@@ ff@@ ness or cra@@ mp@@ s@@ , muscle pain@@ , weak@@ ness@@ ; invol@@ un@@ tary loss of ur@@ ine@@ , difficulty in passing ur@@ ine@@ ; pro@@ lon@@ ged and@@ / or painful er@@ ec@@ tion@@ ; difficulty controlling core body temperature or over@@ he@@ at@@ ing@@ , chest pain@@ , and sw@@ elling of hand@@ s@@ , an@@ kles or fe@@ et@@ .
In elderly patients with demen@@ ti@@ a@@ , more fatal cases have been reported while taking ari@@ pi@@ pra@@ z@@ ole@@ .
In addi@@ tion@@ , cases of stroke or "@@ mini@@ " stroke have been repor@@ te@@ d.
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
17@@ 1 5.
HO@@ W TO ST@@ ORE AB@@ IL@@ I@@ F@@ Y
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use AB@@ IL@@ I@@ F@@ Y after the exp@@ iry date which is stated on the bli@@ ster and on the car@@ ton@@ .
Store in the original package in order to protect from mo@@ ist@@ ure@@ .
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
These measures will help to protect the environ@@ ment@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AB@@ IL@@ I@@ F@@ Y contains The active substance is ari@@ pi@@ pra@@ z@@ ole@@ .
Each or@@ o@@ disp@@ er@@ sible tab@@ let contains 30 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
The other ingredients are cal@@ ci@@ um si@@ lic@@ ate@@ , cros@@ car@@ m@@ ell@@ ose so@@ di@@ um@@ , cros@@ po@@ vi@@ don@@ e@@ , si@@ lic@@ on di@@ ox@@ ide@@ , x@@ y@@ li@@ t@@ ol@@ , micro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ os@@ e@@ , as@@ part@@ ame@@ , ac@@ es@@ ul@@ fame pot@@ assi@@ um@@ , van@@ illa fla@@ vo@@ ur@@ , t@@ art@@ ari@@ c aci@@ d@@ , magne@@ si@@ um ste@@ ar@@ ate@@ , red iron oxide (@@ E@@ 17@@ 2@@ )@@ .
What AB@@ IL@@ I@@ F@@ Y looks like and cont@@ ents of the pack AB@@ IL@@ I@@ F@@ Y 30 mg or@@ o@@ disp@@ er@@ sible tab@@ lets are round and p@@ ink@@ , marked with "@@ A@@ " over "@@ 6@@ 43@@ " on one side and 30 on the o@@ ther@@ .
They are supp@@ lied in per@@ for@@ ated unit dose bli@@ sters packed in car@@ tons containing 14@@ , 28@@ , or 49 or@@ o@@ disp@@ er@@ sible tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manu@@ fac@@ tur@@ er Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S. r. l.
Con@@ tra@@ da Fon@@ t@@ ana del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one - Italy
For any information about this medic@@ ine@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ :
Belgi@@ qu@@ e@@ / Belgi@@ ë@@ / Belgien BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Luxem@@ bour@@ g@@ / Luxemburg BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Te@@ л@@ .@@ : + 3@@ 59 800 12 400
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ .@@ : + 36 1 30@@ 1 9@@ 700
Č es@@ k@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 20 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
17@@ 2 Dan@@ mark BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B T@@ l@@ f@@ : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ V Tel@@ : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B GM@@ B@@ H & CO@@ .
K@@ G@@ AA Tel@@ : + 49 89 12@@ 1 4@@ 2@@ -@@ 0
Nor@@ ge BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y L@@ T@@ D T@@ l@@ f@@ : + 47 67 55 53 50
E@@ est@@ i Österreich BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ ES@@ M@@ B@@ H Tel@@ : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ@@ : + 30 210 60@@ 7@@ 4@@ 300
Pol@@ ska BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B P@@ OL@@ S@@ KA SP@@ .
Z O@@ . O@@ .
Tel@@ .@@ : + 48 22 57@@ 9@@ 66@@ 66
E@@ spa@@ ñ@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B@@ , S. A.
Tel@@ : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ U@@ T@@ IC@@ A P@@ OR@@ TU@@ G@@ U@@ ES@@ A@@ , S. A.
Tel@@ : + 3@@ 51 21 4@@ 40 70 00
France BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l@@ : + 33 (@@ 0@@ )@@ 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 40 (@@ 0@@ )@@ 21 27@@ 2 16 00
Ireland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 3@@ 53 (@@ 1 800@@ ) 7@@ 49 7@@ 49
Slo@@ ven@@ i@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 38@@ 6 1 2@@ 36 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R H@@ F S@@ í@@ mi@@ : + 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 21 2 59@@ 29@@ 8@@ 4@@ 11
Itali@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Su@@ omi@@ / Fin@@ land O@@ Y BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B (@@ F@@ IN@@ L@@ AND@@ ) AB Pu@@ h@@ / Tel@@ : + 3@@ 58 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ & Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ@@ : + 3@@ 57 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B AB Tel@@ : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 44 (@@ 08@@ 00@@ ) 7@@ 31 17@@ 36
Lie@@ tu@@ va BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 370 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
17@@ 3 Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
17@@ 4 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AB@@ IL@@ I@@ F@@ Y 1 m@@ g@@ / ml oral solution ari@@ pi@@ pra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
This medicine has been prescri@@ bed for you@@ .
Do not pass it on to o@@ ther@@ s.
It may harm them@@ , even if their symptoms are the same as yo@@ urs@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
In this le@@ af@@ let@@ :
1.
What AB@@ IL@@ I@@ F@@ Y is and what it is used for 2.
Before you take AB@@ IL@@ I@@ F@@ Y 3.
How to take AB@@ IL@@ I@@ F@@ Y 4.
Pos@@ sible side effects 5 How to store AB@@ IL@@ I@@ F@@ Y 6.
Further information
1.
WH@@ AT AB@@ IL@@ I@@ F@@ Y IS AND WH@@ AT IT IS US@@ ED FO@@ R
AB@@ IL@@ I@@ F@@ Y is one of a group of medic@@ ines called anti@@ p@@ sycho@@ tic@@ s.
It is used to treat adults who suffer from a disease character@@ ised by symptoms such as hear@@ ing@@ , seeing or sen@@ sing things which are not ther@@ e@@ , suspici@@ ous@@ ness@@ , mistak@@ en belie@@ fs@@ , in@@ co@@ her@@ ent speech and behaviour and emotional flat@@ ness@@ .
People with this condition may also feel depres@@ se@@ d@@ , guil@@ ty@@ , anxious or ten@@ se@@ .
AB@@ IL@@ I@@ F@@ Y is used to treat adults who suffer from a condition with symptoms such as feeling "@@ high@@ "@@ , having excessive amounts of energ@@ y@@ , nee@@ ding much less sleep than us@@ u@@ al@@ , talking very quickly with racing ideas and sometimes severe irrit@@ abili@@ ty@@ .
It also prev@@ ents this condition from returning in patients who have responded to the treatment with AB@@ IL@@ I@@ F@@ Y@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Do not take AB@@ IL@@ I@@ F@@ Y if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ I@@ F@@ Y@@ .
Take special care with AB@@ IL@@ I@@ F@@ Y Before treatment with AB@@ IL@@ I@@ F@@ Y@@ , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ volun@@ tar@@ y@@ , ir@@ regular muscle mov@@ em@@ ent@@ s@@ , especially in the face Cardi@@ ov@@ as@@ cular dise@@ as@@ es@@ , family history of cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ , stroke or "@@ mini@@ " stro@@ ke@@ , ab@@ normal blood pressure
If you notice you are gaining wei@@ ght@@ , experience any difficulty in swal@@ lowing or aller@@ gic symp@@ tom@@ s@@ , please tell your do@@ ct@@ or@@ .
If you are an elderly patient suffering from dementia (@@ loss of memory and other mental abili@@ ti@@ es@@ )@@ , you or your car@@ er@@ / relative should tell your doctor if you have ever had a stroke or "@@ mini@@ " stro@@ ke@@ .
T@@ ell your doctor immediately if you are having any thoughts or feelings about hur@@ ting your@@ sel@@ f@@ .
Su@@ ici@@ dal thoughts and behavi@@ ours have been reported during ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
175 T@@ ell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ le@@ xi@@ bility with high fe@@ ver@@ , swe@@ at@@ ing@@ , al@@ tered mental stat@@ us@@ , or very rapid or ir@@ regular heart be@@ at@@ .
Children and adol@@ es@@ cents AB@@ IL@@ I@@ F@@ Y is not for use in children and adol@@ es@@ cents as it has not been studied in patients under 18 ye@@ ar@@ s.
As@@ k your doctor or pharmac@@ ist for advice before taking AB@@ IL@@ I@@ F@@ Y@@ .
Taking other medic@@ ines Please tell your doctor or pharmac@@ ist if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
Bloo@@ d pressu@@ re@@ -@@ lo@@ wering medi@@ cin@@ es@@ :
AB@@ IL@@ I@@ F@@ Y may increase the effect of medic@@ ines used to lower the blood pressu@@ re@@ .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under contro@@ l.
Taking AB@@ IL@@ I@@ F@@ Y with some medic@@ ines may need to change your dose of AB@@ IL@@ I@@ F@@ Y@@ .
It is especially important to mention the following to your do@@ ct@@ or@@ :
Medic@@ ines to correct heart rhyth@@ m Anti@@ depres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and anxiety Anti@@ f@@ ung@@ al agents Cer@@ tain medic@@ ines to treat HIV infection Anti@@ con@@ vul@@ s@@ ants used to treat ep@@ ile@@ p@@ sy
Taking AB@@ IL@@ I@@ F@@ Y with food and drink AB@@ IL@@ I@@ F@@ Y can be taken regardless of me@@ al@@ s.
Ho@@ we@@ ver@@ , the oral solution should not be dil@@ uted with other liqui@@ ds or mixed with any food prior to administ@@ ration@@ .
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ I@@ F@@ Y@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not take AB@@ IL@@ I@@ F@@ Y if you are pregnant unless you have discussed this with your do@@ ct@@ or@@ .
Be sure to tell your doctor immediately if you are pregn@@ ant@@ , think you may be pregn@@ ant@@ , or if you are planning to become pregn@@ ant@@ .
Bre@@ ast@@ -@@ feeding mothers should not take AB@@ IL@@ I@@ F@@ Y@@ .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
Dri@@ ving and using machines Do not drive or use any tools or machines until you know how AB@@ IL@@ I@@ F@@ Y affects you@@ .
Imp@@ ort@@ ant information about some of the ingredients of AB@@ IL@@ I@@ F@@ Y Each ml of AB@@ IL@@ I@@ F@@ Y oral solution contains 200 mg of fru@@ ct@@ ose and 400 mg of su@@ cros@@ e@@ .
If you have been told by your doctor that you have an int@@ oler@@ ance to some su@@ gar@@ s@@ , contact your doctor before taking this medic@@ ine@@ .
Par@@ ah@@ y@@ dro@@ x@@ y@@ ben@@ zo@@ ates may cause aller@@ gic re@@ actions (@@ possibly dela@@ ye@@ d@@ )@@ .
3.
HO@@ W TO T@@ AK@@ E AB@@ IL@@ I@@ F@@ Y
Al@@ ways take AB@@ IL@@ I@@ F@@ Y exactly as your doctor has told you@@ .
You should check with your doctor or pharmac@@ ist if you are not su@@ re@@ .
The usual dose is 15 ml solution (@@ correspon@@ ding to 15 mg ari@@ pi@@ pra@@ z@@ ole@@ ) once a day@@ .
However your doctor may prescri@@ be a lower or higher dose to a maximum of 30 mg (@@ i@@ . e@@ .
30 m@@ l@@ ) once a day@@ .
The dose of AB@@ IL@@ I@@ F@@ Y oral solution must be measured using the cali@@ br@@ ated cup or the 2 ml cali@@ br@@ ated dro@@ pper supp@@ lied in the car@@ ton@@ .
17@@ 6 If you have the impression that the effect of AB@@ IL@@ I@@ F@@ Y is too strong or too weak@@ , talk to your doctor or pharmac@@ ist@@ .
T@@ ry to take the AB@@ IL@@ I@@ F@@ Y oral solution at the same time each day@@ .
It does not matter whether you take it with or without f@@ ood@@ .
Ho@@ we@@ ver@@ , you should not di@@ lu@@ te with other liqui@@ ds or mix with other food prior to taking AB@@ IL@@ I@@ F@@ Y oral sol@@ u@@ tion@@ .
Even if you feel bet@@ ter@@ , do not alter or dis@@ continue the daily dose of AB@@ IL@@ I@@ F@@ Y without first consul@@ ting your do@@ ct@@ or@@ .
If you take more AB@@ IL@@ I@@ F@@ Y than you should If you realise you have taken more AB@@ IL@@ I@@ F@@ Y oral solution than your doctor has recommended (@@ or if someone else has taken some of your AB@@ IL@@ I@@ F@@ Y oral sol@@ u@@ tion@@ )@@ , contact your doctor right a@@ wa@@ y@@ .
If you cannot reach your do@@ ct@@ or@@ , go to the near@@ est hospital and take the pack with you@@ .
If you forget to take AB@@ IL@@ I@@ F@@ Y If you miss a d@@ os@@ e@@ , take the missed dose as soon as you remember but do not take two d@@ oses in one day@@ .
If you have any further questions on the use of this produc@@ t@@ , ask your doctor or pharmac@@ ist@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AB@@ IL@@ I@@ F@@ Y can cause side effec@@ ts@@ , although not everybody gets them@@ .
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) Un@@ contro@@ ll@@ able twi@@ t@@ ching or jer@@ king mov@@ em@@ ent@@ s@@ , hea@@ da@@ che@@ , ti@@ re@@ dn@@ ess@@ , nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , an uncomfortable feeling in the stom@@ ach@@ , con@@ sti@@ p@@ ation@@ , increased production of s@@ ali@@ v@@ a@@ , light@@ -@@ he@@ ade@@ dn@@ ess@@ , trouble sle@@ ep@@ ing@@ , rest@@ less@@ ness@@ , feeling an@@ xi@@ ous@@ , sle@@ ep@@ in@@ ess@@ , sha@@ king and bl@@ urred visi@@ on@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ .
Some people may feel depres@@ se@@ d.
Other in@@ frequently reported side effec@@ ts@@ :
Ch@@ ang@@ es in the levels of some blood cell@@ s@@ ; unusual heart be@@ at@@ , sudden un@@ explained de@@ ath@@ , heart attack@@ ; aller@@ gic reaction (@@ e@@ . g. sw@@ elling in the mou@@ th@@ , ton@@ gu@@ e@@ , face and thro@@ at@@ , it@@ ch@@ ing@@ , ra@@ sh@@ )@@ ; high blood su@@ gar@@ , on@@ set or wor@@ sen@@ ing of di@@ abet@@ es@@ , ket@@ o@@ aci@@ do@@ sis (@@ ket@@ ones in the blood and ur@@ ine@@ ) or com@@ a@@ , low so@@ dium level in the bloo@@ d@@ ; weight ga@@ in@@ , weight los@@ s@@ , an@@ or@@ ex@@ i@@ a@@ ; nerv@@ ous@@ ness@@ , ag@@ it@@ ation@@ , feeling an@@ xi@@ ous@@ ; thoughts of suici@@ de@@ , suicide attempt and suici@@ de@@ ; speech disor@@ der@@ , sei@@ zu@@ re@@ , combination of fe@@ ver@@ , muscle sti@@ ff@@ ness@@ , faster breath@@ ing@@ , swe@@ at@@ ing@@ , reduced consci@@ ousness and sudden changes in blood pressure and heart rat@@ e@@ ; fa@@ int@@ ing@@ , high blood pressu@@ re@@ , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body@@ ; sp@@ asm of the muscles around the voice bo@@ x@@ , acci@@ dental inhal@@ ation of food with risk of p@@ ne@@ um@@ oni@@ a@@ , difficulty in swal@@ low@@ ing@@ ; infl@@ amm@@ ation of the pan@@ cre@@ as@@ ; infl@@ amm@@ ation of the li@@ ver@@ , y@@ el@@ lowing of the skin and white part of ey@@ es@@ , reports of ab@@ normal liver test valu@@ es@@ , ab@@ dom@@ inal and stomach dis@@ comfort@@ , di@@ arr@@ ho@@ e@@ a@@ ; skin ra@@ sh and sensi@@ tivity to light@@ , unusual hair loss or th@@ inn@@ ing@@ , excessive swe@@ at@@ ing@@ ; sti@@ ff@@ ness or cra@@ mp@@ s@@ , muscle pain@@ , weak@@ ness@@ ; invol@@ un@@ tary loss of ur@@ ine@@ , difficulty in passing ur@@ ine@@ ; pro@@ lon@@ ged and@@ / or painful er@@ ec@@ tion@@ ; difficulty controlling core body temperature or over@@ he@@ at@@ ing@@ , chest pain@@ , and sw@@ elling of hand@@ s@@ , an@@ kles or fe@@ et@@ .
In elderly patients with demen@@ ti@@ a@@ , more fatal cases have been reported while taking ari@@ pi@@ pra@@ z@@ ole@@ .
In addi@@ tion@@ , cases of stroke or "@@ mini@@ " stroke have been repor@@ te@@ d.
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
17@@ 7 5.
HO@@ W TO ST@@ OR@@ E@@ AB@@ IL@@ I@@ F@@ Y
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use AB@@ IL@@ I@@ F@@ Y after the exp@@ iry date which is stated on the bottle and on the car@@ ton@@ .
This medic@@ inal product does not require any special storage condi@@ tions@@ .
Use within 6 months after first op@@ en@@ ing@@ .
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
These measures will help to protect the environ@@ ment@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AB@@ IL@@ I@@ F@@ Y contains The active substance is ari@@ pi@@ pra@@ z@@ ole@@ .
Each ml contains 1 mg of ari@@ pi@@ pra@@ z@@ ole@@ .
The other ingredients are di@@ so@@ dium e@@ de@@ t@@ ate@@ , fru@@ ct@@ os@@ e@@ , g@@ ly@@ cer@@ in@@ , la@@ ctic aci@@ d@@ , meth@@ yl par@@ ah@@ y@@ dro@@ x@@ y@@ ben@@ zo@@ ate (@@ E@@ 2@@ 18@@ )@@ , prop@@ yl@@ ene g@@ ly@@ col@@ , prop@@ yl par@@ ah@@ y@@ dro@@ x@@ y@@ ben@@ zo@@ ate (@@ E@@ 2@@ 16@@ )@@ , so@@ dium hydro@@ x@@ ide@@ , su@@ cros@@ e@@ , pu@@ ri@@ fied water@@ , and natural orange cream with other natural fla@@ vo@@ urs@@ .
What AB@@ IL@@ I@@ F@@ Y looks like and cont@@ ents of the pack AB@@ IL@@ I@@ F@@ Y 1 m@@ g@@ / ml oral solution is a clear@@ , colo@@ ur@@ less to light yellow liquid supp@@ lied in bottles with poly@@ prop@@ yl@@ ene child@@ -@@ resi@@ stant closure containing 50 m@@ l@@ , 150 ml or 4@@ 80 ml per bot@@ t@@ le@@ .
Each car@@ ton contains one bottle and both a cali@@ br@@ ated poly@@ prop@@ yl@@ ene meas@@ uring cup and a cali@@ br@@ ated poly@@ prop@@ yl@@ ene low@@ -@@ den@@ sity pol@@ ye@@ th@@ yl@@ ene d@@ rop@@ per@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manu@@ fac@@ tur@@ er Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S. r. l.
Con@@ tra@@ da Fon@@ t@@ ana del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one - Italy
For any information about this medicine please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ :
Belgi@@ qu@@ e@@ / Belgi@@ ë@@ / Belgien BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Luxem@@ bour@@ g@@ / Luxemburg BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Te@@ л@@ .@@ : + 3@@ 59 800 12 400
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ .@@ : + 36 1 30@@ 1 9@@ 700
Č es@@ k@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 20 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
17@@ 8 Dan@@ mark BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B T@@ l@@ f@@ : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ V Tel@@ : + 31 34 8@@ 57 42 22
Deutschland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B GM@@ B@@ H & CO@@ .
K@@ G@@ AA Tel@@ : + 49 89 12@@ 1 4@@ 2@@ -@@ 0
Nor@@ ge BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y L@@ T@@ D T@@ l@@ f@@ : + 47 67 55 53 50
E@@ est@@ i Österreich BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 72 6@@ 40 13@@ 01
BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ ES@@ M@@ B@@ H Tel@@ : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ@@ : + 30 210 60@@ 7@@ 4@@ 300
Pol@@ ska BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B P@@ OL@@ S@@ KA SP@@ .
Z O@@ . O@@ .
Tel@@ .@@ : + 48 22 57@@ 9@@ 66@@ 66
E@@ spa@@ ñ@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B@@ , S. A.
Tel@@ : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ U@@ T@@ IC@@ A P@@ OR@@ TU@@ G@@ U@@ ES@@ A@@ , S. A.
Tel@@ : + 3@@ 51 21 4@@ 40 70 00
France BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l@@ : + 33 (@@ 0@@ )@@ 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 40 (@@ 0@@ )@@ 21 27@@ 2 16 00
Ireland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 3@@ 53 (@@ 1 800@@ ) 7@@ 49 7@@ 49
Slo@@ ven@@ i@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 38@@ 6 1 2@@ 36 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R H@@ F S@@ í@@ mi@@ : + 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 21 2 59@@ 29@@ 8@@ 4@@ 11
Itali@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Su@@ omi@@ / Fin@@ land O@@ Y BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B (@@ F@@ IN@@ L@@ AND@@ ) AB Pu@@ h@@ / Tel@@ : + 3@@ 58 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ & Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ@@ : + 3@@ 57 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B AB Tel@@ : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 44 (@@ 08@@ 00@@ ) 7@@ 31 17@@ 36
Lie@@ tu@@ va BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 370 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
17@@ 9 Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
180 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AB@@ IL@@ I@@ F@@ Y 7.5 m@@ g@@ / ml Sol@@ ution for In@@ jection ari@@ pi@@ pra@@ z@@ ole
Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
This medicine has been prescri@@ bed for you@@ .
Do not pass it on to o@@ ther@@ s.
It may harm them@@ , even if their symptoms are the same as yo@@ urs@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
In this le@@ af@@ let@@ :
1.
What AB@@ IL@@ I@@ F@@ Y is and what it is used for 2.
Before you use AB@@ IL@@ I@@ F@@ Y 3.
How to use AB@@ IL@@ I@@ F@@ Y 4.
Pos@@ sible side effects 5.
How to store AB@@ IL@@ I@@ F@@ Y 6.
Further information
1.
WH@@ AT AB@@ IL@@ I@@ F@@ Y IS AND WH@@ AT IT IS US@@ ED FO@@ R
AB@@ IL@@ I@@ F@@ Y is one of a group of medic@@ ines called anti@@ p@@ sycho@@ tic@@ s.
AB@@ IL@@ I@@ F@@ Y solution for in@@ jection is used to treat quickly symptoms of ag@@ itation and dist@@ res@@ sing behaviour that may occur in a disease character@@ ised by symptoms such as@@ : hear@@ ing@@ , seeing or sen@@ sing things which are not ther@@ e@@ , suspici@@ ous@@ ness@@ , mistak@@ en belie@@ fs@@ , in@@ co@@ her@@ ent speech and behaviour and emotional flat@@ ness@@ .
People with this condition may also feel depres@@ se@@ d@@ , guil@@ ty@@ , anxious or ten@@ se@@ . feeling "@@ high@@ "@@ , having excessive amounts of energ@@ y@@ , nee@@ ding much less sleep than us@@ u@@ al@@ , talking very quickly with racing ideas and sometimes severe irrit@@ abili@@ ty@@ .
AB@@ IL@@ I@@ F@@ Y solution for in@@ jection is given when treatment with oral formu@@ lations of AB@@ IL@@ I@@ F@@ Y is not appropri@@ ate@@ .
Your doctor will change your treatment to AB@@ IL@@ I@@ F@@ Y tab@@ le@@ ts@@ , AB@@ IL@@ I@@ F@@ Y or@@ o@@ disp@@ er@@ sible tab@@ lets or AB@@ IL@@ I@@ F@@ Y oral solution as soon as appropri@@ ate@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U US@@ E AB@@ IL@@ I@@ F@@ Y
Do not use AB@@ IL@@ I@@ F@@ Y if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ari@@ pi@@ pra@@ z@@ ole or any of the other ingredients of AB@@ IL@@ I@@ F@@ Y@@ .
Take special care with AB@@ IL@@ I@@ F@@ Y Before treatment with AB@@ IL@@ I@@ F@@ Y@@ , tell your doctor if you suffer from High blood sugar or family history of diabetes Sei@@ z@@ ure In@@ volun@@ tar@@ y@@ , ir@@ regular muscle mov@@ em@@ ent@@ s@@ , especially in the face Cardi@@ ov@@ as@@ cular dise@@ as@@ es@@ , family history of cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ , stroke or "@@ mini@@ " stro@@ ke@@ , ab@@ normal blood pressure
If you notice you are gaining wei@@ ght@@ , experience any difficulty in swal@@ lowing or aller@@ gic symp@@ tom@@ s@@ , please tell your do@@ ct@@ or@@ .
If you are an elderly patient suffering from dementia (@@ loss of memory and other mental abili@@ ti@@ es@@ )@@ , you or your car@@ er@@ / relative should tell your doctor if you have ever had a stroke or "@@ mini@@ " stro@@ ke@@ .
18@@ 1 T@@ ell the doctor or nurse if you feel di@@ zzy or fa@@ int after the in@@ jec@@ tion@@ .
You will probably need to lie down until you feel bet@@ ter@@ .
The doctor may also want to measure your blood pressure and pul@@ se@@ .
T@@ ell your doctor immediately if you are having any thoughts or feelings about hur@@ ting your@@ sel@@ f@@ .
Su@@ ici@@ dal thoughts and behavi@@ ours have been reported during ari@@ pi@@ pra@@ z@@ ole treat@@ ment@@ .
T@@ ell your doctor immediately if you suffer from muscle sti@@ ff@@ ness or inf@@ le@@ xi@@ bility with high fe@@ ver@@ , swe@@ at@@ ing@@ , al@@ tered mental stat@@ us@@ , or very rapid or ir@@ regular heart be@@ at@@ .
Children and adol@@ es@@ cents AB@@ IL@@ I@@ F@@ Y is not for use in children and adol@@ es@@ cents as it has not been studied in patients under 18 ye@@ ar@@ s.
As@@ k your doctor or pharmac@@ ist for advice before taking AB@@ IL@@ I@@ F@@ Y@@ .
Taking other medic@@ ines Please tell your doctor or pharmac@@ ist if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
Bloo@@ d pressu@@ re@@ -@@ lo@@ wering medi@@ cin@@ es@@ :
AB@@ IL@@ I@@ F@@ Y may increase the effect of medic@@ ines used to lower the blood pressu@@ re@@ .
Be sure to tell your doctor if you take a medicine to keep your blood pressure under contro@@ l.
Taking AB@@ IL@@ I@@ F@@ Y with some medic@@ ines may need to change your dose of AB@@ IL@@ I@@ F@@ Y@@ .
It is especially important to mention the following to your do@@ ct@@ or@@ :
Medic@@ ines to correct heart rhyth@@ m Anti@@ depres@@ s@@ ants or her@@ bal re@@ me@@ dy used to treat depression and anxiety Anti@@ f@@ ung@@ al agents Cer@@ tain medic@@ ines to treat HIV infection Anti@@ con@@ vul@@ s@@ ants used to treat ep@@ ile@@ p@@ sy
A combination of AB@@ IL@@ I@@ F@@ Y solution for in@@ jection with medic@@ ines taken for anxiety might make you feel dro@@ w@@ sy or di@@ zz@@ y@@ .
Only take other medic@@ ines while you are on AB@@ IL@@ I@@ F@@ Y if your doctor tells you that you can@@ .
Using AB@@ IL@@ I@@ F@@ Y with food and drink AB@@ IL@@ I@@ F@@ Y can be administ@@ ered regardless of me@@ al@@ s.
Al@@ co@@ hol should be avoided when taking AB@@ IL@@ I@@ F@@ Y@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not use AB@@ IL@@ I@@ F@@ Y if you are pregnant unless you have discussed this with your do@@ ct@@ or@@ .
Be sure to tell your doctor immediately if you are pregn@@ ant@@ , think you may be pregn@@ ant@@ , or if you are planning to become pregn@@ ant@@ .
Bre@@ ast@@ -@@ feeding mothers should not take AB@@ IL@@ I@@ F@@ Y@@ .
Be sure to tell your doctor immediately if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
Dri@@ ving and using machines Do not drive or use any tools or machines if you feel dro@@ w@@ sy after receiving AB@@ IL@@ I@@ F@@ Y solution for in@@ jec@@ tion@@ .
3.
HO@@ W TO US@@ E AB@@ IL@@ I@@ F@@ Y
Your doctor will decide how much AB@@ IL@@ I@@ F@@ Y solution for in@@ jection you need and how long you need it for@@ .
The usual dose is 9.@@ 75 mg (@@ 1.3 m@@ l@@ ) for the first in@@ jec@@ tion@@ .
Up to three in@@ jections in 24 hours may be gi@@ ven@@ .
The total dose of AB@@ IL@@ I@@ F@@ Y (@@ all formu@@ la@@ tions@@ ) should not exce@@ ed 30 mg per day@@ .
18@@ 2 AB@@ IL@@ I@@ F@@ Y solution for in@@ jection is ready to use@@ .
The correct amount of solution will be in@@ jected into your muscle by your doctor or nur@@ se@@ .
If you are concerned that you are given more AB@@ IL@@ I@@ F@@ Y solution for in@@ jection than you feel necess@@ ar@@ y@@ , tell your doctor or nurse of your concern@@ .
Only a few d@@ oses of AB@@ IL@@ I@@ F@@ Y solution for in@@ jection may be nee@@ de@@ d.
Your doctor will decide when you need another dose of AB@@ IL@@ I@@ F@@ Y solution for in@@ jec@@ tion@@ .
If you have any further questions on the use of this produc@@ t@@ , ask your doctor or pharmac@@ ist@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AB@@ IL@@ I@@ F@@ Y can cause side effec@@ ts@@ , although not everybody gets them@@ .
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) of AB@@ IL@@ I@@ F@@ Y solution for in@@ jection include sle@@ ep@@ in@@ ess@@ , di@@ zz@@ in@@ ess@@ , hea@@ da@@ che@@ , rest@@ less@@ ness@@ , nau@@ sea and vo@@ mit@@ ing@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may have changes in blood pressu@@ re@@ , may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ , dry mouth or f@@ ati@@ gu@@ e@@ .
In addi@@ tion@@ , the following side effects have been seen in patients treated with oral formu@@ lations of AB@@ IL@@ I@@ F@@ Y@@ :
Comm@@ on side effects (@@ greater than 1 in 100@@ , less than 1 in 10 pati@@ ent@@ s@@ ) Un@@ contro@@ ll@@ able twi@@ t@@ ching or jer@@ king mov@@ em@@ ent@@ s@@ , hea@@ da@@ che@@ , ti@@ re@@ dn@@ ess@@ , nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , an uncomfortable feeling in the stom@@ ach@@ , con@@ sti@@ p@@ ation@@ , increased production of s@@ ali@@ v@@ a@@ , light@@ -@@ he@@ ade@@ dn@@ ess@@ , trouble sle@@ ep@@ ing@@ , rest@@ less@@ ness@@ , feeling an@@ xi@@ ous@@ , sle@@ ep@@ in@@ ess@@ , sha@@ king and bl@@ urred visi@@ on@@ .
Un@@ common side effects (@@ greater than 1 in 1,@@ 00@@ 0@@ , less than 1 in 100 pati@@ ent@@ s@@ ) Some people may feel di@@ zz@@ y@@ , especially when getting up from a lying or sitting position@@ , or may experience a fast heart rat@@ e@@ .
Some people may feel depres@@ se@@ d.
Other in@@ frequently reported side effec@@ ts@@ :
Ch@@ ang@@ es in the levels of some blood cell@@ s@@ ; unusual heart be@@ at@@ , sudden un@@ explained de@@ ath@@ , heart attack@@ ; aller@@ gic reaction (@@ e@@ . g. sw@@ elling in the mou@@ th@@ , ton@@ gu@@ e@@ , face and thro@@ at@@ , it@@ ch@@ ing@@ , ra@@ sh@@ )@@ ; high blood su@@ gar@@ , on@@ set or wor@@ sen@@ ing of di@@ abet@@ es@@ , ket@@ o@@ aci@@ do@@ sis (@@ ket@@ ones in the blood and ur@@ ine@@ ) or com@@ a@@ , low so@@ dium level in the bloo@@ d@@ ; weight ga@@ in@@ , weight los@@ s@@ , an@@ or@@ ex@@ i@@ a@@ ; nerv@@ ous@@ ness@@ , ag@@ it@@ ation@@ , feeling an@@ xi@@ ous@@ ; thoughts of suici@@ de@@ , suicide attempt and suici@@ de@@ ; speech disor@@ der@@ , sei@@ zu@@ re@@ , combination of fe@@ ver@@ , muscle sti@@ ff@@ ness@@ , faster breath@@ ing@@ , swe@@ at@@ ing@@ , reduced consci@@ ousness and sudden changes in blood pressure and heart rat@@ e@@ ; fa@@ int@@ ing@@ , high blood pressu@@ re@@ , block@@ age of a blood vessel by a blood c@@ lot formed elsewhere in the body@@ ; sp@@ asm of the muscles around the voice bo@@ x@@ , acci@@ dental inhal@@ ation of food with risk of p@@ ne@@ um@@ oni@@ a@@ , difficulty in swal@@ low@@ ing@@ ; infl@@ amm@@ ation of the pan@@ cre@@ as@@ ; infl@@ amm@@ ation of the li@@ ver@@ , y@@ el@@ lowing of the skin and white part of ey@@ es@@ , reports of ab@@ normal liver test valu@@ es@@ , ab@@ dom@@ inal and stomach dis@@ comfort@@ , di@@ arr@@ ho@@ e@@ a@@ ; skin ra@@ sh and sensi@@ tivity to light@@ , unusual hair loss or th@@ inn@@ ing@@ , excessive swe@@ at@@ ing@@ ; sti@@ ff@@ ness or cra@@ mp@@ s@@ , muscle pain@@ , weak@@ ness@@ ; invol@@ un@@ tary loss of ur@@ ine@@ , difficulty in passing ur@@ ine@@ ; pro@@ lon@@ ged and@@ / or painful er@@ ec@@ tion@@ ; difficulty controlling core body temperature or over@@ he@@ at@@ ing@@ , chest pain@@ , and sw@@ elling of hand@@ s@@ , an@@ kles or fe@@ et@@ .
In elderly patients with demen@@ ti@@ a@@ , more fatal cases have been reported while taking ari@@ pi@@ pra@@ z@@ ole@@ .
In addi@@ tion@@ , cases of stroke or "@@ mini@@ " stroke have been repor@@ te@@ d.
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ .
18@@ 3 5.
HO@@ W TO ST@@ ORE AB@@ IL@@ I@@ F@@ Y
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use AB@@ IL@@ I@@ F@@ Y after the exp@@ iry date which is stated on the car@@ ton and on the vi@@ al@@ .
Keep the vi@@ al in the ou@@ ter car@@ ton in order to protect from light@@ .
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
These measures will help to protect the environ@@ ment@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AB@@ IL@@ I@@ F@@ Y contains The active substance is ari@@ pi@@ pra@@ z@@ ole@@ .
Each ml contains 7.5 mg ari@@ pi@@ pra@@ z@@ ole@@ .
A vi@@ al contains 9.@@ 75 mg (@@ 1.3 m@@ l@@ ) ari@@ pi@@ pra@@ z@@ ole@@ .
The other ingredients are sul@@ f@@ ob@@ ut@@ y@@ le@@ ther β -@@ cy@@ clo@@ de@@ x@@ tr@@ in (@@ S@@ BE@@ CD@@ )@@ , t@@ art@@ ari@@ c aci@@ d@@ , so@@ dium hydro@@ x@@ ide@@ , and water for in@@ jec@@ tion@@ .
What AB@@ IL@@ I@@ F@@ Y looks like and cont@@ ents of the pack The AB@@ IL@@ I@@ F@@ Y solution for in@@ jection is a clear@@ , colo@@ ur@@ less@@ , aqu@@ e@@ ous sol@@ u@@ tion@@ .
Each car@@ ton contains one sing@@ le@@ -@@ use type I glass vi@@ al with a rubber but@@ yl stop@@ per and a "@@ fli@@ p@@ -@@ off@@ " al@@ uminium se@@ al@@ .
Marketing Auth@@ or@@ isation Hol@@ der Ot@@ su@@ ka P@@ harm@@ ac@@ eu@@ tical Europe L@@ t@@ d.
Hun@@ ton House High@@ bridge Business Park@@ , Oxford Road U@@ x@@ bridge - Midd@@ le@@ sex U@@ B@@ 8 1@@ H@@ U - United Kingdom
Manu@@ fac@@ tur@@ er Bri@@ stol@@ -@@ M@@ yers S@@ qui@@ b@@ b S. r. l.
Con@@ tra@@ da Fon@@ t@@ ana del Cer@@ as@@ o I@@ -@@ 0@@ 30@@ 12 An@@ ag@@ ni@@ -@@ F@@ ros@@ in@@ one - Italy
For any information about this medic@@ ine@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ :
Belgi@@ qu@@ e@@ / Belgi@@ ë@@ / Belgien BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Luxem@@ bour@@ g@@ / Luxemburg BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ EL@@ G@@ I@@ U@@ M S. A. / N. V.
T@@ é@@ l@@ / Tel@@ : + 32 2 3@@ 52 74 60
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Te@@ л@@ .@@ : + 3@@ 59 800 12 400
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ .@@ : + 36 1 30@@ 1 9@@ 700
Č es@@ k@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 20 2@@ 21 0@@ 16 111
Malta BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Dan@@ mark BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B T@@ l@@ f@@ : + 45 45 93 05 06
Ne@@ der@@ land BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B B@@ V Tel@@ : + 31 34 8@@ 57 42 22
18@@ 4 Deutschland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B GM@@ B@@ H & CO@@ .
K@@ G@@ AA Tel@@ : + 49 89 12@@ 1 4@@ 2@@ -@@ 0
Nor@@ ge BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B N@@ OR@@ W@@ A@@ Y L@@ T@@ D T@@ l@@ f@@ : + 47 67 55 53 50
E@@ est@@ i BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 72 6@@ 40 13@@ 01
Österreich BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ ES@@ M@@ B@@ H Tel@@ : + 43 1 60 14 30
Ε@@ λ@@ λ@@ ά@@ δ@@ α BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B A. E.
Τ@@ η@@ λ@@ : + 30 210 60@@ 7@@ 4@@ 300
Pol@@ ska BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B P@@ OL@@ S@@ KA SP@@ .
Z O@@ . O@@ .
Tel@@ .@@ : + 48 22 57@@ 9@@ 66@@ 66
E@@ spa@@ ñ@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B@@ , S. A.
Tel@@ : + 34 91 4@@ 56 53 00
Portugal BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B F@@ AR@@ M@@ AC@@ Ê@@ U@@ T@@ IC@@ A P@@ OR@@ TU@@ G@@ U@@ ES@@ A@@ , S. A.
Tel@@ : + 3@@ 51 21 4@@ 40 70 00
France BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S@@ AR@@ L T@@ é@@ l@@ : + 33 (@@ 0@@ )@@ 8@@ 10 4@@ 10 500
Rom@@ â@@ nia BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 40 (@@ 0@@ )@@ 21 27@@ 2 16 00
Ireland BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 3@@ 53 (@@ 1 800@@ ) 7@@ 49 7@@ 49
Slo@@ ven@@ i@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 38@@ 6 1 2@@ 36 47 00
Í@@ s@@ land V@@ IS@@ TO@@ R H@@ F S@@ í@@ mi@@ : + 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B SP@@ OL@@ .
S R. O@@ .
Tel@@ : + 4@@ 21 2 59@@ 29@@ 8@@ 4@@ 11
Itali@@ a BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B S. R. L.
Tel@@ : + 39 06 50 39 61
Su@@ omi@@ / Fin@@ land O@@ Y BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B (@@ F@@ IN@@ L@@ AND@@ ) AB Pu@@ h@@ / Tel@@ : + 3@@ 58 9 25@@ 1 21 230
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Α@@ Κ@@ Η@@ Σ Π@@ Α@@ Ν@@ Α@@ Γ@@ Ι@@ Ω@@ Τ@@ Ο@@ Υ & Υ@@ Ι@@ Ο@@ Σ Ε .@@ Π .@@ Ε@@ .
Τ@@ η@@ λ@@ : + 3@@ 57 22 67@@ 70@@ 38
S@@ ver@@ ige BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B AB Tel@@ : + 46 8 7@@ 04 71 00
Lat@@ vi@@ ja BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 3@@ 71 67 50 21 85
United Kingdom BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL@@ S L@@ T@@ D Tel@@ : + 44 (@@ 08@@ 00@@ ) 7@@ 31 17@@ 36
Lie@@ tu@@ va BR@@ IS@@ T@@ OL@@ -@@ M@@ Y@@ ER@@ S S@@ Q@@ U@@ IB@@ B G@@ Y@@ Ó@@ G@@ Y@@ S@@ Z@@ ER@@ K@@ ER@@ ES@@ K@@ ED@@ EL@@ M@@ I K@@ FT@@ .
Tel@@ : + 370 5 27@@ 90 7@@ 62
This le@@ af@@ let was last approved in
Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ /
185
European Medic@@ ines Agency
E@@ ME@@ A@@ / H@@ / C@@ / 7@@ 78
EU@@ RO@@ P@@ E@@ AN P@@ U@@ BL@@ IC AS@@ S@@ ES@@ SM@@ EN@@ T RE@@ P@@ OR@@ T (@@ EP@@ AR@@ )
AB@@ RA@@ X@@ AN@@ E
EP@@ AR sum@@ mary for the public
It explains how the Committee for Medic@@ inal Produc@@ ts for Human Use (@@ CH@@ MP@@ ) asse@@ ssed the studies per@@ for@@ med@@ , to reach their recommendations on how to use the medic@@ ine@@ .
If you need more information about your medical condition or your treat@@ ment@@ , read the Pack@@ age Le@@ af@@ let (@@ also part of the EP@@ AR@@ ) or contact your doctor or pharmac@@ ist@@ .
If you want more information on the basis of the CH@@ MP recommend@@ ations@@ , read the Scienti@@ fic Dis@@ c@@ ussion (@@ also part of the EP@@ AR@@ )@@ .
What is Abra@@ x@@ an@@ e@@ ?
Abra@@ x@@ ane is a powder that is made up into a suspension for in@@ fusion (@@ dri@@ p into a v@@ ein@@ )@@ .
It contains the active substance pac@@ li@@ tax@@ el (@@ 5 m@@ g@@ / m@@ l@@ )@@ .
What is Abra@@ x@@ ane used for@@ ?
Abra@@ x@@ ane is used to treat met@@ ast@@ atic breast cancer in patients whose first treatment for their met@@ ast@@ atic disease has stopped working and for whom standard treatment including an ‘ anth@@ ra@@ cy@@ clin@@ e@@ ’ (@@ a type of an@@ tic@@ ancer medic@@ ine@@ ) is not suit@@ ab@@ le@@ . ‘ Met@@ ast@@ ati@@ c@@ ’ means that the cancer has spread to other parts of the body@@ .
Abra@@ x@@ ane is used on its ow@@ n@@ .
The medicine can only be obtained with a prescri@@ p@@ tion@@ .
How is Abra@@ x@@ ane use@@ d@@ ?
Abra@@ x@@ ane should only be given under the super@@ vision of a specialist cancer doctor in wards that are speci@@ alised in giving ‘ cy@@ t@@ oto@@ x@@ ic@@ ’ (@@ cell@@ -@@ kill@@ ing@@ ) medi@@ cin@@ es@@ .
The recommended dose is 260 mg per square met@@ re of body surface area (@@ calcul@@ ated using the patient ’ s height and wei@@ ght@@ )@@ .
It is given over a period of 30 min@@ ut@@ es@@ , every three wee@@ ks@@ .
The dose may be reduced or treatment interrup@@ ted in patients who have certain side effects affecting the blood or the ner@@ ves@@ .
Abra@@ x@@ ane should not be used in patients who have severe problems with their li@@ ver@@ .
The appropriate d@@ oses for patients with mild or moderate liver problems or with ki@@ dney problems are not kno@@ wn@@ .
How does Abra@@ x@@ ane work@@ ?
The active substance in Abra@@ x@@ an@@ e@@ , pac@@ li@@ tax@@ el@@ , belon@@ gs to the group of an@@ tic@@ ancer medic@@ ines known as the ‘ tax@@ an@@ es@@ ’@@ .
P@@ ac@@ li@@ tax@@ el blocks the ability of cancer cells to break down their internal ‘ sk@@ el@@ eton ’ that allows them to divide and multi@@ pl@@ y@@ .
With their sk@@ el@@ eton still in pla@@ ce@@ , the cells cannot divide and they eventually die@@ .
Abra@@ x@@ ane also affects non@@ -@@ cancer cells such as blood and nerve cell@@ s@@ , which can cause side effec@@ ts@@ .
P@@ ac@@ li@@ tax@@ el has been available as an an@@ tic@@ ancer medicine since 199@@ 3.
Con@@ ven@@ tional types of pac@@ li@@ tax@@ el contain sub@@ stances (@@ sol@@ vent@@ s@@ ) that dis@@ solve the pac@@ li@@ tax@@ el@@ , but can cause side effec@@ ts@@ .
Abra@@ x@@ ane does not contain these sol@@ vent@@ s.
7 West@@ fer@@ ry Cir@@ cus@@ , Can@@ ary W@@ har@@ f@@ , London E@@ 14 4@@ HB@@ , UK Tel@@ .
(@@ 44@@ -@@ 20@@ ) 74 18 84 00 Fax (@@ 44@@ -@@ 20@@ ) 74 18 84 16 E@@ -@@ mail@@ : mail@@ @@@ eme@@ a. europa@@ . e@@ u htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . e@@ u ©@@ E@@ ME@@ A 2007 Re@@ production and@@ / or distribution of this document is author@@ ised for non commercial purposes only provided the E@@ ME@@ A is acknowledged body@@ , and therefore its benefits and risk@@ s@@ , in comparison with conventional medic@@ ines containing pac@@ li@@ tax@@ el@@ .
How has Abra@@ x@@ ane been studi@@ ed@@ ?
The effects of Abra@@ x@@ ane were first tested in experim@@ ental models before being studied in hum@@ ans@@ .
The company also presented data from the published liter@@ at@@ ure@@ .
The effec@@ tiveness of Abra@@ x@@ ane has been studied in one main study involving 4@@ 60 women with met@@ ast@@ atic breast canc@@ er@@ , around thre@@ e@@ -@@ quarters of whom had received an anth@@ ra@@ cy@@ cl@@ ine in the pa@@ st@@ .
Around half of the patients in the study had already received treatments for their cancer after it had become met@@ ast@@ ati@@ c.
The effects of Abra@@ x@@ ane (@@ given on its ow@@ n@@ ) were compared with those of a conventional pac@@ li@@ tax@@ el@@ - containing medicine (@@ given together with other medic@@ ines to reduce side effec@@ ts@@ )@@ .
The main measure of effec@@ tiveness was the number of patients who ‘ responded ’ after at least five weeks of treat@@ ment@@ .
This was defined as the pati@@ ent@@ ’ s main tum@@ ours having disappeared or having shr@@ unk in size by at least 30@@ %@@ .
What benefit has Abra@@ x@@ ane shown during the stu@@ dies@@ ?
Abra@@ x@@ ane was more effective than conventional pac@@ li@@ tax@@ el@@ -@@ containing medi@@ cin@@ es@@ .
Over@@ all@@ , in the main stu@@ dy@@ , 72 (@@ 3@@ 1@@ %@@ ) of the 2@@ 29 women receiving Abra@@ x@@ ane responded to treat@@ ment@@ , compared with 37 (@@ 16@@ %@@ ) of the 2@@ 25 receiving conventional pac@@ li@@ tax@@ el@@ -@@ containing medi@@ cin@@ es@@ .
When looking only at the patients who were receiving their first treatment for met@@ ast@@ atic breast canc@@ er@@ , there was no difference between the medic@@ ines in terms of measures of effec@@ tiveness such as the time until the disease got worse and survi@@ val@@ .
In contra@@ st@@ , in patients who had taken other treatments for met@@ ast@@ atic breast cancer be@@ fore@@ , these additional measures showed that Abra@@ x@@ ane was more effective than conventional pac@@ li@@ tax@@ el@@ -@@ containing medi@@ cin@@ es@@ .
Ther@@ e@@ fore@@ , the company with@@ drew its application for the use of Abra@@ x@@ ane as fir@@ st@@ -@@ line treatment during the assessment of the medic@@ ine@@ .
What is the risk associated with Abra@@ x@@ an@@ e@@ ?
The most common side effects with Abra@@ x@@ ane (@@ seen in more than 1 patient in 10@@ ) are neut@@ rop@@ en@@ ia (@@ low levels of neut@@ ro@@ phil@@ s@@ , a type of white blood cell@@ )@@ , an@@ a@@ emi@@ a (@@ low red blood cell coun@@ ts@@ )@@ , leu@@ cop@@ en@@ ia (@@ low levels of leu@@ co@@ cy@@ tes@@ , a type of white blood cell@@ )@@ , thro@@ mbo@@ cy@@ top@@ en@@ ia (@@ low blood plat@@ el@@ et coun@@ ts@@ )@@ , lymp@@ hop@@ en@@ ia (@@ low levels of lymp@@ ho@@ cy@@ tes@@ , a type of white blood cell@@ )@@ , peri@@ pher@@ al neuro@@ pa@@ thy (@@ nerve damage in the hands and fe@@ et@@ )@@ , neuro@@ pa@@ thy (@@ nerve dam@@ age@@ )@@ , hypo@@ aes@@ the@@ sia (@@ reduced sense of touch@@ )@@ , para@@ es@@ the@@ sia (@@ unusual sens@@ ations like p@@ ins and need@@ les@@ )@@ , nau@@ sea (@@ feeling sick@@ )@@ , di@@ arr@@ ho@@ e@@ a@@ , vo@@ mit@@ ing@@ , con@@ sti@@ p@@ ation@@ , stom@@ ati@@ tis (@@ infl@@ amm@@ ation of the lining of the mou@@ th@@ )@@ , al@@ op@@ ec@@ ia (@@ hair los@@ s@@ )@@ , ra@@ sh@@ , ar@@ th@@ r@@ al@@ gia (@@ joint pain@@ )@@ , my@@ al@@ gia (@@ muscle pain@@ )@@ , an@@ or@@ ex@@ ia (@@ loss of appeti@@ te@@ )@@ , f@@ ati@@ gue (@@ ti@@ re@@ dn@@ ess@@ )@@ , as@@ th@@ en@@ ia (@@ weak@@ ness@@ ) and py@@ re@@ x@@ ia (@@ fe@@ ver@@ )@@ .
For the full list of all side effects reported with Abra@@ x@@ an@@ e@@ , see the Pack@@ age Le@@ af@@ let@@ .
Abra@@ x@@ ane should not be used in people who may be hyper@@ sensitive (@@ aller@@ gi@@ c@@ ) to pac@@ li@@ tax@@ el or any of the other ingredi@@ ent@@ s.
It should also not be used in patients who are breast feeding or who have low levels of neut@@ ro@@ ph@@ ils in the blood before starting treat@@ ment@@ .
Why has Abra@@ x@@ ane been appro@@ v@@ ed@@ ?
The Committee for Medic@@ inal Produc@@ ts for Human Use (@@ CH@@ MP@@ ) noted that Abra@@ x@@ ane was more effective than conventional pac@@ li@@ tax@@ el@@ -@@ containing medic@@ ines in patients whose first treatment had stopped work@@ ing@@ , and th@@ at@@ , unlike other pac@@ li@@ tax@@ el@@ -@@ containing medi@@ cin@@ es@@ , it does not need other medic@@ ines to reduce side effec@@ ts@@ .
The Committee decided that Abra@@ x@@ an@@ e@@ ’ s benefits are greater than its risks for the treatment of met@@ ast@@ atic breast cancer in patients who have failed fir@@ st@@ -@@ line treatment for met@@ ast@@ atic disease and for whom stand@@ ard@@ , anth@@ ra@@ cy@@ clin@@ e@@ -@@ containing therapy is not indi@@ cat@@ ed@@ .
The Committee recommended that Abra@@ x@@ ane be given marketing author@@ is@@ ation@@ .
Other information about Abra@@ x@@ an@@ e@@ :
The European Commission granted a marketing author@@ isation val@@ id throughout the European Union for Abra@@ x@@ ane to Abra@@ xis Bio@@ Science Limited on 11 January 200@@ 8.
The full EP@@ AR for Abra@@ x@@ ane can be found her@@ e@@ .
This sum@@ mary was last updated in 11@@ -@@ 200@@ 7.
©@@ E@@ ME@@ A 2007
2@@ / 2
EU Number
Inv@@ ented name
St@@ ren@@ g@@ th
P@@ harm@@ ac@@ eu@@ tical Form
Route of Administration
Pack@@ aging
Cont@@ ent
Pack@@ age size
EU@@ / 1@@ / 07@@ / 4@@ 28@@ / 00@@ 1
Abra@@ x@@ ane
5 m@@ g@@ / ml
Po@@ w@@ der for suspension for in@@ fusion
In@@ tra@@ ven@@ ous use
vi@@ al (@@ g@@ las@@ s@@ )
100 mg
1 vi@@ al
1@@ / 1
AN@@ NE@@ X 1
SU@@ M@@ MAR@@ Y O@@ F P@@ RO@@ D@@ UC@@ T CH@@ AR@@ AC@@ TER@@ IS@@ T@@ IC@@ S
1 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Abra@@ x@@ ane 5 m@@ g@@ / ml powder for suspension for in@@ fu@@ sion@@ .
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each vi@@ al contains 100 mg of pac@@ li@@ tax@@ el@@ .
After re@@ constitu@@ tion@@ , each ml of suspension contains 5 mg of pac@@ li@@ tax@@ el@@ .
Ex@@ cip@@ i@@ ents The recon@@ stit@@ uted medic@@ inal product contains approximately 4@@ 25 mg so@@ dium per d@@ os@@ e@@ .
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Po@@ w@@ der for suspension for in@@ fu@@ sion@@ .
The recon@@ stit@@ uted suspension has a p@@ H of 6@@ -@@ 7.5 and an os@@ mol@@ ality of 30@@ 0@@ -@@ 360 m@@ O@@ sm@@ / k@@ g.
The powder is white to y@@ el@@ low@@ .
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Abra@@ x@@ ane mon@@ o@@ therapy is indicated for the treatment of met@@ ast@@ atic breast cancer in patients who have failed fir@@ st@@ -@@ line treatment for met@@ ast@@ atic disease and for whom stand@@ ard@@ , anth@@ ra@@ cy@@ cl@@ ine containing therapy is not indicated (@@ See also section 4.@@ 4@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
Abra@@ x@@ ane should only be administ@@ ered under the super@@ vision of a qualified onc@@ ologist in units speci@@ alised in the administration of cy@@ t@@ oto@@ x@@ ic ag@@ ent@@ s.
The procedure for re@@ constitution is described in section 6.@@ 6.
The recommended dose of Abra@@ x@@ ane is 260 m@@ g@@ / m2 administ@@ ered in@@ tra@@ ven@@ ously over 30 minutes every 3 wee@@ ks@@ .
D@@ ose adju@@ st@@ ments during treat@@ ment@@ :
Pati@@ ents who experience severe neut@@ rop@@ en@@ ia (@@ neut@@ rop@@ hi@@ l count < 0.@@ 50 x 10@@ 9@@ / l for a week or lon@@ ger@@ ) or severe sens@@ ory neuro@@ pa@@ thy during Abra@@ x@@ ane therapy should have the dose reduced to 220 m@@ g@@ / m2 for subsequent cour@@ ses@@ .
Following rec@@ ur@@ r@@ ence of severe neut@@ rop@@ en@@ ia or severe sens@@ ory neuro@@ path@@ y@@ , additional dose reduction should be made to 180 m@@ g@@ / m@@ 2.
Abra@@ x@@ ane should not be administ@@ ered until neut@@ rop@@ hi@@ l counts recover to > 1.5 x 10@@ 9@@ / l.
For grade 3 sens@@ ory neuro@@ pa@@ thy with@@ hold treatment until resolution to grade 1 or 2@@ , followed by a dose reduction for all subsequent cour@@ ses@@ .
2 Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ :
In@@ sufficient data are currently available to recommend dose modi@@ fications in patients with mild to moderate he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see sections 4.@@ 4. and 5.@@ 2@@ )@@ .
Pati@@ ents with severe he@@ pati@@ c im@@ pa@@ ir@@ ment should not be treated with pac@@ li@@ tax@@ el@@ .
Pati@@ ents with im@@ paired ren@@ al func@@ tion@@ :
Studies in patients with im@@ paired ren@@ al function have not been performed and in@@ sufficient data are currently available to recommend dose modi@@ fications in patients with ren@@ al im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
Abra@@ x@@ ane is not recommended for use in children below age 18 years due to in@@ sufficient data on safety and eff@@ ic@@ ac@@ y@@ .
El@@ derly pati@@ ent@@ s@@ :
In the clinical stu@@ dies@@ , no tox@@ ici@@ ties occurred notably more frequently among elderly patients who received Abra@@ x@@ an@@ e@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
L@@ act@@ ation@@ .
Pati@@ ents who have bas@@ eline neut@@ rop@@ hi@@ l counts < 1.5 x 10@@ 9@@ / l.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
Abra@@ x@@ ane is an alb@@ umin@@ -@@ bound nan@@ op@@ article formu@@ lation of pac@@ li@@ tax@@ el@@ , which may have substan@@ tially different pharmac@@ ological properties compared to other formu@@ lations of pac@@ li@@ tax@@ el (@@ see sections 5.@@ 1 and 5.@@ 2@@ )@@ ..
Hy@@ per@@ sensi@@ tiv@@ it@@ y@@ :
If hyper@@ sensi@@ tivity occ@@ urs@@ , the medic@@ inal product should be dis@@ continued immedi@@ at@@ el@@ y@@ , symp@@ tom@@ atic treatment should be initi@@ at@@ ed@@ , and that patient should not be rech@@ all@@ eng@@ ed with pac@@ li@@ tax@@ el@@ .
Ha@@ em@@ at@@ olog@@ y@@ :
B@@ one mar@@ row supp@@ res@@ sion (@@ primarily neut@@ rop@@ eni@@ a@@ ) occ@@ urs frequently with Abra@@ x@@ an@@ e@@ .
Ne@@ ut@@ rop@@ en@@ ia is d@@ os@@ e@@ -@@ dependent and a d@@ os@@ e@@ -@@ limi@@ ting tox@@ ic@@ it@@ y@@ .
Fre@@ qu@@ ent monitoring of blood cell counts should be performed during Abra@@ x@@ ane therap@@ y@@ .
Pati@@ ents should not be re@@ treated with subsequent cy@@ cles of Abra@@ x@@ ane until neut@@ ro@@ ph@@ ils recover to > 1.5 x 10@@ 9@@ / l and plat@@ el@@ ets recover to > 100 x 10@@ 9@@ / l.
Neuro@@ path@@ y@@ :
Sens@@ ory neuro@@ pa@@ thy occ@@ urs frequently with Abra@@ x@@ an@@ e@@ , although development of severe symptoms is less common@@ .
The occ@@ ur@@ r@@ ence of grade 1 or 2 sens@@ ory neuro@@ pa@@ thy does not generally require dose re@@ duc@@ tion@@ .
If grade 3 sens@@ ory neuro@@ pa@@ thy develop@@ s@@ , treatment should be with@@ held until resolution to grade 1 or 2 followed by a dose reduction for all subsequent courses of Abra@@ x@@ ane is recommended (@@ see section 4.@@ 2@@ )@@ .
3 H@@ ep@@ atic Imp@@ air@@ ment@@ :
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment may be at increased risk of tox@@ ic@@ it@@ y@@ , particularly from my@@ el@@ os@@ u@@ pp@@ res@@ sion@@ , and such patients should be closely monit@@ ored for development of pro@@ found my@@ el@@ os@@ u@@ pp@@ res@@ sion@@ .
The use of Abra@@ x@@ ane has not been formally studied in patients specifically with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
Pati@@ ents with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ bili@@ ru@@ bin > 5 x UL@@ N or AS@@ L@@ / AL@@ T > 10 x UL@@ N@@ ) should not be treated with Abra@@ x@@ an@@ e@@ .
The appropriate dose regim@@ en in patients with less severe he@@ pati@@ c im@@ pa@@ ir@@ ment is unk@@ no@@ wn@@ .
Cardi@@ oto@@ x@@ ic@@ it@@ y@@ :
While cardi@@ oto@@ x@@ ic@@ ity un@@ equi@@ vo@@ cally related to Abra@@ x@@ ane has not been demonstr@@ at@@ ed@@ , cardi@@ ac events are not un@@ common in the indicated pop@@ ula@@ tion@@ , especially in patients who have previously received anth@@ ra@@ cy@@ c@@ lines or have underlying cardi@@ ac or pul@@ mon@@ ary dise@@ as@@ e@@ .
Thus patients receiving Abra@@ x@@ ane should be vig@@ il@@ antly monit@@ ored by physi@@ cians for the occ@@ ur@@ r@@ ence of cardi@@ ac event@@ s.
Sex@@ ually active men and women should use effective methods of contra@@ c@@ eption during treatment and up to six months after treatment for men@@ , and one month after treatment for women (@@ see section 4.@@ 6@@ )@@ .
The effec@@ tiveness and safety of Abra@@ x@@ ane in patients with central nervous system (@@ CN@@ S@@ ) met@@ ast@@ ases has not been establi@@ sh@@ ed@@ .
CN@@ S met@@ ast@@ ases are generally not well controlled by sy@@ ste@@ mic ch@@ emo@@ therap@@ y@@ .
Gast@@ ro@@ inte@@ st@@ inal Symp@@ tom@@ s@@ :
If patients experience nau@@ se@@ a@@ , vo@@ mi@@ ting and di@@ arr@@ ho@@ ea following the administration of Abra@@ x@@ an@@ e@@ , they may be treated with commonly used anti@@ -@@ eme@@ tics and con@@ sti@@ p@@ ating ag@@ ent@@ s.
Ex@@ cip@@ i@@ ent@@ s@@ :
When re@@ constitu@@ te@@ d@@ , Abra@@ x@@ ane contains approximately 4@@ 25 mg so@@ dium per d@@ os@@ e@@ .
To be taken into consideration by patients on a controlled so@@ dium di@@ et@@ .
4.@@ 5 Inter@@ actions with other medic@@ inal products and other forms of inter@@ action
No inter@@ action studies have been per@@ for@@ med@@ .
The met@@ aboli@@ sm of pac@@ li@@ tax@@ el is cat@@ aly@@ se@@ d@@ , in part@@ , by cy@@ to@@ ch@@ rome P@@ 450 is@@ o@@ enz@@ ym@@ es C@@ Y@@ P@@ 2@@ C@@ 8 and C@@ Y@@ P@@ 3@@ A4 (@@ see section 5.@@ 2@@ )@@ .
Ther@@ e@@ fore@@ , caution should be exerc@@ ised when administ@@ ering pac@@ li@@ tax@@ el con@@ co@@ mit@@ antly with medic@@ ines known to in@@ hi@@ bit (@@ e@@ . g. er@@ y@@ thro@@ my@@ cin@@ , flu@@ ox@@ et@@ ine@@ , i@@ mi@@ da@@ z@@ ole anti@@ f@@ ung@@ al@@ s@@ ) or indu@@ ce (@@ e@@ . g. ri@@ f@@ amp@@ ic@@ in@@ , car@@ b@@ amaz@@ ep@@ ine@@ , phen@@ y@@ to@@ in@@ , e@@ fa@@ vi@@ ren@@ z@@ , ne@@ vi@@ rap@@ ine@@ ) either C@@ Y@@ P@@ 2@@ C@@ 8 or C@@ Y@@ P@@ 3@@ A@@ 4.
Abra@@ x@@ ane is indicated for mon@@ o@@ -@@ therap@@ y@@ .
Abra@@ x@@ ane should not be used in combination with other an@@ tic@@ ancer ag@@ ent@@ s.
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
Pre@@ gn@@ anc@@ y@@ :
There are very limited data on the use of pac@@ li@@ tax@@ el in human pregn@@ anc@@ y@@ .
P@@ ac@@ li@@ tax@@ el is suspected to cause serious birth def@@ ects when administ@@ ered during pregn@@ anc@@ y@@ .
Studies in animals have shown re@@ productive tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Abra@@ x@@ ane should not be used in pregn@@ anc@@ y@@ , and in women of child@@ bearing potential not using effective contra@@ cep@@ tion@@ , unless the clinical condition of the mother requires treatment with pac@@ li@@ tax@@ el@@ .
4 Women of child@@ bearing potential should use effective contra@@ c@@ eption during and up to 1 month after receiving treatment with Abra@@ x@@ an@@ e@@ .
Male patients treated with Abra@@ x@@ ane are advised not to father a child during and up to six months after treat@@ ment@@ .
L@@ act@@ ation@@ :
It is not known if pac@@ li@@ tax@@ el is ex@@ cre@@ ted in human mil@@ k@@ .
Because of potential serious ad@@ verse re@@ actions in bre@@ ast@@ -@@ feeding inf@@ an@@ ts@@ , Abra@@ x@@ ane is contra@@ indicated during la@@ ct@@ ation@@ .
Bre@@ ast@@ feeding must be dis@@ continued for the dur@@ ation of therap@@ y@@ .
Fer@@ tili@@ ty@@ :
Abra@@ x@@ ane in@@ duced in@@ fertili@@ ty in male rats (@@ see section 5.@@ 3@@ )@@ .
Male patients should seek advice on con@@ servation of sper@@ m prior to treatment because of the possibility of ir@@ re@@ versi@@ ble in@@ fertili@@ ty due to therapy with Abra@@ x@@ an@@ e@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
Abra@@ x@@ ane has minor or moderate influence on the ability to drive and use mach@@ in@@ es@@ .
Abra@@ x@@ ane may cause side effects such as ti@@ red@@ ness (@@ very common@@ ) and di@@ zz@@ iness (@@ common@@ ) that may affect the ability to drive and use mach@@ in@@ er@@ y@@ .
Pati@@ ents should be advised not to drive and use machines if they feel tired or di@@ zz@@ y@@ .
4.@@ 8 Un@@ desi@@ rable effects
The following are the most common and important inci@@ den@@ ces of ad@@ verse re@@ actions related to 2@@ 29 patients with met@@ ast@@ atic breast cancer who were treated with 260 m@@ g@@ / m2 Abra@@ x@@ ane once every three weeks in the pi@@ vot@@ al phase III clinical stu@@ dy@@ .
Bloo@@ d and lymp@@ h@@ atic system disor@@ der@@ s@@ :
Ne@@ ut@@ rop@@ en@@ ia was the most not@@ able important ha@@ em@@ at@@ ological tox@@ ic@@ ity (@@ reported in 79@@ % of pati@@ ent@@ s@@ )@@ , and was rapidly re@@ versi@@ ble and dose dep@@ end@@ ent@@ ; leu@@ kop@@ en@@ ia was reported in 7@@ 1@@ % of pati@@ ent@@ s.
Gra@@ de 4 neut@@ rop@@ en@@ ia (@@ < 0.5 x 10@@ 9@@ / l@@ ) occurred in 9@@ % of patients treated with Abra@@ x@@ an@@ e@@ .
Feb@@ ri@@ le neut@@ rop@@ en@@ ia occurred in four patients on Abra@@ x@@ an@@ e@@ .
An@@ a@@ emi@@ a (@@ H@@ b < 10 g@@ / dl@@ ) was observed in 46@@ % of patients on Abra@@ x@@ an@@ e@@ , and was severe (@@ H@@ b < 8 g@@ / dl@@ ) in three cas@@ es@@ .
Ly@@ mp@@ hop@@ en@@ ia was observed in 45@@ % of the pati@@ ent@@ s.
Ner@@ v@@ ous system disor@@ der@@ s@@ :
In gener@@ al@@ , the frequ@@ ency and sever@@ ity of neur@@ oto@@ x@@ ic@@ ity was d@@ os@@ e@@ -@@ dependent in patients receiving Abra@@ x@@ an@@ e@@ .
Peri@@ pher@@ al neuro@@ pa@@ thy (@@ mostly Gra@@ de 1 or 2 sens@@ ory neuro@@ path@@ y@@ ) was observed in 68@@ % of patients on Abra@@ x@@ ane with 10@@ % being Gra@@ de 3@@ , and no cases of Gra@@ de 4.
Gast@@ ro@@ inte@@ st@@ inal disor@@ der@@ s@@ :
Nau@@ sea occurred in 29@@ % of the patients and di@@ arr@@ ho@@ ea in 25@@ % of the pati@@ ent@@ s.
Sk@@ in and sub@@ cut@@ an@@ e@@ ous system disor@@ der@@ s@@ :
Alo@@ p@@ ec@@ ia was observed in 90@@ % of the patients treated with Abra@@ x@@ an@@ e@@ .
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
Arth@@ r@@ al@@ gia occurred in 32@@ % of patients on Abra@@ x@@ ane and was severe in 6@@ % of cas@@ es@@ .
My@@ al@@ gia occurred in 24@@ % of patients on Abra@@ x@@ ane and was severe in 7@@ % of cas@@ es@@ .
The symptoms were usually tran@@ si@@ ent@@ , typically occurred three days after Abra@@ x@@ ane administration and resolved within a week@@ .
General disor@@ ders and administration site disor@@ der@@ s@@ :
As@@ th@@ eni@@ a@@ / F@@ ati@@ gue was reported in 40@@ % of the pati@@ ent@@ s.
Table 1 lists ad@@ verse re@@ actions associated with the administration of Abra@@ x@@ ane to patients from studies in which Abra@@ x@@ ane has been administ@@ ered as a single agent at any dose in any indication (@@ N = 78@@ 9@@ )@@ .
5 The frequ@@ ency of un@@ desi@@ rable effects listed in table 1 is defined using the following conven@@ tion@@ :
Very common (@@ ≥ 1@@ / 10@@ )@@ ; common (@@ ≥ 1@@ / 100@@ , < 1@@ / 10@@ )@@ ; un@@ common (@@ ≥ 1@@ / 1,@@ 00@@ 0@@ , < 1@@ / 100@@ )@@ ; rare (@@ ≥ 1@@ / 10,@@ 00@@ 0@@ , < 1@@ / 1,@@ 00@@ 0@@ )@@ ; very rare (@@ < 1@@ / 10,@@ 00@@ 0@@ )@@ .
Within each frequ@@ ency gro@@ up@@ ing@@ , un@@ desi@@ rable effects are presented in order of decre@@ asing seri@@ ous@@ ness@@ .
Table 1@@ :
Ad@@ verse re@@ actions reported with Abra@@ x@@ ane at any dose in clinical tri@@ al@@ s.
Common@@ :
Dec@@ re@@ ased wei@@ ght@@ , increased al@@ an@@ ine am@@ in@@ ot@@ ran@@ s@@ fer@@ as@@ e@@ , increased as@@ part@@ ate am@@ in@@ ot@@ ran@@ s@@ fer@@ as@@ e@@ , decre@@ ased ha@@ em@@ at@@ oc@@ rit@@ , decre@@ ased red blood cell coun@@ t@@ , increased body temperat@@ ure@@ , increased Investig@@ ations@@ : gam@@ ma@@ -@@ gl@@ ut@@ am@@ yl@@ trans@@ fer@@ as@@ e@@ , increased blood al@@ kal@@ ine ph@@ osp@@ hat@@ ase
In@@ cre@@ ased blood pressu@@ re@@ , increased wei@@ ght@@ , increased blood la@@ ct@@ ate de@@ hydro@@ gen@@ as@@ e@@ , increased blood cre@@ at@@ in@@ ine@@ , increased blood glu@@ cos@@ e@@ , increased blood ph@@ osph@@ or@@ us@@ , decre@@ ased blood pot@@ assi@@ um Cardi@@ ac disor@@ der@@ s@@ :
Common@@ :
T@@ ach@@ y@@ car@@ dia Very Common@@ :
Ne@@ ut@@ rop@@ eni@@ a@@ , an@@ a@@ emi@@ a@@ , leu@@ kop@@ eni@@ a@@ , thro@@ mbo@@ cy@@ top@@ eni@@ a@@ ,
Bloo@@ d and lymp@@ h@@ atic system disor@@ der@@ s@@ :
lymp@@ hop@@ en@@ ia Common@@ :
Feb@@ ri@@ le neut@@ rop@@ en@@ ia Very Common@@ :
Peri@@ pher@@ al neuro@@ path@@ y@@ , neuro@@ path@@ y@@ , hypo@@ aes@@ the@@ si@@ a@@ , para@@ es@@ the@@ si@@ a.
Ner@@ v@@ ous system disor@@ der@@ s@@ :
Common@@ :
Peri@@ pher@@ al sens@@ ory neuro@@ path@@ y@@ , hea@@ da@@ che@@ , dys@@ ge@@ usi@@ a@@ , di@@ zz@@ in@@ ess@@ , peri@@ pher@@ al motor neuro@@ path@@ y@@ , at@@ a@@ xi@@ a@@ , sens@@ ory distur@@ b@@ anc@@ e@@ , som@@ n@@ ol@@ en@@ ce@@ .
Un@@ common@@ :
Poly@@ neuro@@ path@@ y@@ , ar@@ ef@@ le@@ xi@@ a@@ , dy@@ sk@@ ine@@ si@@ a@@ , h@@ yp@@ or@@ ef@@ le@@ xi@@ a@@ , neur@@ al@@ gi@@ a@@ , sens@@ ory los@@ s@@ , syn@@ cop@@ e@@ , po@@ stur@@ al di@@ zz@@ in@@ ess@@ , neuro@@ path@@ ic pain@@ , tre@@ m@@ or Common@@ :
In@@ cre@@ ased la@@ cri@@ m@@ ation@@ , bl@@ urred visi@@ on@@ , dry e@@ ye@@ , ker@@ at@@ o@@ con@@ jun@@ cti@@ vi@@ tis si@@ cc@@ a@@ , ma@@ dar@@ o@@ sis E@@ ye disor@@ der@@ s@@ :
Un@@ common@@ :
E@@ ye irrit@@ ation@@ , eye pain@@ , ab@@ normal visi@@ on@@ , reduced visual ac@@ u@@ it@@ y@@ , con@@ jun@@ cti@@ vi@@ tis@@ , visual distur@@ b@@ anc@@ e@@ , eye p@@ ru@@ rit@@ us E@@ ar and lab@@ y@@ r@@ inth disor@@ der@@ s@@ :
Common@@ :
Dy@@ sp@@ no@@ e@@ a@@ , ep@@ ist@@ ax@@ is@@ , ph@@ ar@@ yn@@ gol@@ ar@@ yn@@ ge@@ al pain@@ , cou@@ gh@@ , r@@ hin@@ i@@ tis@@ , r@@ hin@@ or@@ r@@ ho@@ ea
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ der@@ :
Un@@ common@@ :
Produc@@ tive cou@@ gh@@ , exer@@ tional dy@@ sp@@ no@@ e@@ a@@ , sin@@ us con@@ gesti@@ on@@ , decre@@ ased breath so@@ und@@ s@@ , ple@@ ural eff@@ u@@ sion@@ , aller@@ gic r@@ hin@@ i@@ tis@@ , ho@@ ar@@ sen@@ ess@@ , n@@ as@@ al con@@ gesti@@ on@@ , n@@ as@@ al dr@@ yn@@ ess@@ , whe@@ e@@ zing
R@@ are@@ :
Inter@@ sti@@ tial p@@ ne@@ um@@ oni@@ tis Very Common@@ :
Nau@@ se@@ a@@ , di@@ arr@@ ho@@ e@@ a@@ , vo@@ mit@@ ing@@ , con@@ sti@@ p@@ ation@@ , stom@@ ati@@ tis
Common@@ :
Ab@@ dom@@ inal pain@@ , ab@@ dom@@ inal di@@ sten@@ sion@@ , upper ab@@ dom@@ inal pain@@ , Gast@@ ro@@ inte@@ st@@ inal dy@@ sp@@ ep@@ si@@ a@@ , ga@@ stro@@ o@@ es@@ op@@ ha@@ ge@@ al re@@ flu@@ x dise@@ as@@ e@@ , oral hypo@@ aes@@ the@@ sia disor@@ der@@ s@@ :
Un@@ common@@ :
Dy@@ sph@@ ag@@ i@@ a@@ , flat@@ ul@@ en@@ ce@@ , g@@ los@@ so@@ dy@@ ni@@ a@@ , dry mou@@ th@@ , gin@@ gi@@ val pain@@ , loose sto@@ ol@@ s@@ , o@@ es@@ oph@@ ag@@ i@@ tis@@ , lower ab@@ dom@@ inal pain@@ , mouth ul@@ cer@@ ation@@ , oral pain@@ , rec@@ tal ha@@ emor@@ rh@@ age Ren@@ al and ur@@ inary disor@@ der@@ s@@ :
Un@@ common@@ :
Dy@@ su@@ ri@@ a@@ , pol@@ la@@ ki@@ uri@@ a@@ , ha@@ em@@ at@@ uri@@ a@@ , no@@ ctu@@ ri@@ a@@ , poly@@ uri@@ a@@ , ur@@ inary in@@ contin@@ ence
Ad@@ verse re@@ actions reported with Abra@@ x@@ ane at any dose in clinical tri@@ al@@ s.
Very Common@@ :
Alo@@ p@@ eci@@ a@@ , ra@@ sh
Common@@ :
N@@ ail disor@@ der@@ , p@@ ru@@ rit@@ us@@ , dry sk@@ in@@ , er@@ y@@ them@@ a@@ , nail disc@@ olo@@ ur@@ ation@@ , skin hyper@@ pig@@ ment@@ ation@@ , on@@ y@@ chol@@ y@@ sis Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ :
Arth@@ r@@ al@@ gi@@ a@@ , my@@ al@@ gi@@ a.
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ der@@ s@@ :
Met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ :
Inf@@ ections and
Common@@ :
Ch@@ est wall pain@@ , mus@@ cular weak@@ ness@@ , neck pain@@ , gro@@ in pain@@ , muscle sp@@ as@@ ms@@ , mus@@ cul@@ os@@ kel@@ et@@ al pain@@ , flan@@ k pain@@ , li@@ mb dis@@ comfort@@ , muscle weakness Very common@@ :
An@@ or@@ ex@@ ia Common@@ :
D@@ eh@@ y@@ dra@@ tion@@ , decre@@ ased appeti@@ te@@ , hypo@@ kal@@ a@@ emi@@ a Un@@ common@@ :
Hyp@@ op@@ hosp@@ hat@@ a@@ emi@@ a@@ , flu@@ id re@@ ten@@ tion@@ , hypo@@ alb@@ umin@@ a@@ emi@@ a@@ , poly@@ di@@ p@@ si@@ a@@ , hyper@@ g@@ ly@@ ca@@ emi@@ a@@ , hypo@@ cal@@ ca@@ emi@@ a@@ , hypo@@ g@@ ly@@ ca@@ emi@@ a@@ , h@@ yp@@ on@@ at@@ ra@@ emi@@ a Common@@ :
Inf@@ ec@@ tion@@ , ur@@ inary tra@@ ct inf@@ ec@@ tion@@ , fol@@ li@@ cu@@ li@@ tis@@ , upper resp@@ ir@@ atory tra@@ ct inf@@ ec@@ tion@@ , can@@ di@@ di@@ asi@@ s@@ , sin@@ usi@@ tis
in@@ fest@@ ations@@ :
In@@ j@@ ur@@ y@@ , pois@@ oning and proce@@ dur@@ al complic@@ ations@@ :
Ne@@ op@@ las@@ ms ben@@ ign@@ ,
Un@@ common@@ :
Con@@ tu@@ sion R@@ are@@ :
Radi@@ ation recall phenomenon
mal@@ ign@@ ant and un@@ speci@@ fied (@@ including cy@@ sts and pol@@ yp@@ s@@ )@@ :
V@@ as@@ cular disor@@ der@@ s@@ :
Un@@ common@@ :
Met@@ ast@@ atic pain@@ , tum@@ our ne@@ cro@@ sis Common@@ :
Fl@@ ush@@ ing@@ , hot fl@@ ush@@ es@@ , hyper@@ ten@@ sion@@ , lymp@@ ho@@ e@@ de@@ ma Un@@ common@@ :
Hyp@@ ot@@ en@@ sion@@ , peri@@ pher@@ al col@@ dn@@ ess@@ , or@@ tho@@ st@@ atic h@@ yp@@ ot@@ ension R@@ are@@ :
Th@@ ro@@ mbo@@ sis Very Common@@ :
F@@ ati@@ gu@@ e@@ , as@@ th@@ eni@@ a@@ , py@@ re@@ xi@@ a.
Common@@ :
Peri@@ pher@@ al oe@@ de@@ ma@@ , mu@@ cos@@ al infl@@ amm@@ ation@@ , pain@@ , rig@@ or@@ s@@ , oe@@ de@@ ma@@ , weak@@ ness@@ , decre@@ ased performance stat@@ us@@ , chest pain@@ , influ@@ enz@@ a@@ -@@ like ill@@ ness@@ , mal@@ ai@@ se@@ , le@@ th@@ ar@@ gy@@ , hyper@@ py@@ re@@ x@@ ia
Ch@@ est dis@@ comfort@@ , ab@@ normal ga@@ it@@ , sw@@ ell@@ ing@@ , in@@ jection site reaction Un@@ common@@ 1@@ :
Hy@@ per@@ sensi@@ tivity
H@@ ep@@ at@@ o@@ bili@@ ary disor@@ ders Re@@ productive system and breast disor@@ der@@ s@@ :
Bre@@ ast pain
7 Table 1@@ :
Ad@@ verse re@@ actions reported with Abra@@ x@@ ane at any dose in clinical tri@@ al@@ s.
Un@@ common@@ :
Rest@@ less@@ ness 1 The frequ@@ ency of hyper@@ sensi@@ tivity re@@ actions is calcul@@ ated based on one definitely related case in a population of 7@@ 89 patients
Post@@ -@@ marketing experience
Cran@@ ial nerve pal@@ si@@ es@@ , vocal c@@ ord par@@ esi@@ s@@ , and rare reports of severe hyper@@ sensi@@ tivity re@@ actions have been reported during post@@ -@@ marketing surveillance of Abra@@ x@@ an@@ e@@ .
In some patients previously exposed to cap@@ ec@@ it@@ ab@@ ine@@ , reports of pal@@ mar@@ -@@ plan@@ t@@ ar er@@ y@@ thro@@ dy@@ sa@@ es@@ the@@ si@@ ae have been reported as part of the continuing surveillance of Abra@@ x@@ an@@ e@@ .
Because these events have been reported volun@@ tar@@ ily during clinical prac@@ tic@@ e@@ , true estimates of frequ@@ ency cannot be made and a caus@@ al relationship to the events has not been establi@@ sh@@ ed@@ .
4.@@ 9 Over@@ dose
There is no known anti@@ d@@ ote for pac@@ li@@ tax@@ el over@@ d@@ os@@ e@@ .
In the event of an over@@ d@@ os@@ e@@ , the patient should be closely monit@@ or@@ ed@@ .
Tre@@ at@@ ment should be directed at the major anticipated tox@@ ici@@ ti@@ es@@ , which are bone mar@@ row supp@@ res@@ sion@@ , mu@@ co@@ si@@ tis and peri@@ pher@@ al neuro@@ path@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ :
Ta@@ x@@ an@@ es@@ , AT@@ C Co@@ de@@ :
L@@ 0@@ 1@@ CD@@ 01
P@@ ac@@ li@@ tax@@ el is an anti@@ mi@@ cr@@ ot@@ ub@@ ule agent that promot@@ es the assembly of mi@@ cr@@ ot@@ ub@@ ules from t@@ ub@@ ul@@ in di@@ mers and stabili@@ ses mi@@ cr@@ ot@@ ub@@ ules by preventing de@@ poly@@ mer@@ is@@ ation@@ .
This stability results in the in@@ hibition of the normal dynamic re@@ organisation of the mi@@ cr@@ ot@@ ub@@ ule network that is essential for vital inter@@ phase and mi@@ to@@ tic cell@@ ular func@@ tions@@ .
In addi@@ tion@@ , pac@@ li@@ tax@@ el indu@@ ces ab@@ normal ar@@ ra@@ ys or “ bund@@ les ” of mi@@ cr@@ ot@@ ub@@ ules throughout the cell cycle and multiple ast@@ ers of mi@@ cr@@ ot@@ ub@@ ules during mi@@ to@@ si@@ s.
Abra@@ x@@ ane contains human ser@@ um alb@@ umin@@ -@@ pac@@ li@@ tax@@ el nan@@ op@@ artic@@ les@@ .
Alb@@ um@@ in is known to medi@@ ate en@@ do@@ th@@ el@@ ial tran@@ sc@@ y@@ to@@ sis of p@@ las@@ ma constitu@@ ents and in vit@@ ro studies demonstrated that the presence of alb@@ um@@ in en@@ han@@ ces transport of pac@@ li@@ tax@@ el across en@@ do@@ th@@ el@@ ial cell@@ s.
It is hy@@ pothe@@ si@@ sed that this enhanced tran@@ sen@@ do@@ th@@ el@@ ial transport is medi@@ ated by the g@@ p@@ -@@ 60 alb@@ um@@ in rec@@ ep@@ tor@@ , and that there is accum@@ ulation of pac@@ li@@ tax@@ el in the area of tum@@ our due to the alb@@ umin@@ -@@ bin@@ ding protein SP@@ AR@@ C (@@ secre@@ ted protein aci@@ dic rich in cy@@ stein@@ e@@ )@@ .
Bre@@ ast car@@ cin@@ om@@ a@@ :
Data from 106 patients acc@@ ru@@ ed in two sing@@ le@@ -@@ arm op@@ en@@ -@@ label studies and from 4@@ 54 patients treated in a rand@@ o@@ mis@@ ed Phase III compar@@ ative study are available to support the use of Abra@@ x@@ ane in met@@ ast@@ atic breast canc@@ er@@ .
This information is presented bel@@ ow@@ .
Sing@@ le@@ -@@ arm op@@ en@@ -@@ label studies
In one stu@@ dy@@ , Abra@@ x@@ ane was administ@@ ered as a 30@@ -@@ minute in@@ fusion at a dose of 175 m@@ g@@ / m2 to 43 patients with met@@ ast@@ atic breast canc@@ er@@ .
The second trial utili@@ sed a dose of 300 m@@ g@@ / m2 as a 30 minute in@@ fusion in 63 patients with met@@ ast@@ atic breast canc@@ er@@ .
Pati@@ ents were treated without ster@@ oid pre@@ - treatment or planned G@@ -@@ CS@@ F supp@@ ort@@ .
Cy@@ cles were administ@@ ered at 3 week inter@@ val@@ s.
The response rates in all patients were 3@@ 9.@@ 5@@ % (@@ 9@@ 5@@ % C@@ I@@ :
24.@@ 9@@ % - 5@@ 4.@@ 2@@ %@@ ) and 4@@ 7.@@ 6@@ %
3@@ 5.@@ 3@@ % - 60@@ .0@@ %@@ )@@ , respec@@ ti@@ vel@@ y@@ .
The medi@@ an time to disease progres@@ sion was 5.@@ 3 months (@@ 175 m@@ g@@ / m@@ 2@@ ; 9@@ 5@@ % C@@ I@@ :
4.@@ 6 – 6.@@ 2 mon@@ th@@ s@@ ) and 6.@@ 1 months (@@ 300 m@@ g@@ / m@@ 2@@ ; 9@@ 5@@ % C@@ I@@ :
4.@@ 2 – 9.@@ 8 mon@@ th@@ s@@ )@@ .
Rand@@ o@@ mis@@ ed compar@@ ative stu@@ dy@@ :
This multi@@ -@@ centre trial was conducted in patients with met@@ ast@@ atic breast canc@@ er@@ , who were treated every 3 weeks with sing@@ le@@ -@@ agent pac@@ li@@ tax@@ el@@ , either as sol@@ vent@@ -@@ based pac@@ li@@ tax@@ el 175 m@@ g@@ / m2 given as a 3@@ -@@ hour in@@ fusion with pre@@ medication to prevent hyper@@ sensi@@ tivity (@@ N = 2@@ 25@@ )@@ , or as Abra@@ x@@ ane 260 m@@ g@@ / m2 given as a 30 minute in@@ fusion without pre@@ medication (@@ N = 2@@ 29@@ )@@ .
Six@@ ty@@ -@@ four percent of patients had im@@ paired performance status (@@ E@@ CO@@ G 1 or 2@@ ) at study entr@@ y@@ ; 79@@ % had vi@@ sc@@ eral met@@ ast@@ as@@ es@@ ; and 76@@ % had > 3 sites of met@@ ast@@ as@@ es@@ .
Fo@@ ur@@ teen percent of the patients had not received prior ch@@ emo@@ therap@@ y@@ ; 27@@ % had received ch@@ emo@@ therapy in the adju@@ v@@ ant setting on@@ ly@@ , 40@@ % in the met@@ ast@@ atic setting on@@ ly@@ , and 19@@ % in both met@@ ast@@ atic and adju@@ v@@ ant sett@@ ings@@ .
Fi@@ ft@@ y@@ -@@ nine percent received study medic@@ inal product as second or greater than secon@@ d@@ -@@ line therap@@ y@@ .
Se@@ vent@@ y@@ -@@ seven percent of the patients had been previously exposed to anth@@ ra@@ cy@@ clin@@ es@@ .
Res@@ ults for overall response rate and time to disease progres@@ sion@@ , and progres@@ sion@@ -@@ free survival and survival for patients receiving > 1@@ st@@ -@@ line therap@@ y@@ , are shown bel@@ ow@@ .
Table 2@@ :
Res@@ ults for overall response rat@@ e@@ , medi@@ an time to disease progres@@ sion@@ , and progres@@ sion@@ -@@ free survival as asse@@ ssed by the investig@@ ator
Eff@@ ic@@ acy vari@@ able
Abra@@ x@@ ane (@@ 260 m@@ g@@ / m@@ 2@@ )
Sol@@ vent@@ -@@ based pac@@ li@@ tax@@ el (@@ 175 m@@ g@@ / m@@ 2@@ )
p@@ -@@ value
Respon@@ se rate [@@ 9@@ 5@@ % C@@ I@@ ] (@@ %@@ )
> 1@@ st@@ -@@ line therapy
2@@ 6.5 [@@ 18.@@ 98@@ , 34@@ .0@@ 5@@ ] (@@ n = 13@@ 2@@ )
13.@@ 2 [@@ 7.@@ 54@@ , 18.@@ 9@@ 3@@ ] (@@ n = 13@@ 6@@ )
0.0@@ 06@@ a
*@@ Medi@@ an time to disease progres@@ sion [@@ 9@@ 5@@ % C@@ I@@ ] (@@ wee@@ ks@@ )
20.@@ 9 [@@ 15.@@ 7@@ , 25.@@ 9@@ ] (@@ n = 13@@ 1@@ )
16.@@ 1 [@@ 15@@ .0@@ , 19.@@ 3@@ ] (@@ n = 13@@ 5@@ )
0.0@@ 11@@ b
*@@ Medi@@ an Pro@@ gres@@ sion Free Sur@@ vi@@ val [@@ 9@@ 5@@ % C@@ I@@ ] (@@ wee@@ ks@@ )
20.@@ 6 [@@ 15.@@ 6@@ , 25.@@ 9@@ ] (@@ n = 13@@ 1@@ )
16.@@ 1 [@@ 15@@ .0@@ , 18.@@ 3@@ ] (@@ n = 13@@ 5@@ )
0.0@@ 10@@ b
*@@ Sur@@ vi@@ val [@@ 9@@ 5@@ % C@@ I@@ ] (@@ wee@@ ks@@ )
5@@ 6.@@ 4 [@@ 4@@ 5.@@ 1@@ , 7@@ 6.@@ 9@@ ] (@@ n = 13@@ 1@@ )
4@@ 6.@@ 7 [@@ 39@@ .0@@ , 5@@ 5.@@ 3@@ ] (@@ n = 13@@ 6@@ )
0.0@@ 20@@ b
* This data is based on Clin@@ ical Stu@@ dy Report@@ :
C@@ A@@ 0@@ 12@@ -@@ 0 Ad@@ den@@ d@@ um dated Final (@@ 23 Mar@@ ch@@ -@@ 200@@ 5@@ ) a Chi@@ -@@ squ@@ ared test b Lo@@ g@@ -@@ rank test
9 2@@ 29 patients treated with Abra@@ x@@ ane in the rand@@ omi@@ z@@ ed@@ , controlled clinical trial were evalu@@ ated for safet@@ y@@ .
Ne@@ ur@@ oto@@ x@@ ic@@ ti@@ y to pac@@ li@@ tax@@ el was evalu@@ ated through improvement by one grade for patients experiencing grade 3 peri@@ pher@@ al neuro@@ pa@@ thy at any time during therap@@ y@@ .
The natural course of peri@@ pher@@ al neuro@@ pa@@ thy to resolution to bas@@ eline due to cum@@ ula@@ tive tox@@ ic@@ ity of Abra@@ x@@ ane after > 6 courses of treatment was not evalu@@ ated and remains unk@@ no@@ wn@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
The pharmac@@ ok@@ ine@@ tics of total pac@@ li@@ tax@@ el following 30@@ - and 18@@ 0@@ -@@ minute in@@ fu@@ sions of Abra@@ x@@ ane at dose levels of 80 to 3@@ 75 m@@ g@@ / m2 were determined in clinical stu@@ dies@@ .
The drug exposure (@@ AU@@ C@@ ) increased lin@@ early from 26@@ 53 to 16@@ 7@@ 36 n@@ g. hr@@ / ml following d@@ osing from 80 to 300 m@@ g@@ / m@@ 2.
Following in@@ tra@@ ven@@ ous administration of Abra@@ x@@ ane to patients with met@@ ast@@ atic breast cancer at the recommended clinical dose of 260 m@@ g@@ / m@@ 2@@ , pac@@ li@@ tax@@ el p@@ las@@ ma conc@@ ent@@ rations declined in a multi@@ p@@ ha@@ sic man@@ ner@@ .
The mean C@@ max of pac@@ li@@ tax@@ el@@ , which occurred at the end of the in@@ fu@@ sion@@ , was 18.@@ 7 µ@@ g@@ / m@@ l.
The mean total clear@@ ance was 15 l@@ / hr@@ / m@@ 2.
The terminal half@@ -@@ life was about 27 ho@@ urs@@ .
The mean volume of distribution was 6@@ 32 l@@ / m@@ 2@@ ; the large volume of distribution indic@@ ates extensive extra@@ v@@ as@@ cular distribution and@@ / or tissue bin@@ ding of pac@@ li@@ tax@@ el@@ .
In a study in patients with advanced solid tum@@ o@@ urs@@ , the pharmac@@ ok@@ ine@@ tic characterist@@ ics of pac@@ li@@ tax@@ el following Abra@@ x@@ ane administ@@ ered in@@ tra@@ ven@@ ously at 260 m@@ g@@ / m2 over 30 minutes were compared with those following 175 m@@ g@@ / m2 of the sol@@ vent@@ -@@ based pac@@ li@@ tax@@ el in@@ jection administ@@ ered over 3 ho@@ urs@@ .
The clear@@ ance of pac@@ li@@ tax@@ el with Abra@@ x@@ ane was larger (@@ 43@@ %@@ ) than that following a sol@@ vent@@ -@@ based pac@@ li@@ tax@@ el in@@ jection and its volume of distribution was also higher (@@ 5@@ 3@@ %@@ )@@ .
Differ@@ ences in C@@ max and C@@ max correc@@ ted for dose reflected differences in total dose and rate of in@@ fu@@ sion@@ .
There were no differences in terminal half@@ -@@ li@@ ves@@ .
The protein bin@@ ding of pac@@ li@@ tax@@ el following Abra@@ x@@ ane administration is estimated at about 90@@ %@@ .
Based on the published liter@@ at@@ ure@@ , in vit@@ ro studies of bin@@ ding to human ser@@ um prot@@ ein@@ s@@ , using pac@@ li@@ tax@@ el at conc@@ ent@@ rations ranging from 0.0@@ 3 to 1.2 µ@@ M@@ , indicate that about 8@@ 7@@ % of pac@@ li@@ tax@@ el is bo@@ und@@ ; the presence of ran@@ i@@ ti@@ d@@ ine@@ , de@@ x@@ am@@ eth@@ as@@ one@@ , or di@@ phen@@ hy@@ dra@@ mine did not affect protein bin@@ ding of pac@@ li@@ tax@@ el@@ .
Based on the published liter@@ at@@ ure@@ , in vit@@ ro studies with human liver mi@@ cros@@ om@@ es and tissue sli@@ ces show that pac@@ li@@ tax@@ el is met@@ aboli@@ sed primarily to 6@@ α -@@ hydro@@ x@@ yp@@ ac@@ li@@ tax@@ el@@ ; and to two minor met@@ aboli@@ tes@@ , 3@@ ’ -@@ p@@ -@@ hydro@@ x@@ yp@@ ac@@ li@@ tax@@ el and 6@@ α -@@ 3@@ ’ -@@ p@@ -@@ di@@ hydro@@ x@@ yp@@ ac@@ li@@ tax@@ el@@ .
The formation of these hydro@@ x@@ y@@ lated met@@ aboli@@ tes is cat@@ aly@@ sed by C@@ Y@@ P@@ 2@@ C@@ 8@@ , -@@ 3@@ A@@ 4@@ , and both -@@ 2@@ C@@ 8 and -@@ 3@@ A4 respec@@ ti@@ vel@@ y@@ .
The effect of ren@@ al or he@@ pati@@ c dys@@ function on the di@@ sposition of pac@@ li@@ tax@@ el has not been formally investig@@ at@@ ed@@ .
In patients with met@@ ast@@ atic breast canc@@ er@@ , after a 30 minute in@@ fusion of Abra@@ x@@ ane at 260 m@@ g@@ / m@@ 2@@ , the mean value for cum@@ ula@@ tive ur@@ inary ex@@ cre@@ tion of un@@ changed active substance accoun@@ ted for 4@@ % of the total administ@@ ered dose with less than 1@@ % as the met@@ aboli@@ tes 6@@ α -@@ hydro@@ x@@ yp@@ ac@@ li@@ tax@@ el and 3@@ ’ -@@ p@@ -@@ hydro@@ x@@ yp@@ ac@@ li@@ tax@@ el@@ , indic@@ ating extensive non@@ -@@ ren@@ al clear@@ anc@@ e@@ .
P@@ ac@@ li@@ tax@@ el is princip@@ ally elim@@ inated by he@@ pati@@ c met@@ aboli@@ sm and bili@@ ary ex@@ cre@@ tion@@ .
P@@ harm@@ ac@@ ok@@ ine@@ tics of pac@@ li@@ tax@@ el in patients aged over 65 years seems compar@@ able to that in patients less than 65 ye@@ ar@@ s.
Ho@@ we@@ ver@@ , little information in patients over 75 years is available as only 3 patients over 75 years of age where included in the pharmac@@ ok@@ ine@@ tic analy@@ si@@ s.
5.@@ 3 P@@ rec@@ lin@@ ical safety data
The car@@ cin@@ o@@ gen@@ ic potential of pac@@ li@@ tax@@ el has not been studi@@ ed@@ .
Ho@@ we@@ ver@@ , based on the published liter@@ at@@ ure@@ , pac@@ li@@ tax@@ el is a potentially car@@ cin@@ o@@ gen@@ ic and gen@@ oto@@ x@@ ic agent at clinical d@@ os@@ es@@ , based upon its pharmac@@ o@@ dynamic mechan@@ ism of ac@@ tion@@ .
P@@ ac@@ li@@ tax@@ el has been shown to be cla@@ sto@@ gen@@ ic in vit@@ ro (@@ ch@@ ro@@ mos@@ ome aber@@ rations in human lymp@@ ho@@ cy@@ tes@@ ) and in vi@@ vo (@@ mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ )@@ .
P@@ ac@@ li@@ tax@@ el has been shown to be gen@@ oto@@ x@@ ic in vi@@ vo (@@ mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ )@@ , but it did not indu@@ ce mut@@ agen@@ ic@@ ity
10 in the Am@@ es test or the Chinese ham@@ ster ov@@ ar@@ y@@ / hypo@@ x@@ anth@@ ine@@ -@@ gu@@ an@@ ine ph@@ osph@@ ori@@ bos@@ yl trans@@ fer@@ ase (@@ CH@@ O@@ / H@@ G@@ PR@@ T@@ ) gene mut@@ ation as@@ sa@@ y@@ .
P@@ ac@@ li@@ tax@@ el at d@@ oses below the human therapeu@@ tic dose was associated with low fertili@@ ty and fo@@ et@@ al tox@@ ic@@ ity in rats@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Human alb@@ um@@ in solution (@@ containing so@@ di@@ um@@ , so@@ dium cap@@ ry@@ late and N@@ -@@ ac@@ et@@ yl DL tr@@ yp@@ top@@ han@@ ate@@ )@@ .
6.@@ 2 In@@ comp@@ ati@@ bilities
This medic@@ inal product must not be mixed with other medic@@ inal products except those mentioned in section 6.@@ 6.
6.@@ 3 Shel@@ f life
U@@ no@@ pen@@ ed vi@@ al@@ s@@ :
24 months
St@@ ability of recon@@ stit@@ uted suspension in the vi@@ al@@ :
After first re@@ constitu@@ tion@@ , the suspension should be filled into an in@@ fusion bag immedi@@ at@@ el@@ y@@ .
Ho@@ we@@ ver@@ , chemical and physical in use stability has been demonstrated for 8 hours at 2@@ °@@ C - 8@@ °@@ C in the original car@@ ton@@ , and protected from bright light@@ .
St@@ ability of the recon@@ stit@@ uted suspension in the in@@ fusion bag@@ :
After re@@ constitu@@ tion@@ , the recon@@ stit@@ uted suspension in the in@@ fusion bag should be used immedi@@ at@@ el@@ y@@ .
However chemical and physical in use stability has been demonstrated for 8 hours not above 25@@ °@@ C.
6.@@ 4 Special prec@@ au@@ tions for storage
U@@ no@@ pen@@ ed vi@@ al@@ s@@ :
Keep the vi@@ al in the ou@@ ter car@@ ton in order to protect from light@@ .
For storage conditions of the recon@@ stit@@ uted medic@@ inal produc@@ t@@ , see section 6.@@ 3.
6.5 Nature and cont@@ ents of container
Vi@@ al 50@@ ml (@@ type 1 g@@ las@@ s@@ ) with a stop@@ per (@@ but@@ yl rub@@ ber@@ )@@ , with an over@@ seal (@@ al@@ umini@@ um@@ )@@ .
P@@ ack size one vi@@ al of 100 mg pac@@ li@@ tax@@ el@@ .
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Pre@@ par@@ ation and administration prec@@ au@@ tions@@ :
P@@ ac@@ li@@ tax@@ el is a cy@@ t@@ oto@@ x@@ ic an@@ tic@@ ancer medic@@ inal product and@@ , as with other potentially toxic com@@ po@@ und@@ s@@ , caution should be exerc@@ ised in handling Abra@@ x@@ an@@ e@@ .
The use of glo@@ ves@@ , go@@ gg@@ les and protective clothing is recommen@@ de@@ d.
If the suspension contacts the sk@@ in@@ , the skin should be w@@ ashed immediately and thor@@ ou@@ ghly with soap and water@@ .
If it contacts mu@@ c@@ ous mem@@ bran@@ es@@ , the mem@@ bran@@ es should be fl@@ ushed thor@@ ou@@ ghly with water@@ .
Abra@@ x@@ ane should only be prepared and administ@@ ered by personnel appropri@@ ately trained in the handling of cy@@ t@@ oto@@ x@@ ic ag@@ ent@@ s.
Pre@@ gn@@ ant staff should not handle Abra@@ x@@ an@@ e@@ .
11 Re@@ constitution and administration of the produc@@ t@@ :
Abra@@ x@@ ane is supp@@ lied as a ster@@ ile ly@@ ophi@@ li@@ sed powder for re@@ constitution before use@@ .
After re@@ constitu@@ tion@@ , each ml of suspension contains 5 mg of pac@@ li@@ tax@@ el@@ .
Using a ster@@ ile sy@@ rin@@ ge@@ , 20 ml of so@@ dium ch@@ l@@ ori@@ de 9 m@@ g@@ / ml (@@ 0.@@ 9@@ %@@ ) solution for in@@ fusion should slowly be in@@ jected into a vi@@ al of Abra@@ x@@ ane over a minimum of 1 min@@ u@@ te@@ .
The solution should be directed onto the inside wall of the vi@@ al@@ .
The solution should not be in@@ jected directly onto the powder as this will result in fo@@ am@@ ing@@ .
Once the addition is comple@@ te@@ , the vi@@ al should be allowed to stand for a minimum of 5 minutes to ensure proper we@@ tting of the soli@@ d.
Th@@ en@@ , the vi@@ al should gently and slowly be s@@ wir@@ led and@@ / or in@@ ver@@ ted for at least 2 minutes until complete resu@@ sp@@ ension of any powder occ@@ urs@@ .
The generation of fo@@ am must be avo@@ ide@@ d.
If fo@@ aming or cl@@ umping occ@@ urs@@ , the solution must stand for at least 15 minutes until fo@@ am subsi@@ des@@ .
The recon@@ stit@@ uted suspension should be mil@@ ky and hom@@ o@@ genous without visible pre@@ cip@@ it@@ at@@ es@@ .
If pre@@ cip@@ it@@ ates or sett@@ ling are visi@@ ble@@ , the vi@@ al should be gently in@@ ver@@ ted again to ensure complete resu@@ sp@@ ension prior to use@@ .
Some sett@@ ling of the recon@@ stit@@ uted suspension may occ@@ ur@@ .
Comple@@ te resu@@ sp@@ ension should be ensured by mild ag@@ itation before use@@ .
Dis@@ card the recon@@ stit@@ uted suspension if pre@@ cip@@ it@@ ates are observ@@ ed@@ .
Cal@@ cul@@ ate the exact total d@@ osing volume of 5 m@@ g@@ / ml suspension required for the patient and in@@ ject the appropriate amount of recon@@ stit@@ uted Abra@@ x@@ ane into an emp@@ ty@@ , steri@@ le@@ , P@@ VC or non@@ -@@ P@@ VC type in@@ tra@@ ven@@ ous bag@@ .
The use of speci@@ alized DE@@ H@@ P@@ -@@ free solution con@@ tain@@ ers or administration sets is not necessary to prepare or ad@@ minister Abra@@ x@@ ane in@@ fu@@ sion@@ s.
In@@ -@@ line fil@@ ters should not be use@@ d.
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Abra@@ xis Bio@@ Science Limited West Forest G@@ ate Well@@ ington Road W@@ ok@@ ingham Ber@@ kshire R@@ G@@ 40 2@@ A@@ Q United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
10.
D@@ AT@@ E O@@ F L@@ AS@@ T RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
13
A.
M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER RE@@ SP@@ ON@@ S@@ IB@@ LE FO@@ R B@@ AT@@ CH RE@@ LE@@ AS@@ E
Name
and address of the manufacturer responsible for bat@@ ch release
Catal@@ ent UK Pack@@ aging L@@ t@@ d.
Lanc@@ aster Way W@@ ing@@ ates Industrial Park Wes@@ thou@@ ghton BL@@ 5 3@@ X@@ X United Kingdom
B.
CON@@ D@@ IT@@ I@@ ON@@ S O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION
•
CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S RE@@ G@@ AR@@ D@@ ING SU@@ P@@ PL@@ Y AND US@@ E I@@ MP@@ O@@ SED ON THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medic@@ inal product subject to restricted medical prescription (@@ See Anne@@ x I@@ :
Sum@@ mary of Product Char@@ ac@@ ter@@ ist@@ ic@@ s@@ , section 4.@@ 2@@ )@@ .
• CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE S@@ AF@@ E AND E@@ FF@@ EC@@ T@@ IV@@ E US@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Not applic@@ able
• O@@ TH@@ ER CON@@ D@@ IT@@ I@@ ON@@ S
P@@ harm@@ ac@@ o@@ vig@@ il@@ ance system The MA@@ H must ensure that the system of pharmac@@ o@@ vig@@ il@@ anc@@ e@@ , as described in version 2.0 presented in Mo@@ dule 1.@@ 8.@@ 1. of the Marketing Auth@@ or@@ isation App@@ lic@@ ation@@ , is in place and func@@ tioning before and whilst the product is on the market@@ .
Ris@@ k Management Plan The MA@@ H com@@ mits to performing the studies and additional pharmac@@ o@@ vig@@ il@@ ance activities detailed in the P@@ harm@@ ac@@ o@@ vig@@ il@@ ance Plan@@ , as agreed in version 4 of the Ris@@ k Management Plan (@@ R@@ MP@@ ) and presented in Mo@@ dule 1.@@ 8.@@ 2. of the Marketing Auth@@ or@@ isation App@@ lic@@ ation and any subsequent updates of the R@@ MP agreed by the CH@@ MP@@ .
As per the CH@@ MP Gui@@ del@@ ine on Ris@@ k Management Systems for medic@@ inal products for human use@@ , the updated R@@ MP should be submitted at the same time as the next Peri@@ o@@ dic Safety Update Report (@@ P@@ S@@ UR@@ )@@ .
In addi@@ tion@@ , an updated R@@ MP should be submitted • When new information is received that may impact on the current Safety Speci@@ fic@@ ation@@ , P@@ harm@@ ac@@ o@@ vig@@ il@@ ance Plan or risk mini@@ mis@@ ation activities • Within 60 days of an important (@@ pharmac@@ o@@ vig@@ il@@ ance or risk mini@@ mis@@ ation@@ ) mi@@ lestone being reached • At the request of the E@@ ME@@ A
15 A.
LA@@ B@@ EL@@ LIN@@ G
16 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING AND THE IM@@ ME@@ DI@@ AT@@ E P@@ AC@@ K@@ AG@@ ING Car@@ ton and Vi@@ al
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Abra@@ x@@ ane 5 m@@ g@@ /@@ ml powder for suspension for in@@ fusion
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
Each vi@@ al contains 100 mg pac@@ li@@ tax@@ el@@ .
After re@@ constitu@@ tion@@ , each ml of suspension contains 5 mg of pac@@ li@@ tax@@ el@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Human alb@@ um@@ in solution (@@ containing so@@ di@@ um@@ , so@@ dium cap@@ ry@@ late and N@@ -@@ ac@@ et@@ yl DL tr@@ yp@@ top@@ han@@ ate@@ )
Con@@ tains so@@ di@@ um@@ , see package le@@ af@@ let for further inform@@ ation@@ .
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
Po@@ w@@ der for suspension for in@@ fusion One vi@@ al of 100 mg pac@@ li@@ tax@@ el
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Read the package le@@ af@@ let before use@@ .
Single use vi@@ al In@@ tra@@ ven@@ ous use
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
Only to be prepared and administ@@ ered by personnel appropri@@ ately trained in handling cy@@ t@@ oto@@ x@@ ic@@ s.
Abra@@ x@@ ane may have substan@@ tially different pharmac@@ ological properties compared to other pac@@ li@@ tax@@ el formu@@ la@@ tions@@ .
8.
EX@@ P IR@@ Y D@@ AT@@ E
EX@@ P@@ .@@ :
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
U@@ no@@ pen@@ ed Vi@@ al@@ s@@ :
Keep the vi@@ al in the ou@@ ter car@@ ton in order to protect from light@@ .
After first re@@ constitu@@ tion@@ :
8 hours in a re@@ fri@@ ger@@ ator in the vi@@ al when kept in the ou@@ ter car@@ ton in order to protect from light@@ .
In an in@@ fusion bag@@ : up to 8 hours not above 25@@ o@@ C
17 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Abra@@ xis Bio@@ Science Limited West Forest G@@ ate Well@@ ington Road W@@ ok@@ ingham Ber@@ kshire R@@ G@@ 40 2@@ A@@ Q United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
13.
B@@ AT@@ CH N@@ UM@@ BER
Bat@@ ch@@ :
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
Justi@@ fication for not including Bra@@ ille accep@@ te@@ d.
19 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
Abra@@ x@@ ane 5 m@@ g@@ /@@ ml powder for suspension for in@@ fusion P@@ ac@@ li@@ tax@@ el
Read all of this le@@ af@@ let carefully before you start using this medic@@ ine@@ .
- Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
- If you have any further questi@@ ons@@ , ask your do@@ ct@@ or@@ .
- If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ ,
please tell your do@@ ct@@ or@@ .
In this le@@ af@@ let@@ :
1.
What Abra@@ x@@ ane is and what it is used for 2.
Before you use Abra@@ x@@ ane 3.
How to use Abra@@ x@@ ane 4.
Pos@@ sible side effects 5.
How to store Abra@@ x@@ ane 6.
Further information
1.
WH@@ AT AB@@ RA@@ X@@ AN@@ E IS AND WH@@ AT IT IS US@@ ED FO@@ R
Abra@@ x@@ ane is a medicine containing pac@@ li@@ tax@@ el in human alb@@ um@@ in (@@ portion of bloo@@ d@@ )@@ .
P@@ ac@@ li@@ tax@@ el belon@@ gs to a group of medic@@ ines called tax@@ an@@ es used to treat canc@@ er@@ s.
Abra@@ x@@ ane is used for the treatment of breast cancer when other therap@@ ies have been tried but have not worked and if you are un@@ suitable for anth@@ ra@@ cy@@ cl@@ ine containing treat@@ ment@@ s.
2.
BE@@ F@@ ORE Y@@ O@@ U US@@ E AB@@ RA@@ X@@ AN@@ E
Do not use Abra@@ x@@ ane • if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to pac@@ li@@ tax@@ el or any of the other ingredients of Abra@@ x@@ ane • if you are breast feeding • if you have a low white blood cell count (@@ bas@@ eline neut@@ rop@@ hi@@ l counts < 1.5 x 10@@ 9@@ /@@ l - your doctor will advi@@ se you on th@@ is@@ )
Take special care with Abra@@ x@@ ane • if you have poor ki@@ dney function • if you experience num@@ bn@@ ess@@ , t@@ ing@@ ling@@ , pri@@ cking sens@@ ations@@ , sensi@@ tivity to touch@@ , or muscle weakness • if you have severe liver problems • if you have heart problems
If you experience any of these conditions your doctor may wish to stop treatment or reduce the d@@ os@@ e@@ .
Taking other medic@@ ines Please tell your doctor if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ , because they could inter@@ act with Abra@@ x@@ an@@ e@@ .
Using Abra@@ x@@ ane with food and drink Abra@@ x@@ ane is un@@ affected by food and dr@@ ink@@ .
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding P@@ ac@@ li@@ tax@@ el may cause serious birth def@@ ects and should therefore not be used if you are pregn@@ ant@@ .
20 Women of child@@ bearing age should use effective contra@@ c@@ eption during and up to 1 month after receiving treatment with Abra@@ x@@ an@@ e@@ .
Male patients are advised to not father a child during and up to six months after treatment and should seek advice on con@@ servation of sper@@ m prior to treatment because of the possibility of ir@@ re@@ versi@@ ble in@@ fertili@@ ty due to therapy with Abra@@ x@@ an@@ e@@ .
Because of the possibility of harm to the inf@@ ant@@ , bre@@ ast@@ -@@ feeding must be dis@@ continued for the dur@@ ation of treat@@ ment@@ .
As@@ k your doctor for advice before taking this medic@@ ine@@ .
Dri@@ ving and using machines Abra@@ x@@ ane may cause side effects such as ti@@ red@@ ness (@@ very common@@ ) and di@@ zz@@ iness (@@ common@@ ) that may affect your ability to drive and use mach@@ in@@ er@@ y@@ .
If you experience these symp@@ tom@@ s@@ , do not drive or operate mach@@ in@@ ery until they have fully resol@@ v@@ ed@@ .
If you are given other medic@@ ines as part of your treat@@ ment@@ , you should ask your doctor for advice on driving and using mach@@ in@@ es@@ .
Imp@@ ort@@ ant information about some of the ingredients of Abra@@ x@@ ane This medic@@ inal product contains approximately 4@@ 25 mg so@@ dium per d@@ os@@ e@@ .
This should be taken into consideration by patients on a controlled so@@ dium di@@ et@@ .
3.
HO@@ W TO US@@ E AB@@ RA@@ X@@ AN@@ E
Abra@@ x@@ ane will be given to you by a doctor or nurse into a v@@ ein from an in@@ tra@@ ven@@ ous dri@@ p.
The dose you receive is based on your body surface area and blood test resul@@ ts@@ .
The usual dose is 260 m@@ g@@ /@@ m2 of body surface are@@ a.
How often will you receive Abra@@ x@@ an@@ e@@ ?
Abra@@ x@@ ane is usually given every three wee@@ ks@@ .
How long will it take to give you your in@@ tra@@ ven@@ ous dri@@ p@@ ?
Abra@@ x@@ ane is given over a 30 minute peri@@ od@@ .
If you have any further questions on the use of this product ask your do@@ ct@@ or@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , Abra@@ x@@ ane can cause side@@ -@@ effec@@ ts@@ , although not everyone gets them@@ .
The very common side@@ -@@ effects (@@ reported in at least 1 out of 10 pati@@ ent@@ s@@ ) are@@ : • L@@ oss of hair • Ab@@ normal decre@@ ase in the number of neut@@ ro@@ ph@@ ils in the blood • Dec@@ re@@ ase in the number of white blood cells in the blood • Def@@ ici@@ ency of red blood cells • Re@@ duction in the number of lymp@@ ho@@ cy@@ tes in the blood • Eff@@ ect of peri@@ pher@@ al ner@@ ves (@@ pain@@ , and num@@ bn@@ ess@@ ) • P@@ ain in a joint or jo@@ ints • P@@ ain in the muscles • Nau@@ se@@ a@@ , di@@ arr@@ ho@@ ea • Vo@@ mi@@ ting • We@@ ak@@ ness and ti@@ red@@ ness
The common side@@ -@@ effects (@@ reported in at least 1 in 100 pati@@ ent@@ s@@ ) are@@ : • Sk@@ in ra@@ sh@@ , it@@ ch@@ ing@@ , dry sk@@ in@@ , nail disorder • Inf@@ ec@@ tion@@ , fe@@ ver@@ , fl@@ ushing
21 • Th@@ ro@@ at or ab@@ dom@@ inal pain • Indi@@ gesti@@ on@@ , ab@@ dom@@ inal dis@@ comfort@@ , or con@@ sti@@ p@@ ation • Di@@ ff@@ ic@@ ul@@ ty in breathing • L@@ oss of appeti@@ te@@ , weight loss • B@@ one pain@@ , muscle pain • Di@@ zz@@ in@@ ess@@ , di@@ mini@@ shed mus@@ cular coordin@@ ation or difficulty in reading • Ch@@ ang@@ es in heart rate or rhyth@@ m • Sw@@ elling of mu@@ cos@@ al and soft tis@@ su@@ es@@ , sor@@ eness of the mouth or ton@@ gu@@ e@@ , oral th@@ rush • S@@ leep problems
The un@@ common side@@ -@@ effects (@@ reported in at least 1 in 1000 pati@@ ent@@ s@@ ) are@@ : • In@@ cre@@ ased blood pressu@@ re@@ , increased wei@@ ght@@ , increased la@@ ct@@ ate in the bloo@@ d@@ , decre@@ ased ki@@ dney func@@ tion@@ , increased blood su@@ gar@@ , increased ph@@ osph@@ or@@ us in the bloo@@ d@@ , decre@@ ased pot@@ assi@@ um in the blood • Ner@@ ve disor@@ der@@ , decre@@ ased or lack of refle@@ x@@ es@@ , invol@@ un@@ tary mov@@ em@@ ent@@ s@@ , pain along a ner@@ ve@@ , loss of feel@@ ing@@ , fa@@ int@@ ing@@ , di@@ zz@@ iness when standing up@@ , painful num@@ b@@ ness or t@@ ing@@ ling@@ , sha@@ king • Ir@@ rit@@ ated ey@@ es@@ , painful ey@@ es@@ , red ey@@ es@@ , it@@ chy ey@@ es@@ , bl@@ urred or double visi@@ on@@ , reduced visi@@ on@@ , or seeing flash@@ ing lights • E@@ ar pain@@ , r@@ inging in your ears • Cou@@ gh@@ ing with ph@@ leg@@ m@@ , short@@ ness of breath when walking or climbing sta@@ ir@@ s@@ , stu@@ ffy n@@ os@@ e@@ , run@@ ny n@@ os@@ e@@ , or dry n@@ os@@ e@@ , decre@@ ased breath so@@ und@@ s@@ , water on the lung@@ , loss of voic@@ e@@ , difficulty breathing • Di@@ ff@@ ic@@ ul@@ ty swal@@ low@@ ing@@ , gas@@ , dry mou@@ th@@ , loose sto@@ ol@@ s@@ , heart@@ bur@@ n@@ , stomach cra@@ mp@@ s@@ , painful or s@@ ore mouth and gum@@ s@@ , rec@@ tal ble@@ eding • Pa@@ in@@ ful ur@@ in@@ ation@@ , frequent ur@@ in@@ ation@@ , blood in the ur@@ ine@@ , inability to hold your ur@@ ine • F@@ ing@@ ern@@ ail pain@@ ; f@@ ing@@ ern@@ ail dis@@ comfort@@ , loss of f@@ ing@@ ern@@ ail@@ s@@ , hi@@ ves@@ , skin pain@@ , red skin from sun@@ light@@ , skin disc@@ ol@@ or@@ ation@@ , red ra@@ sh@@ , it@@ chy ra@@ sh@@ , increased swe@@ at@@ ing@@ , night swe@@ ats@@ , white areas on the sk@@ in@@ , less hair@@ , overall it@@ ch@@ ing@@ , sor@@ es@@ , s@@ wollen face • Ch@@ est pain@@ , neck pain@@ , gro@@ in pain@@ , muscle cra@@ mp@@ s@@ , pain or weak@@ ness@@ , back pain@@ , pain in the arm or leg • Dec@@ re@@ ased ph@@ osph@@ or@@ us in the bloo@@ d@@ , flu@@ id re@@ ten@@ tion@@ , low alb@@ um@@ in in the bloo@@ d@@ , increased thir@@ st@@ , decre@@ ased cal@@ ci@@ um in the bloo@@ d@@ , decre@@ ased sugar in the bloo@@ d@@ , decre@@ ased so@@ dium in the blood • Thr@@ ush@@ , pain and sw@@ elling in the nose and thro@@ at@@ , skin inf@@ ec@@ tions@@ , infection in the lungs@@ , infection due to c@@ ath@@ eter line@@ , inf@@ ec@@ tion@@ , red@@ ness or sw@@ elling at the site where the need@@ le entered the body • Bru@@ ising • P@@ ain at site of tum@@ our@@ , death of the tum@@ our • Dec@@ re@@ ased blood pressu@@ re@@ , decre@@ ased blood pressure when standing up@@ , col@@ dness in your hands and feet • Ch@@ est pain or heav@@ in@@ ess@@ , difficulty wal@@ king@@ , sw@@ elling • Aller@@ gic reaction • Dec@@ re@@ ased liver func@@ tion@@ , increased size of liver • P@@ ain in the breast • Rest@@ less@@ ness
The rare side@@ -@@ effects (@@ reported in at least 1 in 10,000 pati@@ ent@@ s@@ ) are@@ : • L@@ ung infection • Sk@@ in reaction to another agent following radiation • Bloo@@ d c@@ lot
If any of the side@@ -@@ effects becomes seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your do@@ ct@@ or@@ .
22 5.
HO@@ W TO ST@@ ORE AB@@ RA@@ X@@ AN@@ E
Keep out of the reach and sight of chil@@ dr@@ en@@ .
Do not use Abra@@ x@@ ane after the exp@@ iry date which is stated on the car@@ ton and the vi@@ al after EX@@ P.
The exp@@ iry date ref@@ ers to the last day of that mon@@ th@@ .
U@@ no@@ pen@@ ed vi@@ al@@ s@@ :
Keep the vi@@ al in the ou@@ ter car@@ ton in order to protect from light@@ .
After first re@@ constitution the suspension should be used immedi@@ at@@ el@@ y@@ .
If not used immedi@@ at@@ el@@ y@@ , the suspension may be stor@@ ed in a re@@ fri@@ ger@@ ator (@@ 2@@ °@@ C – 8@@ °@@ C@@ ) for up to 8 hours in the vi@@ al when kept in the ou@@ ter car@@ ton in order to protect it from light@@ .
The recon@@ stit@@ uted suspension in the in@@ tra@@ ven@@ ous dri@@ p may be stor@@ ed for up to 8 hours at a temperature not above 25@@ º@@ C.
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What Abra@@ x@@ ane contains
• The active substance is pac@@ li@@ tax@@ el@@ .
Each vi@@ al contains 100 mg of pac@@ li@@ tax@@ el@@ . • After re@@ constitu@@ tion@@ , each ml of suspension contains 5 mg of pac@@ li@@ tax@@ el@@ . • The other ing@@ re@@ dient is human alb@@ um@@ in (@@ containing so@@ di@@ um@@ , so@@ dium cap@@ ry@@ late and N@@ -@@ ac@@ et@@ yl DL tr@@ yp@@ top@@ han@@ ate@@ )@@ .
What Abra@@ x@@ ane looks like and cont@@ ents of the pack
Abra@@ x@@ ane is a white to yellow powder for suspension for in@@ fusion available in glass vi@@ als containing 100 mg pac@@ li@@ tax@@ el@@ .
Marketing Auth@@ or@@ isation Hol@@ der Abra@@ xis Bio@@ Science Limited West Forest G@@ ate Well@@ ington Road W@@ ok@@ ingham Ber@@ kshire R@@ G@@ 40 2@@ A@@ Q United Kingdom
Manu@@ fac@@ tur@@ er Catal@@ ent UK Pack@@ aging Ltd Lanc@@ aster Way W@@ ing@@ ates Industrial Park Wes@@ thou@@ ghton BL@@ 5 3@@ X@@ X United Kingdom
This le@@ af@@ let was last approved in {@@ M@@ M@@ /@@ Y@@ Y@@ Y@@ Y@@ }
--------@@ --------@@ --------@@ --------@@ --------@@ --------@@ --------@@ --------@@ --------@@ --------@@ --------@@ --------@@ --------@@ --------@@ ----@@ --@@ ---
The following information is intended for medical or healthcare professionals on@@ ly@@ :
Instru@@ ctions for use@@ , handling and dispos@@ al
23 P@@ ac@@ li@@ tax@@ el is a cy@@ t@@ oto@@ x@@ ic an@@ tic@@ ancer medic@@ inal product and@@ , as with other potentially toxic com@@ po@@ und@@ s@@ , caution should be exerc@@ ised in handling Abra@@ x@@ an@@ e@@ .
Glo@@ ves@@ , go@@ gg@@ les and protective clothing should be use@@ d.
If Abra@@ x@@ ane suspension contacts the sk@@ in@@ , the skin should be w@@ ashed immediately and thor@@ ou@@ ghly with soap and water@@ .
If Abra@@ x@@ ane contacts mu@@ c@@ ous mem@@ bran@@ es@@ , the mem@@ bran@@ es should be fl@@ ushed thor@@ ou@@ ghly with water@@ .
Abra@@ x@@ ane should only be prepared and administ@@ ered by personnel appropri@@ ately trained in the handling of cy@@ t@@ oto@@ x@@ ic ag@@ ent@@ s.
Pre@@ gn@@ ant staff should not handle Abra@@ x@@ an@@ e@@ .
Re@@ constitution of the product and administration
Abra@@ x@@ ane should be ad@@ min ist@@ ered under the super@@ vision of a qualified onc@@ ologist in units speci@@ alised in the administration of cy@@ t@@ oto@@ x@@ ic ag@@ ent@@ s.
Abra@@ x@@ ane is supp@@ lied as a ster@@ ile ly@@ ophi@@ li@@ sed powder for re@@ constitution before use@@ .
After re@@ constitu@@ tion@@ , each ml of suspension contains 5 mg of pac@@ li@@ tax@@ el@@ .
Using a ster@@ ile sy@@ rin@@ ge@@ , 20 ml of so@@ dium ch@@ l@@ ori@@ de 9 m@@ g@@ /@@ ml (@@ 0.@@ 9@@ %@@ ) solution for in@@ fusion should be in@@ jected into a vi@@ al of Abra@@ x@@ ane over a minimum of 1 min@@ u@@ te@@ .
The solution should be directed onto the inside wall of the vi@@ al@@ .
The solution should not be in@@ jected directly onto the powder as this will result in fo@@ am@@ ing@@ .
Once the addition is comple@@ te@@ , the vi@@ al should be allowed to stand for a minimum of 5 minutes to ensure proper we@@ tting of the soli@@ d.
The n@@ , the vi@@ al should gently and slowly be s@@ wir@@ led and@@ /@@ or in@@ ver@@ ted for at least 2 minutes until complete resu@@ sp@@ ension of any powder occ@@ urs@@ .
The generation of fo@@ am should be avo@@ ide@@ d.
If fo@@ aming or cl@@ umping occ@@ urs@@ , the suspension should stand for at least 15 minutes until fo@@ am subsi@@ des@@ .
The recon@@ stit@@ uted suspension should be mil@@ ky and hom@@ o@@ genous without visible pre@@ cip@@ it@@ at@@ es@@ .
If pre@@ cip@@ it@@ ates or sett@@ ling are visi@@ ble@@ , the vi@@ al should be gently in@@ ver@@ ted again to ensure complete resu@@ sp@@ ension prior to use@@ .
Some sett@@ ling of the recon@@ stit@@ uted suspension may occ@@ ur@@ .
Comple@@ te resu@@ sp@@ ension should be ensured by mild ag@@ itation of the vi@@ al before use@@ .
If pre@@ cip@@ it@@ ates are observ@@ ed@@ , the recon@@ stit@@ uted suspension should be disc@@ ar@@ de@@ d.
The exact total d@@ osing volume of 5 m@@ g@@ /@@ ml suspension required for the patient should be calcul@@ ated and the appropriate amount of recon@@ stit@@ uted Abra@@ x@@ ane should be in@@ jected into an emp@@ ty@@ , steri@@ le@@ , poly@@ vin@@ yl ch@@ l@@ ori@@ de (@@ P@@ V@@ C@@ ) type IV bag@@ .
The use of speci@@ alized DE@@ H@@ P@@ -@@ free solution con@@ tain@@ ers or administration sets is not necessary to prepare or ad@@ minister Abra@@ x@@ ane in@@ fu@@ sion@@ s.
In@@ -@@ line fil@@ ters should not be use@@ d.
Par@@ enter@@ al medic@@ inal products should be inspec@@ ted visu@@ ally for partic@@ ulate matter and disc@@ ol@@ or@@ ation prior to administration whenever solution and container per@@ mit@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
St@@ ability U@@ no@@ pen@@ ed vi@@ als of Abra@@ x@@ ane are stable until the date indicated on the package when the vi@@ al is kept in the ou@@ ter car@@ ton in order to protect from light@@ .
Neither free@@ zing nor re@@ fri@@ ger@@ ation adver@@ sely affects the stability of the produc@@ t.
St@@ ability of the recon@@ stit@@ uted suspension in the vi@@ al After first re@@ constitu@@ tion@@ , the suspension should be filled into an in@@ fusion bag immedi@@ at@@ el@@ y@@ .
Ho@@ we@@ ver@@ , chemical and physical in use stability has been demonstrated for 8 hours at 2@@ °@@ C - 8@@ °@@ C in the original car@@ ton@@ , and protected from bright light@@ .
St@@ ability of the recon@@ stit@@ uted suspension in the in@@ fusion bag After re@@ constitu@@ tion@@ , the recon@@ stit@@ uted suspension in the in@@ fusion bag should be used immedi@@ at@@ el@@ y@@ .
However chemical and physical in use stability has been demonstrated for 8 hours not above 25@@ °@@ C.
24
AN@@ NE@@ X
CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE S@@ AF@@ E AND E@@ FF@@ EC@@ T@@ IV@@ E US@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T TO BE I@@ MP@@ LE@@ M@@ EN@@ T@@ ED B@@ Y THE ME@@ M@@ BER ST@@ AT@@ ES
1 CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE S@@ AF@@ E AND E@@ FF@@ EC@@ T@@ IV@@ E US@@ E O@@ F ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T TO BE I@@ MP@@ LE@@ M@@ EN@@ T@@ ED B@@ Y THE ME@@ M@@ BER ST@@ AT@@ ES
The Member States shall ensure that prior to launch the MA@@ H provides health care professionals in di@@ aly@@ sis centres and retail pharmac@@ ies with@@ :
• Educ@@ ational le@@ af@@ let • Sum@@ mary of product characterist@@ ics (@@ SP@@ C@@ ) and Pack@@ age Le@@ af@@ let and Lab@@ elling • C@@ ool boxes for patients clearly lab@@ elled with a visual aid indic@@ ating correct use of produc@@ t.
The educational le@@ af@@ let shall contain the following key elem@@ ent@@ s@@ : • That the use of e@@ po@@ et@@ in al@@ fa products can cause immun@@ o@@ gen@@ ic@@ ity which in rare cases may lead to P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) • That with other e@@ po@@ et@@ in produc@@ ts@@ , the risk of immun@@ o@@ gen@@ ic@@ ity in Chr@@ onic Ki@@ dney Di@@ se@@ ase (@@ C@@ K@@ D@@ ) is increased with the sub@@ cut@@ an@@ e@@ ous (@@ sc@@ ) rou@@ te@@ . • There is in@@ sufficient data on Ab@@ se@@ amed to know the size of any increased immun@@ o@@ gen@@ ic@@ ity risk with s@@ c use • Ther@@ e@@ fore@@ , the s@@ c route is not recommended for patients with C@@ K@@ D • The loss of eff@@ ic@@ acy or other symptoms of the development of immun@@ o@@ gen@@ ic@@ ity should be investigated • Any suspected case of P@@ ure Red C@@ ell A@@ pla@@ sia or development of immun@@ o@@ gen@@ ic@@ ity should be reported to the MA@@ H
2
European Medic@@ ines Agency
E@@ ME@@ A@@ / H@@ / C@@ / 7@@ 27
EU@@ RO@@ P@@ E@@ AN P@@ U@@ BL@@ IC AS@@ S@@ ES@@ SM@@ EN@@ T RE@@ P@@ OR@@ T (@@ EP@@ AR@@ )
AB@@ SE@@ AM@@ ED
EP@@ AR sum@@ mary for the public
It explains how the Committee for Medic@@ inal Produc@@ ts for Human Use (@@ CH@@ MP@@ ) asse@@ ssed the studies per@@ for@@ med@@ , to reach their recommendations on how to use the medic@@ ine@@ .
If you need more information about your medical condition or your treat@@ ment@@ , read the Pack@@ age Le@@ af@@ let (@@ also part of the EP@@ AR@@ ) or contact your doctor or pharmac@@ ist@@ .
If you want more information on the basis of the CH@@ MP recommend@@ ations@@ , read the Scienti@@ fic Dis@@ c@@ ussion (@@ also part of the EP@@ AR@@ )@@ .
What is Ab@@ se@@ am@@ ed@@ ?
Ab@@ se@@ amed is a solution for in@@ jec@@ tion@@ .
It is available in pre@@ -@@ filled sy@@ ring@@ es containing between 1,000 and 10,000 international units (@@ I@@ U@@ ) of the active sub@@ st@@ anc@@ e@@ , e@@ po@@ et@@ in al@@ fa@@ .
Ab@@ se@@ amed is a ‘ bio@@ simi@@ lar@@ ’ medic@@ ine@@ .
This means that Ab@@ se@@ amed is similar to a bi@@ ological medicine that is already author@@ ised in the European Union (@@ EU@@ ) and contains the same active substance (@@ also known as the ‘ reference medic@@ ine@@ ’@@ )@@ .
The reference medicine for Ab@@ se@@ amed is E@@ pre@@ x@@ / Er@@ y@@ po@@ .
For more information on bio@@ similar medi@@ cin@@ es@@ , see the questi@@ on@@ -@@ and@@ -@@ answer document her@@ e@@ .
What is Ab@@ se@@ amed used for@@ ?
Ab@@ se@@ amed is used in the following situ@@ ations@@ : • to treat an@@ a@@ emi@@ a (@@ low red blood cell coun@@ ts@@ ) that is causing symptoms in patients with ‘ chronic ren@@ al fail@@ ure@@ ’ (@@ long@@ -@@ ter@@ m@@ , progressive decre@@ ase in the ability of the ki@@ d@@ neys to work proper@@ ly@@ ) or other ki@@ dney proble@@ ms@@ ; • to treat an@@ a@@ emi@@ a in adults receiving ch@@ emo@@ therapy for certain types of cancer and to reduce the need for blood trans@@ fu@@ sions@@ ; • to increase the amount of blood that can be take in adult patients with moderate an@@ a@@ emi@@ a who are going to have an operation and don@@ ate their own blood before surgery (@@ au@@ t@@ olog@@ ous blood trans@@ fu@@ sion@@ )@@ ; • to reduce the need for blood trans@@ fu@@ sions in adults with mild an@@ a@@ emi@@ a who are about to under@@ go major or@@ th@@ op@@ a@@ edi@@ c (@@ bon@@ e@@ ) sur@@ ger@@ y@@ , such as hip sur@@ ger@@ y@@ .
It is used in patients with normal blood iron levels who could experience complic@@ ations if they were to receive a blood trans@@ fu@@ sion@@ , if they do not have the opportunity to don@@ ate their own blood before surgery and are expected to lose 900 to 1,@@ 800 ml of bloo@@ d.
The medicine can only be obtained with a prescri@@ p@@ tion@@ .
How is Ab@@ se@@ amed use@@ d@@ ?
Tre@@ at@@ ment with Ab@@ se@@ amed must be started under the super@@ vision of a doctor who has experience in the management of patients with the conditions that the medicine is used for@@ .
For patients with ki@@ dney problems and patients who are going to don@@ ate their own bloo@@ d@@ , Ab@@ se@@ amed must be in@@ jected into a v@@ ein@@ .
7 West@@ fer@@ ry Cir@@ cus@@ , Can@@ ary W@@ har@@ f@@ , London E@@ 14 4@@ HB@@ , UK Tel@@ .
(@@ 44@@ -@@ 20@@ ) 74 18 84 00 Fax (@@ 44@@ -@@ 20@@ ) 74 18 84 16 E@@ -@@ mail@@ : mail@@ @@@ eme@@ a. europa@@ . e@@ u htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . e@@ u
© European Medic@@ ines Agen@@ cy@@ , 200@@ 9.
Re@@ production is author@@ ised provided the source is acknowle@@ dge@@ d. have been trained appropri@@ at@@ el@@ y@@ .
The d@@ os@@ e@@ , the frequ@@ ency of in@@ jection and how long it is used for depend on why Ab@@ se@@ amed is being use@@ d@@ , and are adjusted according to the pati@@ ent@@ ’ s respon@@ se@@ .
For patients with chronic ren@@ al failure or receiving ch@@ emo@@ therap@@ y@@ , ha@@ emo@@ glob@@ in levels should remain within the recommended range (@@ between 10 and 12 grams per deci@@ li@@ tre in adults and between 9.@@ 5 and 11 g@@ / dl in chil@@ dr@@ en@@ )@@ .
Ha@@ emo@@ glob@@ in is the protein in red blood cells that carries oxy@@ gen around the body@@ .
For these pati@@ ent@@ s@@ , the lowest dose that provides adequate control of symptoms should be use@@ d.
The iron levels of all patients should be checked before treatment to make sure that they are not too low@@ , and iron supp@@ lements should be used throughout treat@@ ment@@ .
For full deta@@ il@@ s@@ , see the Pack@@ age Le@@ af@@ let@@ .
How does Ab@@ se@@ amed work@@ ?
A hor@@ mone called er@@ y@@ thro@@ po@@ ie@@ tin stimul@@ ates the production of red blood cells from the bone mar@@ ro@@ w@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is produced by the ki@@ d@@ ne@@ y@@ s.
In patients receiving ch@@ emo@@ therapy or with ki@@ dney proble@@ ms@@ , an@@ a@@ emi@@ a can be caused by a lack of er@@ y@@ thro@@ po@@ ie@@ tin@@ , or by the body not responding enough to the er@@ y@@ thro@@ po@@ ie@@ tin it has natur@@ all@@ y@@ .
In these cas@@ es@@ , er@@ y@@ thro@@ po@@ ie@@ tin is used to replace the missing hor@@ mone or to increase red blood cell coun@@ ts@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is also used before surgery to increase the number of red blood cells and help mini@@ mise the consequences of blood los@@ s.
The active substance in Ab@@ se@@ am@@ ed@@ , e@@ po@@ et@@ in al@@ fa@@ , is a copy of human er@@ y@@ thro@@ po@@ ie@@ tin and works in exactly the same way as the natural hor@@ mone to stim@@ ulate red blood cell produc@@ tion@@ .
The e@@ po@@ et@@ in al@@ fa in Ab@@ se@@ amed is produced by ‘ re@@ com@@ bin@@ ant DNA techn@@ olog@@ y@@ ’@@ : it is made by a cell that has received a gene (@@ DN@@ A@@ )@@ , which makes it able to produce e@@ po@@ et@@ in al@@ fa@@ .
How has Ab@@ se@@ amed been studi@@ ed@@ ?
Ab@@ se@@ amed was studied to show that it is compar@@ able with the reference medic@@ ine@@ , E@@ pre@@ x@@ / Er@@ y@@ po@@ , in experim@@ ental models and in hum@@ ans@@ .
Ab@@ se@@ am@@ ed@@ , in@@ jected into a v@@ ein@@ , was compared with the reference medicine in one main study involving 4@@ 79 patients with an@@ a@@ emi@@ a caused by ki@@ dney problem@@ s.
All of the patients had been taking E@@ pre@@ x@@ / Er@@ yp@@ o in@@ jected into a v@@ ein for at least eight weeks before they were either switched to Ab@@ se@@ amed or remained on E@@ pre@@ x@@ / Er@@ y@@ po@@ .
The main measure of effec@@ tiveness was the change in the levels of ha@@ emo@@ glob@@ in between the start of the study and the ev@@ al@@ uation peri@@ od@@ , between weeks 25 and 29.
The company also presented the results of a study compar@@ ing the effects of Ab@@ se@@ amed in@@ jected under the skin with those of E@@ pre@@ x@@ / Er@@ yp@@ o in 1@@ 14 cancer patients who were receiving ch@@ emo@@ therap@@ y@@ .
What benefit has Ab@@ se@@ amed shown during the stu@@ dies@@ ?
Ab@@ se@@ amed was as effective as E@@ pre@@ x@@ / Er@@ yp@@ o in increasing and maintaining red blood cell coun@@ ts@@ .
In the study of patients with an@@ a@@ emi@@ a caused by ki@@ dney proble@@ ms@@ , patients switching to Ab@@ se@@ amed maintained ha@@ emo@@ glob@@ in levels to the same extent as those continuing to take E@@ pre@@ x@@ / Er@@ y@@ po@@ .
On aver@@ age@@ , the levels of the patients taking Ab@@ se@@ amed increased by 0.@@ 14@@ 7 g@@ / dl from a starting value of 11.@@ 7 g@@ / d@@ l.
In compar@@ is@@ on@@ , those continuing to take E@@ pre@@ x@@ / Er@@ yp@@ o had an increase of 0.0@@ 63 g@@ / dl from a starting value of 12.@@ 0 g@@ / d@@ l.
The study in patients receiving ch@@ emo@@ therapy showed that Ab@@ se@@ amed was also as effective as E@@ pre@@ x@@ / Er@@ yp@@ o when it was in@@ jected under the sk@@ in@@ .
What is the risk associated with Ab@@ se@@ am@@ ed@@ ?
The most common side effect with Ab@@ se@@ amed is an increase in blood pressu@@ re@@ , which can sometimes lead to symptoms of en@@ cep@@ hal@@ op@@ ath@@ y (@@ brain proble@@ ms@@ ) such as su@@ dden@@ , stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ che and con@@ fu@@ sion@@ .
Ab@@ se@@ amed can also lead to skin ra@@ sh and flu@@ -@@ like symp@@ tom@@ s.
For the full list of all side effects reported with Ab@@ se@@ am@@ ed@@ , see the Pack@@ age Le@@ af@@ let@@ .
Ab@@ se@@ amed should not be used in people who may be hyper@@ sensitive (@@ aller@@ gi@@ c@@ ) to e@@ po@@ et@@ in al@@ fa or any of the other ingredi@@ ent@@ s.
It must not be used in the following gro@@ up@@ s@@ : • patients who have developed pure red cell ap@@ la@@ sia (@@ reduced or stopped red blood cell produc@@ tion@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin@@ ; • patients with high blood pressure that is not contro@@ lle@@ d@@ ; • patients who are going to don@@ ate their own blood who have had a heart attack or stroke within the last mon@@ th@@ , who have ang@@ ina p@@ ec@@ tor@@ is (@@ a severe type of chest pain@@ ) or who are at risk of deep 2@@ / 3 ven@@ ous thro@@ mbo@@ sis (@@ DV@@ T@@ : formation of blood cl@@ ots in the deep v@@ eins of the body@@ , usually in the leg@@ )@@ ; • patients who cannot receive medic@@ ines for the pre@@ vention of blood cl@@ ot@@ s@@ ; • patients about to under@@ go major or@@ th@@ op@@ a@@ edi@@ c surgery who have severe cardi@@ ov@@ as@@ cular (@@ heart and blood ves@@ sel@@ ) problems including a recent heart attack or stro@@ ke@@ .
Ab@@ se@@ amed is not recommended for in@@ jection under the skin in the treatment of ki@@ dney problems because further studies are needed to make sure that this does not cause aller@@ gic re@@ ac@@ tions@@ .
Why has Ab@@ se@@ amed been appro@@ v@@ ed@@ ?
The Committee for Medic@@ inal Produc@@ ts for Human Use (@@ CH@@ MP@@ ) concluded th@@ at@@ , in accord@@ ance with EU requi@@ re@@ ment@@ s@@ , Ab@@ se@@ amed has been shown to have a compar@@ able qual@@ it@@ y@@ , safety and eff@@ ic@@ acy profile to E@@ pre@@ x@@ / Er@@ y@@ po@@ .
The Committee recommended that Ab@@ se@@ amed be given marketing author@@ is@@ ation@@ .
Which measures are being taken to ensure the safe use of Ab@@ se@@ am@@ ed@@ ?
The company that makes Ab@@ se@@ amed will provide information p@@ acks for healthcare workers in all Member Stat@@ es@@ , including information on the safety of the medic@@ ine@@ .
The company will also provide cool boxes for pati@@ ent@@ s@@ , which will include illu@@ stra@@ tions showing how the medicine should be use@@ d.
Other information about Ab@@ se@@ am@@ ed@@ :
The European Commission granted a marketing author@@ isation val@@ id throughout the EU for Ab@@ se@@ amed to Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG on 28 August 200@@ 7.
The full EP@@ AR for Ab@@ se@@ amed can be found her@@ e@@ .
This sum@@ mary was last updated in 12@@ -@@ 200@@ 8.
3@@ / 3
EU Number
Inv@@ ented name
St@@ ren@@ g@@ th
P@@ harm@@ ac@@ eu@@ tical Form
Route of Administration
Pack@@ aging
Cont@@ ent
Pack@@ age size
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 1
Ab@@ se@@ amed
1000 I@@ U@@ / 0.5 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.5 ml (@@ 2000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 2
Ab@@ se@@ amed
1000 I@@ U@@ / 0.5 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.5 ml (@@ 2000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 3
Ab@@ se@@ amed
2000 I@@ U@@ / 1.@@ 0 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
1.@@ 0 ml (@@ 2000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 4
Ab@@ se@@ amed
2000 I@@ U@@ / 1.@@ 0 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
1.@@ 0 ml (@@ 2000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 5
Ab@@ se@@ amed
3000 I@@ U@@ / 0.@@ 3 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 3 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 6
Ab@@ se@@ amed
3000 I@@ U@@ / 0.@@ 3 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 3 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 7
Ab@@ se@@ amed
4000 I@@ U@@ / 0.@@ 4 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 4 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 8
Ab@@ se@@ amed
4000 I@@ U@@ / 0.@@ 4 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 4 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 9
Ab@@ se@@ amed
5000 I@@ U@@ / 0.5 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.5 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 10
Ab@@ se@@ amed
5000 I@@ U@@ / 0.5 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.5 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 11
Ab@@ se@@ amed
6000 I@@ U@@ / 0.@@ 6 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 6 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 12
Ab@@ se@@ amed
6000 I@@ U@@ / 0.@@ 6 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 6 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 13
Ab@@ se@@ amed
8000 I@@ U@@ / 0.@@ 8 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 8 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 14
Ab@@ se@@ amed
8000 I@@ U@@ / 0.@@ 8 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 8 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 15
Ab@@ se@@ amed
10@@ 000 I@@ U@@ / 1.@@ 0 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
1.@@ 0 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 16
Ab@@ se@@ amed
10@@ 000 I@@ U@@ / 1.@@ 0 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
1.@@ 0 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 17
Ab@@ se@@ amed
7000 I@@ U@@ / 0.@@ 7 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 7 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
1@@ / 2 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 18
Ab@@ se@@ amed
7000 I@@ U@@ /
0.@@ 7 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 7 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 19
Ab@@ se@@ amed
9@@ 000 I@@ U@@ /
0.@@ 9 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 9 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
1 pre@@ -@@ filled sy@@ r@@ inge
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 20
Ab@@ se@@ amed
9@@ 000 I@@ U@@ /
0.@@ 9 ml
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
Sub@@ cut@@ an@@ e@@ ous or in@@ tra@@ ven@@ ous use
pre@@ -@@ filled sy@@ r@@ inge (@@ g@@ las@@ s@@ )
0.@@ 9 ml (@@ 10@@ 000 I@@ U@@ / m@@ l@@ )
6 pre@@ -@@ filled sy@@ ring@@ es
2@@ / 2
AN@@ NE@@ X I
SU@@ M@@ MAR@@ Y O@@ F P@@ RO@@ D@@ UC@@ T CH@@ AR@@ AC@@ TER@@ IS@@ T@@ IC@@ S
1 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 1000 I@@ U@@ / 0.5 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 2000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 16.@@ 8 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 0.5 ml contains 1000 international units (@@ I@@ U@@ ) correspon@@ ding to 8.@@ 4 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
2 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
3 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
4 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
5 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
6 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
8 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
9 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
11 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
12 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
13 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
14 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 0.5 ml (@@ 1000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 1 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 2
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
15 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 2000 I@@ U@@ / 1 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 2000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 16.@@ 8 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 1 ml contains 2000 international units (@@ I@@ U@@ ) correspon@@ ding to 16.@@ 8 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
4.@@ 2 Pos@@ ology and method of administration
Tre@@ at@@ ment with Ab@@ se@@ amed has to be initi@@ ated under the super@@ vision of physi@@ cians experienced in the management of patients with the above indic@@ ations@@ .
16 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
17 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
18 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
19 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
20 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
22 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
23 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
25 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
26 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
27 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
28 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 1 ml (@@ 2000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 3 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 4
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
29 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 3000 I@@ U@@ / 0.@@ 3 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 10 000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 8@@ 4.@@ 0 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 0.@@ 3 ml contains 3000 international units (@@ I@@ U@@ ) correspon@@ ding to 25.@@ 2 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
4.@@ 2 Pos@@ ology and method of administration
Tre@@ at@@ ment with Ab@@ se@@ amed has to be initi@@ ated under the super@@ vision of physi@@ cians experienced in the management of patients with the above indic@@ ations@@ .
30 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
31 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
32 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
33 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
34 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
36 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
37 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
39 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
40 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
41 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
42 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 0.@@ 3 ml (@@ 3000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 5 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 6
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
43 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 4000 I@@ U@@ / 0.@@ 4 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 10 000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 8@@ 4.@@ 0 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 0.@@ 4 ml contains 4000 international units (@@ I@@ U@@ ) correspon@@ ding to 3@@ 3.@@ 6 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
4.@@ 2 Pos@@ ology and method of administration
Tre@@ at@@ ment with Ab@@ se@@ amed has to be initi@@ ated under the super@@ vision of physi@@ cians experienced in the management of patients with the above indic@@ ations@@ .
44 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
45 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
46 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
47 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
48 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
50 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
51 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
53 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
54 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
55 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
56 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 0.@@ 4 ml (@@ 4000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 7 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 8
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
57 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 5000 I@@ U@@ / 0.5 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 10 000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 8@@ 4.@@ 0 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 0.5 ml contains 5000 international units (@@ I@@ U@@ ) correspon@@ ding to 4@@ 2.0 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
4.@@ 2 Pos@@ ology and method of administration
Tre@@ at@@ ment with Ab@@ se@@ amed has to be initi@@ ated under the super@@ vision of physi@@ cians experienced in the management of patients with the above indic@@ ations@@ .
58 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
59 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
60 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
61 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
62 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
64 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
65 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
67 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
68 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
69 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
70 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 0.5 ml (@@ 5000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 9 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 10
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
71 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 6000 I@@ U@@ / 0.@@ 6 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 10 000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 8@@ 4.@@ 0 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 0.@@ 6 ml contains 6000 international units (@@ I@@ U@@ ) correspon@@ ding to 50@@ .@@ 4 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
4.@@ 2 Pos@@ ology and method of administration
Tre@@ at@@ ment with Ab@@ se@@ amed has to be initi@@ ated under the super@@ vision of physi@@ cians experienced in the management of patients with the above indic@@ ations@@ .
72 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
73 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
74 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
75 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
76 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
78 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
79 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
81 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
82 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
83 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
84 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 0.@@ 6 ml (@@ 6000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 11 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 12
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
85 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 7000 I@@ U@@ / 0.@@ 7 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 10 000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 8@@ 4.@@ 0 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 0.@@ 7 ml contains 7000 international units (@@ I@@ U@@ ) correspon@@ ding to 5@@ 8.@@ 8 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
4.@@ 2 Pos@@ ology and method of administration
Tre@@ at@@ ment with Ab@@ se@@ amed has to be initi@@ ated under the super@@ vision of physi@@ cians experienced in the management of patients with the above indic@@ ations@@ .
86 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
87 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
88 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
89 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
90 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
92 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
93 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
95 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
96 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
97 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
98 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 0.@@ 7 ml (@@ 7000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 17 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 18
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
99 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 8000 I@@ U@@ / 0.@@ 8 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 10 000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 8@@ 4.@@ 0 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 0.@@ 8 ml contains 8000 international units (@@ I@@ U@@ ) correspon@@ ding to 6@@ 7.@@ 2 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
4.@@ 2 Pos@@ ology and method of administration
Tre@@ at@@ ment with Ab@@ se@@ amed has to be initi@@ ated under the super@@ vision of physi@@ cians experienced in the management of patients with the above indic@@ ations@@ .
100 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
101 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
102 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
103 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
104 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
106 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
10@@ 7 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
10@@ 9 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
110 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
111 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
112 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 0.@@ 8 ml (@@ 8000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 13 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 14
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
1@@ 13 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 9@@ 000 I@@ U@@ / 0.@@ 9 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 10 000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 8@@ 4.@@ 0 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 0.@@ 9 ml contains 9@@ 000 international units (@@ I@@ U@@ ) correspon@@ ding to 7@@ 5.@@ 6 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
4.@@ 2 Pos@@ ology and method of administration
Tre@@ at@@ ment with Ab@@ se@@ amed has to be initi@@ ated under the super@@ vision of physi@@ cians experienced in the management of patients with the above indic@@ ations@@ .
1@@ 14 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
115 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
1@@ 16 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
1@@ 17 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
1@@ 18 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
120 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
12@@ 1 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
123 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
12@@ 4 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
125 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
12@@ 6 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 0.@@ 9 ml (@@ 9@@ 000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 19 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 20
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
12@@ 7 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 10 000 I@@ U@@ / 1 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each ml of solution contains 10 000 I@@ U of e@@ po@@ et@@ in al@@ fa@@ * correspon@@ ding to 8@@ 4.@@ 0 micro@@ grams per ml 1 pre@@ -@@ filled sy@@ r@@ inge of 1 ml contains 10 000 international units (@@ I@@ U@@ ) correspon@@ ding to 8@@ 4.@@ 0 micro@@ grams e@@ po@@ et@@ in al@@ fa
* Pro@@ duced in CH@@ O cell line by re@@ com@@ bin@@ ant DNA technology
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge (@@ in@@ jec@@ tion@@ )
Cle@@ ar colo@@ ur@@ less solution
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a associated with chronic ren@@ al failure (@@ CR@@ F@@ ) in adult and pa@@ edi@@ atri@@ c pati@@ ent@@ s@@ :
- Tre@@ at@@ ment of an@@ a@@ emi@@ a associated with chronic ren@@ al failure in pa@@ edi@@ atri@@ c and adult patients on
ha@@ emo@@ di@@ aly@@ sis and adult patients on per@@ it@@ one@@ al di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
- Tre@@ at@@ ment of severe an@@ a@@ emi@@ a of ren@@ al orig@@ in accompanied by clinical symptoms in adult patients
with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis (@@ See section 4.@@ 4@@ )@@ .
Tre@@ at@@ ment of an@@ a@@ emi@@ a and reduction of trans@@ fusion requirements in adult patients receiving ch@@ emo@@ therapy for solid tum@@ o@@ urs@@ , mal@@ ign@@ ant lymp@@ homa or multiple my@@ el@@ om@@ a@@ , and at risk of trans@@ fusion as asse@@ ssed by the pati@@ ent@@ '@@ s general status (@@ e@@ . g. cardi@@ ov@@ as@@ cular stat@@ us@@ , pre@@ -@@ existing an@@ a@@ emi@@ a at the start of ch@@ emo@@ therap@@ y@@ )@@ .
Ab@@ se@@ amed can be used to increase the yield of au@@ t@@ olog@@ ous blood from patients in a pre@@ don@@ ation program@@ me@@ .
Its use in this indication must be balanced against the reported risk of thro@@ mbo@@ em@@ bo@@ lic event@@ s.
Tre@@ at@@ ment should only be given to patients with moderate an@@ a@@ emi@@ a (@@ ha@@ emo@@ glob@@ in (@@ H@@ b@@ ) 10 – 13 g@@ / dl [@@ 6.@@ 2 – 8.@@ 1 mm@@ ol@@ / l@@ ]@@ , no iron def@@ ici@@ en@@ cy@@ )@@ , if blood saving procedures are not available or in@@ sufficient when the scheduled major elec@@ tive surgery requires a large volume of blood (@@ 4 or more units of blood for fem@@ ales or 5 or more units for mal@@ es@@ )@@ .
Ab@@ se@@ amed can be used to reduce exposure to allo@@ gen@@ ei@@ c blood trans@@ fu@@ sions in adult non@@ -@@ iron def@@ icient patients prior to major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , having a high perceived risk for trans@@ fusion complic@@ ations@@ .
Use should be restricted to patients with moderate an@@ a@@ emi@@ a (@@ e@@ . g.
H@@ b 10 - 13 g@@ / dl@@ ) who do not have an au@@ t@@ olog@@ ous pre@@ don@@ ation programme available and with an expected blood loss of 900 to 1800 m@@ l.
4.@@ 2 Pos@@ ology and method of administration
Tre@@ at@@ ment with Ab@@ se@@ amed has to be initi@@ ated under the super@@ vision of physi@@ cians experienced in the management of patients with the above indic@@ ations@@ .
12@@ 8 Pos@@ ology
Tre@@ at@@ ment of symp@@ tom@@ atic an@@ a@@ emi@@ a in adult and pa@@ edi@@ atri@@ c chronic ren@@ al failure pati@@ ent@@ s@@ :
In patients with chronic ren@@ al failure the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ously (@@ see section 4.@@ 4@@ )@@ .
The ha@@ emo@@ glob@@ in concentration aimed for is between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ , except in pa@@ edi@@ atri@@ c patients in whom the ha@@ emo@@ glob@@ in concentration should be between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
Ab@@ se@@ amed should be administ@@ ered in@@ tra@@ ven@@ ously in order to increase ha@@ emo@@ glob@@ in to not greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A rise in ha@@ emo@@ glob@@ in of greater than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) over a four week period should be avo@@ ide@@ d.
If it occ@@ urs@@ , appropriate dose adju@@ st@@ ments should be made as provi@@ de@@ d.
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose man@@ a@@ gem@@ ent@@ , with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
In pa@@ edi@@ atri@@ c patients the recommended target ha@@ emo@@ glob@@ in range is between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be avo@@ ide@@ d.
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the sustained ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) reduce the e@@ po@@ et@@ in al@@ fa dose by 25@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and then rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous level@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of an@@ a@@ emi@@ a and of the symptoms of an@@ a@@ emi@@ a.
Iron status should be evalu@@ ated prior to and during treatment and iron supp@@ lement@@ ation administ@@ ered if necess@@ ar@@ y@@ .
In addi@@ tion@@ , other causes of an@@ a@@ emi@@ a@@ , such as vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ cy@@ , should be exclu@@ ded before instit@@ uting therapy with e@@ po@@ et@@ in al@@ fa@@ .
Non response to e@@ po@@ et@@ in al@@ fa therapy may have the following cau@@ ses@@ : iron@@ , fol@@ ate@@ , or vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ ; al@@ uminium in@@ tox@@ ic@@ ation@@ ; inter@@ current inf@@ ec@@ tions@@ ; infl@@ am@@ mat@@ ory or trau@@ matic epis@@ o@@ des@@ ; occ@@ ult blood los@@ s@@ ; ha@@ em@@ ol@@ ysi@@ s@@ , and bone mar@@ row fi@@ bro@@ sis of any origin@@ .
Ad@@ ult ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of at least four wee@@ ks@@ .
At each step@@ , the increase or reduction in dose should be of 25 I@@ U@@ / kg 3 times per week@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
The recommended total weekly dose is between 75 and 300 I@@ U@@ / kg given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6 g@@ / dl or@@ < 3.@@ 75 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 8 g@@ /@@ dl or@@ > 5 mm@@ ol@@ /@@ l@@ )@@ .
Pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
12@@ 9 Cor@@ rec@@ tion ph@@ as@@ e@@ :
50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
When a dose adju@@ st@@ ment is necess@@ ar@@ y@@ , this should be done in steps of 25 I@@ U@@ / kg 3 times per week at inter@@ vals of at least 4 weeks until the desi@@ red goal is achie@@ v@@ ed@@ .
Ma@@ intenance ph@@ as@@ e@@ :
H@@ b between 9.@@ 5 and 11 g@@ / dl (@@ 5.@@ 9 - 6.@@ 8 mm@@ ol@@ / l@@ )@@ .
Gener@@ all@@ y@@ , children under 30 kg require higher maintenance d@@ oses than children over 30 kg and ad@@ ul@@ ts@@ .
The following maintenance d@@ oses were observed in clinical trials after 6 months of treat@@ ment@@ :
Wei@@ ght (@@ kg )@@ < 10 10 - 30 > 30
Medi@@ an 100 75 33
U@@ su@@ al maintenance dose 75 - 150 60 - 150 30 - 100
The clinical data available suggest that those patients whose initial ha@@ emo@@ glob@@ in is very low (@@ < 6.@@ 8 g@@ / dl or@@ < 4.@@ 25 mm@@ ol@@ /@@ l@@ ) may require higher maintenance d@@ oses than those whose initial an@@ a@@ emi@@ a is less severe (@@ H@@ b > 6.@@ 8 g@@ /@@ dl or@@ > 4.@@ 25 mm@@ ol@@ /@@ l@@ )@@ .
Ad@@ ult per@@ it@@ one@@ al di@@ aly@@ sis pati@@ ent@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 2 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 25 and 50 I@@ U@@ / kg 2 times per week into 2 equal in@@ jec@@ tions@@ .
Ad@@ ult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ si@@ s@@ :
The treatment is divided into two sta@@ ges@@ :
Cor@@ rec@@ tion ph@@ as@@ e@@ :
Star@@ ting dose of 50 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ , followed if necessary by a dose increase with 25 I@@ U@@ / kg incre@@ ments (@@ 3 times per week@@ ) until the desi@@ red goal is achieved (@@ this should be done in steps of at least four wee@@ ks@@ )@@ .
Ma@@ intenance ph@@ as@@ e@@ :
D@@ ose adju@@ st@@ ment in order to maintain ha@@ emo@@ glob@@ in values at the desi@@ red level@@ :
H@@ b between 10 and 12 g@@ / dl (@@ 6.@@ 2 - 7.5 mm@@ ol@@ / l@@ )@@ .
Ma@@ intenance dose between 17 and 33 I@@ U@@ / kg 3 times per week by the in@@ tra@@ ven@@ ous rou@@ te@@ .
The maximum dose should not exce@@ ed 200 I@@ U@@ / kg 3 times per week@@ .
Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a@@ :
E@@ po@@ et@@ in al@@ fa should be administ@@ ered by the sub@@ cut@@ an@@ e@@ ous route to patients with an@@ a@@ emi@@ a (@@ e@@ . g. ha@@ emo@@ glob@@ in concentration ≤ 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ )@@ .
An@@ a@@ emi@@ a symptoms and sequ@@ el@@ ae may v@@ ary with age@@ , gen@@ der@@ , and overall burden of dise@@ as@@ e@@ ; a physi@@ ci@@ an@@ ´@@ s ev@@ al@@ uation of the individual pati@@ ent@@ ´@@ s clinical course and condition is necess@@ ar@@ y@@ .
D@@ ue to in@@ tra@@ -@@ patient vari@@ abili@@ ty@@ , occasi@@ onal individual ha@@ emo@@ glob@@ in values for a patient above and below the desi@@ red ha@@ emo@@ glob@@ in level may be observ@@ ed@@ .
Ha@@ emo@@ glob@@ in vari@@ ability should be addressed through dose management with consideration for the ha@@ emo@@ glob@@ in target range of 10 g@@ / dl (@@ 6.@@ 2 mm@@ ol@@ / l@@ ) to 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
A sustained ha@@ emo@@ glob@@ in level of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) should be
130 avo@@ ide@@ d@@ ; guidance for appropriate dose adju@@ st@@ ment for when ha@@ emo@@ glob@@ in values exce@@ eding 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) are observed are described bel@@ ow@@ .
Pati@@ ents should be monit@@ ored closely to ensure that the lowest approved dose of E@@ po@@ et@@ in al@@ fa is used to provide adequate control of the symptoms of an@@ a@@ emi@@ a.
E@@ po@@ et@@ in al@@ fa therapy should continue until one month after the end of ch@@ emo@@ therap@@ y@@ .
The initial dose is 150 I@@ U@@ / kg given sub@@ cut@@ an@@ e@@ ously 3 times per week@@ .
Altern@@ ati@@ vel@@ y@@ , e@@ po@@ et@@ in al@@ fa can be administ@@ ered at an initial dose of 450 I@@ U@@ / kg sub@@ cut@@ an@@ e@@ ously once wee@@ kl@@ y@@ .
If ha@@ emo@@ glob@@ in has increased by at least 1 g@@ / dl (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l above bas@@ eline after 4 weeks of treat@@ ment@@ , the dose should remain at 150 I@@ U@@ / kg 3 times a week or 450 I@@ U@@ / kg once wee@@ kl@@ y@@ .
If the ha@@ emo@@ glob@@ in increase is < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , increase the dose to 300 I@@ U@@ / kg 3 times per week@@ .
If after an additional 4 weeks of therapy at 300 I@@ U@@ / kg 3 times per week@@ , the ha@@ emo@@ glob@@ in has increased ≥ 1 g@@ / dl (@@ ≥ 0.@@ 62 mm@@ ol@@ / l@@ ) or the re@@ tic@@ u@@ lo@@ cy@@ te count has increased ≥ 40,000 cell@@ s@@ / µ@@ l the dose should remain at 300 I@@ U@@ / kg 3 times per week@@ .
Ho@@ we@@ ver@@ , if the ha@@ emo@@ glob@@ in has increased < 1 g@@ / dl (@@ < 0.@@ 62 mm@@ ol@@ / l@@ ) and the re@@ tic@@ u@@ lo@@ cy@@ te count has increased < 40,000 cell@@ s@@ / µ@@ l above bas@@ el@@ ine@@ , response to e@@ po@@ et@@ in al@@ fa therapy is unlikely and treatment should be dis@@ continu@@ ed@@ .
The recommended d@@ osing regim@@ en is described in the following diag@@ ra@@ m@@ :
13@@ 1 150 I@@ U@@ / kg 3@@ x@@ / week or 450 I@@ U@@ / kg once weekly
for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l
Tar@@ get H@@ b (@@ appro@@ x@@ .
12 g@@ / dl@@ )
300 I@@ U@@ / kg 3@@ x@@ / week for 4 weeks
Re@@ tic@@ u@@ lo@@ cy@@ te count increase ≥ 4@@ 0,@@ 00@@ 0@@ / µ@@ l or H@@ b increase ≥ 1 g@@ / dl
Re@@ tic@@ u@@ lo@@ cy@@ te count increase < 4@@ 0,@@ 00@@ 0@@ / µ@@ l and H@@ b increase < 1 g@@ / dl
Dis@@ continue therapy
D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ :
If the ha@@ emo@@ glob@@ in is rising by more than 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per mon@@ th@@ , or if the ha@@ emo@@ glob@@ in exce@@ eds 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ , the dose should be reduced by approximately 25 to 50@@ %@@ .
If the ha@@ emo@@ glob@@ in exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ , dis@@ continue therapy until it falls below 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) and than rein@@ stitute e@@ po@@ et@@ in al@@ fa therapy at a dose 25@@ % below the previous d@@ os@@ e@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ me@@ :
Ab@@ se@@ amed should be given by the in@@ tra@@ ven@@ ous rou@@ te@@ .
At the time of don@@ ating bloo@@ d@@ , Ab@@ se@@ amed should be administ@@ ered after the comple@@ tion of the blood don@@ ation proce@@ du@@ re@@ .
Mil@@ dly an@@ a@@ e@@ mic patients (@@ ha@@ em@@ at@@ o@@ cri@@ t of 33 - 39@@ %@@ ) requiring pre@@ deposit of ≥ 4 units of blood should be treated with Ab@@ se@@ amed at a dose of 600 I@@ U@@ / kg body weight 2 times weekly for 3 weeks prior to sur@@ ger@@ y@@ .
200 mg oral elem@@ ental iron da@@ ily@@ ) throughout the course of treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started as soon as possi@@ ble@@ , even several weeks prior to initi@@ ating the au@@ t@@ olog@@ ous pre@@ deposi@@ t@@ , in order to achieve high iron stores prior to starting Ab@@ se@@ amed therap@@ y@@ .
Tre@@ at@@ ment of adult patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ :
The sub@@ cut@@ an@@ e@@ ous route of administration should be use@@ d.
13@@ 2 The recommended dose is 600 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa@@ , given weekly for three weeks (@@ days 21@@ , 14 and 7@@ ) prior to surgery and on the day of surgery (@@ day 0@@ )@@ .
In cases where there is a medical need to shor@@ ten the lead time before surgery to less than three wee@@ ks@@ , 300 I@@ U@@ / kg e@@ po@@ et@@ in al@@ fa should be given daily for 10 consecutive days prior to sur@@ ger@@ y@@ , on the day of surgery and for four days immediately ther@@ e@@ after@@ .
When performing ha@@ em@@ at@@ ologi@@ c asse@@ ss@@ ments during the pre@@ operative peri@@ od@@ , if the ha@@ emo@@ glob@@ in level reaches 15 g@@ / dl@@ , or high@@ er@@ , administration of e@@ po@@ et@@ in al@@ fa should be stopped and further d@@ oses should not be gi@@ ven@@ .
Care should be taken to ensure that at the out@@ set of the treatment patients are not iron def@@ ici@@ ent@@ .
All patients being treated with e@@ po@@ et@@ in al@@ fa should receive adequate iron supp@@ lement@@ ation (@@ e@@ . g. oral iron sub@@ stitution of 200 mg Fe@@ 2@@ + da@@ ily@@ ) throughout the course of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Iron supp@@ lement@@ ation should be started prior to e@@ po@@ et@@ in al@@ fa therap@@ y@@ , to achieve adequate iron stor@@ es@@ .
Me@@ th@@ od of administration
Ad@@ minister the amount requi@@ re@@ d.
This medic@@ inal product must not be administ@@ ered by in@@ tra@@ ven@@ ous in@@ fu@@ sion@@ , or mixed with other medic@@ inal produc@@ ts@@ .
1.
In@@ tra@@ ven@@ ous in@@ jec@@ tion@@ : over at least one to five min@@ ut@@ es@@ , depending on the total d@@ os@@ e@@ .
In ha@@ emo@@ di@@ aly@@ sed pati@@ ent@@ s@@ , a bol@@ us in@@ jection may be given during the di@@ aly@@ sis session through a suitable ven@@ ous port in the di@@ aly@@ sis line@@ .
Altern@@ ati@@ vel@@ y@@ , the in@@ jection can be given at the end of the di@@ aly@@ sis session via the f@@ ist@@ ula need@@ le t@@ ub@@ ing@@ , followed by 10 ml of is@@ ot@@ onic sal@@ ine to rin@@ se the t@@ ub@@ ing and ensure satis@@ factory in@@ jection of the product into the circu@@ la@@ tion@@ .
A s@@ lower in@@ jection is prefer@@ able in patients who react to the treatment with “ flu@@ -@@ li@@ ke@@ ” symp@@ tom@@ s.
2.
Sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ : a maximum volume of 1 ml at one in@@ jection site should generally not be exce@@ e@@ de@@ d.
In case of larger vol@@ um@@ es@@ , more than one site should be chosen for the in@@ jec@@ tion@@ .
The in@@ jections are given in the thi@@ ghs or the an@@ ter@@ ior ab@@ dom@@ inal w@@ all@@ .
In chronic ren@@ al failure patients Ab@@ se@@ amed has not to be administ@@ ered sub@@ cut@@ an@@ e@@ ous@@ ly@@ !
The in@@ tra@@ ven@@ ous route has to be used (@@ please see section 4.@@ 4 - chronic ren@@ al failure pati@@ ent@@ s@@ )@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ent@@ s.
Pati@@ ents who develop P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) following treatment with any er@@ y@@ thro@@ po@@ ie@@ tin should not receive Ab@@ se@@ amed or any other er@@ y@@ thro@@ po@@ ie@@ tin (@@ see section 4.@@ 4 - P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )@@ .
Un@@ controlled hyper@@ ten@@ sion@@ .
In the indication “ increasing the yield of au@@ t@@ olog@@ ous bloo@@ d@@ ”@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ ction or stroke in the month prec@@ eding treat@@ ment@@ , un@@ stable ang@@ ina p@@ ec@@ tor@@ is@@ , increased risk of deep ven@@ ous thro@@ mbo@@ sis such as history of ven@@ ous thro@@ mbo@@ em@@ bo@@ lic dise@@ as@@ e@@ .
Pati@@ ents who for any reason cannot receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ .
The use of e@@ po@@ et@@ in al@@ fa in patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery and not particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation programme is contra@@ indicated in patients with severe cor@@ on@@ ar@@ y@@ , peri@@ pher@@ al ar@@ teri@@ al@@ , car@@ o@@ ti@@ d or cer@@ eb@@ ral v@@ as@@ cular dise@@ as@@ e@@ , including patients with recent m@@ yo@@ cardi@@ al inf@@ ar@@ ction or cer@@ eb@@ ral v@@ as@@ cular acci@@ dent@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
General
In all patients receiving e@@ po@@ et@@ in al@@ fa@@ , blood pressure should be closely monit@@ ored and controlled as necess@@ ar@@ y@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of un@@ treat@@ ed@@ , in@@ adequ@@ ately treated
It may be necessary to add or increase anti@@ hyper@@ ten@@ sive treat@@ ment@@ .
If blood pressure cannot be contro@@ lle@@ d@@ , e@@ po@@ et@@ in al@@ fa treatment should be dis@@ continu@@ ed@@ .
E@@ po@@ et@@ in al@@ fa should be used with caution in the presence of ep@@ ile@@ p@@ sy and chronic liver fail@@ ure@@ .
There may be a moderate d@@ os@@ e@@ -@@ dependent rise in the plat@@ el@@ et count within the normal range during treatment with e@@ po@@ et@@ in al@@ fa@@ .
This reg@@ resses during the course of continued therap@@ y@@ .
It is recommended that the plat@@ el@@ et count is regularly monit@@ ored during the first 8 weeks of therap@@ y@@ .
All other causes of an@@ a@@ emi@@ a (@@ iron def@@ ici@@ en@@ cy@@ , ha@@ em@@ ol@@ ysi@@ s@@ , blood los@@ s@@ , vit@@ amin B@@ 12 or fol@@ ate def@@ ici@@ en@@ ci@@ es@@ ) should be considered and treated prior to initi@@ ating therapy with e@@ po@@ et@@ in al@@ fa@@ .
In most cas@@ es@@ , the fer@@ rit@@ in values in the ser@@ um fall simul@@ tane@@ ously with the rise in packed cell vol@@ um@@ e@@ .
In order to ensure optim@@ um response to e@@ po@@ et@@ in al@@ fa@@ , adequate iron stores should be assu@@ red@@ :
200 - 300 mg Fe@@ 2@@ +@@ / day or@@ ally (@@ 100 - 200 mg Fe@@ 2@@ +@@ / day for pa@@ edi@@ atri@@ c
pati@@ ent@@ s@@ ) is recommended for chronic ren@@ al failure patients whose ser@@ um fer@@ rit@@ in levels are below 100 n@@ g@@ / ml
- oral iron sub@@ stitution of 200 - 300 mg Fe@@ 2@@ +@@ / day is recommended for all cancer patients whose
trans@@ fer@@ rin sat@@ ur@@ ation is below 20@@ %@@ .
All of these addi@@ tive factors of an@@ a@@ emi@@ a should also be carefully considered when deciding to increase the dose of e@@ po@@ et@@ in al@@ fa in cancer pati@@ ent@@ s.
Good blood management practices should always be used in the per@@ is@@ ur@@ gi@@ cal setting
P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) Anti@@ body@@ -@@ medi@@ ated PR@@ CA has been very rarely reported after months to years of sub@@ cut@@ an@@ e@@ ous er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ .
In patients developing sudden lack of eff@@ ic@@ acy defined by a decre@@ ase in ha@@ emo@@ glob@@ in (@@ 1 to 2 g@@ / dl per mon@@ th@@ ) with increased need for trans@@ fu@@ sions@@ , a re@@ tic@@ u@@ lo@@ cy@@ te count should be obtained and typical causes of non@@ -@@ response (@@ e@@ . g. iron@@ , fol@@ ate or@@ , vit@@ amin B@@ 12 def@@ ici@@ en@@ cy@@ , al@@ uminium in@@ tox@@ ic@@ ation@@ , infection or infl@@ amm@@ ation@@ , blood loss and ha@@ em@@ ol@@ ysi@@ s@@ ) should be investig@@ at@@ ed@@ .
If the re@@ tic@@ u@@ lo@@ cy@@ te count correc@@ ted for an@@ a@@ emi@@ a (@@ i@@ . e.@@ , the re@@ tic@@ u@@ lo@@ cy@@ te “ inde@@ x@@ ”@@ ) is low (@@ < 20,@@ 00@@ 0@@ / mm@@ 3 or < 20,@@ 00@@ 0@@ / micro@@ li@@ tre or < 0.@@ 5@@ %@@ )@@ , plat@@ el@@ et and white blood cell counts are normal@@ , and if no other cause of loss of effect has been found@@ , anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin anti@@ bodies should be determined and bone mar@@ row examination should be considered for diagnosis of PR@@ C@@ A.
If anti@@ -@@ er@@ y@@ thro@@ po@@ ie@@ tin@@ , anti@@ body@@ -@@ medi@@ ated PR@@ CA is suspec@@ te@@ d@@ , therapy with Ab@@ se@@ amed should be dis@@ continued immedi@@ at@@ el@@ y@@ .
No other er@@ y@@ thro@@ po@@ ie@@ tic therapy should be commen@@ ced because of the risk of cross@@ -@@ re@@ ac@@ tion@@ .
Ap@@ pro@@ pri@@ ate therapy such as blood trans@@ fu@@ sions may be given to patients when indi@@ cat@@ ed@@ .
Chr@@ onic ren@@ al failure patients
Immun@@ o@@ gen@@ ic@@ ity data for sub@@ cut@@ an@@ e@@ ous use of Ab@@ se@@ amed in patients at risk for anti@@ body@@ -@@ in@@ duced PR@@ C@@ A@@ , i@@ . e@@ . patients with ren@@ al an@@ a@@ emi@@ a@@ , are not suff@@ ici@@ ent@@ .
Ther@@ e@@ fore@@ , in patients with ren@@ al an@@ a@@ emi@@ a the medic@@ inal product has to be administ@@ ered in@@ tra@@ ven@@ ous@@ ly@@ .
In patients with chronic ren@@ al fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration recommended in section 4.@@ 2.
In clinical tri@@ al@@ s@@ , an increased risk of death and serious cardi@@ ov@@ as@@ cular events was observed when er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents (@@ ES@@ As@@ ) were administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ )@@ .
Contro@@ lled clinical trials have not shown significant benefits attri@@ but@@ able to the administration of e@@ po@@ et@@ ins when ha@@ emo@@ glob@@ in concentration is increased beyond the level necessary to control symptoms of an@@ a@@ emi@@ a and to avoid blood trans@@ fu@@ sion@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
The rate of increase in ha@@ emo@@ glob@@ in should be approximately 1 g@@ / dl
13@@ 4 (@@ 0.@@ 62 mm@@ ol@@ / l@@ ) per month and should not exce@@ ed 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month to mini@@ mise risks of an increase in hyper@@ ten@@ sion@@ .
Hy@@ per@@ kal@@ a@@ emi@@ a has been observed in isolated cas@@ es@@ .
Cor@@ rec@@ tion for an@@ a@@ emi@@ a may lead to increased appeti@@ te@@ , and pot@@ assi@@ um and protein in@@ take@@ .
Di@@ aly@@ sis prescri@@ p@@ tions may have to be adjusted perio@@ di@@ cally to maintain ure@@ a@@ , cre@@ at@@ in@@ ine and pot@@ assi@@ um in the desi@@ red ran@@ ge@@ .
Ser@@ um elec@@ tro@@ ly@@ tes should be monit@@ ored in chronic ren@@ al failure pati@@ ent@@ s.
If an elev@@ ated (@@ or ris@@ ing@@ ) ser@@ um pot@@ assi@@ um level is dete@@ cted then consideration should be given to ce@@ asing e@@ po@@ et@@ in al@@ fa administration until hyper@@ kal@@ a@@ emi@@ a has been correc@@ te@@ d.
An increase in he@@ par@@ in dose during ha@@ emo@@ di@@ aly@@ sis is frequently required during the course of therapy with e@@ po@@ et@@ in al@@ fa as a result of the increased packed cell vol@@ um@@ e@@ .
O@@ cc@@ lu@@ sion of the di@@ aly@@ sis system is possible if he@@ par@@ in@@ isation is not optim@@ um@@ .
In patients with chronic ren@@ al failure and clin@@ ically evi@@ dent i@@ scha@@ e@@ mic heart disease or con@@ gesti@@ ve heart fail@@ ure@@ , maintenance ha@@ emo@@ glob@@ in concentration should not exce@@ ed the upper limit of the target ha@@ emo@@ glob@@ in concentration as recommended under section 4.@@ 2.
Based on information available to dat@@ e@@ , correc@@ tion of an@@ a@@ emi@@ a with e@@ po@@ et@@ in al@@ fa in adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis does not acceler@@ ate the rate of progres@@ sion of ren@@ al in@@ suff@@ ici@@ en@@ cy@@ .
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
In cancer patients receiving ch@@ emo@@ therap@@ y@@ , the 2 - 3 week delay between e@@ po@@ et@@ in al@@ fa administration and the appearance of er@@ y@@ thro@@ po@@ ie@@ tin@@ -@@ in@@ duced red cells should be taken into account when asse@@ ssing if e@@ po@@ et@@ in al@@ fa therapy is appropriate (@@ patient at risk of being trans@@ fu@@ se@@ d@@ )@@ .
Ha@@ emo@@ glob@@ in levels should be measured on a regular basis until a stable level is achieved and perio@@ di@@ cally ther@@ e@@ after@@ .
If the rate of increase in ha@@ emo@@ glob@@ in exce@@ eds 2 g@@ / dl (@@ 1.@@ 25 mm@@ ol@@ / l@@ ) per month or the ha@@ emo@@ glob@@ in level exce@@ eds 13 g@@ / dl (@@ 8.@@ 1 mm@@ ol@@ / l@@ )@@ m@@ , the dose adap@@ tation detailed in section 4.@@ 2 should be thor@@ ou@@ ghly performed to mini@@ mise the risk for thro@@ mbo@@ tic events (@@ see section 4.@@ 2 Tre@@ at@@ ment of patients with ch@@ emo@@ therapy in@@ duced an@@ a@@ emi@@ a - D@@ os@@ age adju@@ st@@ ment to maintain ha@@ emo@@ glob@@ in concentration between 10 g@@ / dl - 12 g@@ / dl@@ )@@ .
As an increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ TV@@ Es@@ ) has been observed in cancer patients receiving er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ see section 4.@@ 8@@ )@@ , this risk should be carefully weighed against the benefit to be deri@@ ved from treatment (@@ with e@@ po@@ et@@ in al@@ fa@@ ) particularly in cancer patients with an increased risk of thro@@ mbo@@ tic v@@ as@@ cular event@@ s@@ , such as obesity and patients with a prior history of TV@@ Es (@@ e@@ . g. deep v@@ ein thro@@ mbo@@ sis or pul@@ mon@@ ary em@@ bo@@ li@@ sm@@ )@@ .
An investig@@ ational study (@@ B@@ EST stu@@ dy@@ ) in women with met@@ ast@@ atic breast cancer was designed to determine whether e@@ po@@ et@@ in al@@ fa treatment that extended beyond the correc@@ tion of an@@ a@@ emi@@ a could improve treatment out@@ com@@ es@@ .
In that study the inci@@ dence of fatal thro@@ mbo@@ em@@ bo@@ lic events was higher in patients receiving e@@ po@@ et@@ in al@@ fa than in those receiving pla@@ c@@ eb@@ o (@@ see section 5.@@ 1@@ )@@ .
In view of the abo@@ ve@@ , in some clinical situations blood trans@@ fu@@ sions should be the preferred treatment for the management of an@@ a@@ emi@@ a in patients with canc@@ er@@ .
The decision to ad@@ minister re@@ com@@ bin@@ ant er@@ y@@ thro@@ po@@ ie@@ t@@ ins should be based on a benef@@ it@@ -@@ risk assessment with the participation of the individual pati@@ ent@@ , which should also take into account the specific clinical con@@ tex@@ t.
Fac@@ tors that should be considered in this assessment should include the type of tum@@ our and its sta@@ ge@@ ; the degree of an@@ a@@ emi@@ a@@ ; li@@ fe@@ -@@ expec@@ t@@ anc@@ y@@ ; the environment in which the patient is being treat@@ ed@@ ; and patient pre@@ ference (@@ see section 5.@@ 1@@ )@@ .
Ad@@ ult surgery patients in an au@@ t@@ olog@@ ous pre@@ don@@ ation programme
All special warnings and prec@@ au@@ tions associated with au@@ t@@ olog@@ ous pre@@ don@@ ation program@@ mes@@ , especially routine volume repla@@ c@@ em@@ ent@@ , should be respec@@ te@@ d.
135 Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery the cause of an@@ a@@ emi@@ a should be established and treat@@ ed@@ , if possi@@ ble@@ , before the start of e@@ po@@ et@@ in al@@ fa treat@@ ment@@ .
Th@@ ro@@ mbo@@ tic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be deri@@ ved from the treatment in this patient gro@@ up@@ .
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery should receive adequate anti@@ thro@@ mbo@@ tic pro@@ ph@@ y@@ la@@ x@@ is@@ , as thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal pati@@ ent@@ s@@ , especially in those with underlying cardi@@ ov@@ as@@ cular dise@@ as@@ e@@ .
In addi@@ tion@@ , special prec@@ au@@ tion should be taken in patients with predi@@ sposition for development of deep v@@ ein thro@@ mbo@@ sis (@@ DV@@ T@@ s@@ )@@ .
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
Ther@@ e@@ fore@@ , it should not be used in patients with bas@@ eline ha@@ emo@@ glob@@ in > 13 g@@ / d@@ l.
Tum@@ our growth potential
Er@@ y@@ thro@@ po@@ ie@@ t@@ ins are growth factors that primarily stim@@ ulate red blood cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
As with all growth fac@@ tor@@ s@@ , there is a concern that e@@ po@@ et@@ ins could stim@@ ulate the growth of tum@@ o@@ urs@@ .
In several controlled stu@@ dies@@ , e@@ po@@ et@@ ins have not been shown to improve overall survival or decre@@ ase the risk of tum@@ our progres@@ sion in patients with an@@ a@@ emi@@ a associated with canc@@ er@@ .
In controlled clinical stu@@ dies@@ , use of E@@ po@@ et@@ in al@@ fa and other er@@ y@@ thro@@ po@@ ie@@ si@@ s@@ -@@ stimul@@ ating agents (@@ ES@@ As@@ ) have sho@@ wn@@ :
- decre@@ ased lo@@ cor@@ egi@@ onal control in patients with advanced head and neck cancer receiving
radiation therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of greater than 14 g@@ / dl (@@ 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- shor@@ ten@@ ed overall survival and increased deaths attri@@ buted to disease progres@@ sion at 4 months in
patients with met@@ ast@@ atic breast cancer receiving ch@@ emo@@ therapy when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 - 14 g@@ / dl (@@ 7.5 – 8.@@ 7 mm@@ ol@@ / l@@ )@@ ,
- increased risk of death when administ@@ ered to target a ha@@ emo@@ glob@@ in of 12 g@@ / dl (@@ 7.5 mm@@ ol@@ / l@@ ) in
patients with active mal@@ ign@@ ant disease receiving neither ch@@ emo@@ therapy nor radiation therap@@ y@@ .
ES@@ As are not indicated for use in this patient pop@@ ula@@ tion@@ .
Ex@@ cip@@ i@@ ents
This medic@@ inal product contains less than 1 m@@ mo@@ l so@@ dium (@@ 23 m@@ g@@ ) per d@@ os@@ e@@ , i@@ . e@@ . essentially “ so@@ di@@ um@@ - free@@ ”@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
No evidence exists that indic@@ ates that treatment with e@@ po@@ et@@ in al@@ fa al@@ ters the met@@ aboli@@ sm of other medic@@ inal produc@@ ts@@ .
Ho@@ we@@ ver@@ , since cy@@ clos@@ por@@ in is bound by red blood cells there is potential for an inter@@ ac@@ tion@@ .
If e@@ po@@ et@@ in al@@ fa is given con@@ co@@ mit@@ antly with cy@@ clos@@ por@@ in@@ , blood levels of cy@@ clos@@ por@@ in should be monit@@ ored and the dose of cy@@ clos@@ por@@ in adjusted as the ha@@ em@@ at@@ o@@ cri@@ t ri@@ ses@@ .
No evidence exists that indic@@ ates an inter@@ action between e@@ po@@ et@@ in al@@ fa and G@@ -@@ CS@@ F or GM@@ -@@ CS@@ F with regard to ha@@ em@@ at@@ ological differ@@ enti@@ ation or proli@@ fer@@ ation of tum@@ our bi@@ op@@ sy spec@@ im@@ ens in vit@@ ro@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate and well@@ -@@ controlled studies in pregnant wom@@ en@@ .
Studies in animals have shown re@@ production tox@@ ic@@ ity (@@ see section 5.@@ 3@@ )@@ .
Con@@ sequ@@ ent@@ ly@@ :
- In chronic ren@@ al failure pati@@ ent@@ s@@ , e@@ po@@ et@@ in al@@ fa should be used in pregnancy only if the potential
benefit out@@ weigh@@ s the potential risk to the fo@@ et@@ us@@ .
- In pregnant or la@@ ct@@ ating sur@@ gi@@ cal patients particip@@ ating in an au@@ t@@ olog@@ ous blood pre@@ don@@ ation
program@@ me@@ , the use of e@@ po@@ et@@ in al@@ fa is not recommen@@ de@@ d.
4.@@ 7 Eff@@ ects on ability to drive and use machines
Ab@@ se@@ amed has no influence on the ability to drive and use mach@@ in@@ es@@ .
4.@@ 8 Un@@ desi@@ rable effects
The most frequent ad@@ verse reaction is an increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
Hy@@ per@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms can occ@@ ur@@ .
Att@@ en@@ tion should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ -@@ like hea@@ da@@ ches as a possible warning sign@@ al@@ .
General
Non@@ -@@ specific skin ra@@ shes have been described in association with e@@ po@@ et@@ in al@@ fa@@ .
"@@ Flu@@ -@@ li@@ ke@@ " symptoms such as hea@@ dach@@ es@@ , joint pa@@ ins@@ , feelings of weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , and ti@@ red@@ ness may occ@@ ur@@ , especially at the start of treat@@ ment@@ .
Th@@ ro@@ mbo@@ cy@@ to@@ sis has been observed but its occ@@ ur@@ r@@ ence is very rare (@@ see section 4.@@ 4@@ )@@ .
Th@@ ro@@ mbo@@ tic@@ / v@@ as@@ cular event@@ s@@ , such as m@@ yo@@ cardi@@ al i@@ scha@@ emi@@ a@@ , m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , cer@@ eb@@ ro@@ v@@ as@@ cular acci@@ dents (@@ cer@@ eb@@ ral ha@@ emor@@ rh@@ age and cer@@ eb@@ ral inf@@ ar@@ c@@ tion@@ )@@ , tran@@ si@@ ent i@@ scha@@ e@@ mic attack@@ s@@ , deep v@@ ein thro@@ mbo@@ si@@ s@@ , ar@@ ter@@ ial thro@@ mbo@@ si@@ s@@ , pul@@ mon@@ ary em@@ bo@@ li@@ , an@@ eur@@ y@@ sm@@ s@@ , re@@ tin@@ al thro@@ mbo@@ si@@ s@@ , and cl@@ ot@@ ting of an artificial ki@@ dney have been reported in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s@@ , including patients receiving e@@ po@@ et@@ in al@@ fa@@ .
Hy@@ per@@ sensi@@ tivity re@@ actions have been rarely reported with e@@ po@@ et@@ in al@@ fa including isolated cases of an@@ gi@@ oe@@ de@@ ma and an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ .
Anti@@ body@@ -@@ medi@@ ated er@@ y@@ thro@@ bla@@ stop@@ en@@ ia (@@ PR@@ C@@ A@@ ) has been reported after months to years of treatment with e@@ po@@ et@@ in al@@ fa@@ .
In most of these pati@@ ent@@ s@@ , anti@@ bodies to er@@ y@@ thro@@ po@@ ie@@ t@@ ins have been observed (@@ see sections 4.@@ 3 and 4.@@ 4 – P@@ ure Red C@@ ell A@@ pla@@ si@@ a@@ )
Ad@@ ult and pa@@ edi@@ atri@@ c ha@@ emo@@ di@@ aly@@ sis pati@@ ent@@ s@@ , adult per@@ it@@ one@@ al di@@ aly@@ sis patients and adult patients with ren@@ al in@@ suff@@ ici@@ ency not yet under@@ going di@@ aly@@ sis
The most frequent ad@@ verse reaction during treatment with e@@ po@@ et@@ in al@@ fa is a d@@ os@@ e@@ -@@ dependent increase in blood pressure or ag@@ gra@@ vation of existing hyper@@ ten@@ sion@@ .
These increases in blood pressure can be treated with medic@@ inal produc@@ ts@@ .
Mor@@ e@@ over@@ , monitoring of the blood pressure is recommended particularly at the start of therap@@ y@@ .
The following re@@ actions have also occurred in isolated patients with normal or low blood pressu@@ re@@ : hyper@@ ten@@ sive crisis with en@@ cep@@ hal@@ op@@ ath@@ y@@ -@@ like symptoms (@@ e@@ . g. hea@@ da@@ ches and confused stat@@ e@@ ) and gener@@ alised ton@@ o@@ cl@@ onal sei@@ zu@@ res@@ , requiring the immediate attention of a physi@@ cian and intensive medical car@@ e@@ .
Par@@ tic@@ ular attention should be paid to sudden stab@@ bing mi@@ gra@@ ine@@ - like hea@@ da@@ ches as a possible warning sign@@ al@@ .
Sh@@ unt thro@@ mb@@ oses may occ@@ ur@@ , especially in patients who have a ten@@ dency to h@@ yp@@ ot@@ ension or whose ar@@ teri@@ o@@ ven@@ ous f@@ ist@@ ula@@ e exhi@@ bit complic@@ ations (@@ e@@ . g. sten@@ os@@ es@@ , an@@ eur@@ y@@ sm@@ s@@ , et@@ c@@ .@@ )@@ .
Early sh@@ unt re@@ vision and thro@@ mbo@@ sis pro@@ ph@@ y@@ la@@ xis by administration of ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic aci@@ d@@ , for ex@@ amp@@ le@@ , is recommended in these pati@@ ent@@ s.
Ad@@ ult cancer patients with symp@@ tom@@ atic an@@ a@@ emi@@ a receiving ch@@ emo@@ therapy
Hy@@ per@@ tension may occur in e@@ po@@ et@@ in al@@ fa treated pati@@ ent@@ s.
Con@@ sequ@@ ent@@ ly@@ , ha@@ emo@@ glob@@ in and blood pressure should be closely monit@@ or@@ ed@@ .
13@@ 7 An increased inci@@ dence of thro@@ mbo@@ tic v@@ as@@ cular events (@@ see section 4.@@ 4 and section 4.@@ 8 - General@@ ) has been observed in patients receiving er@@ y@@ thro@@ po@@ ie@@ tic ag@@ ent@@ s.
Sur@@ gery patients in au@@ t@@ olog@@ ous pre@@ don@@ ation programmes
Independent of er@@ y@@ thro@@ po@@ ie@@ tin treat@@ ment@@ , thro@@ mbo@@ tic and v@@ as@@ cular events may occur in sur@@ gi@@ cal patients with underlying cardi@@ ov@@ as@@ cular disease following repeated ph@@ le@@ bot@@ om@@ y@@ .
Ther@@ e@@ fore@@ , routine volume replacement should be performed in such pati@@ ent@@ s.
Pati@@ ents scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c surgery
In patients scheduled for major elec@@ tive or@@ th@@ op@@ a@@ edi@@ c sur@@ ger@@ y@@ , with a bas@@ eline ha@@ emo@@ glob@@ in of 10 to 13 g@@ / dl@@ , the inci@@ dence of thro@@ mbo@@ tic@@ / v@@ as@@ cular events (@@ most of which were DV@@ T@@ s@@ )@@ , in the overall patient population of the clinical tri@@ al@@ s@@ , appeared to be similar across the different e@@ po@@ et@@ in al@@ fa d@@ osing groups and pla@@ c@@ eb@@ o gro@@ up@@ , although the clinical experience is limi@@ te@@ d.
Mor@@ e@@ over@@ , in patients with a bas@@ eline ha@@ emo@@ glob@@ in of > 13 g@@ / dl@@ , the possibility that e@@ po@@ et@@ in al@@ fa treatment may be associated with an increased risk of post@@ operative thro@@ mbo@@ tic@@ / v@@ as@@ cular events cannot be exclu@@ de@@ d.
4.@@ 9 Over@@ dose
The therapeu@@ tic margin of e@@ po@@ et@@ in al@@ fa is very wide@@ .
Over@@ dose of e@@ po@@ et@@ in al@@ fa may produce effects that are exten@@ sions of the pharmac@@ ological effects of the hor@@ mon@@ e@@ .
Ph@@ le@@ bot@@ omy may be performed if exc@@ essi@@ vely high ha@@ emo@@ glob@@ in levels occ@@ ur@@ .
Additional supportive care should be provided as necess@@ ar@@ y@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : anti@@ an@@ a@@ emi@@ c@@ , AT@@ C co@@ de@@ :
B@@ 03@@ X@@ A@@ 01
Er@@ y@@ thro@@ po@@ ie@@ tin is a g@@ ly@@ cop@@ rot@@ ein that stimul@@ at@@ es@@ , as a mi@@ to@@ si@@ s@@ -@@ stimul@@ ating factor and differ@@ enti@@ ating hor@@ mon@@ e@@ , the formation of er@@ y@@ thro@@ cy@@ tes from prec@@ urs@@ ors of the stem cell com@@ part@@ ment@@ .
The apparent mol@@ ecu@@ lar weight of er@@ y@@ thro@@ po@@ ie@@ tin is 3@@ 2,000 to 40,000 dal@@ ton@@ .
The protein fra@@ ction of the mol@@ ec@@ ule contri@@ butes about 58@@ % and consi@@ sts of 16@@ 5 am@@ ino aci@@ ds@@ .
The four car@@ boh@@ y@@ dr@@ ate cha@@ ins are attached via three N@@ -@@ g@@ ly@@ co@@ si@@ dic bonds and one O@@ -@@ g@@ ly@@ co@@ si@@ dic bond to the prot@@ ein@@ .
E@@ po@@ et@@ in al@@ fa obtained by gene technology is g@@ ly@@ cos@@ y@@ lated and is iden@@ tical in its am@@ ino acid and car@@ boh@@ y@@ dr@@ ate com@@ position to en@@ do@@ genous human er@@ y@@ thro@@ po@@ ie@@ tin that has been isolated from the ur@@ ine of an@@ a@@ e@@ mic pati@@ ent@@ s.
Ab@@ se@@ amed has the highest possible pu@@ rity according to the present state of the art@@ .
In partic@@ ul@@ ar@@ , no resi@@ du@@ es of the cell line used for the production are dete@@ ct@@ able at the conc@@ ent@@ rations of the active ing@@ re@@ dient that are used in hum@@ ans@@ .
The bi@@ ological eff@@ ic@@ acy of e@@ po@@ et@@ in al@@ fa has been demonstrated in various animal models in vi@@ vo (@@ normal and an@@ a@@ e@@ mic rats@@ , poly@@ cy@@ th@@ a@@ e@@ mic mi@@ ce@@ )@@ .
After administration of e@@ po@@ et@@ in al@@ fa@@ , the number of er@@ y@@ thro@@ cy@@ tes@@ , the H@@ b values and re@@ tic@@ u@@ lo@@ cy@@ te counts increase as well as the 59@@ Fe@@ -@@ incorpor@@ ation rat@@ e@@ .
An increased 3@@ H@@ -@@ th@@ y@@ mid@@ ine incorpor@@ ation in the er@@ y@@ thro@@ id nu@@ cle@@ ated sp@@ le@@ en cells has been found in vit@@ ro (@@ m@@ ouse sp@@ le@@ en cell cul@@ ture@@ ) after inc@@ ub@@ ation with e@@ po@@ et@@ in al@@ fa@@ .
It could be shown with the aid of cell cul@@ tures of human bone mar@@ row cells that e@@ po@@ et@@ in al@@ fa stimul@@ ates er@@ y@@ thro@@ po@@ ie@@ sis specifically and does not affect leu@@ cop@@ o@@ ie@@ si@@ s.
Cy@@ t@@ oto@@ x@@ ic actions of e@@ po@@ et@@ in al@@ fa on bone mar@@ row cells could not be dete@@ c@@ te@@ d.
13@@ 8 7@@ 21 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were included in three pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , 38@@ 9 patients with ha@@ em@@ at@@ ological mal@@ ign@@ an@@ cies (@@ 2@@ 21 multiple my@@ el@@ om@@ a@@ , 14@@ 4 non@@ -@@ Hodg@@ kin@@ '@@ s lymp@@ hom@@ a@@ , and 24 other ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ ) and 3@@ 32 with solid tum@@ ours (@@ 17@@ 2 bre@@ ast@@ , 64 gy@@ na@@ ec@@ ologi@@ cal@@ , 23 lung@@ , 22 pro@@ stat@@ e@@ , 21 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 30 other tum@@ our typ@@ es@@ )@@ .
In two lar@@ ge@@ , op@@ en@@ -@@ label stu@@ dies@@ , 26@@ 97 cancer patients receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therapy were inclu@@ de@@ d@@ , 18@@ 95 with solid tum@@ ours (@@ 6@@ 83 bre@@ ast@@ , 260 lung@@ , 17@@ 4 gy@@ na@@ ec@@ ologi@@ cal@@ , 300 ga@@ stro@@ -@@ inte@@ stin@@ al@@ , and 4@@ 78 other tum@@ our typ@@ es@@ ) and 8@@ 02 with ha@@ em@@ at@@ ological mal@@ ign@@ anci@@ es@@ .
In a prosp@@ ec@@ ti@@ ve@@ , rand@@ omi@@ se@@ d@@ , dou@@ ble@@ -@@ blin@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trial conducted in 3@@ 75 an@@ a@@ e@@ mic patients with various non@@ -@@ my@@ elo@@ id mal@@ ign@@ an@@ cies receiving non@@ -@@ plat@@ in@@ um ch@@ emo@@ therap@@ y@@ , there was a significant reduction of an@@ a@@ emi@@ a@@ -@@ related sequ@@ el@@ ae (@@ e@@ . g. f@@ ati@@ gu@@ e@@ , decre@@ ased energ@@ y@@ , and activity re@@ duc@@ tion@@ )@@ , as measured by the following instruments and sc@@ al@@ es@@ :
Fun@@ c@@ tional As@@ se@@ ssment of Cancer Therap@@ y@@ - An@@ a@@ emi@@ a (@@ F@@ AC@@ T@@ -@@ An@@ ) general sc@@ ale@@ , F@@ AC@@ T@@ -@@ An f@@ ati@@ gue sc@@ ale@@ , and Cancer Lin@@ ear An@@ alogue Sc@@ ale (@@ CL@@ AS@@ )@@ .
Two other sm@@ aller@@ , rand@@ omi@@ se@@ d@@ , pla@@ c@@ ebo@@ -@@ controlled trials failed to show a significant improvement in quality of life par@@ ame@@ ters on the E@@ OR@@ T@@ C@@ -@@ Q@@ L@@ Q@@ -@@ C@@ 30 scale or CL@@ AS@@ , respec@@ ti@@ vel@@ y@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin is a growth factor that primarily stimul@@ ates red cell produc@@ tion@@ .
Er@@ y@@ thro@@ po@@ ie@@ tin rec@@ ep@@ tors may be expressed on the surface of a variety of tum@@ our cell@@ s.
Sur@@ vi@@ val and tum@@ our progres@@ sion have been examined in five large controlled studies involving a total of 28@@ 33 pati@@ ent@@ s@@ , of which four were dou@@ ble@@ -@@ blind pla@@ c@@ ebo@@ -@@ controlled studies and one was an op@@ en- label stu@@ dy@@ .
The studies either recru@@ ited patients who were being treated with ch@@ emo@@ therapy (@@ two stu@@ dies@@ ) or used patient pop@@ ulations in which er@@ y@@ thro@@ po@@ ie@@ sis stimul@@ ating agents are not indi@@ cat@@ ed@@ : an@@ a@@ emi@@ a in patients with cancer not receiving ch@@ emo@@ therap@@ y@@ , and head and neck cancer patients receiving radio@@ therap@@ y@@ .
The target ha@@ emo@@ glob@@ in concentration in two studies was > 13 g@@ / dl@@ ; in the remaining three studies it was 12 - 14 g@@ / d@@ l.
In the op@@ en@@ -@@ label study there was no difference in overall survival between patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and contro@@ l@@ s.
In the four pla@@ c@@ ebo@@ -@@ controlled studies the ha@@ zard rati@@ os for overall survival ran@@ ged between 1.@@ 25 and 2.@@ 47 in favour of contro@@ l@@ s.
These studies have shown an consistent un@@ explained stati@@ st@@ ically significant excess mort@@ ality in patients who have an@@ a@@ emi@@ a associated with various common canc@@ ers who received re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin compared to contro@@ l@@ s.
Overall survival outcome in the trials could not be stati@@ s@@ fac@@ tor@@ ily explained by differences in the inci@@ dence of thro@@ mbo@@ sis and related complic@@ ations between those given re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and those in the control gro@@ up@@ .
A system@@ atic review has also been performed involving more than 9@@ 000 cancer patients particip@@ ating in 57 clinical tri@@ al@@ s.
Met@@ a@@ -@@ analysis of overall survival data produced a ha@@ zard ratio point estimate of 1.@@ 08 in favour of controls (@@ 9@@ 5@@ % C@@ I@@ :
0.@@ 99@@ , 1,@@ 18@@ ; 42 trials and 8@@ 16@@ 7 pati@@ ent@@ s@@ )@@ .
An increased relative risk of thro@@ mbo@@ em@@ bo@@ lic events (@@ R@@ R 1.@@ 67@@ , 9@@ 5@@ % C@@ I@@ :
1.@@ 35@@ , 2@@ .0@@ 6@@ , 35 trials and 67@@ 69 pati@@ ent@@ s@@ ) was observed in patients treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin@@ .
There is an increased risk for thro@@ mbo@@ em@@ bo@@ lic events in patients with cancer treated with re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin and a negative impact on overall survival cannot be exclu@@ de@@ d.
The extent to which these out@@ comes might apply to the administration of re@@ com@@ bin@@ ant human er@@ y@@ thro@@ po@@ ie@@ tin to patients with canc@@ er@@ , treated with ch@@ emo@@ therapy to achieve ha@@ emo@@ glob@@ in conc@@ ent@@ rations less than 13 g@@ / dl@@ , is unclear because few patients with these characterist@@ ics were included in the data re@@ vie@@ we@@ d.
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
In@@ tra@@ ven@@ ous route
Me@@ as@@ u@@ rement of e@@ po@@ et@@ in al@@ fa following multiple dose in@@ tra@@ ven@@ ous administration revealed a half@@ -@@ life of approximately 4 hours in normal volunteers and a somewhat more pro@@ lon@@ ged half@@ -@@ life in ren@@ al failure pati@@ ent@@ s@@ , approximately 5 ho@@ urs@@ .
A half@@ -@@ life of approximately 6 hours has been reported in chil@@ dr@@ en@@ .
Sub@@ cut@@ an@@ e@@ ous route
Following sub@@ cut@@ an@@ e@@ ous in@@ jec@@ tion@@ , ser@@ um levels of e@@ po@@ et@@ in al@@ fa are much lower than the levels achieved following in@@ tra@@ ven@@ ous in@@ jec@@ tion@@ , the levels increase slowly and reach a peak between 12 and
13@@ 9 18 hours post@@ d@@ os@@ e@@ .
The peak is always well below the peak achieved using the in@@ tra@@ ven@@ ous route (@@ approximately 1@@ / 20th of the valu@@ e@@ )@@ .
There is no accum@@ ula@@ tion@@ : the levels remain the s@@ ame@@ , whether they are determined 24 hours after the first in@@ jection or 24 hours after the last in@@ jec@@ tion@@ .
The half@@ -@@ life is difficult to evalu@@ ate for the sub@@ cut@@ an@@ e@@ ous route and is estimated about 24 ho@@ urs@@ .
The bio@@ availability of sub@@ cut@@ an@@ e@@ ous in@@ jec@@ table e@@ po@@ et@@ in al@@ fa is much lower than that of the in@@ tra@@ ven@@ ous medic@@ inal produc@@ t@@ : approximately 20@@ %@@ .
5.@@ 3 P@@ rec@@ lin@@ ical safety data
In some prec@@ lin@@ ical tox@@ ic@@ ological studies in dogs and rats@@ , but not in mon@@ ke@@ ys@@ , e@@ po@@ et@@ in al@@ fa therapy was associated with sub@@ clinical bone mar@@ row fi@@ bro@@ sis (@@ bone mar@@ row fi@@ bro@@ sis is a known complic@@ ation of chronic ren@@ al failure in humans and may be related to secondary hyper@@ par@@ ath@@ y@@ ro@@ i@@ dis@@ m or unknown fac@@ tor@@ s.
The inci@@ dence of bone mar@@ row fi@@ bro@@ sis was not increased in a study of ha@@ emo@@ di@@ aly@@ sis patients who were treated with e@@ po@@ et@@ in al@@ fa for 3 years compared to a matched control group of di@@ aly@@ sis patients who had not been treated with e@@ po@@ et@@ in al@@ fa@@ .@@ )@@ .
In animal stu@@ dies@@ , e@@ po@@ et@@ in al@@ fa has been shown to decre@@ ase fo@@ et@@ al body wei@@ ght@@ , delay ossi@@ fication and increase fo@@ et@@ al mort@@ ality when given in weekly d@@ oses of approximately 20 times the recommended human weekly d@@ os@@ e@@ .
These changes are interpre@@ ted as being secondary to decre@@ ased mat@@ ern@@ al body weight ga@@ in@@ .
E@@ po@@ et@@ in al@@ fa did not show any changes in bac@@ ter@@ ial and m@@ amm@@ ali@@ an cell culture mut@@ agen@@ ic@@ ity tests and an in vi@@ vo mic@@ ron@@ u@@ cle@@ us test in mi@@ ce@@ .
Long@@ -@@ term car@@ cin@@ o@@ gen@@ ic@@ ity studies have not been carried out@@ .
There are confli@@ cting reports in the liter@@ ature regarding whether er@@ y@@ thro@@ po@@ ie@@ t@@ ins may play a major role as tum@@ our proli@@ fer@@ ator@@ s.
These reports are based on in vit@@ ro findings from human tum@@ our s@@ amp@@ les@@ , but are of uncertain significance in the clinical situ@@ ation@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
So@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate Dis@@ o@@ dium ph@@ osph@@ ate di@@ hydr@@ ate So@@ dium ch@@ l@@ ori@@ de G@@ ly@@ c@@ ine Poly@@ sor@@ b@@ ate 80 Water for in@@ jections Hy@@ dro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ ) So@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities
In the absence of comp@@ ati@@ bility stu@@ dies@@ , this medic@@ inal product must not be mixed with other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
2 years
6.@@ 4 Special prec@@ au@@ tions for storage
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Do not free@@ ze@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
140 For the purpose of ambul@@ atory use@@ , the patient may remove Ab@@ se@@ amed from the re@@ fri@@ ger@@ ator and store it not above 25@@ °@@ C for one single period of up to 3 day@@ s.
6.5 Nature and cont@@ ents of container
Pre@@ -@@ filled sy@@ ring@@ es (@@ glass type I@@ ) with pl@@ unger (@@ Te@@ fl@@ on@@ -@@ faced rub@@ ber@@ ) sealed in a bli@@ ster@@ .
The sy@@ ring@@ es contain 1 ml (@@ 10 000 I@@ U@@ ) of sol@@ u@@ tion@@ .
Sy@@ ring@@ es are em@@ bos@@ sed with gradu@@ ation rings and the filling volume is indicated by a sti@@ ck@@ -@@ on label in order to enable partial use if requi@@ re@@ d.
P@@ ack of 1 or 6 sy@@ rin@@ ges@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
Ab@@ se@@ amed must not be used
- if the solution is clou@@ dy or there are partic@@ les in it@@ .
- if the seal is bro@@ ken@@ .
- if the solution has been acci@@ dentally fro@@ zen@@ .
The pre@@ -@@ filled sy@@ ring@@ es are ready to use (@@ see section 4.@@ 2 – Me@@ th@@ od of administ@@ ration@@ )@@ .
After in@@ jection of the necessary amount of the solution from the pre@@ -@@ filled sy@@ rin@@ ge@@ , disc@@ ard any remaining cont@@ ent@@ s.
The pre@@ -@@ filled sy@@ r@@ inge should not be sha@@ ken@@ .
Any un@@ used product or waste material should be disp@@ osed of in accord@@ ance with local requi@@ re@@ ment@@ s.
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co KG Ku@@ h@@ lo@@ weg 37 D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ lohn
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 15 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 0@@ 16
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
28 August 2007
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
14@@ 1 AN@@ NE@@ X II
A.
M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ER O@@ F THE B@@ I@@ OL@@ O@@ G@@ IC@@ AL AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE AND M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER RE@@ SP@@ ON@@ S@@ IB@@ LE FO@@ R B@@ AT@@ CH RE@@ LE@@ AS@@ E
B.
CON@@ D@@ IT@@ I@@ ON@@ S O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION
14@@ 2 A.
M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ER O@@ F THE B@@ I@@ OL@@ O@@ G@@ IC@@ AL AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE AND M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER RE@@ SP@@ ON@@ S@@ IB@@ LE FO@@ R B@@ AT@@ CH RE@@ LE@@ AS@@ E
Name and address of the manufacturer of the bi@@ ological active substance
Rent@@ sch@@ ler Bi@@ ot@@ echn@@ ologie GmbH Er@@ win@@ -@@ Rent@@ schl@@ er@@ -@@ Stra@@ sse 21 D@@ -@@ 88@@ 4@@ 71 L@@ aup@@ heim Germany
Name and address of the manufacturer responsible for bat@@ ch release
Hex@@ al AG Industri@@ est@@ rasse 25 D@@ -@@ 8@@ 36@@ 07 Holz@@ kirchen Germany
B.
CON@@ D@@ IT@@ I@@ ON@@ S O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION
• CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S RE@@ G@@ AR@@ D@@ ING SU@@ P@@ PL@@ Y AND US@@ E I@@ MP@@ O@@ SED ON THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medic@@ inal product subject to restricted medical prescription (@@ See Anne@@ x I@@ :
Sum@@ mary of Product Char@@ ac@@ ter@@ isi@@ tic@@ s@@ , S@@ ection 4.@@ 2@@ )@@ .
• CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE S@@ AF@@ E AND E@@ FF@@ EC@@ T@@ IV@@ E US@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Pri@@ or to launch and as agreed with compet@@ ent authorities in the Member Stat@@ es@@ , the MA@@ H shall provide healthcare professionals in di@@ aly@@ sis centres and retail pharmac@@ ies with the follo@@ w@@ ing@@ : • Educ@@ ational le@@ af@@ let • Sum@@ mary of product characterist@@ ics (@@ SP@@ C@@ ) and Pack@@ age Le@@ af@@ let and Lab@@ elling • C@@ ool boxes for patients clearly lab@@ elled with a visual aid indic@@ ating correct use of produc@@ t.
The educational le@@ af@@ let shall contain the following key elem@@ ent@@ s@@ : • That the use of e@@ po@@ et@@ in al@@ fa products can cause immun@@ o@@ gen@@ ic@@ ity which in rare cases may lead to P@@ ure Red C@@ ell A@@ pla@@ sia (@@ PR@@ C@@ A@@ ) • That with other e@@ po@@ et@@ in produc@@ ts@@ , the risk of immun@@ o@@ gen@@ ic@@ ity in Chr@@ onic Ki@@ dney Di@@ se@@ ase (@@ C@@ K@@ D@@ ) is increased with the sub@@ cut@@ an@@ e@@ ous (@@ sc@@ ) rou@@ te@@ . • There is in@@ sufficient data on Ab@@ se@@ amed to know the size of any increased immun@@ o@@ gen@@ ic@@ ity risk with sub@@ cut@@ an@@ e@@ ous use • Ther@@ e@@ fore@@ , the s@@ c route is not recommended for patients with C@@ K@@ D • The loss of eff@@ ic@@ acy or other symptoms of the development of immun@@ o@@ gen@@ ic@@ ity should be investigated • Any suspected case of P@@ ure Red C@@ ell A@@ pla@@ sia or development of immun@@ o@@ gen@@ ic@@ ity should be reported to the MA@@ H
• O@@ TH@@ ER CON@@ D@@ IT@@ I@@ ON@@ S
P@@ harm@@ ac@@ o@@ vig@@ il@@ ance system
The MA@@ H must ensure that the system of pharmac@@ o@@ vig@@ il@@ anc@@ e@@ , as described in version 3.@@ 0 presented in Mo@@ dule 1.@@ 8.@@ 1. of the Marketing Auth@@ or@@ isation App@@ lic@@ ation@@ , is in place and func@@ tioning before and whilst the product is on the market@@ .
14@@ 3 Ris@@ k Management plan
The MA@@ H com@@ mits to performing the studies and additional pharmac@@ o@@ vig@@ il@@ ance activities detailed in the P@@ harm@@ ac@@ o@@ vig@@ il@@ ance Plan@@ , as agreed in Version 5 of the Ris@@ k Management Plan (@@ R@@ MP@@ ) presented in Mo@@ dule 1.@@ 8.@@ 2. of the Marketing Auth@@ or@@ isation App@@ lic@@ ation and any subsequent updates of the R@@ MP agreed by the CH@@ MP@@ .
As per the CH@@ MP Gui@@ del@@ ine on Ris@@ k Management Systems for medic@@ inal products for human use@@ , the updated R@@ MP should be submitted at the same time as the next Peri@@ o@@ dic Safety Update Report (@@ P@@ S@@ UR@@ )@@ .
In addi@@ tion@@ , an updated R@@ MP should be submitted • When new information is received that may impact on the current Safety Speci@@ fic@@ ation@@ , P@@ harm@@ ac@@ o@@ vig@@ il@@ ance Plan or risk mini@@ mis@@ ation activities • Within 60 days of an important (@@ pharmac@@ o@@ vig@@ il@@ ance or risk mini@@ mis@@ ation@@ ) mi@@ lestone being reached • At the request of the E@@ ME@@ A
14@@ 4 AN@@ NE@@ X III
LA@@ B@@ EL@@ LIN@@ G AND P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T
14@@ 5 A.
LA@@ B@@ EL@@ LIN@@ G
14@@ 6 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 1000 I@@ U@@ / 0.5 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
E@@ po@@ et@@ in al@@ fa
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
1 pre@@ -@@ filled sy@@ r@@ inge of 0.5 ml contains 1000 international units (@@ I@@ U@@ ) correspon@@ ding to 8.@@ 4 micro@@ grams e@@ po@@ et@@ in al@@ fa
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Ex@@ cip@@ i@@ ent@@ s@@ : so@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate@@ , di@@ so@@ dium ph@@ osph@@ ate di@@ hydr@@ ate@@ , so@@ dium ch@@ l@@ ori@@ de@@ , g@@ ly@@ c@@ ine@@ , poly@@ sor@@ b@@ ate 80@@ , hydro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )@@ , so@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )@@ , and water for in@@ jections
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ rin@@ ge@@ .
1 pre@@ -@@ filled sy@@ r@@ inge of 0.5 ml 6 pre@@ -@@ filled sy@@ ring@@ es of 0.5 ml
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
For sub@@ cut@@ an@@ e@@ ous and in@@ tra@@ ven@@ ous use@@ .
Read the package le@@ af@@ let before use@@ .
Do not sha@@ ke@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
14@@ 7 9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
Do not free@@ ze@@ .
10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co K@@ G@@ , Ku@@ h@@ lo@@ weg 37@@ , D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ loh@@ n@@ , Germany
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 1 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 2
13.
B@@ AT@@ CH N@@ UM@@ BER
Bat@@ ch
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
Ab@@ se@@ amed 1000 I@@ U@@ / 0.5 ml
14@@ 8 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ T@@ ER
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 1000 I@@ U@@ / 0.5 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
E@@ po@@ et@@ in al@@ fa
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Bat@@ ch
5.
O@@ TH@@ ER
14@@ 9 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON SM@@ ALL IM@@ ME@@ DI@@ AT@@ E P@@ AC@@ K@@ AG@@ ING UN@@ IT@@ S
LA@@ B@@ EL@@ / S@@ Y@@ R@@ IN@@ GE
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Ab@@ se@@ amed 1000 I@@ U@@ / 0.5 ml in@@ jection
E@@ po@@ et@@ in al@@ fa IV@@ / SC
2.
ME@@ TH@@ O@@ D O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
CON@@ T@@ EN@@ TS B@@ Y WE@@ IG@@ H@@ T@@ , B@@ Y V@@ OL@@ U@@ ME O@@ R B@@ Y UN@@ IT
6.
O@@ TH@@ ER
150 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 2000 I@@ U@@ / 1 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
E@@ po@@ et@@ in al@@ fa
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
1 pre@@ -@@ filled sy@@ r@@ inge of 1 ml contains 2000 international units (@@ I@@ U@@ ) correspon@@ ding to 16.@@ 8 micro@@ grams e@@ po@@ et@@ in al@@ fa
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Ex@@ cip@@ i@@ ent@@ s@@ : so@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate@@ , di@@ so@@ dium ph@@ osph@@ ate di@@ hydr@@ ate@@ , so@@ dium ch@@ l@@ ori@@ de@@ , g@@ ly@@ c@@ ine@@ , poly@@ sor@@ b@@ ate 80@@ , hydro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )@@ , so@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )@@ , and water for in@@ jections
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ rin@@ ge@@ .
1 pre@@ -@@ filled sy@@ r@@ inge of 1 ml 6 pre@@ -@@ filled sy@@ ring@@ es of 1 ml
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
For sub@@ cut@@ an@@ e@@ ous and in@@ tra@@ ven@@ ous use@@ .
Read the package le@@ af@@ let before use@@ .
Do not sha@@ ke@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
15@@ 1 9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
Do not free@@ ze@@ .
10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co K@@ G@@ , Ku@@ h@@ lo@@ weg 37@@ , D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ loh@@ n@@ , Germany
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 3 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 4
13.
B@@ AT@@ CH N@@ UM@@ BER
Bat@@ ch
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
Ab@@ se@@ amed 2000 I@@ U@@ / 1 ml
15@@ 2 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ T@@ ER
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 2000 I@@ U@@ / 1 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
E@@ po@@ et@@ in al@@ fa
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Bat@@ ch
5.
O@@ TH@@ ER
15@@ 3 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON SM@@ ALL IM@@ ME@@ DI@@ AT@@ E P@@ AC@@ K@@ AG@@ ING UN@@ IT@@ S
LA@@ B@@ EL@@ / S@@ Y@@ R@@ IN@@ GE
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
Ab@@ se@@ amed 2000 I@@ U@@ / 1 ml in@@ jection
E@@ po@@ et@@ in al@@ fa IV@@ / SC
2.
ME@@ TH@@ O@@ D O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
4.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
5.
CON@@ T@@ EN@@ TS B@@ Y WE@@ IG@@ H@@ T@@ , B@@ Y V@@ OL@@ U@@ ME O@@ R B@@ Y UN@@ IT
6.
O@@ TH@@ ER
15@@ 4 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING
O@@ U@@ T@@ ER C@@ AR@@ T@@ ON
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 3000 I@@ U@@ / 0.@@ 3 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
E@@ po@@ et@@ in al@@ fa
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
1 pre@@ -@@ filled sy@@ r@@ inge of 0.@@ 3 ml contains 3000 international units (@@ I@@ U@@ ) correspon@@ ding to 25.@@ 2 micro@@ grams e@@ po@@ et@@ in al@@ fa
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Ex@@ cip@@ i@@ ent@@ s@@ : so@@ dium di@@ hydro@@ gen ph@@ osph@@ ate di@@ hydr@@ ate@@ , di@@ so@@ dium ph@@ osph@@ ate di@@ hydr@@ ate@@ , so@@ dium ch@@ l@@ ori@@ de@@ , g@@ ly@@ c@@ ine@@ , poly@@ sor@@ b@@ ate 80@@ , hydro@@ ch@@ l@@ ori@@ c acid (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )@@ , so@@ dium hydro@@ xi@@ de (@@ for p@@ H@@ -@@ adju@@ st@@ ment@@ )@@ , and water for in@@ jections
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
Sol@@ ution for in@@ jection in a pre@@ -@@ filled sy@@ rin@@ ge@@ .
1 pre@@ -@@ filled sy@@ r@@ inge of 0.@@ 3 ml 6 pre@@ -@@ filled sy@@ ring@@ es of 0.@@ 3 ml
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
For sub@@ cut@@ an@@ e@@ ous and in@@ tra@@ ven@@ ous use@@ .
Read the package le@@ af@@ let before use@@ .
Do not sha@@ ke@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P
15@@ 5 9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
Store and transport re@@ fri@@ ger@@ ated (@@ 2@@ °@@ C - 8@@ °@@ C@@ )@@ .
Keep the pre@@ -@@ filled sy@@ r@@ inge in the ou@@ ter car@@ ton in order to protect from light@@ .
Do not free@@ ze@@ .
10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce Arznei@@ mittel P@@ ü@@ tter GmbH & Co K@@ G@@ , Ku@@ h@@ lo@@ weg 37@@ , D@@ -@@ 58@@ 6@@ 38 I@@ ser@@ loh@@ n@@ , Germany
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 5 EU@@ / 1@@ / 07@@ / 4@@ 12@@ / 00@@ 6
13.
B@@ AT@@ CH N@@ UM@@ BER
Bat@@ ch
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
Ab@@ se@@ amed 3000 I@@ U@@ / 0.@@ 3 ml
15@@ 6 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
BL@@ IS@@ T@@ ER
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ab@@ se@@ amed 3000 I@@ U@@ / 0.@@ 3 ml solution for in@@ jection in a pre@@ -@@ filled sy@@ r@@ inge
E@@ po@@ et@@ in al@@ fa
2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medi@@ ce
